UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 1 of 149  
STATISTICAL ANALYSIS PLAN  
AMENDMENT 2 
Study: AS0005  
Product: Certolizumab Pegol 
MULTICENTER, OPEN-LABEL (PART A) FOLLOWED BY A RANDOMIZED, 
DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY 
(PART B) TO EVALUATE MAINTENANCE OF REMISSION IN SUBJECTS 
WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) RECEIVING EITHER 
CERTOLIZUMAB PEGOL 200MG Q2W OR 200MG Q4W AS COMPARED TO 
PLACEBO   
SAP/Amendment Number  Date  
Final SAP  30 Mar 2017  
SAP Amendment 1 23 April 2018 
SAP Amendment 2  07 May 2019 
  
Confidentiality Statement 
Confidential 
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  REDACTED COPY GROUP, PLACEBO
REDACTED COPY GROUP, PLACEBO
(PART B) TO EVALUATE MAINTENANCE OF REMISSION IN SUBJECTS 
REDACTED COPY (PART B) TO EVALUATE MAINTENANCE OF REMISSION IN SUBJECTS 
WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) RECEIVING EITHER 
REDACTED COPY WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) RECEIVING EITHER 
G Q2W OR 200MG Q4W AS COMPARED TO 
REDACTED COPY G Q2W OR 200MG Q4W AS COMPARED TO 
PLACEBO
REDACTED COPY PLACEBO
30 Mar 2017REDACTED COPY 30 Mar 2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LABEL (PART A) FOLLOWED BY A RANDOMIZED, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LABEL (PART A) FOLLOWED BY A RANDOMIZED, 
GROUP, PLACEBO
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. GROUP, PLACEBO CONTROLLED STUDY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CONTROLLED STUDY 
(PART B) TO EVALUATE MAINTENANCE OF REMISSION IN SUBJECTS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (PART B) TO EVALUATE MAINTENANCE OF REMISSION IN SUBJECTS 
WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) RECEIVING EITHER 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) RECEIVING EITHER 
G Q2W OR 200MG Q4W AS COMPARED TO 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. G Q2W OR 200MG Q4W AS COMPARED TO 
PLACEBO
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PLACEBO
[ADDRESS_846689] OF ABBREVIATIONS .................................................................................................... 9  
1 INTRODUCTION ........................................................................................................... 13  
2 PROTOCOL SUMMARY ............................................................................................... 13  
2.1 Study objectives ........................................................................................................... 13  
2.1.1  Primary objectives ............................................................................................... 13  
2.1.2  Secondary objectives ........................................................................................... 13  
2.1.3  Other objectives ................................................................................................... 14  
2.1.4  Pharmacokinetic, pharmacogenomic and immunological objectives .................. 14  
2.2 Study variables ............................................................................................................. 14  
2.2.1  Efficacy variables ................................................................................................ 14  
[IP_ADDRESS]  Primary efficacy variable .......................................................................... 14  
[IP_ADDRESS]  Secondary efficacy variables ..................................................................... 14  
[IP_ADDRESS]  Other efficacy variables ............................................................................. 15  
2.2.2  Pharmacokinetic, pharmacogenomic and immunogenicity variables ................. 19  
[IP_ADDRESS]  Pharmacokinetic variables ......................................................................... 19  
[IP_ADDRESS]  Biomarkers ................................................................................................ 19  
[IP_ADDRESS]  Pharmacogenomic variables ...................................................................... 19  
[IP_ADDRESS]  Immunogenicity variables ......................................................................... [ADDRESS_846690] ................................................................................... 21  
2.3.5  Planned number of subjects and sites .................................................................. 22  
2.4 Determination of sample size ....................................................................................... 22  
3 DATA ANALYSIS CONSIDERATIONS ...................................................................... 22  
3.1 General presentation of summaries and analyses ........................................................ 22  
3.2 General study level definitions .................................................................................... 23  
3.2.1  Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ....................... 23  
3.2.2  ASAS20, ASAS40, ASAS5/6 response, and ASAS Partial Remission .............. 24  
3.2.3  Bath Ankylosing Spondylitis Functional Index (BASFI) .................................... 25  
3.2.4  MRI assessments ................................................................................................. 25  
3.2.5  Bath Ankylosing Spondylitis Metrology Index (BASMI) ................................... 27  
3.2.6  Total and nocturnal spi[INVESTIGATOR_18303] ................................................................... 28  
3.2.7  Ankylosing Spondylitis Disease Activity Score (ASDAS) ................................. 28  
3.2.8  Ankylosing Spondylitis Quality of Life (ASQoL) .............................................. [ADDRESS_846691]
Planned number of subjects and sites
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Planned number of subjects and sites
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Determination of sample size
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Determination of sample size
DATA ANALYSIS CONSID
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. DATA ANALYSIS CONSID
General presentation of summaries and analyses
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. General presentation of summaries and analyses
General study level definitions
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. General study level definitions
3.2.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.1
3.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.2
3.2.3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.3
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 3 of 149 3.2.9  Work Productivity Survey (WPS) ....................................................................... 30  
3.2.10  Patient’s Global Assessment of Disease Activity (PtGADA, NRS) ................... 31  
3.2.11  Short-Form 36-item Health Survey (SF-36) ........................................................ 32  
3.2.12  Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) ......................... 32  
3.2.13  Swollen and Tender Joint Counts (44) ................................................................ 32  
3.2.14  Physician’s Global Assessment of Disease Activity (PhGADA) ........................ 33  
3.2.15  Spi[INVESTIGATOR_18171] ..................................................................................................... 33  
3.2.16  Health status (EQ- 5D-3L) .................................................................................... 33  
3.2.17  Resource utilization ............................................................................................. 33  
3.2.18  Extra-articular assessments .................................................................................. 34  
3.2.19  Fecal and serum calprotectin ............................................................................... 34  
3.2.20  Inflammatory Bowel Disease Questionnaire (IBD- Q) ........................................ 34  
3.2.21  Sustained Remission ............................................................................................ 36  
3.2.22  Flare ..................................................................................................................... 36  
[IP_ADDRESS]  Observed case ............................................................................................ 37  
[IP_ADDRESS]  Alternative handling of premature withdrawal.......................................... 37  
[IP_ADDRESS]  Mixed model with repeated measures (MMRM) imputation of ASDAS . 37  
[IP_ADDRESS]  Referenced based multiple imputation of ASDAS .................................... [ADDRESS_846692], prior and concomitant medications ............................................................. 42  
3.3 Analysis time points ..................................................................................................... 42  
3.3.1  Relative day ......................................................................................................... 44  
3.3.2  End date of the Treatment Period ........................................................................ 45  
3.4 Definition of Baseline values ....................................................................................... 45  
3.5 Protocol deviations....................................................................................................... 46  
3.6 Analysis sets................................................................................................................. 46  
3.6.1  Enrolled Set ......................................................................................................... 46  
3.6.2  Open- Label Set  .................................................................................................... 46  
3.6.3  Randomized Set ................................................................................................... 46  
3.6.4  Safety Set  ............................................................................................................. 46  
3.6.5  Safety Set Part B .................................................................................................. 46  
3.6.6  Full Analysis Set .................................................................................................. 46  
3.6.7  Per Protocol Set ................................................................................................... 46  REDACTED COPY Alternative handling of premature withdrawal
REDACTED COPY Alternative handling of premature withdrawal
Mixed model with repeated measures (MMRM) imputation of ASDAS
REDACTED COPY Mixed model with repeated measures (MMRM) imputation of ASDAS
Referenced based multiple imputation 
REDACTED COPY Referenced based multiple imputation 
................................
REDACTED COPY ................................ ................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
CZP antibody status REDACTED COPY CZP antibody status
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 33
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 33
....................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .................... 33
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 33
.............................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. .............................
..................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ..................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ...............
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...............
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ............................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ............................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
Alternative handling of premature withdrawal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Alternative handling of premature withdrawal
Mixed model with repeated measures (MMRM) imputation of ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Mixed model with repeated measures (MMRM) imputation of ASDAS
Referenced based multiple imputation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Referenced based multiple imputation of ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of ASDAS
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
Modified [LOCATION_001] criteria
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Modified [LOCATION_001] criteria
Modified ASAS Classification Criteria
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Modified ASAS Classification Criteria
Past, prior and concomitant medications
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Past, prior and concomitant medications
Analysis time points
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Analysis time points ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
Relative day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Relative day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
End date of th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. End date of th
Definition of Baseline values
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Definition of Baseline values
Protocol deviations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Protocol deviations
Analysis sets
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Analysis sets
3.6.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.6.1
3.6.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.6.2
3.6.3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.6.3
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 4 of 149 3.6.8  Pharmacokinetic Set B ......................................................................................... 47  
3.6.9  Flared Set ............................................................................................................. 47  
3.6.10  Escape Therapy Set .............................................................................................. 47  
3.6.11  Part B Full-dose Set ............................................................................................. 47  
3.6.12  General use of the Analysis Sets ......................................................................... 47  
3.7 Treatment assignment and treatment groups ............................................................... 47  
3.8 Center pooling strategy ................................................................................................ 48  
3.9 Coding dictionaries ...................................................................................................... 48  
3.10  Changes to protocol-defined analyses ......................................................................... 48  
4 STATISTICAL/ANALYTIC AL ISSUES  ....................................................................... 49  
4.1 Adjustments for covariates .......................................................................................... 49  
4.2 Handling of dropouts or missing data .......................................................................... 49  
4.3 Interim analyses and data monitoring .......................................................................... 53  
4.4 Multicenter studies ....................................................................................................... 54  
4.5 Multiple comparisons/multiplicity ............................................................................... [ADDRESS_846693], prior and concomitant medications ..................................................................... 58  
7 MEASUREMENTS OF TREATMENT COMPLIANCE ............................................... 59  
8 EFFICACY ANALYSES ................................................................................................ 60  
8.1 Primary efficacy variable ............................................................................................. 60  
8.1.1  Primary analysis of the primary efficacy variable ............................................... 60  
8.1.2  Secondary analyses of the primary efficacy variable .......................................... 61  
8.1.3  Supportive and sensitivity analyses of the primary efficacy variable ................. 61  
8.2 Secondary efficacy variables ....................................................................................... 62  
8.2.1  Part A ................................................................................................................... 62  
[IP_ADDRESS]  Percentage of subjects achieving sustained remission at Week 48 ........... 62  
[IP_ADDRESS]  ASDAS disease activity (ASDAS-ID, ASDAS-LD, ASDAS-HD and 
ASDAS-vHD) at Week 48 ........................................................................ 62  
[IP_ADDRESS]  ASDAS clinical improvement (ASDAS-MI and ASDAS-CII) at Week [ADDRESS_846694], prior and concomitant medications
MEASUREMENTS OF TREA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MEASUREMENTS OF TREA
EFFICACY ANALYSES
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. EFFICACY ANALYSES
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Primary efficacy variable
Primary analysis of the primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Primary analysis of the primary efficacy variable
Secondary analyses of the primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Secondary analyses of the primary efficacy variable
Supportive and sensitivity analyses of the primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Supportive and sensitivity analyses of the primary efficacy variable
Secondary efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Secondary efficacy variables
8.2.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.2.1
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 5 of 149 [IP_ADDRESS]  Time to flare .............................................................................................. 62  
[IP_ADDRESS]  Continuous secondary efficacy variables .................................................. 63  
[IP_ADDRESS]  Binary secondary efficacy variables .......................................................... 63  
8.2.3  Subjects experiencing a flare in Part B ................................................................ 64  
[IP_ADDRESS]  Continuous secondary efficacy variables .................................................. 64  
[IP_ADDRESS]  Binary secondary efficacy variables .......................................................... 64  
8.3 Other efficacy variables ............................................................................................... 64  
8.3.1  Part A ................................................................................................................... 64  
[IP_ADDRESS]  ASDAS disease activity (ASDAS-ID, ASDAS-LD, ASDAS-HD and 
ASDAS-vHD) and clinical improvement (ASDAS-CII, ASDAS- MI) ..... 64  
[IP_ADDRESS]  ASAS20, ASAS40, ASAS5/6, and ASAS PR response ........................... 64  
[IP_ADDRESS]  ASDAS, BASDAI, and BASMI ................................................................ 65  
[IP_ADDRESS]  SIJ SPARCC and spi[INVESTIGATOR_18241]-a in the Berlin modification scores .. 65  
[IP_ADDRESS]  Individual ASAS core components ........................................................... 65  
[IP_ADDRESS]  PhGADA ................................................................................................... 65  
[IP_ADDRESS]  Nocturnal spi[INVESTIGATOR_18172] (NRS) ..................................................................... 65  
[IP_ADDRESS]  Fatigue (NRS) (from BASDAI) ................................................................ 65  
[IP_ADDRESS]  BASDAI50 response ................................................................................. 66  
[IP_ADDRESS]  C-reactive protein (CRP) ........................................................................... 66  
[IP_ADDRESS]  Ankylosing Spondylitis Quality of Life (ASQoL) .................................... 66  
[IP_ADDRESS]  Work Productivity Survey (WPS) ............................................................. 66  
[IP_ADDRESS]  EuroQoL Health Status Questionnaire 5 dimensions 3 levels (EQ-5D- 3L)66 
[IP_ADDRESS]  Maastricht Ankylosis Spondylitis Enthesitis Score (MASES) .................. 66  
[IP_ADDRESS]  Swollen and tender joint counts (44 joint count)....................................... 66  
[IP_ADDRESS]  Spi[INVESTIGATOR_18171] .......................................................................................... 67  
[IP_ADDRESS]  Number of uveitis flares, IBD exacerbations and psoriasis exacerbations 67  
[IP_ADDRESS]  Fecal calprotectin ...................................................................................... 67  
[IP_ADDRESS]  Serum calprotectin ..................................................................................... 67  
[IP_ADDRESS]  Inflammatory Bowel Disease Questionnaire (IBD- Q) .............................. 67  
[IP_ADDRESS]  Correlation between fecal calprotectin, serum calprotectin, IBD-Q and 
CRP  ........................................................................................................... 68  
[IP_ADDRESS]  Short-Form 36-Item Health Survey (SF-36) ............................................. 68  
[IP_ADDRESS]  Resources utilization ................................................................................. 68  
8.3.2  Part B ................................................................................................................... 68  
[IP_ADDRESS]  ASDAS clinical improvement (ASDAS-CII, ASDAS- MI) ...................... 68  
[IP_ADDRESS]  ASAS20, ASAS40, ASAS5/6, and ASAS PR response ........................... 69  
[IP_ADDRESS]  ASDAS, BASDAI, BASFI and BASMI ................................................... 69  
[IP_ADDRESS]  Individual ASAS core components ........................................................... 69  
[IP_ADDRESS]  Fatigue NRS .............................................................................................. 70  REDACTED COPY ................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
Ankylosing Spondylitis Quality of Life (ASQoL)
REDACTED COPY Ankylosing Spondylitis Quality of Life (ASQoL)
Work Productivity Survey (WPS)
REDACTED COPY Work Productivity Survey (WPS)
EuroQoL Health Status Questionnaire 5 dimensions 3 levels REDACTED COPY EuroQoL Health Status Questionnaire 5 dimensions 3 levels 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 64
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 64
...................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................... 64
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 64
HD and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. HD and 
CII, ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CII, ASDAS -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -MI)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MI)
...........................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...........................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
a in the Berlin modification scores
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a in the Berlin modification scores
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
Ankylosing Spondylitis Quality of Life (ASQoL)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ankylosing Spondylitis Quality of Life (ASQoL)
Work Productivity Survey (WPS)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Work Productivity Survey (WPS)
EuroQoL Health Status Questionnaire 5 dimensions 3 levels 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. EuroQoL Health Status Questionnaire 5 dimensions 3 levels 
Maastricht Ankylosis Spondylitis Enthesitis Score (MASES)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maastricht Ankylosis Spondylitis Enthesitis Score (MASES)
Swollen and tender joint counts (44 joint count)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Swollen and tender joint counts (44 joint count)
Spi[INVESTIGATOR_634087]. Spi[INVESTIGATOR_634088], IBD exacerbations and psoriasis exacerbations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number of uveitis flares, IBD exacerbations and psoriasis exacerbations
Fecal calprotectin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Fecal calprotectin
S
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Serum calprotectin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. erum calprotectin
Inflammatory Bowel Disease Questionnaire (IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Inflammatory Bowel Disease Questionnaire (IBD
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
8.3.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.3.2
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 6 of 149 [IP_ADDRESS]  BASDAI50 response ................................................................................. 70  
[IP_ADDRESS]  ASQoL ....................................................................................................... 70  
[IP_ADDRESS]  Work Productivity Survey (WPS) ............................................................. 70  
[IP_ADDRESS]  Number of uveitis flares, IBD exacerbations and psoriasis exacerbations 71  
[IP_ADDRESS]  Correlation between fecal calprotectin, serum calprotectin, IBD-Q and 
CRP  ........................................................................................................... 71  
[IP_ADDRESS]  Short-Form 36-Item Health Survey (SF-36) ............................................. 71  
[IP_ADDRESS]  Descriptive summaries of other efficacy variables ................................... 72  
8.3.3  Subjects experiencing a flare in Part B ................................................................ 73  
9 PHARMACOKINETICS AND PHARMACODYNAMICS .......................................... 74  
9.1 Pharmacokinetics ......................................................................................................... 74  
9.2 Immunogenicity ........................................................................................................... 75  
10 SAFETY ANALYSES ..................................................................................................... 77  
10.1  Extent of exposure ....................................................................................................... 77  
10.1.1  Part A ................................................................................................................... 77  
10.1.2  Part B ................................................................................................................... 78  
[IP_ADDRESS]  All subjects in SSB – Prior to Flare .......................................................... 78  
[IP_ADDRESS]  After flare .................................................................................................. 79  
[IP_ADDRESS]  Full-dose CZP in Part B ............................................................................ 79  
10.1.3  Part A and Part B full-dose CZP therapy ............................................................. 80  
10.2  Adverse events ............................................................................................................. 82  
10.3  Clinical laboratory evaluations .................................................................................... 90  
10.4  Vital signs, physical findings, and other observations related to safety ...................... 94  
10.4.1  Vital signs ............................................................................................................ 94  
10.4.2  Other safety variables .......................................................................................... 94  
[IP_ADDRESS]  Pregnancy testing ...................................................................................... 94  
[IP_ADDRESS]  Physical assessments ................................................................................. 94  
[IP_ADDRESS]  Tuberculosis assessments .......................................................................... 95  
11 REFERENCES ................................................................................................................ 96  
12 APPENDICES ................................................................................................................. 97  
12.1  Rules for medical resource utilization ......................................................................... 97  
12.1.1  Healthcare Resource Utilization .......................................................................... 97  
12.1.2  Counting rules ...................................................................................................... 97  
[IP_ADDRESS]  In-patient hospi[INVESTIGATOR_94947] ............................... 97  
[IP_ADDRESS]  Healthcare provider consultations not foreseen by [CONTACT_760] ............... 98  
[IP_ADDRESS]  Concomitant medical procedures .............................................................. 98  
12.2  Compliance ratio calculation ....................................................................................... 98  
12.3  SAP Amendment 1 .................................................................................................... 100  REDACTED COPY Prior to Flare
REDACTED COPY Prior to Flare ................................
REDACTED COPY ................................
................................
REDACTED COPY ................................ ................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
dose CZP therapy
REDACTED COPY dose CZP therapy
................................
REDACTED COPY ................................
Clinical laboratory evaluations REDACTED COPY Clinical laboratory evaluations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 71
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 71
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ...
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ...72
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 72
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................ ..........
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ..........
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
dose CZP therapy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose CZP therapy
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
Vital signs, physical findings, and other observations related to safety
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Vital signs, physical findings, and other observations related to safety
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ................................
variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. variables
Pregnancy testing
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pregnancy testing
Physical assessments
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Physical assessments
Tuberculosis assessments
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Tuberculosis assessments
REFERENCES
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. REFERENCES
APPENDICES
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. APPENDICES
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Rules for medical r
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Rules for medical r
12.1.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 12.1.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 12.1.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 12.1.2
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 7 of 149 12.4  SAP Amendment 2 .................................................................................................... 111  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_846695] OF TABLES  
Table 3.1:  BASMI linear definition .................................................................................. 28  
Table 3.2:  Tender and swollen joint scoring ..................................................................... 32  
Table 3.3:  Flare Definition and Time to Flare .................................................................. 41  
Table 3.4:  List of countries in each region ........................................................................ 48  
Table 10.1:  Definitions of Markedly Abnormal Hematology Values ................................. 92  
Table 10.2:  Definitions of Markedly Abnormal Biochemistry Values ............................... 92  
Table 12.1:  Example ........................................................................................................... [ADDRESS_846696] OF ABBREVIATION S 
ADAb  anti-CZP antibody 
ABS  absolute value 
AE adverse event 
ALT alanine aminotransferase 
ANCOVA  analysis of covariance 
AP alkaline phosphatase 
AS ankylosing spondylitis 
ASAS  Assessment of SpondyloArthritis international Society 
ASAS20, 40 Assessment of SpondyloArthritis international Society 
20%, 40% response criteria 
ASAS5/6 ASAS 5 out of 6 response criteria 
ASDAS  Ankylosing Spondylitis Disease Activity Score 
ASDAS -CII Ankylosing Spondylitis Disease Activity Score – Clinically 
Important Improvement  
ASDAS -HD Ankylosing Spondylitis Disease Activity Score – High 
Disease activity 
ASDAS -ID Ankylosing Spondylitis Disease Activity Score – Inactive 
Disease 
ASDAS -LD Ankylosing Spondylitis Disease Activity Score – Low 
Disease activity  
ASDAS -MI Ankylosing Spondylitis Disease Activity Score – Major 
Improvement 
ASDAS -vHD  Ankylosing Spondylitis Disease Activity Score – very High 
Disease activity  
ASQoL Ankylosing Spondylitis Quality of Life 
ASspi[CONTACT_9268]-a Ankylosing Spondylitis spi[INVESTIGATOR_634089]50 Bath Ankylosing Spondylitis Disease Activity Index 50% 
response criteria 
BASFI  Bath Ankylosing Spondylitis Functional Index  
BASMI  Bath Ankylosing Spondylitis Metrology Index  
BLQ  below the limit of quantification 
CD Crohn’s disease  REDACTED COPY Spondylitis Disease Activity Score 
REDACTED COPY Spondylitis Disease Activity Score 
Ankylosing Spondylitis Disease Activity Score 
REDACTED COPY Ankylosing Spondylitis Disease Activity Score 
Ankylosing Spondylitis Disease Activity Score 
REDACTED COPY Ankylosing Spondylitis Disease Activity Score 
DiseaseREDACTED COPY Disease
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nternational Society
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nternational Society
nternational Society 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nternational Society 
Ankylosing Spondylitis Disease Activity Score
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ankylosing Spondylitis Disease Activity Score
Ankylosing Spondylitis Disease Activity Score 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ankylosing Spondylitis Disease Activity Score 
Spondylitis Disease Activity Score 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Spondylitis Disease Activity Score 
Ankylosing Spondylitis Disease Activity Score 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ankylosing Spondylitis Disease Activity Score 
Ankylosing Spondylitis Disease Activity Score 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ankylosing Spondylitis Disease Activity Score 
activity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. activity
Ankylosing Spondylitis Disease 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ankylosing Spondylitis Disease 
Improvement
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Improvement
Ankylosing Spondylitis Disease Activity Score 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ankylosing Spondylitis Disease Activity Score 
Disease activity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Disease activity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI
BASDAI50
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI50
UCB   [ADDRESS_846697] 
MAR missing at random 
MASES Maastricht Ankylosis Spondylitis Enthesitis Score 
MCMC Markov chain Monte Carlo 
MCS Mental Component Summary REDACTED COPY Escape Therapy Set
REDACTED COPY Escape Therapy Set
Full Analysis Set
REDACTED COPY Full Analysis Set
human immunodeficiency virusREDACTED COPY human immunodeficiency virus
human leukocyte antigen B27REDACTED COPY human leukocyte antigen B27
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. EuroQol Health Status Questionnaire 5 dimensions 3 levels
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. EuroQol Health Status Questionnaire 5 dimensions 3 levels
human immunodeficiency virus
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. human immunodeficiency virus
human leukocyte antigen B27
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. human leukocyte antigen B27
High Level Term
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. High Level Term
Health
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Health
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LLOQ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LLOQ
LOCF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LOCF
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 11 of 149 MedDRA® Medical Dictionary for Regulatory Activities 
MH marked abnormal high 
ML marked abnormal low 
MMRM  Mixed model with repeated measures 
mNY  modified [LOCATION_001] 
MRI magnetic resonance imaging 
MSR minimum significant ratio 
N normal 
NA not applicable 
NAb  neutralizing antibody 
nr-axSpA non-radiographic axial spondyloarthritis 
NRI non-responder imputation 
NRS  numeric rating s cale 
NSAID  non-steroidal anti -inflammatory drug  
OLS  Open-Label Set 
PCS Physical Component Summary 
PDS Protocol Deviation Specification 
PhGADA  Physician’s Global Assessment of Disease Activity  
PK pharmacokinetics 
PKSA Pharmacokinetic Set A 
PKSB Pharmacokinetic Set B 
PBO  placebo 
PPS Per Protocol Set 
PR partial remission 
PT preferred term 
PtGADA Patient’s Global Assessment of Disease Activity 
Q2W  every [ADDRESS_846698] deviation  
SDTM  Study Data Tabulation Model  REDACTED COPY Physical Component Summary
REDACTED COPY Physical Component Summary
Protocol Deviation Specification
REDACTED COPY Protocol Deviation Specification
Physician’s Global Assessment of Disease
REDACTED COPY Physician’s Global Assessment of Disease
pharmacokinetics
REDACTED COPY pharmacokinetics
Pharmacokinetic Set AREDACTED COPY Pharmacokinetic Set A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. inflammatory drug
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. inflammatory drug
Physical Component Summary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Physical Component Summary
Protocol Deviation Specification
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Protocol Deviation Specification
Physician’s Global Assessment of Disease
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Physician’s Global Assessment of Disease
pharmacokinetics
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. pharmacokinetics
Pharmacokinetic Set A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic Set A
Pharmacokinetic Set B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic Set B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. placebo
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. placebo
Q4W
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q4W
r
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. r-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -axSpA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA
RCTC
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. RCTC
UCB   [ADDRESS_846699] MedDRA® query  
SOC  system organ class  
SPARCC  Sacroiliac SpondyloArthritis Research Consortium of 
Canada  
SS Safety Set 
SSB Safety Set Part B 
STIR  short-tau-inversion recovery 
TB tuberculosis  
TE treatment -emergent  
TNF  tumor necrosis factor  
[LOCATION_006] [LOCATION_008]  
ULN  upper limit of normal  
VAS  visual analog scale 
VU vertebral units 
WHO-DD World Health Organization Drug Dictionary 
WPS Work Productivity Survey 
REDACTED COPY visual analog scale
REDACTED COPY visual analog scale
vertebral units
REDACTED COPY vertebral units
World Health Organization Drug Dictionary
REDACTED COPY World Health Organization Drug Dictionary
REDACTED COPY Work Productivity Survey
REDACTED COPY Work Productivity Survey
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. World Health Organization Drug Dictionary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. World Health Organization Drug Dictionary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Work Productivity Survey
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Work Productivity Survey
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 13 of 149 1 INTRODUCTION  
This Statistical Analysis Plan (SAP) is designed to support a Clinical Study Report (CSR). This 
SAP complies with International Council for Harmonisation (ICH) guidelines ICH E3 (Structure 
and Content of Clinical Study Reports, 1995), ICH E9 (Statistical Principles for Clinical Trials, 1998) and ICH E10 (Choice of Control Group in Clinical Trials, 2000) and is based upon the following protocol and amendments: 
 Final Protocol dated 27 Mar 2015  
 Protocol Amendment 0.1 (Taiwan) dated 13 Aug 2015 
 Protocol Amendment 0.2 [LOCATION_008] ([LOCATION_006]) dated 31 Jul 2015  
 Protocol Amendment 1 dated 24 Nov 2015 
 Protocol Amendment 1.1 (Taiwan) dated 18 Dec 2015 
 Protocol Amendment 1.2 ([LOCATION_006]) dated 18 Dec 2015 
 Protocol Amendment 2 dated 24 Jan 2018 
 Protocol Amendment 2.1 (Taiwan) dated 27 Feb 18 
 Protocol Amendment 2.2 ([LOCATION_006]) dated 27 Feb 18 
This SAP does not cover the analysis of genetics, genomics and proteomics data. 
2 PROTOCOL SUMMARY  
2.1 Study objectives 
2.1.1  Primary objectives 
The primary objective of the study is to evaluate the percentage of subjects who do not 
experience a flare on certolizumab pegol (CZP) 200mg every 2 weeks (Q2W; full-dose) or 
200mg every 4 weeks (Q4W; half-dose) as compared to placebo (PBO) (CZP withdrawal) during 
Part B. 
2.1.2  Secondary objectives 
The secondary objectives are to: 
 Evaluate the percentage of subjects achieving sustained remission at the end of Part A 
 For subjects randomized into Part B: 
 Evaluate the time to flare and other measures of signs and symptoms 
 Compare the percentage of subjects who do not experience a flare between CZP full-dose 
and half-dose 
 Evaluate the efficacy of re-initiation of treatment with the CZP full-dose in subjects who 
experience a flare following a withdrawal or dose reduction of CZP 
 Assess safety and tolerability of CZP 
 Evaluate inflammatory changes over time as assessed by [CONTACT_9252] (MRI) REDACTED COPY This SAP does not cover the analysis of genetics, genomics and proteomics data.
REDACTED COPY This SAP does not cover the analysis of genetics, genomics and proteomics data.
PROTOCOL SUMMARY
REDACTED COPY PROTOCOL SUMMARY
Primary objectives REDACTED COPY Primary objectives
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This SAP does not cover the analysis of genetics, genomics and proteomics data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This SAP does not cover the analysis of genetics, genomics and proteomics data.
The primary objective of the study is to evaluate the percentage of subjects wh
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The primary objective of the study is to evaluate the percentage of subjects wh
experience a flare on certolizumab pegol (CZP) 200mg every 2 weeks (Q2W; full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experience a flare on certolizumab pegol (CZP) 200mg every 2 weeks (Q2W; full
200mg every 4 weeks (Q4W; half
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 200mg every 4 weeks (Q4W; half -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. - 200mg every 4 weeks (Q4W; half - 200mg every 4 weeks (Q4W; half
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 200mg every 4 weeks (Q4W; half - 200mg every 4 weeks (Q4W; half dose) as compared to placebo (PBO) (CZP withdrawal) during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose) as compared to placebo (PBO) (CZP withdrawal) during 
Secondary objectives
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Secondary objectives
The secondary objectives are to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The secondary objectives are to:
the percentage of subjects achieving sustained remission at the end of Part A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the percentage of subjects achieving sustained remission at the end of Part A
For subjects randomized into Part B:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For subjects randomized into Part B:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Evaluate the time to flare and other measures of signs and symptoms
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Evaluate the time to flare and other measures of signs and symptoms

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Compare the percentage of subjects who do not experience a flare between
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Compare the percentage of subjects who do not experience a flare between
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 14 of 149 2.1.3  Other objectives 
The other objectives are to evaluate: 
 Physical function 
 Signs and symptoms of the disease  Morning stiffness 
 Fatigue 
 Extra-articular manifestations of axial spondyloarthritis (axSpA) 
 Health-related Quality of Life (HRQoL) 
 Work and household productivity 
 Subject's health status 
 Direct medical resource utilization 
 Correlation of fecal calprotectin, serum calprotectin, Inflammatory Bowel Disease 
Questionnaire (IBD-Q) and C-reactive protein (CRP) 
2.1.4  Pharmacokinetic, pharmacogenomic and immunological objectives 
Pharmacokinetic and immunological objectives are to follow the CZP concentrations throughout 
the study, as well as the evolution of immunogenicity, respectively. Other pharmacogenomic 
objectives are: 
 Exploratory biomarkers and cytokines 
 Possible genetics, genomics, and proteomics 
2.2 Study variables 
2.2.1  Efficacy variables 
[IP_ADDRESS] Primary efficacy variable 
The primary efficacy variable is the percentage of subjects in Part B who do not experience a 
flare. 
[IP_ADDRESS] Secondary efficacy variables 
[IP_ADDRESS].1  Secondary efficacy variables for subjects entering Part A 
 Percentage of subjects achieving sustained remission at Week 48 
 Ankylosing Spondylitis Disease Activity Score (ASDAS) disease activity (ASDAS-Inactive 
Disease [ASDAS-ID], ASDAS- Low Disease activity [ASDAS- LD] (formally called ASDAS 
Moderate Diasease), ASDAS-High Disease activity [ASDAS-HD], and ASDAS-very High 
Disease activity [ASDAS-vHD]) and clinical improvement (ASDAS-Clinically Important Improvement [ASDAS-CII], ASDAS-Major Improvement [ASDAS-MI]) at Week 48 
[IP_ADDRESS].2  Secondary efficacy variables for subjects entering Part B 
 Time to flare REDACTED COPY Pharmacokinetic, pharmacogenomic and immunological objectives
REDACTED COPY Pharmacokinetic, pharmacogenomic and immunological objectives
Pharmacokinetic and immunological objectives are to follow the CZP concentrations throughout 
REDACTED COPY Pharmacokinetic and immunological objectives are to follow the CZP concentrations throughout 
the study, as well as the evolution of immunogenicity, respectively. Other pharmacogenomic 
REDACTED COPY the study, as well as the evolution of immunogenicity, respectively. Other pharmacogenomic 
Exploratory biomarkers and cytokines
REDACTED COPY Exploratory biomarkers and cytokines
Possible genetics, genomics, and proteomicsREDACTED COPY Possible genetics, genomics, and proteomics
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Correlation of fecal calprotectin, serum calprotectin, Inflammatory Bowel Disease 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Correlation of fecal calprotectin, serum calprotectin, Inflammatory Bowel Disease 
Pharmacokinetic, pharmacogenomic and immunological objectives
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic, pharmacogenomic and immunological objectives
Pharmacokinetic and immunological objectives are to follow the CZP concentrations throughout 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic and immunological objectives are to follow the CZP concentrations throughout 
the study, as well as the evolution of immunogenicity, respectively. Other pharmacogenomic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the study, as well as the evolution of immunogenicity, respectively. Other pharmacogenomic 
Possible genetics, genomics, and proteomics
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Possible genetics, genomics, and proteomics
Study variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Study variables
Efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Efficacy variables
Primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Primary efficacy variable
The primary efficacy variable is the percentage of subjects in Part B who do not experience a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The primary efficacy variable is the percentage of subjects in Part B who do not experience a 
Secondary efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Secondary efficacy variables
Secondary efficacy variables for subjects entering Part A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Secondary efficacy variables for subjects entering Part A
Percentage of subjects achieving sustained remission at Week 48
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Percentage of subjects achieving sustained remission at Week 48
Ankylosing Spondylitis Disease Activity Score (ASDAS) disease activity (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ankylosing Spondylitis Disease Activity Score (ASDAS) disease activity (ASDAS
Disease 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Disease 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 15 of 149  ASDAS disease activity (ASDAS-ID, ASDAS- LD, ASDAS-HD, and ASDAS-vHD) and 
clinical improvement (ASDAS-CII, ASDAS-MI) at Week 96 
 Assessment of SpondyloArthritis International Society (ASAS) response criteria ASAS20, 
ASAS40, ASAS5/6, and ASAS partial remission ( PR) response at Week 96 
 Change from Part A Baseline in ASDAS, Bath Ankylosing Spondylitis Disease Activity 
Index  (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Bath 
Ankylosing Spondylitis Metrology Index (BASMI) at Week 96 
 BASDAI50 response at Week 96 
 Change from Part A Baseline in Sacroiliac Joint (SIJ) Sacroiliac SpondyloArthritis Research Consortium of Canada (SPARCC) and spi[INVESTIGATOR_634090] (ASspi[CONTACT_9268]-a) in the Berlin modification scores at Week 96 
[IP_ADDRESS].3  Secondary efficacy variables for subjects who experience a flare in 
Part B 
These variables will be evaluated at Escape Week 12.  
 ASDAS disease activity (ASDAS-ID, ASDAS- LD, ASDAS-HD, and ASDAS-vHD) and 
clinical improvement (ASDAS-CII, ASDAS- MI) 
 ASAS20, ASAS40, ASAS5/6, and ASAS PR response 
 Change from Part B Baseline in ASDAS, BASDAI, BASFI and BASMI 
 Change from Part B Baseline in SIJ SPARCC and spi[INVESTIGATOR_18241]-a in Berlin modification 
scores 
[IP_ADDRESS] Other efficacy variables 
[IP_ADDRESS].1  Other efficacy variables for subjects entering Part A 
The following variables will be evaluated at all scheduled study visits where the assessment is 
performed through Week 48. 
 ASAS20, ASAS40, ASAS5/6, and ASAS PR response 
 BASDAI50 response 
 Change from Part A Baseline in ASDAS, BASDAI and BASMI 
 ASDAS disease activity (ASDAS-ID, ASDAS- LD, ASDAS-HD, and ASDAS-vHD) and 
clinical improvement (ASDAS-CII, ASDAS- MI)  
 Change f rom Part A Baseline in SIJ SPARCC and spi[INVESTIGATOR_18241]-a in the Berlin 
modification scores 
 Change from Part A Baseline in all individual ASAS core components, ie:  Patient’s Global Assessment of Disease Activity (PtGADA) 
 Total spi[INVESTIGATOR_18172] (Numeric Rating Scale [NRS]) 
 BASFI REDACTED COPY ASAS20, ASAS40, ASAS5/6, and ASAS PR response
REDACTED COPY ASAS20, ASAS40, ASAS5/6, and ASAS PR response
in ASDAS, BASDAI, BASFI and BASMI
REDACTED COPY in ASDAS, BASDAI, BASFI and BASMI
in SIJ SPARCC and spi[INVESTIGATOR_634091]. Sacroiliac SpondyloArthritis Research 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Sacroiliac SpondyloArthritis Research 
ankylosing spondylitis spi[INVESTIGATOR_634092]. ankylosing spondylitis spi[INVESTIGATOR_634093] a flare in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Secondary efficacy variables for subjects who experience a flare in 
, ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , ASDAS -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -HD, and ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. HD, and ASDAS
ASAS20, ASAS40, ASAS5/6, and ASAS PR response
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS20, ASAS40, ASAS5/6, and ASAS PR response
in ASDAS, BASDAI, BASFI and BASMI
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in ASDAS, BASDAI, BASFI and BASMI
in SIJ SPARCC and spi[INVESTIGATOR_634094]. in SIJ SPARCC and spi[INVESTIGATOR_634095]. Other efficacy variables
Other efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Other efficacy variable
The following variables will be evaluated at all scheduled study visits where the assessment is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following variables will be evaluated at all scheduled study visits where the assessment is 
gh Week 48.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. gh Week 48.
ASAS20, ASAS40, ASAS5/6, and ASAS PR response
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS20, ASAS40, ASAS5/6, and ASAS PR response
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI50 response
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI50 response
Change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline
ASDAS disease activity (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS disease activity (ASDAS
clinical improvement (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. clinical improvement (ASDAS
Change f
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change f
modification scores
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. modification scores

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 16 of 149  Average of Questions 5 and 6 of the BASDAI concerning morning stiffness 
 Change from Part A Baseline in nocturnal spi[INVESTIGATOR_18172] (NRS) 
 Change from Part A Baseline in spi[INVESTIGATOR_18171], as assessed by [CONTACT_634180] 
 Change from Part A Baseline in spi[INVESTIGATOR_18171], as assessed by [CONTACT_634181] 
 Change from Part A Baseline in Physician’s Global Assessment of Disease Activity 
(PhGADA) 
 Change from Part A Baseline in Fatigue (NRS) (from BASDAI) 
 Change from Part A Baseline in CRP 
 Change from Part A Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) 
 Change from Part A Baseline in Work Productivity Survey (WPS) 
 Health status as assessed by [CONTACT_634182] 5 dimensions 3 levels (EQ-5D- 3L): domains, visual analog scale (VAS) actual score and change from Part A 
Baseline in VAS score 
 Change from Part A Baseline in Maastricht Ankylosis Spondylitis Enthesitis Score (MASES) 
 Change from Part A Baseline in swollen and tender joint counts (44 joint count) 
 Number of uveitis flares 
 Number of inflammatory bowel disease (IBD) exacerbations 
 Change from Part A Baseline in fecal calprotectin 
 Change from Part A Baseline in serum calprotectin 
 Change from Part A Baseline in the IBD-Q 
 Correlation between fecal calprotectin, serum calprotectin, IBD-Q and CRP 
 Number of psoriasis exacerbations (in subjects with concurrent psoriasis) 
 Change from Part A Baseline in all Short-Form 36-Item Health Survey (SF-36) domains, SF-36 Physical Component Summary (PCS), and SF-36 Mental Component Summary 
(MCS) 
 Resources utilization: concomitant medical procedures, healthcare provider consultations not 
foreseen by [CONTACT_760], in-patient hospi[INVESTIGATOR_306134] 
[IP_ADDRESS].[ADDRESS_846700] administration of study medication in Part B. 
 ASAS20, ASAS40, ASAS5/6, and ASAS PR response using Part A Baseline as a refere nce 
 BASDAI50 response using Part A Baseline as a reference REDACTED COPY in swollen and tender joint counts (44 join
REDACTED COPY in swollen and tender joint counts (44 join
Number of inflammatory bowel disease (IBD) exacerbations
REDACTED COPY Number of inflammatory bowel disease (IBD) exacerbations
in fecal calprotectin
REDACTED COPY in fecal calprotectin
in serum calprotectinREDACTED COPY in serum calprotectin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in Ankylosing Spondylitis Quality of Life (ASQoL)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in Ankylosing Spondylitis Quality of Life (ASQoL)
Health status as assessed by [CONTACT_634182] 5 dimensions 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Health status as assessed by [CONTACT_634182] 5 dimensions 
): domains, visual analog scale (VAS) actual score and change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ): domains, visual analog scale (VAS) actual score and change from 
in Maastricht Ankylosis Spondylitis Enthesitis Score (MASES)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in Maastricht Ankylosis Spondylitis Enthesitis Score (MASES)
in swollen and tender joint counts (44 join
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in swollen and tender joint counts (44 join
Number of inflammatory bowel disease (IBD) exacerbations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number of inflammatory bowel disease (IBD) exacerbations
in fecal calprotectin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in fecal calprotectin
in serum calprotectin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in serum calprotectin
in the IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in the IBD
l calprotectin, serum calprotectin, IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. l calprotectin, serum calprotectin, IBD
Number of psoriasis exacerbations (in subjects with concurrent psoriasis)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number of psoriasis exacerbations (in subjects with concurrent psoriasis)
Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline
36 Physical Component Summary (PCS), and SF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 Physical Component Summary (PCS), and SF
Resources utilization: concomitant medical procedures, healthcare provider consultations not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Resources utilization: concomitant medical procedures, healthcare provider consultations not 
foreseen by [CONTACT_760], 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. foreseen by [CONTACT_760], 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS].2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS].[ADDRESS_846701] administration of study medication in Part B.
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 17 of 149  ASDAS disease activity (ASDAS-ID, ASDAS- LD, ASDAS-HD, and ASDAS-vHD) and 
ASDAS clinical improvement (ASDAS-CII, ASDAS- MI) using Part A Baseline as a 
reference 
 Change from Part A Baseline in ASDAS, BASDAI and BASMI 
 Change from Part B Baseline in ASDAS, BASDAI, BASFI and BASMI 
 Change from Part A Baseline and change from Part B Baseline in all individual ASAS core 
components, ie: 
 PtGADA 
 Total spi[INVESTIGATOR_18172] (NRS)  
 BASFI 
 Average of Questions 5 and 6 of the BASDAI concerning morning stiffness 
 Change from Part A Baseline and change from Part B Baseline in nocturnal spi[INVESTIGATOR_18172] 
(NRS)  
 Change from Part A Baseline and change from Part B Baseline in spi[INVESTIGATOR_18171], as assessed 
by [CONTACT_634180] 
 Change from Part A Baseline and change from Part B Baseline in spi[INVESTIGATOR_18171], as assessed by [CONTACT_634181] 
 Change from Part A Baseline and change from Part B Baseline in PhGADA 
 Change from Part A Baseline and change from Part B Baseline in Fatigue (NRS) (from BASDAI) 
 Change from Part A Baseline and change from Part B Baseline in CRP 
 Change from Part A Baseline and change from Part B Baseline in ASQoL 
 Change from Part A Baseline in SIJ SPARCC and spi[INVESTIGATOR_18241]-a in the Berlin 
modification scores 
 Change from Part B Baseline in SIJ SPARCC and spi[INVESTIGATOR_18241]-a in the Berlin 
modification scores 
 Change from Part A Baseline and change from Part B Baseline in WPS 
 Health status as assessed by [CONTACT_20367]-5D- 3L: domains, VAS actual score, change from Part A 
Baseline in VAS score and change from Part B Baseline in VAS score 
 Change from Part A Baseline and change from Part B Baseline in MASES 
 Change from Part A Baseline and change from Part B Baseline in swollen and tender joint counts (44 joint count) 
 Number of uveitis flares 
 Number of IBD exacerbations  
 Change from Part A Baseline and change from Part B Baseline in fecal calprotectin  REDACTED COPY hange from 
REDACTED COPY hange from Part B Baseline in spi[INVESTIGATOR_18171], as assessed 
REDACTED COPY Part B Baseline in spi[INVESTIGATOR_18171], as assessed 
hange from 
REDACTED COPY hange from 
c
REDACTED COPY change from 
REDACTED COPY hange from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in all individual ASAS core 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in all individual ASAS core 
d 6 of the BASDAI concerning morning stiffness
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. d 6 of the BASDAI concerning morning stiffness
in nocturnal spi[INVESTIGATOR_634096]. in nocturnal spi[INVESTIGATOR_634097] B Baseline in spi[INVESTIGATOR_18171], as assessed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B Baseline in spi[INVESTIGATOR_18171], as assessed 
Part B Baseline in spi[INVESTIGATOR_18171], as assessed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B Baseline in spi[INVESTIGATOR_18171], as assessed 
hange from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hange from Part B Baseline in PhGADA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B Baseline in PhGADA
hange from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hange from 
and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hange from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and 
Part A Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline 
Part B Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B Baseline 
modification scores
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. modification scores
Change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Health status as assessed by [CONTACT_122268]. Health status as assessed by [CONTACT_634183]. Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eline
Change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 18 of 149  Change from Part A Baseline and change from Part B Baseline in serum calprotectin 
 Change from Part A Baseline and change from Part B Baseline in the IBD-Q 
 Number of psoriasis exacerbations (in subjects with concurrent psoriasis) 
 Correlation between fecal calprotectin, serum calprotectin, IBD-Q and CRP 
 Number of psoriasis exacerbations (in subjects with concurrent psoriasis) 
 Change from Part A Baseline and change from Part B Baseline in all SF-36 domains, SF-36 
PCS, and SF-36 MCS 
 Resources utilization: concomitant medical procedures, healthcare provider consultations not foreseen by [CONTACT_760], in-patient hospi[INVESTIGATOR_634098] d emergency room visits 
[IP_ADDRESS].3  Other efficacy variables for subjects who experience a flare in Part B 
The following variables will be evaluated at all scheduled study visits for subjects experiencing a flare in Part B where the assessment is performed following escape week 0. 
 ASDAS disease activity (ASDAS-ID, ASDAS- LD, ASDAS-HD, and ASDAS-vHD) 
andASDAS clinical improvement (ASDAS-CII, ASDAS- MI) using Flare Baseline as 
reference 
 ASAS20, ASAS40, ASAS5/6, and ASAS PR response using Flare Baseline as reference 
 Change from Part B Baseline in ASDAS, BASDAI, BASFI and BASMI 
 Change from Flare Baseline in ASDAS, BASDAI, BASFI and BASMI 
 Change from Part A Baseline, change from Part B Baseline and change from Flare Baseline 
in all individual ASAS core components, ie: 
 PtGADA 
 Total spi[INVESTIGATOR_18172] (NRS) 
 BASFI 
 Average of Questions 5 and 6 of the BASDAI concerning morning stiffness 
 Change from Part B Baseline and change from Flare Baseline in nocturnal spi[INVESTIGATOR_18172] (NRS) 
 Change from Part B Baseline and change from Flare Baseline in spi[INVESTIGATOR_18171], as assessed 
by [CONTACT_634180] 
 Change from Part B Baseline and change from Flare Baseline in spi[INVESTIGATOR_18171], as assessed 
by [CONTACT_634181] 
 Change from Part B Baseline and change from Flare Baseline in PhGADA  
 Change from Part B Baseline and change from Flare Baseline in Fatigue (NRS) (from 
BASDAI) 
 BASDAI50 response using Flare Baseline as reference  
 Change from Part B Baseline and change from Flare Baseline in CRP REDACTED COPY ASAS20, ASAS40, ASAS5/6, and ASAS PR response
REDACTED COPY ASAS20, ASAS40, ASAS5/6, and ASAS PR response
in ASDAS, BASDAI
REDACTED COPY in ASDAS, BASDAI
in ASDAS, BASDAI
REDACTED COPY in ASDAS, BASDAI
hange from 
REDACTED COPY hange from 
in all individual ASAS core components REDACTED COPY in all individual ASAS core components
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 domains, SF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 domains, SF -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -36 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 
Resources utilization: concomitant medical procedures, healthcare provider consultations not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Resources utilization: concomitant medical procedures, healthcare provider consultations not 
emergency room visits
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emergency room visits
who experience a flare in Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. who experience a flare in Part B
The following variables will be evaluated at all scheduled study visits for subjects experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following variables will be evaluated at all scheduled study visits for subjects experiencing a 
scape week 0.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scape week 0.
HD, and ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. HD, and ASDAS
MI) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MI) using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using 
ASAS20, ASAS40, ASAS5/6, and ASAS PR response
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS20, ASAS40, ASAS5/6, and ASAS PR response using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using 
in ASDAS, BASDAI
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in ASDAS, BASDAI , BASFI
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , BASFI
in ASDAS, BASDAI
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in ASDAS, BASDAI
hange from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hange from Part B Baseline and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B Baseline and 
in all individual ASAS core components
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in all individual ASAS core components , ie:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , ie:
)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. )
Average of Questions [ADDRESS_846702] expansion

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from Part B Baseline and c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from Part B Baseline and c

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 19 of 149  Change from Part B Baseline and change from Flare Baseline in ASQoL 
 Change from Part A Baseline in SIJ SPARCC and Spi[INVESTIGATOR_18241]-a in Berlin modification 
scores 
 Change from Part B Baseline in SIJ SPARCC and Spi[INVESTIGATOR_18241]-a in Berlin modification 
scores 
 Change from Flare Baseline in SIJ SPARCC and Spi[INVESTIGATOR_18241]-a in Berlin modification 
scores 
 Change from Part B Baseline and change from Flare Baseline in WPS 
 Health status as assessed by [CONTACT_20367]-5D- 3L: domains, VAS actual score, and change from 
Part B Baseline and change from Flare Baseline  in VAS score 
 Change from Part B Baseline and change from Flare Baseline in MASES 
 Number of uveitis flares 
 Number of IBD exacerbations   
 Change from Part B Baseline and change from Flare Baseline in fecal calprotectin 
 Change from Part B Baseline and change from Flare Baseline in serum calprotectin 
 Change from Part B Baseline and change from Flare Baseline in the IBD-Q 
 Correlation between fecal calprotectin, serum calprotectin, IBD-Q and CRP 
 Number of psoriasis exacerbations (in subjects with concurrent psoriasis) 
 Change from Part B Baseline and change from Flare Baseline in all SF-36 domains, SF-36 
PCS, and SF-36 MCS  
 Resources utilization: concomitant medical procedures, healthcare provider consultations not foreseen by [CONTACT_760], in-patient hospi[INVESTIGATOR_306134] 
2.2.2  Pharmacokinetic, pharmacogenomic and immunogenicity variables 
[IP_ADDRESS] Pharmacokinetic variables 
Plasma concentrations of CZP will be measured at Part A Baseline and subsequent time points as described in Table 5.1 and Table 5.2 of the protocol only for subjects randomized into Part B (see Section 3.10) . These plasma samples may be used additionally for analyses of CZP and its 
constituent moieties using alternative methods.  
[IP_ADDRESS] Biomarkers 
Any a nalysis for the biomarker will be described in a separate document.  
[IP_ADDRESS] Pharmacogenomic variables 
Any a nalysis for the pharmacogenomic will be described in a separate document. 
[IP_ADDRESS] Immunogenicity variables 
Anti-CZP antibody (ADAb) levels will be assessed at Part A Baseline and subsequent time 
points as described in the protocol. REDACTED COPY Flare Baseline
REDACTED COPY Flare Baseline
hange from 
REDACTED COPY hange from Flare Baseline
REDACTED COPY Flare Baseline
, serum calprotectin,
REDACTED COPY , serum calprotectin,
Number of psoriasis exacerbations (in subjects with concurre
REDACTED COPY Number of psoriasis exacerbations (in subjects with concurre
Part B Baseline and REDACTED COPY Part B Baseline and cREDACTED COPY change from REDACTED COPY hange from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a in Berlin modification 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a in Berlin modification 
: domains, VAS actual score, and change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. : domains, VAS actual score, and change from 
in MASES
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in MASES
Flare Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Flare Baseline in fecal calprotectin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in fecal calprotectin
Flare Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Flare Baseline
Flare Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Flare Baseline
, serum calprotectin,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , serum calprotectin,
Number of psoriasis exacerbations (in subjects with concurre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number of psoriasis exacerbations (in subjects with concurre
hange from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hange from 
Resources utilization: concomitant medical procedures, healthcare provider consultations not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Resources utilization: concomitant medical procedures, healthcare provider consultations not 
in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -patient 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. patient 
Pharmacokinetic
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic
Pharmacokinetic variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic variables
Plasma concentrations of CZP will be measured at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Plasma concentrations of CZP will be measured at 
described in Table 5.1 and Table 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. described in Table 5.1 and Table 
(see Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (see Section 3.10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.10)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ). These plasma samples may be used additionally for analyses of CZP and i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . These plasma samples may be used additionally for analyses of CZP and i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. constituent moieties using alternative methods. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. constituent moieties using alternative methods. 
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
Any a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Any a nalysis for the biomarker will be described in a separate document. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nalysis for the biomarker will be described in a separate document. 
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 20 of 149 Determination of ADAb will be done using a validated screening, confirmation, and titration 
ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) 
assay. The NAb will be not part of the CSR. The immunogenicity samples will be processed 
according to dedicated Bioanalytical Analysis plans. 
2.2.3  Safety variables 
Safety variables to be assessed are adverse events (AEs), physical examination, vital signs, chest 
x-ray, interferon-gamma release assay (IGRA) test for tuberculosis, and measurements of laboratory parameters (hematology, biochemistry, and urinalysis). The safety variables will be stated or listed as described within the appropriate Sections. 
2.[ADDRESS_846703] 
Study AS0005 is a multicenter, open-label (Part A) followed by a randomized, double-blind, 
parallel-group, PBO -controlled (Part B) clinical study to evaluate the efficacy, safety, 
pharmacokinetics (PK), and immunogenicity of CZP in adult subjects with axSpA in sustained 
remission who continued either on full-dose treatment (CZP 200mg Q2W), on a dose reduction 
(CZP 200mg Q4W), or withdrawal of CZP treatment. The study includes 2 parts, A and B, as 
follows. 
2.3.1  Part A 
Part A consists of two study periods.  
Period 1 (Screening Period): Up to 5 Weeks before Baseline 
Period 2 (Open-Label Period): Week 0 (Baseline) to Week [ADDRESS_846704] not achieved sustained remission at the end of Period 2 (Week 48) will be 
discontinued from the study and treated at the discretion of their physician. Those subjects who 
discontinue prematurely from the study for any reason will be treated at the discretion of their 
physician. 
2.3.2 Part B 
Period 3 (Double-Blind Period): Week [ADDRESS_846705] meet the sustained remission criteria in order to be randomized to Part B. These 
subjects in sustained remission will be randomized in a 1:1:1 ratio to one of the following 
treatment arms: 
 CZP administered at a dose of 200mg Q2W (full-dose) 
 CZP administered at a dose of 200mg Q4W (half-dose) 
 PBO  
All subjects who discontinue prematurely from the study for any reason during the Double-Blind 
Period will be treated at the discretion of the Investigator. 
The final study assessments will be performed at Week 96. Subjects experiencing a flare during 
the Double-Blind Period will receive escape-treatment as defined in Section  2.3.3.  REDACTED COPY (Screening Period): Up to 5 Weeks before Baseline
REDACTED COPY (Screening Period): Up to 5 Weeks before Baseline
Label Period): Week 0 (Baseline) to Week 48
REDACTED COPY Label Period): Week 0 (Baseline) to Week 48
cts will receive 3 loading doses of CZP 400mg at Weeks 0, 2, and 
REDACTED COPY cts will receive 3 loading doses of CZP 400mg at Weeks 0, 2, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Safety variables to be assessed are adverse events (AEs), physical examination, vital signs, chest 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Safety variables to be assessed are adverse events (AEs), physical examination, vital signs, chest 
safety variables will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. safety variables will be 
label (Part A) followed by a randomized, double
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. label (Part A) followed by a randomized, double
udy to evaluate the efficacy, safety, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. udy to evaluate the efficacy, safety, 
pharmacokinetics (PK), and immunogenicity of CZP in adult subjects with axSpA in sustained 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. pharmacokinetics (PK), and immunogenicity of CZP in adult subjects with axSpA in sustained 
dose treatment (CZP 200mg Q2W), on a dose reduction 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose treatment (CZP 200mg Q2W), on a dose reduction 
P treatment. The study includes 2 parts, A and B, as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. P treatment. The study includes 2 parts, A and B, as 
(Screening Period): Up to 5 Weeks before Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (Screening Period): Up to 5 Weeks before Baseline
Label Period): Week 0 (Baseline) to Week 48
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Label Period): Week 0 (Baseline) to Week [ADDRESS_846706] not achieved sustained remission at the end of Period 2 (Week 48) will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All subjects who have not achieved sustained remission at the end of Period 2 (Week 48) will be 
discontinued from the study and treated at the discretion of their
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. discontinued from the study and treated at the discretion of their
discontinue prematurely from the study for any reason will be treated at the discretion of their 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. discontinue prematurely from the study for any reason will be treated at the discretion of their 
Blind Period): Week 48 to Week 96, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Blind Period): Week [ADDRESS_846707] meet the sustained remission 
subjects in sustained remission will be randomized in a 1:1:1 ratio to one of the following 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects in sustained remission will be randomized in a 1:1:1 ratio to one of the following 
treatment arms:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment arms:
CZP administered at a dose of 200mg Q2W (full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP administered at a dose of 200mg Q2W (full

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP administered at a dose of 200mg Q4W (hal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP administered at a dose of 200mg Q4W (hal

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 21 of 149 Period 4 (Safety Follow Up Period): [ADDRESS_846708] a Safety Follow Up 
(SFU) Visit [ADDRESS_846709] (escape treatment). This visit will take place [ADDRESS_846710] assessment that resulted in meeting the flare criteria; or, at the discretion of the Investigator, at an earlier time point. As the start of escape treatment may vary from subject to subject, it will be referred to as “Escape Week 0”. Subjects will remain on the escape treatment 
for at least 12 weeks or until Week 96 of the regular visit schedule as described in Table 5.1 in 
the protocol, whichever is longer. 
The assessment-schedule for subjects experiencing a flare in Part B will start 2 weeks after the 
flare condition is fulfilled; or, at the discretion of the Investigator, at an earlier time point and 
will end 2 weeks before Week 96 after Baseline of the regular assessment schedule. If the flare occurs late in Part B (at or after Week 82), the subject must receive the escape treatment for 12 weeks (eg, starting at Week 84 until Week 96). The final assessments at study end (as laid down for Week 96) must be performed [ADDRESS_846711] study dose administration accordingly. 
Subjects receiving PBO  or half-dose CZP (200mg Q4W) who experience a flare during the 
Double-Blind Period will escape to full-dose treatment (CZP 200mg Q2W) until the end of that 
period or for at least 12 weeks, whichever is longer. The escapers need to come back to the site 
at the time point of the escape (Week 0), 2 and 4 weeks after escape (Weeks 2 and 4), and every 
12 weeks thereafter until the originally scheduled Week 96.  
Subjects escapi[INVESTIGATOR_634099]-dose CZP (200mg Q2W) will receive a loading dose of CZP 
(400mg Q2W) at the 3 consecutive visits after the flare. Subjects escapi[INVESTIGATOR_634100]-dose CZP to full-dose CZP will receive CZP 200mg Q2W at the 3 consecutive visits after the flare. In order to maintain the blind, subjects escapi[INVESTIGATOR_634100]-dose CZP to full-dose CZP will receive a PBO-
administration and a CZP 200mg administration at these 3 visits.  
Subjects randomized to the CZP full-dose (200mg Q2W) treatment during the Double-Blind 
Period who qualify for escape will remain on their current treatment allocation. As with subjects 
escapi[INVESTIGATOR_634100]-dose CZP to full-dose CZP, these subjects will receive a PBO and C ZP 
200mg injection at the [ADDRESS_846712], there is a planned duration of up to 109 weeks, as follows: 
 Up to 5 weeks of Screening Period 
 48 weeks in the Open-Label Period 
 48 weeks in the Double-Blind Period  REDACTED COPY weeks (eg, starting at Week 84 until Week 96). The final 
REDACTED COPY weeks (eg, starting at Week 84 until Week 96). The final 
for Week 96) must be performed [ADDRESS_846713] study dose administration accordingly.
REDACTED COPY for Week 96) must be performed [ADDRESS_846714] study dose administration accordingly.
dose CZP (200mg Q4W) who experience a flare during the 
REDACTED COPY dose CZP (200mg Q4W) who experience a flare during the 
dose treatment (CZP 200mg Q2W) until the end of that 
REDACTED COPY dose treatment (CZP 200mg Q2W) until the end of that 
period or for at least [ADDRESS_846715] 12 weeks, whichever is longer. The escapers need to come back to the site 
of the escape (Week 0), 2 and 4 weeks after escape (Weeks 2 and 4), and every 
REDACTED COPY of the escape (Week 0), 2 and 4 weeks after escape (Weeks 2 and 4), and every 
thereafter until the originally scheduled Week 96. REDACTED COPY thereafter until the originally scheduled Week 96. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. planned dose of investigational product (escape treatment). This visit will take place [ADDRESS_846716] (escape treatment). This visit will take place [ADDRESS_846717], it will be referred to as “Escape Week 0”. Subjects will remain on the escape treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subject, it will be referred to as “Escape Week 0”. Subjects will remain on the escape treatment 
96 of the regular visit schedule as described in Table 5.1 in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 96 of the regular visit schedule as described in Table 5.1 in 
schedule for subjects experiencing a flare in Part B will start 2 weeks after the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. schedule for subjects experiencing a flare in Part B will start 2 weeks after the 
Investigator, at an earlier time point
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Investigator, at an earlier time point
will end 2 weeks before Week 96 after Baseline of the regular assessment schedule. If the flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will end 2 weeks before Week 96 after Baseline of the regular assessment schedule. If the flare 
occurs late in Part B (at or after Week 82), the subject must receive the escape treatment for 12 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. occurs late in Part B (at or after Week 82), the subject must receive the escape treatment for 12 
assessments at study end (as laid down 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessments at study end (as laid down 
for Week 96) must be performed [ADDRESS_846718] study dose administration accordingly.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for Week 96) must be performed [ADDRESS_846719] study dose administration accordingly.
dose CZP (200mg Q4W) who experience a flare during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose CZP (200mg Q4W) who experience a flare during the 
dose treatment (CZP 200mg Q2W) until the end of that 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose treatment (CZP 200mg Q2W) until the end of that 
period or for at least [ADDRESS_846720] 12 weeks, whichever is longer. The escapers need to come back to the site 
of the escape (Week 0), 2 and 4 weeks after escape (Weeks 2 and 4), and every 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of the escape (Week 0), 2 and 4 weeks after escape (Weeks 2 and 4), and every 
thereafter until the originally scheduled Week 96. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. thereafter until the originally scheduled Week 96. 
dose CZP (200mg Q2W) will receive a loading dose of CZP 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose CZP (200mg Q2W) will receive a loading dose of CZP 
(400mg Q2W) at the 3 consecutive visits after the flare. Subjects escapi[INVESTIGATOR_634101]. (400mg Q2W) at the 3 consecutive visits after the flare. Subjects escapi[INVESTIGATOR_634102] 200mg Q2W at the 3 consecutive visits after the flare. In order to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ill receive CZP 200mg Q2W at the 3 consecutive visits after the flare. In order to 
maintain the blind, subjects escapi[INVESTIGATOR_634101]. maintain the blind, subjects escapi[INVESTIGATOR_634103] a CZP 200mg administration at these 3 visits. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. administration and a CZP 200mg administration at these 3 visits. 
mized to the CZP full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mized to the CZP full
Period who qualify for escape will remain on their current treatment allocation. As with subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Period who qualify for escape will remain on their current treatment allocation. As with subjects 
escapi[INVESTIGATOR_634101]. escapi[INVESTIGATOR_634101]. -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. - escapi[INVESTIGATOR_634100] - escapi[INVESTIGATOR_634101]. escapi[INVESTIGATOR_634100] - escapi[INVESTIGATOR_634104]. dose CZP to full
200mg injection at the 3 visits after the flare in order to maintain the blind to the randomized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 200mg injection at the 3 visits after the flare in order to maintain the blind to the randomized 
treatment. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment. 
After the loading dose, all escaped subjects will continue full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. After the loading dose, all escaped subjects will continue full
label fashion.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. label fashion.
2.3.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2.3.4
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 22 of 149  An SFU Visit [ADDRESS_846721] dose administration (Period 4). 
Of note, the last dosing in the Double-Blind Period occurs at Week [ADDRESS_846722] visit (SFU) of the last subject in the study. 
It is planned to enroll the subjects at approximately 95 sites. 
The study will be conducted in North America, Western Europe, Eastern Europe and Asia. 
2.4 Determination of sample size 
It is anticipated that approximately 210 subjects will be randomized in a 1:1:1 ratio to the 
CZP 200mg Q2W, CZP 200mg Q4W, and PBO treatment groups. The primary efficacy analysis 
is based on the proportion of subjects who do not experience a flare during Part B of the study. 
The proportion of subjects who do not experience a flare during Part B is assumed to be 80%, 
75%, and 45% for the CZP 200mg Q2W, CZP 200mg Q4W, and PBO treatment groups, respectively. Given these assumptions, a sample size of 70 subjects per group provides 98% 
power to detect a significant difference between the CZP 200mg Q2W dose and PBO and 94% 
power to detect a significant difference between the CZP 200mg Q4W dose and PBO using a 2-sided significance level of 0.05.  
Given that subjects enter Part B only if they have achieved sustained remission in Part A, it is 
necessary to estimate the number of subjects needed to enroll in Part A. It is assumed that approximately 28% of subjects enrolled in Part A will achieve sustained remission and qualify 
for Part B. This means that about [ADDRESS_846723] 210 
subjects who are randomized into Part B.  
3 DATA ANALYSIS CONSID ERATIONS  
3.1 General presentation of summaries and analyses 
Statistical analysis and generation of tables, figures, and listings will be performed using SAS® 
Version 9.3 or higher. 
Frequency tables (frequency counts and percentages) will be presented for categorical data. If 
there are missing values, either a missing category will be included in the display or the number 
of non-missing results will be used for calculations. REDACTED COPY It is planned to enroll the subjects at approximately 95 sites.
REDACTED COPY It is planned to enroll the subjects at approximately 95 sites.
The study will be conducted in North America, Western Europe, Eastern Europe and Asia.
REDACTED COPY The study will be conducted in North America, Western Europe, Eastern Europe and Asia.
on of sample size
REDACTED COPY on of sample size
It is anticipated that approximately 210 subjects will be randomized in a 1:1:1 ratio to the 
REDACTED COPY It is anticipated that approximately 210 subjects will be randomized in a 1:1:[ADDRESS_846724] visit (SFU) of the last subject in the study.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of the study is defined as the date of the last visit (SFU) of the last subject in the study.
It is planned to enroll the subjects at approximately 95 sites.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. It is planned to enroll the subjects at approximately 95 sites.
The study will be conducted in North America, Western Europe, Eastern Europe and Asia.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The study will be conducted in North America, Western Europe, Eastern Europe and Asia.
on of sample size
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. on of sample size
It is anticipated that approximately 210 subjects will be randomized in a 1:1:1 ratio to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. It is anticipated that approximately 210 subjects will be randomized in a 1:1:1 ratio to the 
200mg Q2W, CZP 200mg Q4W, and PBO treatment groups. The primary efficacy analysis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 200mg Q2W, CZP 200mg Q4W, and PBO treatment groups. The primary efficacy analysis 
is based on the proportion of subjects who do not experienc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is based on the proportion of subjects who do not experienc
The proportion of subjects who do not experience a flare during Part B is assumed to be 80%, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The proportion of subjects who do not experience a flare during Part B is assumed to be 80%, 
75%, and 45% for the CZP 200mg Q2W, CZP 200mg Q4W, and PBO treatment groups, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 75%, and 45% for the CZP 200mg Q2W, CZP 200mg Q4W, and PBO treatment groups, 
respectively. Given these assumptions, a sample 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. respectively. Given these assumptions, a sample 
power to detect a significant difference between the CZP 200mg Q2W dose and PBO and 94% 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. power to detect a significant difference between the CZP 200mg Q2W dose and PBO and 94% 
power to detect a significant difference between the CZP 200mg Q4W dose and PBO using a [ADDRESS_846725] achieved sustained remission in Part A, it is 
necessary to estimate the number of subjects needed to enroll in Part A. It is assumed that 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. necessary to estimate the number of subjects needed to enroll in Part A. It is assumed that 
approximately 28% of subjects enrolled in Part A will achieve susta
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. approximately 28% of subjects enrolled in Part A will achieve susta
for Part B. This means that about [ADDRESS_846726] 210 
subjects who are randomized into Part B. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects who are randomized into Part B. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.1
UCB   07 May 19  
Statistical Analysis Plan  Certolizumab Pegol  AS0005  
   
Confidential  Page 23 of 149 In case imputation was performed , summary statistics will not utilize the ‘n’ (number of 
available measurements).  In addition, for the primary variables and selected outputs  the 95% 
confidence interval (CI) based on the Exact Binomial distribution will be presente d. 
In general percentages will be calculated based on the utilized analysis set, however in case only 
subsets are affected, the N of the subset will  be used as denominator.  
Unless otherwise noted, all percentages will be displayed to [ADDRESS_846727]. No percentage will 
be displayed for zero counts, and no decimal will be presented when the percentage is 100%.  
Continuous variables will be summarized wi th n (number of available measurements), arithmetic 
mean, standard deviation (SD), median, minimum, and maximum  (with 25th and 75th percentiles 
where specified). For CZP plasma concentration levels and CRP observed values and ratio of 
post-Baseline over Baseline values  the geometric mean and the corresponding coefficient of 
variation (CV) will be presented. The CV will be calculated as  
𝐶𝑉=√𝑒𝑠𝑡𝑑 𝑙𝑛2−1∗100 
where “std ln” represents the standard deviation of the natural logarithm transformed paramete r. 
The mean, SD, and median will be displayed to [ADDRESS_846728] than collected in the 
electronic Case Report Form (eCRF). Minimum and maximum values will be displayed to the 
same level of precision as collected in the eCRF. Unless otherwise specified , all statistical 
hypothesis tests will be 2 -sided and the level of significance for all tests will be 0.05. P -values 
will be displayed to 3 decimal places.  
The study design has three different periods : Part A, Part B and Escape Part. The outputs  will be  
presented for each period . Summaries for Part A will be presented by [CONTACT_634184]. 
Summaries for Part B will be presented by [CONTACT_634185] -flare assessments 
in the subset of subjects experiencing a flare in Part B and start esca pe therapy . For the subset of 
subjects experiencing a flare in Part B and start escape therapy, separate summaries will be 
produced  for the Escape Part . 
3.2 General study level definitions  
3.2.1  Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)  
The BASDAI is a validated self -reported instrument which consists of 6 horizontal NRSs, each 
with 10 units to measure the severity of the 5 major symptoms: fatigue, spi[INVESTIGATOR_18172], peripheral 
joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the 
last week. To give each symptom equal weighting, the average of the 2 scores relating to 
morning stiffness is taken. The resulting 0 to 50 sum score is divided by 5 to give a final 
BASDAI score between 0 and 10, with lower scores indicat ing lower disease activity.  
The BASDAI is calculated as follows:  
𝐵𝐴𝑆𝐷𝐴𝐼 =𝑄1+𝑄2+𝑄3+𝑄4+𝑄5+𝑄6
2
5 
When calculating observed case value, following rules will be applied:  
  
 REDACTED COPY electronic Case Report Form (eCRF). Minimum and maximum values will be displayed to the 
REDACTED COPY electronic Case Report Form (eCRF). Minimum and maximum values will be displayed to the 
same level of precision as collected in the eCRF. Unless otherwise specified
REDACTED COPY same level of precision as collected in the eCRF. Unless otherwise specified
sided and the level of significance for all tests will be 0.05. P
REDACTED COPY sided and the level of significance for all tests will be 0.05. P
The study design has three different periods
REDACTED COPY The study design has three different periods :
REDACTED COPY :Part A, Part B and Escape Part. The 
REDACTED COPY Part A, Part B and Escape Part. The 
Summaries for Part A will be presented by [CONTACT_634184]. 
REDACTED COPY Summaries for Part A will be presented by [CONTACT_634184]. 
Summaries for Part B will be presented by [CONTACT_634186] B will be presented by [CONTACT_634187] a REDACTED COPY experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Unless otherwise noted, all percentages will be displayed to [ADDRESS_846729]. No percentage will 
be displayed for zero counts, and no decimal will be presented when the percentage is 100%.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be displayed for zero counts, and no decimal will be presented when the percentage is 100%.
th n (number of available measurements), arithmetic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. th n (number of available measurements), arithmetic 
(with 25th and 75th percentiles 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (with 25th and 75th percentiles 
observed values and ratio of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. observed values and ratio of 
coefficient of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. coefficient of 
where “std ln” represents the standard deviation of the natural logarithm transformed paramete
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. where “std ln” represents the standard deviation of the natural logarithm transformed paramete
The mean, SD, and median will be displayed to [ADDRESS_846730] than collected in the 
electronic Case Report Form (eCRF). Minimum and maximum values will be displayed to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. electronic Case Report Form (eCRF). Minimum and maximum values will be displayed to the 
same level of precision as collected in the eCRF. Unless otherwise specified
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. same level of precision as collected in the eCRF. Unless otherwise specified
sided and the level of significance for all tests will be 0.05. P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sided and the level of significance for all tests will be 0.05. P
Part A, Part B and Escape Part. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A, Part B and Escape Part. The 
Summaries for Part A will be presented by [CONTACT_634184]. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summaries for Part A will be presented by [CONTACT_634184]. 
Summaries for Part B will be presented by [CONTACT_634188]. Summaries for Part B will be presented by [CONTACT_634187] a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a flare in Part B and start esca
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B and start esca
flare in Part B and start escape therapy, separate summaries will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B and start escape therapy, separate summaries will be 
General study level definitions
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. General study level definitions
nkylosing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nkylosing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is a validated self
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is a validated self
with 10 units to measure the severity of the 5 major symptoms: fatigue, spi[INVESTIGATOR_18172], peripheral 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with 10 units to measure the severity of the 5 major symptoms: fatigue, spi[INVESTIGATOR_18172], peripheral 
joint pain and swelling, enthesitis, and morning stiffness (both severity and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. joint pain and swelling, enthesitis, and morning stiffness (both severity and 
last week. To give each symptom equal weighting, the average of the [ADDRESS_846731] week. To give each symptom equal weighting, the average of the 2 scores relating to 
morning stiffness is taken. The resulting 0 to 50 sum score is divided by 5 to give a final 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. morning stiffness is taken. The resulting 0 to 50 sum score is divided by 5 to give a final 
BASDAI score between 0 and 10, with lower scores indicat
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI score between 0 and 10, with lower scores indicat
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The BASDAI is calculated as follows: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The BASDAI is calculated as follows: 
UCB   07 May 19  
Statistical Analysis Plan  Certolizumab Pegol  AS0005  
   
Confidential  Page 24 of 149  
 
 if 1 major sympt om of the BASDAI is missing, the sum score of the remaining symptoms 
will be divided by [CONTACT_634189]  
 If more than [ADDRESS_846732] (LOCF) imputation, following rules will be 
applied:  
 If more than one but not all components are missing at a visit, the previous value for the 
missing components will be carried forward to replace the missing components, assuming the 
previous values were from a post -baseline assessment and used to calculate the BASDAI 
score. If there are no previous post -baseline value s available for any of the missing 
components to carry forward, the previous visit’s total BASDAI score will be car ried 
forward, assuming the previous visit was a post -baseline assessment. Otherwise the LOCF 
score is missing at that visit.  
 If all components are missing at a visit, the previous visit’s total BASDAI score will be 
carried forward, assuming the previous v isit was a post -baseline assessment. Otherwise the 
LOCF score is missing at that visit.  
The response variable BASDAI50 will be defined as an improvement (reduction) of at least 50% 
in the BASDAI compared to Baseline.  
Fatigue item of the BASDAI  
Fatigue as a major symptom of ankylosing spondylitis (AS) can effectively be measured with 
single item questions such as the BASDAI item. This item has shown moderate to good 
reliability and responsiveness. The fatigue ite m score will range from 0 to 10 . 
3.2.2  ASAS20, ASAS40, ASAS5/6 response, and ASAS Partial Remission  
The ASAS20 is defined as an improvement (decrease) of ≥20% and absolute improvement 
(decrease) of ≥[ADDRESS_846733] 3 out of 4 domains as follows:  
 PtGADA (see Section 3.2.10 ) 
 Pain assessment (total spi[INVESTIGATOR_18233])  
 Function (represented by [CONTACT_18379], Section 3.2.3 ) 
 Inflammation (the mean of the BASDAI questions 5 and 6, [see Section 3.2.1 ] concer ning 
morning stiffness intensity and duration)  
and absence of deterioration in the potential remaining domain (deterioration is defined as a 
relative worsening (increase) of ≥20% and absolute worsening (increase) of ≥1 unit.  
The ASAS40 is defined as an imp rovement (decrease) of ≥40% and absolute improvement 
(decrease) ≥[ADDRESS_846734] 3 out of 4 domains and no worsening (increase) 
at all in the remaining domain.  REDACTED COPY isit was a post
REDACTED COPY isit was a post
The response variable BASDAI50 will be defined as an improvement (reduction) of at least 50% 
REDACTED COPY The response variable BASDAI50 will be defined as an improvement (reduction) of at least 50% 
nkylosing REDACTED COPY nkylosing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. servation carried forward (LOCF) imputation, following rules will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. servation carried forward (LOCF) imputation, following rules will be 
If more than one but not all components are missing at a visit, the previous value for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If more than one but not all components are missing at a visit, the previous value for the 
missing components will be carried forward to replace the missing components, assuming 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing components will be carried forward to replace the missing components, assuming 
baseline assessment and used to calculate the BASDAI 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline assessment and used to calculate the BASDAI 
available for any of the missing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. available for any of the missing 
components to carry forward, the previous visit’s total BASDAI score will be car
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. components to carry forward, the previous visit’s total BASDAI score will be car
baseline assessment. Otherwise the LOCF 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline assessment. Otherwise the LOCF 
If all components are missing at a visit, the previous visit’s total BASDAI score will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If all components are missing at a visit, the previous visit’s total BASDAI score will be 
isit was a post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. isit was a post baseline assessment. Otherwise the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline assessment. Otherwise the 
The response variable BASDAI50 will be defined as an improvement (reduction) of at least 50% 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The response variable BASDAI50 will be defined as an improvement (reduction) of at least 50% 
nkylosing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nkylosing s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. spondylitis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. pondylitis 
single item questions such as the BASDAI item. This item has shown moderate to good 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. single item questions such as the BASDAI item. This item has shown moderate to good 
reliability and responsiveness. The fatigue ite
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. reliability and responsiveness. The fatigue ite
SAS20, ASAS40, ASAS5/6 response, and ASAS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SAS20, ASAS40, ASAS5/6 response, and ASAS 
The ASAS20 is defined as an improvement (decrease) of ≥20% and absolute improvement 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The ASAS20 is defined as an improvement (decrease) of ≥20% and absolute improvement 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (decrease) of ≥[ADDRESS_846735] 3 out of 4 domains as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (decrease) of ≥[ADDRESS_846736] 3 out of 4 domains as follows:
PtGADA (see Section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PtGADA (see Section 
Pain assessment (total spi[INVESTIGATOR_18233])
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pain assessment (total spi[INVESTIGATOR_18233])
Function (represented by [CONTACT_18379], Section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Function (represented by [CONTACT_18379], Section 
Inflammation (the mean of the BASDAI questions 5 and 6, [see Section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Inflammation (the mean of the BASDAI questions 5 and 6, [see Section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. morning stiffness intensity and duration)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. morning stiffness intensity and duration)
and absence of deterioration in the potential remaining domain (deterioration is defined as a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and absence of deterioration in the potential remaining domain (deterioration is defined as a 
relative worsening (increase) of ≥20% and absolute worsening (increase) of ≥1 unit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. relative worsening (increase) of ≥20% and absolute worsening (increase) of ≥1 unit.
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 25 of 149 The ASAS5/6 response is defined as an improvement of ≥20% in at least 5 out of 6 domains 
comprised of the 4 domains above plus additional domains of spi[INVESTIGATOR_18171] (ie, BASMI, lateral 
lumbar flexion), and CRP. The lateral lumbar flexion value is taken as the mean of left and right assessment values and improvement is a ≥20% increase. Improvement in CRP is a ≥20% 
decrease. If the CRP value is below the lower limit of quantification (LLOQ), then it will be 
imputed as the midpoint between 0 and the LLOQ. 
The ASAS PR response is defined as a score of ≤2 units on a 0 to 10 NRS in each of the 4 
domains listed above for ASAS20. 
When calculating observed case response status for ASAS20, ASAS40, ASAS5/6 and ASAS PR, 
following rules will be applied: 
 If 1 of the 2 morning stiffness measurements (ie, questions 5 and 6 of BASDAI 
questionnaire) is missing, the other one will be used for the inflammation calculation.  
 If one or more components are missing at a visit, the response status will be treated as 
missing at that visit. No imputation will be performed. Subjects will not be handled as non-
responder. 
When performing non-responder imputation (NRI) for ASAS20, ASAS40, ASAS5/6 and ASAS 
PR, following rules will be applied: 
 If some but not all components are missing at a visit, the previous value for the missing 
components will be carried forward to replace the missing values, assuming the previous values were from a post-baseline assessment. The response status will then be assessed. If there is no previous post-baseline value available to carry forward for any of the missing 
components, a 0 unit improvement value and 0% improvement value will be imputed for the 
missing components. The response status will then be assessed.  
 If all components are missing at a visit, then the subject will be considered a non-responder 
at that visit. 
3.2.3  Bath Ankylosing Spondylitis Functional Index (BASFI) 
The BASFI comprises [ADDRESS_846737] week. The NRS version will be used for the answering options of each item on a scale of 0 (“Easy”) to 10 (“Impossible”). The BASFI is the mean of the [ADDRESS_846738] for any of the missing 
improvement value and 0% improvement value will be imputed for the 
REDACTED COPY improvement value and 0% improvement value will be imputed for the 
missing components. The response status will then be assessed. REDACTED COPY missing components. The response status will then be assessed. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. When calculating observed case response status for ASAS20, ASAS40, ASAS5/6 and ASAS PR, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. When calculating observed case response status for ASAS20, ASAS40, ASAS5/6 and ASAS PR, 
If 1 of the 2 morning stiffness measurements (ie, questions 5 and 6 of BASDAI 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If 1 of the 2 morning stiffness measurements (ie, questions 5 and 6 of BASDAI 
is missing, the other one will be used for the inflammation calculation. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is missing, the other one will be used for the inflammation calculation. 
one or more components are missing at a visit, the response status will be treated as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. one or more components are missing at a visit, the response status will be treated as 
missing at that visit. No imputation will be performed. Subjects will not be handled as non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing at that visit. No imputation will be performed. Subjects will not be handled as non
imputation (NRI) for ASAS20, ASAS40, ASAS5/6 and ASAS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. imputation (NRI) for ASAS20, ASAS40, ASAS5/[ADDRESS_846739] for any of the missing 
improvement value and 0% improvement value will be imputed for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. improvement value and 0% improvement value will be imputed for the 
missing components. The response status will then be assessed. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing components. The response status will then be assessed. 
If all components are missing at a visit, then the subject will be considered a non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If all components are missing at a visit, then the subject will be considered a non
nkylosing
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nkylosing
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The BASFI comprises [ADDRESS_846740] week. The NRS version will be used for the 
answering options of each item on a scale of 0 (“Easy”) to 10 (“Impossible”). The BASFI is the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. answering options of each item on a scale of 0 (“Easy”) to 10 (“Impossible”). The BASFI is the 
mean of the [ADDRESS_846741] independent review. Whenever an adjudication is present th e average score 
across all 3 reviewers will be used for analysis. Two different MRI scores will be used for 
analysis (SPARCC, Berlin modification of the ASspi[CONTACT_9268]-a). 
The SPARCC scoring method for lesions found on the MRI is based on an abnormal increased 
signal on the short- tau-inversion recovery (STIR) sequence, representing bone marrow edema 
(defined as an increased signal in bone marrow on a T2-weighted sequence, reflecting an increased concentration of “free water” related to a bone lesion). Each SIJ is divided into 4 
quadrants and will be assessed for left and right: upper iliac, lower iliac, upper sacral, and lower 
sacral. The presence of increased signal on STIR in each of these 4 quadrants are scored on a 
dichotomous basis, where 1 = increased signal and 0 = normal signal. Joints that include a lesion exhibiting intense signal are each given an additional score of 1 per slice that demonstrated this 
feature. Similarly, each joint that included a lesion demonstrating continuous increased signal of 
depth greater or equal 1 cm from the articular surface is also given an additional score of 1. The scoring is repeated in each of 6 consecutive coronal slices. Total SIJ SPARCC scores can range from 0 to 72. 
The Berlin modification of the ASspi[CONTACT_9268]-a is a scoring system with a concentration on STIR 
sequences without other fat saturation techniques. This scoring method quantifies active changes 
in 23 vertebral units (VU) of the spi[INVESTIGATOR_050] (from C2 to S1) or 24 VUs if a transitional vertebra is 
present. If a transitional vertebra is present, L5/L6 and L6/SI will be assessed instead of L5/SI. A 
VU is defined as the region between [ADDRESS_846742] level of inflammation in a particular VU.  
Total spi[INVESTIGATOR_18241]-a score in the Berlin modification can range from 0 to 69. This score will 
increase if there are transitional vertebrae. 
The following imputation rules should be used for calculating the total for both SIJ SPARCC 
scores and spi[INVESTIGATOR_18241]-a score in the Berlin modification: 
 If all scores are not applicable ( NA) at a visit, the imputed total is blank for that visit. 
 Treat NA as 0 when computing the total score. 
 Carry the NA score from the Baseline Visit forward to all post-Baseline visits unless all 
scores at Baseline are NA. 
 Carry the numeric score from the last visit with non-NA score forward if a score is NA at a post-Baseline visit (unless all scores are NA post-Baseline). 
 If ALL the Baseline scores are NA, then do not carry forward the Baseline scores. Treat the 
subsequent visit as a surrogate Baseline. 
For MRI the relative day after scheduled MRI visit will be calculated. REDACTED COPY scoring is repeated in each of 6 consecutive coronal slices. Total SIJ SPARCC scores can range 
REDACTED COPY scoring is repeated in each of 6 consecutive coronal slices. Total SIJ SPARCC scores can range 
a is a scoring system with a concentration on STIR 
REDACTED COPY a is a scoring system with a concentration on STIR 
niques. This scoring method quantifies active changes 
REDACTED COPY niques. This scoring method quantifies active changes 
in 23 vertebral units (VU) of the spi[INVESTIGATOR_050] (from C2 to S1)
REDACTED COPY in 23 vertebral units (VU) of the spi[INVESTIGATOR_050] (from C2 to S1)
is present
REDACTED COPY is present
defined as the region between 2 virtual lines through the middle of each vertebra. Active REDACTED COPY defined as the region between 2 virtual lines through the middle of each vertebra. Active 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The SPARCC scoring method for lesions found on the MRI is based on an abnormal increased 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The SPARCC scoring method for lesions found on the MRI is based on an abnormal increased 
ow edema 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ow edema 
weighted sequence, reflecting an 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. weighted sequence, reflecting an 
increased concentration of “free water” related to a bone lesion). Each SIJ is divided into 4 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. increased concentration of “free water” related to a bone lesion). Each SIJ is divided into 4 
ower iliac, upper sacral, and lower 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ower iliac, upper sacral, and lower 
sacral. The presence of increased signal on STIR in each of these 4 quadrants are scored on a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sacral. The presence of increased signal on STIR in each of these 4 quadrants are scored on a 
dichotomous basis, where 1 = increased signal and 0 = normal signal. Joints that include a lesion 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dichotomous basis, where 1 = increased signal and 0 = normal signal. Joints that include a lesion 
e each given an additional score of 1 per slice that demonstrated this 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e each given an additional score of 1 per slice that demonstrated this 
feature. Similarly, each joint that included a lesion demonstrating continuous increased signal of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. feature. Similarly, each joint that included a lesion demonstrating continuous increased signal of 
depth greater or equal 1 cm from the articular surface is also given an additional sco
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. depth greater or equal 1 cm from the articular surface is also given an additional sco
scoring is repeated in each of 6 consecutive coronal slices. Total SIJ SPARCC scores can range 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scoring is repeated in each of 6 consecutive coronal slices. Total SIJ SPARCC scores can range 
a is a scoring system with a concentration on STIR 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a is a scoring system with a concentration on STIR 
niques. This scoring method quantifies active changes 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. niques. This scoring method quantifies active changes 
in 23 vertebral units (VU) of the spi[INVESTIGATOR_050] (from C2 to S1)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in 23 vertebral units (VU) of the spi[INVESTIGATOR_050] (from C2 to S1)
is present
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is present ,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ,L5/L6 and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. L5/L6 and 
defined as the region between [ADDRESS_846743] level of infl
a score in the Berlin modification can range from 0 to 69.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a score in the Berlin modification can range from 0 to 69.
increase if there are transitional vertebrae.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. increase if there are transitional vertebrae.
The following imputation rules should be used for calculating the total for both SIJ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following imputation rules should be used for calculating the total for both SIJ
scores and spi[INVESTIGATOR_634105]. scores and spi[INVESTIGATOR_634106]. If all scores are 
Treat NA as 0 when computing the total score.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treat NA as 0 when computing the total score.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Carry the NA score from the Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Carry the NA score from the Baseline 
scores at Baseline are NA.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores at Baseline are NA.

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 27 of 149 In case of out of window images/scores regarding the visit date, the following rules will apply: 
 MRI assessments assigned to Baseline:  If Baseline MRI was performed from Screening up to 2 weeks after Baseline it will be 
assigned to Baseline, if beyond it will not be used. 
 MRI assessments assigned to Week 48: 
 If Week 48 MRI was performed ±2 weeks around the Week 48 Visit, it will be assigned 
to Week 48, otherwise Week 48 will be treated as missing. 
 MRI assessments assigned to Week 96:  If Week 96 MRI was performed ±2 weeks around the Week 96 Visit, it will be assigned 
to Week 96, otherwise Week 96 will be treated as missing. 
In subjects experiencing a flare in Part B, following rules will apply: 
 MRI assessments assigned to Escape Week 0: 
 If Escape Week 0 MRI was performed ±2 weeks around the Escape Week 0 Visit, it will 
be assigned to Escape Week 0, otherwise Escape Week 0 will be treated as missing. 
 MRI assessments assigned to Escape Week 12: 
 If Escape Week 12 MRI was performed ±[ADDRESS_846744] been the next scheduled visit with a MRI assessment. The MRI will be used for summaries 
if it was performed ±2 weeks around the scheduled visit it is assigned to. 
3.2.5  Bath Ankylosing Spondylitis Metrology Index (BASMI) 
The BASMI characterizes the spi[INVESTIGATOR_634107]. The BASMI is a disease-
specific measure consisting of [ADDRESS_846745] axial status: cervical rotation; 
tragus to wall distance; lateral spi[INVESTIGATOR_18205]; modified Schober test; intermalleolar distance. The mean of the [ADDRESS_846746]’s limitation of movement due to their axSpA. 
  REDACTED COPY MRI was performed ±2 weeks around the Escape Week 12 
REDACTED COPY MRI was performed ±[ADDRESS_846747] been the next scheduled visit with a MRI assessment. The MRI will be used for summaries 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. isit, it will be assigned 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. isit, it will be assigned 
isit, it will be assigned 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. isit, it will be assigned 
If Escape Week 0 MRI was performed ±2 weeks around the Escape Week 0 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If Escape Week 0 MRI was performed ±2 weeks around the Escape Week 0 
Escape Week 0, otherwise Escape Week 0 will be treated as missing.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape Week 0, otherwise Escape Week 0 will be treated as missing.
MRI was performed ±2 weeks around the Escape Week 12 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MRI was performed ±[ADDRESS_846748] been the next scheduled visit with a MRI assessment. The MRI will be used for summaries 
±2 weeks around the sche
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ±[ADDRESS_846749] axial status: c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. specific measure consisting of [ADDRESS_846750] axial status: c
tragus to wall distance; lateral spi[INVESTIGATOR_18205]; modified Schober test; intermalleolar distance. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tragus to wall distance; lateral spi[INVESTIGATOR_18205]; modified Schober test; intermalleolar distance. The 
mean of the [ADDRESS_846751]’s limitation of movement due to the
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the subject’s limitation of movement due to the
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 28 of 149 Table 3.1: BASMI linear definition  
S = (21.1 cm –A) / 2.1 cm  For the lateral lumbar spi[INVESTIGATOR_18191] (mean 
right/left) 
S = (A – 8 cm) / 3 cm  For the tragus -to-wall distance (mean 
right/left) 
S = (7.4 cm – A) /0.7 cm  For the lumbar flexion (modified Schober)  
S = (124.5 cm – A) / 10 cm  For the maximal intermalleolar distance  
S = (89.3° - A) / 8.5°  For the cervical spi[INVESTIGATOR_634108] (mean right/left)  
Always with the additional condition 0 ≤S ≤10a 
a S=score, A=assessment.  
For cervical rotation, tragus- to-wall distance and lumbar flexion, take the mean of the left and 
right measurements, if both are available. Otherwise, the available measurement will be used. 
With regard of the lumbar flexion (modified Schober), values greater than 9.0 cm will be flagged 
as invalid and treated as if they were missing values.  
When calculating observed case score, if one or more clinical measures are missing at a visit, 
then BASMI total score will be treated as missing at that visit. No imputation will be performed. 
When performing LOCF imputation, following rules will be applied: 
 If up to two clinical measures are missing at a visit, the previous value(s) for the clinical 
measure(s) will be carried forward to replace the missing value(s), assuming the previous 
value(s) were from a post-baseline assessment. If there are no previous post-baseline value(s) 
to carry forward, then the previous visit’s total BASMI score will be carried forward, assuming the previous visit was a post-baseline assessment. Otherwise the LOCF score is missing for that visit. 
 If more than two clinical measures are missing at a visit, then the previous visit’s total BASMI score will be carried forward, assuming the previous visit was a post-baseline assessment. Otherwise the LOCF score is missing for that visit. 
3.2.6  Total and nocturnal spi[INVESTIGATOR_634109]: 
 Pain in the spi[INVESTIGATOR_18248] (ie, “How much pain of your spi[INVESTIGATOR_634110]?”)  
 Pain in the spi[INVESTIGATOR_18249] (ie, “How much pain of your spi[INVESTIGATOR_634111]?”). 
The scores range from 0 to10, with lower scores indicating less pain.  
3.2.7  Ankylosing S pondylitis D isease Activity Score (ASDAS) 
The ASDAS is comprised of a number of assessments which are scored by [CONTACT_634190] a proven formula as listed: REDACTED COPY When calculating observed case score, if one or more clinical m
REDACTED COPY When calculating observed case score, if one or more clinical m
MI total score will be treated as missing at that visit. No imputation will be performed.
REDACTED COPY MI total score will be treated as missing at that visit. No imputation will be performed.
When performing LOCF imputation, following rules will be applied:
REDACTED COPY When performing LOCF imputation, following rules will be applied:
If up to two clinical measures are missing at a visit, the previous value(s) for the clinical 
REDACTED COPY If up to two clinical measures are missing at a visit, the previous value(s) for the clinical 
measure(s) will be carried forward to replace the missing value(s), assuming the previous 
REDACTED COPY measure(s) will be carried forward to replace the missing value(s), assuming the previous 
baseline assessment. If there are no previous post REDACTED COPY baseline assessment. If there are no previous post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the lumbar flexion (modified Schober)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the lumbar flexion (modified Schober)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the maximal intermalleolar distance
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the maximal intermalleolar distance
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the cervical spi[INVESTIGATOR_634108] (mean right/left)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the cervical spi[INVESTIGATOR_634108] (mean right/left)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. wall distance and lumbar flexion, take the me
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. wall distance and lumbar flexion, take the me an of the left and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. an of the left and 
right measurements, if both are available. Otherwise, the available measurement will be used.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. right measurements, if both are available. Otherwise, the available measurement will be used.
With regard of the lumbar flexion (modified Schober), values greater than 9.[ADDRESS_846752] of the lumbar flexion (modified Schober), values greater than 9.0 cm will be flagged 
When calculating observed case score, if one or more clinical m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. When calculating observed case score, if one or more clinical m
MI total score will be treated as missing at that visit. No imputation will be performed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MI total score will be treated as missing at that visit. No imputation will be performed.
When performing LOCF imputation, following rules will be applied:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. When performing LOCF imputation, following rules will be applied:
If up to two clinical measures are missing at a visit, the previous value(s) for the clinical 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If up to two clinical measures are missing at a visit, the previous value(s) for the clinical 
measure(s) will be carried forward to replace the missing value(s), assuming the previous 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. measure(s) will be carried forward to replace the missing value(s), assuming the previous 
baseline assessment. If there are no previous post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline assessment. If there are no previous post
to carry forward, then the previous visit’s total BASMI score will be c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to carry forward, then the previous visit’s total BASMI score will be c
assuming the previous visit was a post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assuming the previous visit was a post
If more than two clinical measures are missing at a visit, then the previous visit’s total 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If more than two clinical measures are missing at a visit, then the previous visit’s total 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASMI score will be carried forward, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASMI score will be carried forward, 
assessment. Otherwise the LOCF score is missing for that visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessment. Otherwise the LOCF score is missing for that visit.
Total and nocturnal spi[INVESTIGATOR_634112]. Total and nocturnal spi[INVESTIGATOR_634113]:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Total and nocturnal spi[INVESTIGATOR_634114]:
in the spi[INVESTIGATOR_18248] (ie, “How muc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in the spi[INVESTIGATOR_18248] (ie, “How muc
have?”)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. have?”)
Pain
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pain
you have at night?”).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. you have at night?”).
The scores range from 0 to10, with lower scores indicating less pain. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The scores range from 0 to10, with lower scores indicating less pain. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 29 of 149 0.121 × Back pain (BASDAI Q2 result, see Section 3.2.1) 
0.058 × Duration of morning stiffness (BASDAI Q6 result) 
0.110 × PtGADA (see Section 3.2.10) 
0.073 × Peripheral pain/swelling (BASDAI Q3 result) 
0.579 × (natural logarithm of the (CRP [mg/L] + 1)) 
Back pain, PtGADA, duration of morning stiffness and peripheral pain/swelling are all assessed 
on an NRS (0 to 10 units). If the CRP value is below the LLOQ, then it will be imputed as the midpoint between [ADDRESS_846753] injection in 
Escape Part will be used for each component. It will be not required that all components are measured at the same visit. 
When calculating observed case score, if one or more components are missing at a visit, then 
ASDAS will be treated as missing at that visit. No imputation will be performed. 
When performing LOCF imputation, following rules will be applied: 
 If only one component is missing at a visit, the previous value for that one component only 
will be carried forward to replace the missing value, assuming the previous value was a post-
baseline assessment, and will be used to calculate the ASDAS score. If there is no previous 
post-baseline value available for that one component to carry forward, the previous visit’s total ASDAS score will be carried forward, assuming the previous visit was a post-baseline assessment. Otherwise the LOCF score is missing at that visit.  
 If more than one component is missing at a visit, the previous visit’s total ASDAS score will be carried forward, assuming the previous visit was a post-baseline assessment. Otherwise the LOCF score is missing at that visit. 
Disease activity is measured by [CONTACT_634191]: 
 ASDAS-Inactive Disease (ASDAS-ID): ASDAS <1.3 
 ASDAS-Low Disease activity (ASDAS- LD): ASDAS ≥1.3, <2.1 
 ASDAS-High Disease activity (ASDAS-HD): ASDAS ≥2.1, ≤3.5 
 ASDAS-very High Disease activity (ASDAS-vHD): ASDAS >3.5 
ASDAS improvement is measured by [CONTACT_634192]: REDACTED COPY Baseline derivation of the ASDAS score the latest value prior to 
REDACTED COPY Baseline derivation of the ASDAS score the latest value prior to 
will be used for each component. It will be not required that all components are 
REDACTED COPY will be used for each component. It will be not required that all components are 
When calculating observed case score, if one or mo
REDACTED COPY When calculating observed case score, if one or mo
ASDAS will be treated as missing at that visit. No imputation will be performed.
REDACTED COPY ASDAS will be treated as missing at that visit. No imputation will be performed.
When performing LOCF imputation, following rules will be applied: REDACTED COPY When performing LOCF imputation, following rules will be applied:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Back pain, PtGADA, duration of morning stiffness and peripheral pain/swelling are all assessed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Back pain, PtGADA, duration of morning stiffness and peripheral pain/swelling are all assessed 
its). If the CRP value is below the LLOQ, then it will be imputed as the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. its). If the CRP value is below the LLOQ, then it will be imputed as the 
the latest value prior to treatment will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the latest value prior to treatment will be 
l components are measured at the same 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. l components are measured at the same 
visit, e.g. PtGADA is available only at screening while the other components are available at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. visit, e.g. PtGADA is available only at screening while the other components are available at 
Baseline then the ASDAS score will be derived combining the screening value of PtGADA and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline then the ASDAS score will be derived combining the screening value of PtGADA and 
For Part B Baseline derivation of the ASDAS score the latest value prior to randomization will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For Part B Baseline derivation of the ASDAS score the latest value prior to randomization will 
be used for each component. It will be not required that all components are measured at the same 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be used for each component. It will be not required that all components are measured at the same 
Baseline derivation of the ASDAS score the latest value prior to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline derivation of the ASDAS score the latest value prior to 
will be used for each component. It will be not required that all components are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used for each component. It will be not required that all components are 
When calculating observed case score, if one or mo
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. When calculating observed case score, if one or mo re components are missing at a visit, then 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. re components are missing at a visit, then 
ASDAS will be treated as missing at that visit. No imputation will be performed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS will be treated as missing at that visit. No imputation will be performed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. When performing LOCF imputation, following rules will be applied:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. When performing LOCF imputation, following rules will be applied:
If only one component is missing at a visit, the previous value fo
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If only one component is missing at a visit, the previous value fo
will be carried forward to replace the missing value, assuming the previous value was a post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be carried forward to replace the missing value, assuming the previous value was a post
baseline assessment, and will be used to calculate the ASDAS score. If there is no previous 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline assessment, and will be used to calculate the ASDAS score. If there is no previous 
baseline value available for that one co
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline value available for that one co
total ASDAS score will be carried forward, assuming the previous visit was a post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. total ASDAS score will be carried forward, assuming the previous visit was a post
assessment. Otherwise the LOCF score is missing at that visit. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessment. Otherwise the LOCF score is missing at that visit. 
If more than one component is missing at a visit, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If more than one component is missing at a visit, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be carried forward, assuming the previous visit was a post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be carried forward, assuming the previous visit was a post
the LOCF score is missing at that visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the LOCF score is missing at that visit.
Disease activity is measured by [CONTACT_634193]. Disease activity is measured by [CONTACT_634194]. ASDAS

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan  Certolizumab Pegol  AS0005  
   
 ASDAS -CII: ASDAS reduction (improvement) of ≥1.1 relative to Baseline  
 ASDAS -MI: ASDAS reduction (improvement) of ≥2.0 relative to Baseline . As a sensitivity 
analysis, ASDAS -MI analyses will be repeated using a Modified ASDAS -MI: ASDAS 
reduction (improvement) of >=2.[ADDRESS_846754] -
baseline (i.e. when CRP<LLOQ and all other components are 0 , then the minimum ASDAS 
score is 0.636 to 3 decimal places).  
3.2.8  Ankylosing Spondyl itis Quality of Life (ASQoL)  
The ASQoL, a validated disease -specific 18 -item questionnaire, has been recently developed 
specifically for measuring health -related quality of life (HRQoL) in subjects with AS. The 
ASQoL has been used and has shown to be respo nsive in axSpA. The ASQoL score ranges from 
0 to 18 with higher score indicating worse HRQoL.  
If three  or less items responses are missing, the ASQoL score will be imputed by [CONTACT_634195] e result with 18. If more 
than three  items responses are missing, the ASQoL score will be left missing.  
3.2.9  Work Productivity Survey (WPS)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. item questionnaire, has been recently developed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. item questionnaire, has been recently developed 
related quality of life (HRQoL) in subjects with AS. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. related quality of life (HRQoL) in subjects with AS. The 
nsive in axSpA. The ASQoL score ranges from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nsive in axSpA. The ASQoL score ranges from 
or less items responses are missing, the ASQoL score will be imputed by [CONTACT_634196]. or less items responses are missing, the ASQoL score will be imputed by [CONTACT_81821] 
e result with 18. If more 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e result with 18. If more 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. items responses are missing, the ASQoL score will be left missing.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. items responses are missing, the ASQoL score will be left missing.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan  Certolizumab Pegol  AS0005  
   
Confidential  Page 31 of 149 3.2.10  Patient’s Global Assessment of Disease Activity ( PtGAD A, NRS)  
Subjects will score their global assessment of their disease activity in response to the question 
“How active was your spondylitis on average during the last week?” using a NRS where 0 is 
“not active” and 10 is “very active”.  REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 32 of 149 3.2.11  Short-Form 36-item Health Survey ( SF-36) 
The SF-36 (Version 2, standard recall) is a 36 item generic HRQoL instrument that uses a recall 
period of 4 weeks. Items are grouped into 8 domains as follows: Physical Functioning (10 items), 
Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items), and a further 
unscaled single item (Q2) for perceived stability or change in health (Health Transition) during 
the last year. The concepts represented by [CONTACT_18385], mental, and social aspects of HRQoL. 
For the calculation of the SF-36 domain scores and the component summaries PCS and MCS, the 
scoring software Optum’s PRO CoRE will be used. The norm-based scores (based on the US 
2009 general population) will be utilized for analysis.  
A response definition for the PCS and MCS is based on the within-subject MCID of 2.[ADDRESS_846755] will be considered a PCS (MCS) responder if the subject has an increase of ≥2.5 points from Baseline. 
3.2.12  Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)  
The MASES comprises 13 items (bilateral costochondral 1, costochondral 7, anterior superior 
iliac spi[INVESTIGATOR_050], posterior iliac spi[INVESTIGATOR_050], iliac crest and proximal insertion of the achilles tendon sites, and the fifth lumbar vertebral body spi[INVESTIGATOR_18239]) (Heuft-Dorenbosch et al, 2003) each scored as 0 
= yes or 1 = no and then summed for a possible score of 0 to 13, with higher scores indicating 
worse enthesitis. 
If 7 or more items are available, MASES will be imputed by [CONTACT_634197] 13. If less than 7 items are available, 
MASES will be treated as missing. 
3.2.13  Swollen and Tender Joint Counts (44) 
Tender and swollen joint counts will be carried out on the following 44 joints: 
 Upper body (4) – bilateral sternoclavicular, and acromioclavicular joints 
 Upper extremity (26) – bilateral shoulders, elbows, wrists (includes radiocarpal, carpal and 
carpometacarpal bones considered as a single unit), metacarpophalangeals (MCPs) I, II, III, IV, and V, and thumb interphalangeals (IPs), and proximal IPs (PI[INVESTIGATOR_18246]) II, III, IV, and V 
 Lower extremity (14) – bilateral knees, ankles, and metatarsophalangeals (I, II, III, IV, and V) 
The assessment for swelling and tenderness is made on the [ADDRESS_846756] and 
ranges from 0 to 44. Artificial, ankylosed, and missing joints are excluded from swelling and 
tenderness assessments. 
Each joint is scored as follows: 
Table 3.2: Tender and swollen joint scoring 
Grade  Swelling response (44)  Tenderness response (44)  
[ADDRESS_846757] and proximal insertio
the fifth lumbar vertebral body spi[INVESTIGATOR_18239]) (Heuft
REDACTED COPY the fifth lumbar vertebral body spi[INVESTIGATOR_18239]) (Heuft -
REDACTED COPY -Dorenbosch et al, 2003) each scored as 0 
REDACTED COPY Dorenbosch et al, 2003) each scored as 0 
= yes or 1 = no and then summed for a possible score of 0 to 13, with higher scores indicating 
REDACTED COPY = yes or 1 = no and then summed for a possible score of 0 to 13, with higher scores indicating 
re items are available, MASES will be imputed by [CONTACT_634198], MASES will be imputed by [CONTACT_634197] 13. If less than 7 items are available, 
REDACTED COPY number of assessments and multiplying the result with 13. If less than 7 items are available, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 domain scores and the component summaries PCS and MCS, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 domain scores and the component summaries PCS and MCS, the 
based scores (based on the US 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based scores (based on the US 
subject MCID of 2.[ADDRESS_846758] will be considered a PCS (MCS) responder if the subject has an inc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A subject will be considered a PCS (MCS) responder if the subject has an inc rease of ≥2.5 points 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rease of ≥2.5 points 
Enthesitis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Enthesitis Score 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Score 
13 items (bilateral costochondral 1, costochondral 7, anterior superior 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 13 items (bilateral costochondral 1, costochondral 7, anterior superior 
iliac spi[INVESTIGATOR_050], posterior iliac spi[INVESTIGATOR_050], iliac crest and proximal insertio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. iliac spi[INVESTIGATOR_050], posterior iliac spi[INVESTIGATOR_050], iliac crest and proximal insertio n of the achilles tendon sites, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. n of the achilles tendon sites, and 
Dorenbosch et al, 2003) each scored as 0 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Dorenbosch et al, 2003) each scored as 0 
= yes or 1 = no and then summed for a possible score of 0 to 13, with higher scores indicating 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. = yes or 1 = no and then summed for a possible score of 0 to 13, with higher scores indicating 
re items are available, MASES will be imputed by [CONTACT_634199]. re items are available, MASES will be imputed by [CONTACT_634197] 13. If less than 7 items are available, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number of assessments and multiplying the result with 13. If less than 7 items are available, 
Swollen and Tender Joint Counts (44)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Swollen and Tender Joint Counts (44)
swollen joint counts will be carried out on the following 44 joints:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. swollen joint counts will be carried out on the following 44 joints:
bilateral sternoclavicular, and acromioclavicular joints
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. bilateral sternoclavicular, and acromioclavicular joints
Upper extremity (26) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Upper extremity (26) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. –
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. –bilateral shoulders, elbows, wrists (includes radiocarpal, carpal and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. bilateral shoulders, elbows, wrists (includes radiocarpal, carpal and 
bones considered as a single unit), metacarpophalangeals (MCPs) I, II, III, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. bones considered as a single unit), metacarpophalangeals (MCPs) I, II, III, 
IV, and V, and thumb interphalangeals (IPs), and proximal IPs (PI[INVESTIGATOR_18246]) II, III, IV, and V
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. IV, and V, and thumb interphalangeals (IPs), and proximal IPs (PI[INVESTIGATOR_18246]) II, III, IV, and V
Lower extremity (14) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Lower extremity (14) 
The assessment for swelling and tenderness is made on the [ADDRESS_846759] and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ranges from 0 to 44. Artificial, ankylosed, and missing joints are excluded from swelling and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ranges from 0 to 44. Artificial, ankylosed, and missing joints are excluded from swelling and 
tenderness assessments.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tenderness assessments.
Each joint is scored as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Each joint is scored as follows:
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 33 of 149 If there are missing observations for tender or swollen joints then the remaining observations will 
be assessed and weighted by [CONTACT_634200]-missing and by [CONTACT_195914] 44 for 
the joint count. If a joint is not evaluable at Baseline, then that joint is set to missing throughout the study.  
If data for more than 50% of the joints are missing at the time of a given assessment, then no 
imputation will be done, and the total count will be set to missing for that visit. 
3.2.14  Physician’s Global A ssessme nt of D isease Activity (PhGADA) 
The Investigator will assess the overall status of the subject with respect to the axSpA signs and 
symptoms and the functional capacity of the subject using a VAS where 0 is “very good, 
asymptomatic and no limitation of normal activities” and 100 is “very poor, very severe symptoms which are intolerable and inability to carry out all normal activities.” 
This assessment by [CONTACT_634201].  
3.2.15  Spi[INVESTIGATOR_18243], additional spi[INVESTIGATOR_18244]: 
 Occiput to wall distance 
 Chest expansion 
3.2.16  Health status (EQ- 5D-3L) 
The EQ-5D- 3L is comprised of a 5-item health status measures and a VAS. Each of the 5 health 
states is divided into 3 levels: no problem, some or moderate problems and extreme problems 
and is scored as 1, 2, and 3, respectively. The EQ-5D- 3L VAS records the respondent’s self-
rated health status on a vertical 20cm scale, 0 to 100 graduated (0=worst imaginable health 
status, 100=best imaginable health status). 
This instrument is to be completed by [CONTACT_423].  
3.2.17  Resource utilization 
The following resource utilization data will be collected through UCB standardized modules: 
 Concomitant medical procedures 
 Health care provider consultations not foreseen by [CONTACT_760] 
 In-patient hospi[INVESTIGATOR_306134] (including length of stay) 
A medical resource will be allocated to Part A as determined by [CONTACT_941] (start) date of the event. 
Specifically, a medical resource will be allocated to Part A if (start) date is on or after the date of 
first study medication in Part A and prior to or on the date of last study medication in Part A + [ADDRESS_846760] study medication in Part B, if any. 
A medical resource will be allocated to Part B as determined by [CONTACT_941] (start) date of the event. 
Specifically, a medical resource will be allocated to Part B if (start) date is on or after the date of 
first study medication in Part B and prior to or on the date of last study medication in Part B + 70 
days. Medical resource with a (start) date after date of first escape full-dose CZP injection will 
be excluded from any summary tables of medical resource in Part B. REDACTED COPY item health status measures and a VAS. Each of the 5 health 
REDACTED COPY item health status measures and a VAS. Each of the 5 health 
vided into 3 levels: no problem, some or moderate 
REDACTED COPY vided into 3 levels: no problem, some or moderate 
and is scored as 1, 2, and 3, respectively. The REDACTED COPY and is scored as 1, 2, and 3, respectively. The 
rated health status on a vertical 20cm scale, 0 to 100 graduated (0=worst imaginable REDACTED COPY rated health status on a vertical 20cm scale, 0 to 100 graduated (0=worst imaginable 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Investigator will assess the overall status of the subject with respect to the axSpA signs and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Investigator will assess the overall status of the subject with respect to the axSpA signs and 
symptoms and the functional capacity of the subject using a VAS where 0 is “very good, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. symptoms and the functional capacity of the subject using a VAS where 0 is “very good, 
al activities” and 100 is “very poor, very severe 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. al activities” and 100 is “very poor, very severe 
symptoms which are intolerable and inability to carry out all normal activities.”
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. symptoms which are intolerable and inability to carry out all normal activities.”
This assessment by [CONTACT_634201]. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This assessment by [CONTACT_634201]. 
assessments performed for the BASMI, additional spi[INVESTIGATOR_634115]. assessments performed for the BASMI, additional spi[INVESTIGATOR_634116] a VAS. Each of the 5 health 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. item health status measures and a VAS. Each of the 5 health 
vided into 3 levels: no problem, some or moderate 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. vided into 3 levels: no problem, some or moderate 
and is scored as 1, 2, and 3, respectively. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and is scored as 1, 2, and 3, respectively. The EQ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. EQ
rated health status on a vertical 20cm scale, 0 to 100 graduated (0=worst imaginable 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rated health status on a vertical 20cm scale, 0 to 100 graduated (0=worst imaginable 
status, 100=best imaginable health status).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. status, 100=best imaginable health status).
This instrument is to be completed by [CONTACT_423]. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This instrument is to be completed by [CONTACT_423]. 
Resource utilization
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Resource utilization
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following resource utilization data will be collected through UCB standardized modules:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following resource utilization data will be collected through UCB standardized modules:
Concomitant medical procedures
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Concomitant medical procedures
care provider consultations not foreseen by [CONTACT_267940]. care provider consultations not foreseen by [CONTACT_634202] h
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. patient h ospi[INVESTIGATOR_634117]. ospi[INVESTIGATOR_059]
A medical resource will be allocated to Part A as determined by [CONTACT_941] (start) date of the event. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A medical resource will be allocated to Part A as determined by [CONTACT_941] (start) date of the event. 
Specifically, a medical
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Specifically, a medical
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. first study medication in Part A and prior to or on the date of last study medication in Part A + [ADDRESS_846761] study medication in Part A + [ADDRESS_846762]-flare as determined by [CONTACT_941] (start) date of the 
event. Specifically, a medical resource will be allocated to Part B post-flare if (start) date is on or 
after the date of first escape full-dose CZP injection in Part B and prior to or on the date of last escape full-dose CZP injection in Part B + 70 days. 
The same rules for (partially) missing start dates as for AEs will be applied to the resource use data. 
For the same subject only one hospi[INVESTIGATOR_634118] “start date of the second 
hospi[INVESTIGATOR_059] - end date of the first hospi[INVESTIGATOR_059] ≤1”. 
In case of complete consultation date, count only once for a same subject, same consultation 
date, same location and same provider. 
If the procedure name, start date and relationship are the same, then only one procedure is 
counted, otherwise if at least one variable among procedure name, start date or relationship is different, distinct/several procedures are counted. 
If concomitant medical procedures, health care provider consultations not foreseen by [CONTACT_12695], and in-patient hospi[INVESTIGATOR_634119] 
A, Part B and Part B post-flare the respective number variable will be set to 0. 
See Section  12.1.2 for specific counting rules for the resource utilization. 
3.2.18  Extra-articular assessments 
The evolution of associated nonmusculoskeletal features including IBD, psoriasis and uveitis 
(including their severity), and flare rate history will be assessed as described in the protocol in 
the schedule of study assessments Table 5.1. For subjects experiencing a flare in Part B, 
corresponding assessments per visit are described in the protocol in the schedule of study 
assessments Table 5.2. 
Incidence of uveitis flares, IBD exacerbations and psoriasis exacerbations will be provided from 
the extra-articular assessments. 
3.2.19  Fecal and serum calprotectin 
The calgranulins, S100A8/S100A9 and S100A12, are calcium-binding proteins of the S100 
family. They are released from activated monocytes and granulocytes at local sites of 
inflammation during the early phase of the immune response. Extracellularly, they exert important pro-inflammatory effects, thereby [CONTACT_634203]. Calgranulins can be measured in serum and stool, and have been found 
to be very sensitive markers of innate immune activation. Moreover, the S100A8/S100A9 
heterodimer, also called calprotectin, has been established for a long time as a fecal marker of disease activity in inflammatory bowel disease. 
Fecal and serum calprotectin levels measured as numerical continuous variables will be assessed 
from the stool and serum samples collected during the stud y. 
3.2.20  Inflammatory Bowel Disease Questionnaire (IBD-Q)  
The IBD-Q is a validated quality of life questionnaire, which combines an assessment of symptoms as a result of IBD, the way the subject has been feeling in general, and how their mood has been over the previous 2 weeks.  REDACTED COPY for specific counting rules for the resource utilization.
REDACTED COPY for specific counting rules for the resource utilization.
The evolution of associated nonmusculoskeletal features including IBD, psoriasis and uveitis 
REDACTED COPY The evolution of associated nonmusculoskeletal features including IBD, psoriasis and uveitis 
heir severity), and flare rate history will be assessed as described in the protocol in 
REDACTED COPY heir severity), and flare rate history will be assessed as described in the protocol in 
the schedule of study assessments Table 5.1. For subjects experiencing a flare in Part B, 
REDACTED COPY the schedule of study assessments Table 5.1. For subjects experiencing a flare in Part B, 
corresponding assessments per visit are described in the protocol in the schedREDACTED COPY corresponding assessments per visit are described in the protocol in the sched
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In case of complete consultation date, count only once for a same subject, same consultation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In case of complete consultation date, count only once for a same subject, same consultation 
only one procedure is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. only one procedure is 
counted, otherwise if at least one variable among procedure name, start date or relationship is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. counted, otherwise if at least one variable among procedure name, start date or relationship is 
If concomitant medical procedures, health care provider consultations not foreseen by
[CONTACT_122253]. If concomitant medical procedures, health care provider consultations not foreseen by
[CONTACT_634204]. emergency room visits are not available during Part 
flare the respective number variable will be set to 0.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare the respective number variable will be set to 0.
for specific counting rules for the resource utilization.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for specific counting rules for the resource utilization.
The evolution of associated nonmusculoskeletal features including IBD, psoriasis and uveitis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The evolution of associated nonmusculoskeletal features including IBD, psoriasis and uveitis 
heir severity), and flare rate history will be assessed as described in the protocol in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. heir severity), and flare rate history will be assessed as described in the protocol in 
the schedule of study assessments Table 5.1. For subjects experiencing a flare in Part B, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the schedule of study assessments Table 5.1. For subjects experiencing a flare in Part B, 
corresponding assessments per visit are described in the protocol in the sched
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. corresponding assessments per visit are described in the protocol in the sched
Incidence of uveitis flares, IBD exacerbations and psoriasis exacerbations will be provided from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Incidence of uveitis flares, IBD exacerbations and psoriasis exacerbations will be provided from 
and serum 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and serum 
The calgranulins, S100A8/S100A9 and S100A12, are calcium
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The calgranulins, S100A8/S100A9 and S100A12, are calcium
family. They are released from activated monocytes and granulocytes at local sites of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. family. They are released from activated monocytes and granulocytes at local sites of 
inflammation during the early phase of the immune response. Extracellularly, they exert 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. inflammation during the early phase of the immune response. Extracellularly, they exert 
inflammatory effects, thereby [CONTACT_634205]. inflammatory effects, thereby [CONTACT_634206]. Calgranulins can be measured in serum and stool, and have been found 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. innate immune reaction. Calgranulins can be measured in serum and stool, and have been found 
to be very sensitive markers of innate immune activation. Moreover, the S100A8/S100A9 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to be very sensitive markers of innate immune activation. Moreover, the S100A8/S100A9 
heterodimer, also called calprotectin, has 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. heterodimer, also called calprotectin, has 
disease activity in inflammatory bowel disease.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. disease activity in inflammatory bowel disease.
Fecal and serum calprotectin levels measured as numerical continuous variables will be assessed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Fecal and serum calprotectin levels measured as numerical continuous variables will be assessed 
from the stool and serum samples collected during the stud
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from the stool and serum samples collected during the stud
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 35 of 149 The IBD-Q contains 32 questions covering 4 domains of subjects’ lives (bowel symptoms, 
systemic symptoms, emotional function, and social function). 
Subjects will be asked to answer questions relating to the impact of their CD on their HR QoL 
over the [ADDRESS_846763] prior to start any study-related activities. 
The method as detailed by [CONTACT_419081], 1989 will be used in the calculation of the IBD-Q score. 
The total IBD-Q global score will be derived as the sum of the responses (from 1 to 7) to all 32 
questions on the IBD-Q and can therefore range from 32 to 224. The IBD-Q score for each of the 
four categories (bowel symptoms, systemic symptoms, emotional function and social function) will be defined as the sum of the responses of the subset of questions of the IBD-Q as specified below: 
 Bowel Symptoms Questions 1, 5, 9, 13, 17, 20, 22, 24, 26, 29 
 Systemic Symptoms Questions 2, 6, 10, 14, 18 
 Emotional Function Questions 3, 7, 11, 15, 19, 21, 23, 25, 27, 30, 31, 32 
 Social Function Questions 4, 8, 12, 16, 28. 
An IBD-Q response is defined as a clinically meaningful improvement in the total IBD-Q global 
score and corresponds to an increase in the total IBD-Q global score ≥16 points from Baseline. 
IBD-Q remission is defined as a total IBD-Q global score ≥170 points.  
The following approach will be applied in the case of partially completed questionnaires.  
The IBD -Q score for the four categories (bowel symptoms, systemic symptoms, emotional 
function and social function) will be calculated if only, at maximum, one of the items responses within the category is missing. The IBD-Q category score will be imputed by [CONTACT_634207]. If two or more items responses are missing within a category, the corresponding IBD-Q category score will be left missing. 
The total IBD-Q global score will be calculated if four or less of the items responses are missing, 
as long as maximum one item per sub score is missing. The total IBD-Q global score will be imputed by [CONTACT_634208] 32. If five or more items responses are missing, the corresponding total IBD- Q 
global score will be left missing. 
Specific counting rules for answers provided to IBD-Q items 
The following rules will apply for analysis of (1) out of range and (2) ambiguous answers (ie, 
invalid or unable to interpret answers) to questionnaires completed by [CONTACT_1766]:  
1. In case of out of range answer (ie, an answer that does not correspond to any possible 
response proposed in the questionnaire, e. g. “?”, “I don’t know” or any value superior or 
inferior to the ones specified in the response options): the answer will be scored as “missing”.  However, in case the subject selects one of the proposed responses but adds a comment (for 
example “6 +++” or “5 ?”), the response (ie, "6" or "5") will be retained for scoring but not 
the comment (ie, "+++" or "?"). In the same way, if the subject selects one of the proposed responses but adds a value superior or inferior to the ones specified in the responses options REDACTED COPY Q response is defined as a clinically meaningful improvement in the total IBD
REDACTED COPY Q response is defined as a clinically meaningful improvement in the total IBD
score and corresponds to an increase in the total IBD
REDACTED COPY score and corresponds to an increase in the total IBD -
REDACTED COPY -Q global score ≥16 points from Baseline. 
REDACTED COPY Q global score ≥16 points from Baseline. 
Q global score ≥170 point
REDACTED COPY Q global score ≥170 point
The following approach will be applied in the case of part
REDACTED COPY The following approach will be applied in the case of part
Q score for the four categories (bowel symptoms, systemic symptoms, emotional 
REDACTED COPY Q score for the four categories (bowel symptoms, systemic symptoms, emotional 
function and social function) will be calculated if REDACTED COPY function and social function) will be calculated if 
The IBDREDACTED COPY The IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q score.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q score.
Q global score will be derived as the sum of the responses (from 1 to 7) to all 32 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q global score will be derived as the sum of the responses (from 1 to 7) to all 32 
Q score for each of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q score for each of the 
and social function) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and social function) 
Q as specified 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q as specified 
ions 3, 7, 11, 15, 19, 21, 23, 25, 27, 30, 31, 32
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ions 3, 7, 11, 15, 19, 21, 23, 25, 27, 30, 31, 32
Q response is defined as a clinically meaningful improvement in the total IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q response is defined as a clinically meaningful improvement in the total IBD
Q global score ≥16 points from Baseline. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q global score ≥16 points from Baseline. 
Q global score ≥170 point
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q global score ≥170 point
The following approach will be applied in the case of part
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following approach will be applied in the case of part
Q score for the four categories (bowel symptoms, systemic symptoms, emotional 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q score for the four categories (bowel symptoms, systemic symptoms, emotional 
function and social function) will be calculated if 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. function and social function) will be calculated if 
The IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The IBD -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Q category score will be imputed by [CONTACT_634209]. Q category score will be imputed by [CONTACT_634210]. score with the number of available items responses and multiplying the result by [CONTACT_634211]. If two or
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. completed items within the category. If two or
category, the corresponding IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. category, the corresponding IBD -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Q category score will be left missing.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q category score will be left missing.
Q global score will be calculated if four or less of the items responses are missing, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q global score will be calculated if four or less of the items responses are missing, 
as long as maximum one item per sub score 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as long as maximum one item per sub score 
imputed by [CONTACT_634212]. imputed by [CONTACT_634208] 32. If five or more items responses are missing, the corresponding total IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the result by 32. If five or more items responses are missing, the corresponding total IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. global score will b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. global score will b e left missing.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e left missing.
Specific counting rules for answers provided to IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Specific counting rules for answers provided to IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following rules will apply for analysis of (1) out of range and (2) ambiguous answers (ie, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following rules will apply for analysis of (1) out of range and (2) ambiguous answers (ie, 
invalid or unable to interpret answers) to questionnaires completed by [CONTACT_1766]: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. invalid or unable to interpret answers) to questionnaires completed by [CONTACT_1766]: 
1.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1.In 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 36 of 149 (for example “4/5” or “-1/2” on a 5-point scale ranging from 0 to 4), the response 
corresponding to the possible responses options (ie, "4" or "2") will be retained for scoring 
but not the values superior or inferior to the responses options (ie, "5" or "-1"). 
2. In case of ambiguous answers (ie, multiple responses to a question allowing only a single 
response, a response marked between two allowed responses): 
a. Multiple responses to a question allowing only a single response: 
 If half or more responses are marked (ie, 4 responses marked on a seven point scale, 3 
responses marked on a 5-point scale, 2 responses to a Yes/No item…): the answer will be scored “missing”. 
 If less than half of the responses are marked: 
 If the responses are NOT adjacent to each other: the answer will be scored “missing”, 
 If the responses are adjacent to each other (“2/3” or “2/3/4”, for instance), the more severe score will be retained (ie the lowest item score for the IBD- Q). 
b. If a response is marked between two allowed responses (for example, the subject marked 
his/her response between 2 and 3 on a 4-point scale allowing only responses 1, 2, 3 and 4): the nearest more severe (lowest) score will be retained. 
3.2.[ADDRESS_846764] has an ASDAS <1.3 at Week 32 or Week 36 (if 
ASDAS <1.[ADDRESS_846765] be <2.1 at Week 36; if ASDAS <2.[ADDRESS_846766] be <1.3 at Week 36) and an ASDAS <1.[ADDRESS_846767] has an ASDAS ≥2.1 at 2 consecutive visits or an ASDAS >3.[ADDRESS_846768] has an intermittent missing ASDAS score ( ie, a missing value at 1 visit but non-
missing values at the previous and subsequent visit), then the missing value will be ignored and the occurrence of a flare will be based on the [ADDRESS_846769] experienced a flare (even if ASDAS scores are available after the missed 
visits). 
There is also the possibility to report one unscheduled ASDAS between two scheduled ASDAS 
assessments. The same rules as for the scheduled ASDAS apply for the unscheduled ASDAS. 
The unscheduled ASDAS will be taken into account for flare calculation for two consecutive 
visits if there are more than [ADDRESS_846770] more severe (lowest) score will be retained.
REDACTED COPY nearest more severe (lowest) score will be retained.
Sustained remission is achieved when a subject has an ASDAS <1.3 at Week 32 or Week 36 (if 
REDACTED COPY Sustained remission is achieved when a subject has an ASDAS <1.3 at Week 32 or Week 36 (if 
ASDAS <1.[ADDRESS_846771] be <2.1 at Week 36
REDACTED COPY ASDAS <1.[ADDRESS_846772] be <2.1 at Week 36
at Week 48. 
REDACTED COPY at Week 48. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the answer will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the answer will be 
If the responses are NOT adjacent to each other: the answer will be scored “missing”,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the responses are NOT adjacent to each other: the answer will be scored “missing”,
If the responses are adjacent to each other (“2/3” or “2/3/4”, for instance), the mor
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the responses are adjacent to each other (“2/3” or “2/3/4”, for instance), the mor
If a response is marked between two allowed responses (for example, the subject marked 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If a response is marked between two allowed responses (for example, the subject marked 
point scale allowing only responses 1, 2, 3 and 4): 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. point scale allowing only responses 1, 2, 3 and 4): 
Sustained remission is achieved when a subject has an ASDAS <1.3 at Week 32 or Week 36 (if 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Sustained remission is achieved when a subject has an ASDAS <1.3 at Week 32 or Week 36 (if 
ASDAS <1.[ADDRESS_846773] be <2.1 at Week 36
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS <1.[ADDRESS_846774] be <2.1 at Week 36 ; if ASDAS <2.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ; if ASDAS <2.[ADDRESS_846775] experienced a
ASDAS >3.5 at any visit during Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS >3.[ADDRESS_846776] has an intermittent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing ASDAS score (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing ASDAS score (
missing values at the previous and subsequent visit), then the missing value will be ignored and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing values at the previous and subsequent visit), then the missing value will be ignored and 
flare will be based on the [ADDRESS_846777]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experienced a flare (even if ASDAS scores are available after the missed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experienced a flare (even if ASDAS scores are available after the missed 
There is also the possibility to report one unscheduled ASDAS between two schedule
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. There is also the possibility to report one unscheduled ASDAS between two schedule
assessme
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessme nts. The same ru
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nts. The same ru
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The unscheduled ASDAS will be taken into account for flare calculation for two consecutive 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The unscheduled ASDAS will be taken into account for flare calculation for two consecutive 
visits if there are more than 13 calendar days between two consecutive ASDAS calculat
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. visits if there are more than 13 calendar days between two consecutive ASDAS calculat
If the ASDAS score is missing at 2 scheduled visits and unscheduled ASDAS entry present in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the ASDAS score is missing at 2 scheduled visits and unscheduled ASDAS entry present in 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 37 of 149 data entered into the eCRF for the individual ASDAS components, not based on data from the 
interactive voice or web response system (IXRS). 
If a subject prematurely withdraws from Part B at any point for any reason, then the subject will 
be considered to have experienced a flare. 
If a subject was incorrectly identified as flared at any point in Part B due to late data entry in 
IXRS and went to escape Part B, then the subject will be considered to have experienced a flare.  
Sensitivity analyses will be conducted using different approaches for definition of flare. These 
approaches are described hereafter. 
[IP_ADDRESS]  Observed case 
Using this approach, a subject will be considered to have experienced a flare only if a subject has 
an ASDAS ≥2.1 at 2 consecutive visits or an ASDAS >3.[ADDRESS_846778]-baseline visit 
during Part B until Week 96 will be evaluable using this approach. 
[IP_ADDRESS]  Alternative handling of premature withdrawal 
In this approach, a different handling of subject experiencing premature withdrawal from Part B 
at any point will be considered. Only subjects with a primary reason for premature withdrawal 
recorded as “adverse event” or “lack of efficacy” will be considered as having a flare. The other subject s experiencing premature withdrawal from Part B will not be considered as having a flare 
(unless other flare criteria are met). 
[IP_ADDRESS]  Mixed model with repeated measures ( MMRM ) imputation of ASDAS 
In this approach, MMRM imputation of missing ASDAS values at any visit in Part B up until 
Week [ADDRESS_846779] has an ASDAS ≥2.1 at 2 consecutive visits or an ASDAS >3.5 at any visit during Part B up until Week 92, taking into 
account both observed and imputed values. 
The MMRM analysis is a special case of the mixed-effects regression model (Siddiqui et al, 
2009) and can be generally written as: 
Y X
Z
where Y   is the continuous variable of which the missing value is estimated; X is the n×p matrix 
of fixed effects in the model; Z is the n×r matrix of variables related to the random component in 
the model; β is the p×1 vector of regression coefficients for the fixed effects; is the r×[ADDRESS_846780] effects; and is the n×1 vector of the random residuals in the model. 
The MMRM imputation of missing ASDAS values will be performed using an 
ANOVA/ANCOVA type of MMRM with randomized treatment arm ( PBO , CZP 200mg Q2W, 
CZP 200mg Q4W), visit (categorical, ie Week 48, 50, 52...), geographic region (North America, 
Western Europe, Eastern Europe and Asia) and mNY classification (mNY positive, mNY 
negative) included  in the model. 
The multiple visits for each subject are the repeated measures as random effect within each subject. REDACTED COPY s with a primary reason for premature withdrawal 
REDACTED COPY s with a primary reason for premature withdrawal 
recorded as “adverse event” or “lack of efficacy” will be considered as having a flare. The other 
REDACTED COPY recorded as “adverse event” or “lack of efficacy” will be considered as having a flare. The other 
from Part B
REDACTED COPY from Part B
Mixed model with repeated measures (
REDACTED COPY Mixed model with repeated measures (
MMRM imputation of missing ASDAS values a
REDACTED COPY MMRM imputation of missing ASDAS values a
premature withdrawal REDACTED COPY premature withdrawal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and went to escape Part B, then the subject will be considered to have experienced a flare. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and went to escape Part B, then the subject will be considered to have experienced a flare. 
These 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These 
only 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. only if a subject has 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. if a subject has 
ASDAS >3.5 at any visit during Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS >3.[ADDRESS_846781]
andling of premature withdrawal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. andling of premature withdrawal
premature withdrawal 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. premature withdrawal 
s with a primary reason for premature withdrawal 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s with a primary reason for premature withdrawal 
recorded as “adverse event” or “lack of efficacy” will be considered as having a flare. The other 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. recorded as “adverse event” or “lack of efficacy” will be considered as having a flare. The other 
from Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from Part B will not be considered as having a flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will not be considered as having a flare 
Mixed model with repeated measures (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Mixed model with repeated measures (
MMRM imputation of missing ASDAS values a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MMRM imputation of missing ASDAS values a
premature withdrawal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. premature withdrawal
assessment at a given visit will be performed. Consequently, using this approach, a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessment at a given visit will be performed. Consequently, using this approach, a 
be considered as having experienced a flare only if a s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be considered as having experienced a flare only if a s
consecutive visits or an ASDAS >3.5 at any visit during Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. consecutive visits or an ASDAS >3.5 at any visit during Part B
account both observed and imputed values.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. account both observed and imputed values.
The MMRM analysis is a special case of the mixed
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The MMRM analysis is a special case of the mixed
2009) and can be generally written as:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2009) and can be generally written as:
is the continuous variable of which the missing value is estimated; 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is the continuous variable of which the missing value is estimated; 
of fixed effects in the model; 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of fixed effects in the model; 
the model; β is the p×1 vector of regression coefficients for the fixed effects; 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the model; β is the p×1 vector of regression coefficients for the fixed effects; 
of random subject effects; and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of random subject effects; and 
The MMRM imputation of missing ASDAS values will be performed using an 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The MMRM imputation of missing ASDAS values will be performed using an 
ANOVA/ANCOVA type of MMRM with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ANOVA/ANCOVA type of MMRM with 
UCB   [ADDRESS_846782]-squares mean at the given 
visit will be used for replacing the missing value.  
[IP_ADDRESS]  Referenced based multiple imputation of ASDAS 
Missing data for the ASDAS scores at any visit in Part B up until Week [ADDRESS_846783] experiencing a flare or of missing assessment at a given visit 
will be handled at each visit via reference based multiple imputation as described below: 
This procedure will use an imputation model developed based on data from the PBO group only 
(Mallinckrodt, 2013). The reference-based multiple imputation assumes that the statistica l 
behavior of the CZP and PBO-treated subjects after discontinuing study medication becomes that 
of the PBO-treated subjects. Data collected after discontinuation of the double-blind study 
treatment for both the CZP and PBO groups will be considered missing. Multiple imputations are used to replace missing outcomes for CZP- and PBO-treated subjects who discontinued using multiple draws from the posterior predictive distribution estimated from the PBO arm.  
For subjects with a non-monotone (intermittent) missing pattern, Markov chain Monte Carlo 
(MCMC) will be used to impute their missing intermittent ASDAS scores by [CONTACT_265913], geographic region and mNY classification. This will be done only once for each subject in order to provide a dataset with monotone missing (seed will be 221).  
Data are processed sequentially by [CONTACT_634213]® PROC MI to impute missing 
outcome data at visits t=1,…. T, where t=1 is Week 48 and t= T is Week 92  
Initialization.   Set t=1 (Part B Baseline visit)  
Iteration . Set t=t+1. Create a data set combining records from CZP- and PBO-treated subjects 
with columns for covariates (geographic region and mNY classification) and outcomes at visits 1 
to t. Outcomes for all CZP-treated subjects are set to missing at visit t and set to observed or 
previously imputed values at visits 1 to t-1. Outcomes for PBO-treated subjects are set to observed at visit t or observed or previously imputed values at visits 1 to t-1. 
Imputation . Run MCMC to impute missing values for visi t t using previous outcomes for visits 1 
to t-1, geographic region and mNY classification. Note that only PBO data will be used to 
estimate the imputation model since no outcome is available for drug-treated subjects at visit t . 
Repeat steps 2a-2d, 20 times with different seed values to create 20 imputed complete data sets 
(seeds will be 51, 52, 53, 54, 55, 56, 57, 58, 59, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 
520, 221). 
Analysis . For each completed data set, the flare status will be calculated using the complete 
datasets (with no missing data). Analysis as described in Section  8.1.1 will be performed in order 
to provide treatment odds ratios, 95% CIs and the p-values from the proc MIanalyze . 
If there are not enough PBO subjects available at the visits to impute the missing ASDAS values 
at the visits in Part B so that the model converted, no data will be presented in the corresponding table.  REDACTED COPY issing pattern, 
REDACTED COPY issing pattern, 
will be used to impute their missing intermittent ASDAS scores by [CONTACT_634214]. This will be done only once for each 
REDACTED COPY and mNY classification. This will be done only once for each 
h monotone missing
REDACTED COPY h monotone missing
Data are processed sequentially by [CONTACT_634213]® PROC MI to impute missing 
REDACTED COPY Data are processed sequentially by [CONTACT_634213]® PROC MI to impute missing 
outcome data at visits t=1,…. T, where REDACTED COPY outcome data at visits t=1,…. T, where t=1 is Week 48 and t=REDACTED COPY t=1 is Week 48 and t=
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. because of subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. because of subject 
or of missing assessment at a given visit 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. or of missing assessment at a given visit 
at each visit via reference based multiple imputation as described below:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. at each visit via reference based multiple imputation as described below:
This procedure will use an imputation model developed based on data from the PBO group only 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This procedure will use an imputation model developed based on data from the PBO group only 
based multiple imputation assumes that the statistica
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based multiple imputation assumes that the statistica
treated subjects after discontinuing study medication becomes that 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treated subjects after discontinuing study medication becomes that 
treated subjects. Data collected after discontinuation of the double
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treated subjects. Data collected after discontinuation of the double
treatment for both the CZP and PBO groups will be considered missin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment for both the CZP and PBO groups will be considered missin g. Multiple imputations are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. g. Multiple imputations are 
treated subjects who discontinued using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treated subjects who discontinued using 
multiple draws from the posterior predictive distribution estimated from the PBO arm. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. multiple draws from the posterior predictive distribution estimated from the PBO arm. 
issing pattern, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. issing pattern, 
will be used to impute their missing intermittent ASDAS scores by [CONTACT_634215]. will be used to impute their missing intermittent ASDAS scores by [CONTACT_634216]. This will be done only once for each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and mNY classification. This will be done only once for each 
h monotone missing
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. h monotone missing
Data are processed sequentially by [CONTACT_634213]® PROC MI to impute missing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Data are processed sequentially by [CONTACT_634213]® PROC MI to impute missing 
t=1 is Week 48 and t=
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. t=1 is Week 48 and t=
Set t=1 (Part B Baseline visit)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Set t=1 (Part B Baseline visit)
+1. Create a data set combining records from CZP
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. +1. Create a data set combining records from CZP
geographic region
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. geographic region
treated subjects are set to missing at v
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treated subjects are set to missing at v
previously imputed values at visits 1 to t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. previously imputed values at visits 1 to t
observed at visit t or observed or previously imputed values at visits 1 to t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. observed at visit t or observed or previously imputed values at visits 1 to t
. Run MCMC to impute missing values for visi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . Run MCMC to impute missing values for visi
geographic region
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. geographic region
estimate the imputation model since no outcome is available for drug
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. estimate the imputation model since no outcome is available for drug
Repeat steps 2a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Repeat steps 2a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (seeds will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (seeds will be 
520, 221)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 520, 221)
Analysis
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Analysis
datasets (with no missing data). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. datasets (with no missing data). 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 39 of 149 3.2.23  Time to flare 
The time to flare will be defined as follows: 
 For subjects who meet the criteria for flare, the flare date will be defined as:  For subjects who first meet the criterion “ASDAS ≥2.1 at 2 consecutive visits”, the date 
of the second ASDAS score will be considered the flare date. 
 For subjects who first meet the criterion “ASDAS >3.5 at any visit”, the date of the 
corresponding ASDAS score will be considered the flare date. 
 The date of the ASDAS score is defined as the date the corresponding BASDAI/PtGADA 
assessments were performed and the CRP sample(s) was (were) collected. If the 
assessments were not performed on the same day, a conservative approach will be used, 
and the latest day will be taken as calculated ASDAS day.  
 Subjects who discontinue the study without Withdrawal Visit will be treated as having 
experienced a flare at the next planned ASDAS visit. The final available ASDAS score date 
+ 32 (4 Weeks + visit window) will be used as flare date. If Week [ADDRESS_846784] 
ASDAS visits, Week 48/Week 50 ASDAS date + 18. (2 weeks + visit window) will be used 
as flare date. 
 Subjects who discontinue the study will be treated as having experienced a flare at the date of their withdrawal visit, if the last ASDAS visit date is not equal with the withdrawal date. If 
the withdrawal date is equal to the last ASDAS visit date, the same approach as for subject 
without Withdrawal Visit will be used for deriving the flare date.  
 Subjects with missing ASDAS scores at [ADDRESS_846785] meets the flare criteria at a later time point. 
 If the date of the second missing ASDAS visit is available, the date of the visit will be 
used.  
 If the date of the second missing ASDAS visit is not available, the last ASDAS date + 60 
(8 weeks +visit window) will be used as flare date. If Week [ADDRESS_846786] ASDAS visits, Week 48 ASDAS date + 32. (4 weeks + visit window) will be used as flare date. If Week 
[ADDRESS_846787] ASDAS visits, Week 50 ASDAS date + 46. (6 weeks + visit window) will 
be used as flare date. 
 For subjects who complete the study without meeting the criteria for flare, the censored date 
will be the last possible date of the event, i.e. Week 96.  
The time to flare will be calculated in days as the difference between the two dates (date of flare 
or censoring date – date of randomization into Part B+ 1). 
Sensitivity analyses will be conducted using different approaches for definition of time to flare. 
These approaches are described hereafter. 
Observed case REDACTED COPY will be treated as having experienced a flare 
REDACTED COPY will be treated as having experienced a flare 
, if the last ASDAS visit date is not equal with
REDACTED COPY , if the last ASDAS visit date is not equal with
the last ASDAS visit date, the same approach as for subject 
REDACTED COPY the last ASDAS visit date, the same approach as for subject 
isit will be used for deriving the flare date. 
REDACTED COPY isit will be used for deriving the flare date. 
Subjects with missing ASDAS scores at 2 or more consecutive visits will
REDACTED COPY Subjects with missing ASDAS scores at 2 or more consecutive visits will
having experienced a flare at the date of the second visit w REDACTED COPY having experienced a flare at the date of the second visit w
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI/PtGADA 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI/PtGADA 
If the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the 
assessments were not performed on the same day, a conservative approach will be used
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessments were not performed on the same day, a conservative approach will be used
be treated as having 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be treated as having 
. The final available ASDAS score date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . The final available ASDAS score date 
+ 32 (4 Weeks + visit window) will be used as flare date. If Week 48 or Week 50 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. + 32 (4 Weeks + visit window) will be used as flare date. If Week 48 or Week 50 
, Week 48/Week 50 ASDAS date + 18. (2 weeks + visit window) will be used 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , Week 48/Week 50 ASDAS date + 18. (2 weeks + visit window) will be used 
will be treated as having experienced a flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be treated as having experienced a flare 
, if the last ASDAS visit date is not equal with
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , if the last ASDAS visit date is not equal with
the last ASDAS visit date, the same approach as for subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the last ASDAS visit date, the same approach as for subject 
isit will be used for deriving the flare date. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. isit will be used for deriving the flare date. 
Subjects with missing ASDAS scores at [ADDRESS_846788] ASDAS date + [ADDRESS_846789] ASDAS date + 60 
(8 weeks +visit window) will be used as flare date. If Week [ADDRESS_846790] ASDAS visits, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (8 weeks +visit window) will be used as flare date. If Week [ADDRESS_846791] ASDAS visits, 
Week 48 ASDAS date + 32. (4 weeks + visit win
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 48 ASDAS date + 32. (4 weeks + visit win
[ADDRESS_846792] ASDAS visits, Week 50 ASDAS date + 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [ADDRESS_846793] ASDAS visits, Week 50 ASDAS date + 
be used as flare date.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be used as flare date.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ubjects who complete the study without meeting the criteria for flare
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ubjects who complete the study without meeting the criteria for flare
will be
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the 
The time to flare will be calculated in days as the difference between the two dates (date of flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The time to flare will be calculated in days as the difference between the two dates (date of flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. or censoring date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. or censoring date 
Sensitivity analyses will be conducted using diff
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Sensitivity analyses will be conducted using diff
UCB   [ADDRESS_846794] has 
an ASDAS ≥2.1 at 2 consecutive visits or an ASDAS >3.[ADDRESS_846795] experiencing premature withdrawal from Part B 
at any point will be considered. Only subjects with a primary reason for premature withdrawal 
recorded as “adverse event” or “lack of efficacy” will be considered as having a flare. The other subject s experiencing premature withdrawal from Part B will not be considered as having a flare 
(unless other flare criteria are met). 
Consequently, subjects with a primary reason for premature withdrawal recorded as “adverse 
event” or “lack of efficacy” will be treated as having experienced a flare at the date of their 
Withdrawal Visit. The other subjects experiencing premature withdrawal from Part B will not be 
considered as having a flare (unless other flare criteria are met) and will be censored at the date 
of their Withdrawal Visit. 
Overview of different approaches for flare definition:  
REDACTED COPY ly, subjects with a primary reason for premature withdrawal recorded as “adverse 
REDACTED COPY ly, subjects with a primary reason for premature withdrawal recorded as “adverse 
will be treated as having experienced a flare 
REDACTED COPY will be treated as having experienced a flare 
experiencing 
REDACTED COPY experiencing 
REDACTED COPY considered as having a flare (unless other flare criteria are met)
REDACTED COPY considered as having a flare (unless other flare criteria are met)
for flare definition: REDACTED COPY for flare definition: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and meets 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and meets 
flare
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare
baseline visit during Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline visit during Part 
premature withdrawal 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. premature withdrawal 
s with a primary reason for prematur
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s with a primary reason for prematur
recorded as “adverse event” or “lack of efficacy” will be considered as having a flare. The other 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. recorded as “adverse event” or “lack of efficacy” will be considered as having a flare. The other 
will not be considered as having a flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will not be considered as having a flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ly, subjects with a primary reason for premature withdrawal recorded as “adverse 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ly, subjects with a primary reason for premature withdrawal recorded as “adverse 
will be treated as having experienced a flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be treated as having experienced a flare 
premature withdrawal 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. premature withdrawal 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. considered as having a flare (unless other flare criteria are met)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. considered as having a flare (unless other flare criteria are met)
for flare definition: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for flare definition: 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 41 of 149 Table 3.3: Flare Definition and Time to Flare 
Reason for flare Event/Censoring 
day Non-
responder 
imputation  Observed 
Case Alternative handling of 
premature 
withdrawal 
ASDAS >=2.1 at 2 consecutive visits Day of 2nd ASDAS Event Event Event 
ASDAS >3.[ADDRESS_846796] discontinued study during Part B due to other 
reason Day of 
discontinuation not 
equal ASDAS visit Event Censored Censored 
No Flare (completed Part B) Week 96 Censored Censored Censored 
Incorrectly ‘flared’ due to delay in data entry 2nd ASDAS visit or 
planned date for the 
2nd ASDAS visit if 
missing  Event Censored Censored 
3.2.[ADDRESS_846797] age 
Age in years will be calculated in the Study Data Tabulation Model (SDTM) data using the 
methodology defined in the UCB Interpretation of the SDTM Implementation Guide. For 
subjects with partial dates of birth (DOB), age will be calculated using the imputed DOB as provided by [CONTACT_165573] (DM). The imputation of partial DOBs by [CONTACT_634217]. 
3.2.[ADDRESS_846798] race 
All subjects enrolled at French sites will not provide race data. Even in the case such data was 
provided by [CONTACT_634218], it will be ignored for tables and only presented in listings. 
3.2.26  Anti-CZP antibody status 
Determination of ADAb will be done using a validated screening, confirmation, and titration 
ADAb bridging assay. The immunogenicity data will be analyzed according to dedicated 
Bioanalytical Analysis plans. 
3.2.27  Modified [LOCATION_001] criteria 
Subjects will be defined as having radiographic axial spondyloarthritis (r-axSpA) or non-
radiographic axial spondyloarthritis (nr- axSpA ) in this study based solely on the radiologic 
criterion. For simplification, r-axSpA will be referred to AS  in the SAP and statistical outputs. If REDACTED COPY Censored
REDACTED COPY Censored
REDACTED COPY REDACTED COPY 2nd ASDAS visit 
REDACTED COPY 2nd ASDAS visit or 
REDACTED COPY or 
lanned date for the 
REDACTED COPY lanned date for the 
2nd ASDAS visit
REDACTED COPY 2nd ASDAS visit
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Censored
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Censored
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Censored
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Censored
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2nd ASDAS visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2nd ASDAS visit if 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. if 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Age in years will be calculated in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Age in years will be calculated in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Study Data Tabulation Model
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Study Data Tabulation Model
methodology defined in the UCB Interpretation of the SDTM Implementation Guide. For 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. methodology defined in the UCB Interpretation of the SDTM Implementation Guide. For 
subjects with partial dates of birth (DOB), age will be calculated using the imputed DOB as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects with partial dates of birth (DOB), age will be calculated using the imputed DOB as 
provided by [CONTACT_165573] (DM). The imputation of parti
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. provided by [CONTACT_165573] (DM). The imputation of parti
CB data management standards
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CB data management standards
Subject race
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subject race
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All subjects enrolled at French sites will not provide race data. Even in the case such data was 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All subjects enrolled at French sites will not provide race data. Even in the case such data was 
provided by [CONTACT_634218], it will be ignored for tables and only presented in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. provided by [CONTACT_634218], it will be ignored for tables and only presented in 
3.2.[ADDRESS_846799] has sacroiliitis grade ≥[ADDRESS_846800] AS/be modified [LOCATION_001] (mNY) positive, otherwise 
they will be considered to have nr-axSPA/be mNY negative. 
The mNY classification will be determined at Screening. MRI will be assessed centrally and by 2 
independent readers. If the results from the readers are different, then the result of the adjudicator 
will be used as the adjudicator's decision was considered final for the inclusion of the subject in the study. If the modified NY criteria data recorded in the ‘Modified NY Criteria for Ankylosing 
Spondylitis’ eCRF differs from the MRI result reported by [CONTACT_9559], the result from central 
review will be used in summary table instead of the result reported in the eCRF.  
3.2.28  Modified ASAS Classification Criteria  
If the results for CRP , human leukocyte antigen B27 ( HLA -B27) or MRI on the ‘M odified 
ASAS Classification Criteria for AS’ eCRF differ from central laboratory results and/or the MRI 
result from central review, respectively, the result of the central laboratory and/or central review of MRI will be used in the summary table for modified ASAS classification criteria.  
3.2.[ADDRESS_846801] study drug administration in Part A (regardless of continuing or stoppi[INVESTIGATOR_56007]) will be considered as prior medication in Part A.  
Prior medication in Part A, stoppi[INVESTIGATOR_634120] A will be considered as ‘past medication’. 
Prior medication in Part A not stopped before first study drug administration in Part A will be 
considered as concomitant medication during Part A. Medication for which the start date is 
between the first date (including the date) of study drug administration in Part A and the date of 
the last study drug administration in Part A +14 days (including the date) and prior to the date of 
first study drug administration in Part B if any, will also be considered as concomitant medication during Part A. 
Medication taken before the date of first study drug administration in Part B (regardless of 
continuing or stoppi[INVESTIGATOR_56007]) will be considered as prior medication in Part B.  
Prior medication in Part B not stopped before first study drug administration in Part B will be considered as concomitant medication during Part B. Medication for which the start date is between the first date (including the date) of study drug administration in Part B and the date of 
the last study drug administration in Part B + 14 days (including the date) will also be considered 
as concomitant medication during Part B. 
In subjects experiencing a flare in Part B, a concomitant medication during Part B taken before 
the date of flare (regardless of continuing or stoppi[INVESTIGATOR_56007]) will be considered pre-
flare concomitant medication in Part B. Concomitant pre-flare medication in Part B not stopped 
before the date of flare will be considered as post-flare concomitant medication during Part B. In 
subjects experiencing a flare in Part B, medication for which the start date is after or on the date 
of flare will also be considered as post-flare concomitant medication during Part B. 
3.[ADDRESS_846802] for 
Part A are the Screening Visit, Week 0, Week 2, Week 4, Week 12, Week 24, Week 32 and REDACTED COPY continuing or stoppi[INVESTIGATOR_56007]) will be considered 
REDACTED COPY continuing or stoppi[INVESTIGATOR_56007]) will be considered 
before the first study drug administration in Part A will be 
REDACTED COPY before the first study drug administration in Part A will be 
Prior medication in Part A not stopped before first study drug a
REDACTED COPY Prior medication in Part A not stopped before first study drug a
considered as concomitant medication during Part A. Medication fo
REDACTED COPY considered as concomitant medication during Part A. Medication fo
between the first date (including the date) of study drug administration in Part A and the date of 
REDACTED COPY between the first date (including the date) of study drug administration in Part A and the date of 
the last study drug administration in Part A REDACTED COPY the last study drug administration in Part A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Modified NY Criteria for Ankylosing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Modified NY Criteria for Ankylosing 
from central 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from central 
‘M
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ‘Modified 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. odified 
central laboratory results 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. central laboratory results and/
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and/
central laboratory 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. central laboratory and/
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and/
for modified ASAS classification criteria
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for modified ASAS classification criteria
Medication taken before the date of first study drug administration in Part A (regardless of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Medication taken before the date of first study drug administration in Part A (regardless of 
as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as prior medication in Part A. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. prior medication in Part A. 
before the first study drug administration in Part A will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. before the first study drug administration in Part A will be 
Prior medication in Part A not stopped before first study drug a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Prior medication in Part A not stopped before first study drug a
considered as concomitant medication during Part A. Medication fo
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. considered as concomitant medication during Part A. Medication fo
between the first date (including the date) of study drug administration in Part A and the date of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. between the first date (including the date) of study drug administration in Part A and the date of 
the last study drug administration in Part A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the last study drug administration in Part A +14 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. +[ADDRESS_846803] study drug administration in Part B (regardless of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Medication taken before the date of first study drug administration in Part B (regardless of 
continuing or stoppi[INVESTIGATOR_56007]) will be considered 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. continuing or stoppi[INVESTIGATOR_56007]) will be considered 
Prior medication in Part B not stopped before first study drug administration in Part B will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Prior medication in Part B not stopped before first study drug administration in Part B will be 
considered as concomitant medication during Part B. Medication for which the start date is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. considered as concomitant medication during Part B. Medication for which the start date is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. between the first date (including the date) of study drug 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. between the first date (including the date) of study drug 
the last study drug administration in Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the last study drug administration in Part B 
as concomitant medication during Part B.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as concomitant medication during Part B.
In subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In subjects experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a 
the date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the date of flare
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of flare
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare co
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare co
before the date of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. before the date of 
subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects 
UCB   [ADDRESS_846804] been the next scheduled visit for the particular assessment 
that is being summarized, unless otherwise specified. These data will be included in the summaries of the assigned visit and the “Early Withdrawal” visit if applicable. If a subject withdraws early during Part A but does not have a Withdrawal Visit in Part A, safety and efficacy data recorded at either the date of the last scheduled or unscheduled visit during the treatment Period, whichever is later, will be included in summaries of “Early Withdrawal” visit. Only post Part A B aseline assessments will be included in the “Early Withdrawal” visit. 
The analysis time point of interest for Part B is Week 96. Additional time points of interest for Part B are Week 48, Week 50, Week 52, Week 54, Week 56, Week 58, Week 60, Week 62, Week 64, Week 66, Week 68, Week 70, Week 72, Week 74, Week 76, Week 78, Week 80, Week 82, Week 84, Week 86, Week 88, Week 90, Week 92 and Week 94. For subjects who 
complete Week 96, safety and efficacy data recorded at a Week 96/withdrawal Visit will be 
included in summaries of the Week 96 visit and the “Last/Withdrawal” visit if applicable. For subjects who withdraw from Part B prior to Week 96, data recorded at the Withdrawal Visit will be assigned to what would have been the next scheduled visit for the particular assessment that is being summarized, unless otherwise specified. These data will be included in the summaries of the assigned visit and the “Last/Withdrawal Visit ” if applicable. If a subject withdraws early 
during Part B but does not have a Week 96/withdrawal Visit, then safety and efficacy data recorded at either the date of the last scheduled or unscheduled visit during the treatment Period, whichever is later, will be included in summaries “Last/Withdrawal Visit ”. For subjects 
experiencing a flare, the last visit prior to escape medication (e.g. Escape Week 0) will be included in the summaries of the “Last/Withdrawal Visit”. Only post Part B Baseline assessments will be included in the “Last/Withdrawal Visit ”.  
The analysis time point of interest for subjects experiencing a flare in Part B is Escape Week 12. Additional time points of interest for this set of subjects are Escape Week 0, Escape Week 2, Escape Week 4, Escape Week 6, Escape Week 8, Escape Week 10, Escape Week 24, Escape Week 36 and the final assessment visit as laid down for Week 96. For subjects who complete the final assessment visit as laid down for Week 96, safety and efficacy data recorded at this visit will be included in summaries of the “Last Visit (Week 96 Termination)” visit and the “Last/Withdrawal Escape ” visit if applicable. For subjects who withdraw prematurely from the 
Escape Part, data recorded at the Withdrawal Visit will be assigned to what would have been the next scheduled visit for the particular assessment that is being summarized, unless otherwise specified. These data will be included in the summaries of the assigned visit and the “Last/Withdrawal Esca pe” visit if applicable. If a subject withdraws early during the Escape Part 
but does not have a Withdrawal Visit, then safety and efficacy data recorded at either the date of 
the last scheduled or unscheduled visit during the Escape Part, whichever is later, will be 
included in summaries “Last/Withdrawal Escape” visit. Only post Flare baseline assessments will be included in the “Last/Withdrawal Escape” visit. 
All visit measurements, even violating the visit window, will be utilized for the respective visit 
as long as they are in the proper sequence. In case of repeated assessments at a particular visit, the last assessment will be used for visit presentation in by-visit summaries (except unscheduled repeats of Week 96). 
PK and ADAb 
REDACTED COPY does not have a Week 96/withdrawal Visit, then safety and efficacy data 
REDACTED COPY does not have a Week 96/withdrawal Visit, then safety and efficacy data 
recorded at either the date of the last scheduled or unscheduled visit during the treatment 
REDACTED COPY recorded at either the date of the last scheduled or unscheduled visit during the treatment 
whichever is later, will be included in summaries “Last/Withdrawal
REDACTED COPY whichever is later, will be included in summaries “Last/Withdrawal
experiencing a flare, the last visit prior to escape medication (e.g. Escape Week 0) will be 
REDACTED COPY experiencing a flare, the last visit prior to escape medication (e.g. Escape Week 0) will be 
included in the summaries of the “Last/Withdrawal Visit”. 
REDACTED COPY included in the summaries of the “Last/Withdrawal Visit”. 
assessments will be included in the “Last/Withdrawal
REDACTED COPY assessments will be included in the “Last/Withdrawal
analysis time point of interest for subjects REDACTED COPY analysis time point of interest for subjects 
Additional time points of interest for this set of subjects are Escape Week 0,REDACTED COPY Additional time points of interest for this set of subjects are Escape Week 0,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ” visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ” visit.
time points of interest for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. time points of interest for 
Part B are Week 48, Week 50, Week 52, Week 54, Week 56, Week 58, Week 60, Week 62, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B are Week 48, Week 50, Week 52, Week 54, Week 56, Week 58, Week 60, Week 62, 
Week 64, Week 66, Week 68, Week 70, Week 72, Week 74, Week 76, Week 78, Week 80, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 64, Week 66, Week 68, Week 70, Week 72, Week 74, Week 76, Week 78, Week 80, 
. For subjects who 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . For subjects who 
withdrawal Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. withdrawal Visit
isit and the “Last/Withdrawal” visit if applicable. For 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. isit and the “Last/Withdrawal” visit if applicable. For 
ata recorded at the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ata recorded at the W
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Withdrawal 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ithdrawal 
be assigned to what would have been the next scheduled visit for the particular assessment that is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be assigned to what would have been the next scheduled visit for the particular assessment that is 
being summarized, unless otherwise specified. These data will be included in the summaries of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. being summarized, unless otherwise specified. These data will be included in the summaries of 
if applicable.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. if applicable. If a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If a subject 
does not have a Week 96/withdrawal Visit, then safety and efficacy data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. does not have a Week 96/withdrawal Visit, then safety and efficacy data 
recorded at either the date of the last scheduled or unscheduled visit during the treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. recorded at either the date of the last scheduled or unscheduled visit during the treatment 
whichever is later, will be included in summaries “Last/Withdrawal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. whichever is later, will be included in summaries “Last/Withdrawal
experiencing a flare, the last visit prior to escape medication (e.g. Escape Week 0) will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a flare, the last visit prior to escape medication (e.g. Escape Week 0) will be 
included in the summaries of the “Last/Withdrawal Visit”. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. included in the summaries of the “Last/Withdrawal Visit”. 
assessments will be included in the “Last/Withdrawal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessments will be included in the “Last/Withdrawal
analysis time point of interest for subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. analysis time point of interest for subjects experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a 
Additional time points of interest for this set of subjects are Escape Week 0,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Additional time points of interest for this set of subjects are Escape Week 0,
Escape Week 4, Escape Week 6, Escape Week 8, Escape Week 10, Escape 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape Week 4, Escape Week 6, Escape Week 8, Escape Week 10, Escape 
Week 36 and the final assessment visit as laid down for Week 96
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 36 and the final assessment visit as laid down for Week 96
final assessment visit as laid down for Week 96, safety and e
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. final assessment visit as laid down for Week 96, safety and e
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be included in summaries of the “
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be included in summaries of the “
Escape
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape ” visit if applicable. For subjects who withdraw prematurely from the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ” visit if applicable. For subjects who withdraw prematurely from the 
, data recorded at the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , data recorded at the 
next scheduled visit for the particular assessment that is being summarized, unless otherwise 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. next scheduled visit for the particular assessment that is being summarized, unless otherwise 
specified. These data will be included in the summaries of the assigned visit and the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. specified. These data will be included in the summaries of the assigned visit and the 
“Last/Withdrawal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. “Last/Withdrawal
does not have a Withdrawal Visit, then safety and efficacy data recorded at either the date of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. does not have a Withdrawal Visit, then safety and efficacy data recorded at either the date of 
the last scheduled or unscheduled visit during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the last scheduled or unscheduled visit during the 
included in summaries “Last/Withdrawal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. included in summaries “Last/Withdrawal
will be included in the “Last/Withdrawal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be included in the “Last/Withdrawal
All visit measurements, even violating the visit window, will be utilized for the respective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All visit measurements, even violating the visit window, will be utilized for the respective 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 44 of 149 For ADAb data the same approach as for the efficacy analysis will be used, i.e for withdrawals to 
assign the withdrawal value to the next scheduled visit for the assessment. However, for PK 
analysis the withdrawal PK result will be only included in summaries of “Withdrawal” and the “Withdrawal Escape” and not assigned to the next scheduled visit. Furthermore, the Withdrawal summaries visit will not summarize  any last visit assessments. 
 
In addition, in the case that a sample is collected one or more days following the scheduled visit date, in which the drug was administered, the PK results for that sample will not be summarized as part of that visit. 
3.3.1  Relative day 
The relative day will be included in different listings as appropriate.  
For Part A, relative day, identified as “relative day [a]”, will be calculated relative to the first 
CZP administration in Part A. Relative day [a] will be calculated as follows:  
Relative day [a] of date X = date X - Date of first CZP administration in Part A+[ADDRESS_846805] CZP administration in Part A. 
Relative day [a] of date X = date X - Date of first CZP administration if date X is before date of 
first CZP administration in Part A. Relative day [a] before first CZP administration in Part A will 
have the prefix “- ”. 
Relative day [a] after last CZP administration in Part A will have the prefix “+”, and will be 
calculated from the date of last CZP administration in Part A (date X - date of last CZP administration in Part A). 
For Part B, relative day, identified as “relat ive day [b]”, will be calculated relative to the first 
study medication administration in Part B. Relative day [b] will be calculated as follows:  
Relative day [b] of date X = date X - Date of first study medication administration in Part B+[ADDRESS_846806] study medication administration in Part B. Relative day [b] of date X = date X - Date of first study medication administration if date X is 
before date of first study medication administration in Part B. Relative day [b] before first 
administration of study medication in Part B will have the prefix “- ”. 
Relative day [b] after last study medication administration in Part B will have the prefix “+”, and 
will be calculated from the date of last study medication administration in Part B (date X - date 
of last study medication administration in Part B). 
For subjects experiencing a flare and starting escape therapy, an additional relative day, 
identified as “relative day [f]”, will be calculated relative to the first study escape therapy 
administration in Part B. This additional relative day [f] will be calculated as follows:  
Relative day [f] of date X = date X - Date of first study escape therapy administration in Part 
B+[ADDRESS_846807] escape therapy administration in Part B. 
Relative day [f] of date X = date X - Date of first escape therapy administration if date X is 
before date of first escape therapy administration in Part B. Relative day [f] before first escape 
therapy administration in Part B will have the prefix “- ”. REDACTED COPY CZP administration in Part A
REDACTED COPY CZP administration in Part A
calculated from the date of last CZP administration in Part A (date X 
REDACTED COPY calculated from the date of last CZP administration in Part A (date X 
“relat
REDACTED COPY “relat ive day [b]”, 
REDACTED COPY ive day [b]”, 
study medication administration in Part B. Relative dayREDACTED COPY study medication administration in Part B. Relative day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date, in which the drug was administered, the PK results for that sample will not be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date, in which the drug was administered, the PK results for that sample will not be summarized 
will be calculated relative to the first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be calculated relative to the first 
will be calculated as follows: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be calculated as follows: 
Date of first CZP administration in Part A+[ADDRESS_846808] CZP administration in Part A+[ADDRESS_846809] the prefix “+”, and will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will have the prefix “+”, and will be 
calculated from the date of last CZP administration in Part A (date X 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. calculated from the date of last CZP administration in Part A (date X 
ive day [b]”, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ive day [b]”, 
study medication administration in Part B. Relative day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study medication administration in Part B. Relative day
Date of first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Date of first 
on or after date of first study medication administration in Part B.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. on or after date of first study medication administration in Part B.
of date X = date X 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of date X = date X 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study medication
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study medication
administration of study medication in Part B will have the prefix “
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. administration of study medication in Part B will have the prefix “
after last study medication
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. after last study medication
will be calculated from the date of last study medication administration in Part B (date X 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be calculated from the date of last study medication administration in Part B (date X 
of last study medication administration in Part B).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of last study medication administration in Part B).
For subjects experiencing a flare and starting escape therapy, an additiona
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For subjects experiencing a flare and starting escape therapy, an additiona
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. identified as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. identified as “relative day [f]”, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. “relative day [f]”, 
administration in Part B. This additional relative day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. administration in Part B. This additional relative day
Relative day 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Relative day 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B+[ADDRESS_846810] 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B+[ADDRESS_846811] 
Relative day 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Relative day 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 45 of 149 Relative day [f] after last escape therapy administration in Part B will have the prefix “+”, and 
will be calculated from the date of last escape therapy administration in Part B (date X - date of last escape therapy administration in Part B). 
Calculations of “Relative Day” will not include partial dates, but will be left blank in these 
instances. 
3.3.2  End date of the Treatment Period 
The end date of the treatment Period will be either Week 48 for subjects who completed Part A 
and did not meet the criteria to be randomized into Part B, Week 96 for subjects completing the treatment Period of Part B, or the date of the Withdrawal Visit for subjects who discontinued during the treatment Period (whether Part A or Part B). If a subject does not have a Week 96/Withdrawal Visit or has visits after Week [ADDRESS_846812] noted “Part A Baselin e” will be defined as the latest 
measurement for that subject up to and including the day of administration of first study 
medication in Part A, unless otherwise stated. If a Part A Baseline measurement is missing or not 
collected, and a Screening value is available, the Screening value will be utilized as Part A Baseline instead. If no measurement is available prior to receiving study medication in Part A, the Part A Baseline value is treated as missing.  
For subjects randomized into Part B, a “Part B Baseline” will be defined as the latest 
measurement for that subject up to and including the day of randomization, unless otherwise 
stated. If a Part B Baseline measurement is missing or not collected, and a post-Baseline Part A 
value is available, the post-Baseline Part A value will be utilized as Part B Baseline instead. If no 
post-Baseline Part A measurement is available prior to randomization, the Part B Baseline value 
is treated as missing.  
For subjects experiencing a flare in Part B, a “Flare Baseline” will be defined as the latest 
measurement for that subject up to and including the day of administration of first escape 
treatment in Part B, unless otherwise stated. If a Flare Baseline measurement is missing or not 
collected, and a post-Baseline Part B value is available, the post-Baseline Part B value will be 
utilized as Flare Baseline instead. If no post-Baseline Part B measurement is available prior to 
receiving study medication in Escape Part, the Flare Baseline value is treated as missing. If a 
subject does not receive study medication in Escape Part, the last available post-Baseline Part B 
measurement will be used as Flare Baseline.    
For each baseline definition, if there is evidence that measurements taken on the same day as 
administration of first study medication (in Part A/Part B) or first escape treatment (for subjects experiencing a flare in Part B) were actually taken after this administration, then only values 
strictly prior to that date (including screening assessment visits if appropriate) will be used for 
that subject. When the date of first dose is derived, it should be based on the first injection of 
study treatment, regardless of whether it is an active treatment. REDACTED COPY measurement for that subject up to and including the day of administration of first study 
REDACTED COPY measurement for that subject up to and including the day of administration of first study 
Part A 
REDACTED COPY Part A 
collected, and a Screening value is available, the Screening value will be utilized as 
REDACTED COPY collected, and a Screening value is available, the Screening value will be utilized as 
Baseline instead. If no measurement is available prior to receiving study medication
REDACTED COPY Baseline instead. If no measurement is available prior to receiving study medication
s treated as missing.
REDACTED COPY s treated as missing.
or subjects randomized into Part B, a “Part B Baseline” will be defined as the latest 
REDACTED COPY or subjects randomized into Part B, a “Part B Baseline” will be defined as the latest 
measurement for that subject up to and including the day of REDACTED COPY measurement for that subject up to and including the day of 
Baseline measurement is missing orREDACTED COPY Baseline measurement is missing or
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nd date of the treatment Period will be either Week 48 for subjects who completed Part A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nd date of the treatment Period will be either Week 48 for subjects who completed Part A 
and did not meet the criteria to be randomized into Part B, Week 96 for subjects completing the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and did not meet the criteria to be randomized into Part B, Week 96 for subjects completing the 
jects who discontinued 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. jects who discontinued 
during the treatment Period (whether Part A or Part B). If a subject does not have a Week 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the treatment Period (whether Part A or Part B). If a subject does not have a Week 
or has visits after Week [ADDRESS_846813] study 
Baseline measurement is missing or not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline measurement is missing or not 
collected, and a Screening value is available, the Screening value will be utilized as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. collected, and a Screening value is available, the Screening value will be utilized as 
Baseline instead. If no measurement is available prior to receiving study medication
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline instead. If no measurement is available prior to receiving study medication
or subjects randomized into Part B, a “Part B Baseline” will be defined as the latest 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. or subjects randomized into Part B, a “Part B Baseline” will be defined as the latest 
measurement for that subject up to and including the day of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. measurement for that subject up to and including the day of 
Baseline measurement is missing or
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline measurement is missing or
Baseline Part A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline Part A
measurement is available prior to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. measurement is available prior to 
experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a flare in Part B, a “
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B, a “
measurement for that subject up to and including the day of administration of first escape 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. measurement for that subject up to and including the day of administration of first escape 
in Part B, unless otherwise stated.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in Part B, unless otherwise stated.
post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. post-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Baseline Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Flare Baseline instead. If no 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline instead. If no 
receiving study medicat
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. receiving study medicat
subject does not receive study medication in Escape Part
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subject does not receive study medication in Escape Part
measurement will be used as Flare Baseline.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. measurement will be used as Flare Baseline.
For each
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For each
administration of first study medication (in Part A/Part B) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. administration of first study medication (in Part A/Part B) 
experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 46 of 149 Cases where the baseline value cannot be derived will be reviewed at the data evaluation meeting 
prior to database lock to determine an appropriate imputed value to use as substitute. 
3.5 Protocol deviations 
Important protocol deviations will be predefined in the AS0005 Protocol Deviation Specification 
(PDS) document. Pre-analysis data evaluation meetings will be held prior to the Part A and Part 
B database locks.  
The aim of the pre-analysis data reviews are to review the Data Management snapshot and draft 
and accept the list of protocol deviations which will then be used to determine exclusion from 
analysis sets as appropriate. These protocol deviations will be assessed as important by a panel including the clinical project manager, lead clinical development representative, study 
statistician, and other appropriate clinical study team members using the criteria pre-specified 
within the PDS document. 
3.6 Analysis sets 
There will be 11 analysis sets used within this study.  
3.6.1  Enrolled Set 
The Enrolled Set (ES) will consist of all subjects who have given informed consent. 
3.6.2  Open-Label Set 
The Open-Label Set (OLS) will consist of all subjects who receive at least 1 dose of study 
medication in the Open-Label Period of the study (Part A). 
3.6.3  Randomized Set 
The Randomized Set (RS) will consist of all subjects randomized into Part B of the study. 3.6.4  Safety Set 
The Safety Set (SS) will consist of all subjects in the ES who have received at least 1 dose of 
study medication. 3.6.5  Safety Set Part B 
The Safety Set Part B (SSB) will consist of all subjects in the RS who have received at least 1 
dose of study medication in the Double-Blind Period of the study (Part B). 
3.6.6  Full Analysis Set 
The Full Analysis Set (FAS) will be used to evaluate the sensitivity of the results of the primary 
efficacy analysis. The FAS will consist of all subjects in the RS who have received at least [ADDRESS_846814] 1 time point following Week 48. 
3.6.7  Per Protocol Set 
The Per Protocol Set (PPS) will be used to evaluate the sensitivity of the results of the primary 
efficacy analysis. The PPS will consist of subjects in the FAS without any important protocol 
deviations that may influence the validity of the data for the primary efficacy variable.  REDACTED COPY e Enrolled Set (ES) will consist of all subjects who have given informed consent.
REDACTED COPY e Enrolled Set (ES) will consist of all subjects who have given informed consent.
Label Set (OLS) will consist of all subjects who receive at least 1 dose of study 
REDACTED COPY Label Set (OLS) will consist of all subjects who receive at least 1 dose of study 
Label Period of the study (Part A).
REDACTED COPY Label Period of the study (Part A).
The Randomized Set (RS) will consist of all subjects randomized into Part B of the study. REDACTED COPY The Randomized Set (RS) will consist of all subjects randomized into Part B of the study.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ement snapshot and draft 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ement snapshot and draft 
and accept the list of protocol deviations which will then be used to determine exclusion from
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and accept the list of protocol deviations which will then be used to determine exclusion from
These protocol deviations will be assessed as important by a panel 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These protocol deviations will be assessed as important by a panel 
lead clinical development representative, study 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. lead clinical development representative, study 
statistician, and other appropriate clinical study team members using the criteria pre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. statistician, and other appropriate clinical study team members using the criteria pre -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -specified 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. specified 
e Enrolled Set (ES) will consist of all subjects who have given informed consent.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e Enrolled Set (ES) will consist of all subjects who have given informed consent.
Label Set (OLS) will consist of all subjects who receive at least 1 dose of study 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Label Set (OLS) will consist of all subjects who receive at least 1 dose of study 
Label Period of the study (Part A).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Label Period of the study (Part A).
The Randomized Set (RS) will consist of all subjects randomized into Part B of the study.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Randomized Set (RS) will consist of all subjects randomized into Part B of the study.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Safety Set (SS) will consist of all subjects in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Safety Set (SS) will consist of all subjects in the 
Safety Set
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Safety Set Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B
rt B (SSB) will consist of all subjects in the RS who have received at least
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rt B (SSB) will consist of all subjects in the RS who have received at least
dose of study medication in the Double
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose of study medication in the Double
Full Analysis Set
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Full Analysis Set
The Full Analysis Set (FAS) will be used to evaluate the sensitivity of the results 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Full Analysis Set (FAS) will be used to evaluate the sensitivity of the results 
efficacy analysis
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. efficacy analysis
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose of study medication in Part B, and have valid ASDAS measurements at Week [ADDRESS_846815] 1 
3.6.7
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.6.7
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 47 of 149 3.6.8  Pharmacokinetic Set B 
The Pharmacokinetic Set B (PKSB) will consist of all subjects from the SSB who provide at 
least 1 PK sample during Part B. 
3.6.9  Flared Set 
The Flared Set (FS) will consist of all subjects from the RS experiencing a flare in Part B. Since 
IXRS will be used to determine whether flare criteria (ASDAS>3.5 once or >2.1 on 2 
consecutive visits, or ASDAS missing on 2 consecutive visits) are met during the course of the 
study, the population will be based on the IXRS data and whether they enter the E scape Part 
according to IXRS.  
3.6.10  Escape Therapy Set  
The Escape Therapy Set (ETS) will consist of all subjects from the FS who have received at least 
1 dose of escape therapy. 
3.6.11  Part B Full-dose Set 
The Part B Full-Dose Set (FDS) will include all subjects from the RS who ever received a dose 
of CZP Q2W during Part B (including escape treatment). 
3.6.12   General use of the Analysis Sets 
Efficacy summaries for variables collected in Part A will be based on the OLS. All efficacy 
analyses for Part B will be performed using the RS. The FAS and PPS will be used for a 
sensitivity analysis on the primary endpoint only. The other efficacy variables for subjects 
experiencing a flare in Part B will be based on the FS.  
All safety summaries in Part A will be based on the SS. All safety summaries in Part B will be 
based on the SSB. The other safety variables for subjects experiencing a flare in Part B will be 
based on the ETS.  
Pharmacokinetic and immunogenicity summaries will be based on PKSB.  
3.7 Treatment assignment and treatment groups 
During Part A, all subjects will receive the same treatment consisting of 3 loading doses of CZP 
subcutaneous 400mg Q2W, followed by [CONTACT_18322] 200mg Q2W. In the tabular summaries for Part A, 
all subjects will be summarized together, under a ”All Subject” column. Summary tables may present subjects overall as well as broken out by [CONTACT_634219]- axSpA  and AS. 
During Part B, subjects are expected to receive their treatment as randomized (PBO, CZP 200mg 
Q2W, CZP 200mg Q4W), unless escape treatment is required as a result of a flare. In the tabular 
summaries for Part B, subjects will be summarized according to their randomized or actual treatment group. Select summary tables will also present subjects broken out by [CONTACT_634220]. In the tabular summaries for subjects experiencing a flare during Part B, subjects will be summarized according to their randomized treatment group; an overall column may also be included in select summary tables of safety data for these subjects. 
Treatment assignments for the RS, FAS, PPS and FS will be according to randomization. 
Treatment assignments for the SSB, PKSB and ETS will be according to the actual treatment subjects received in Part B. REDACTED COPY General use of the Analysis Sets
REDACTED COPY General use of the Analysis Sets
for variables collected in Part A will be based on the OLS. All efficacy 
REDACTED COPY for variables collected in Part A will be based on the OLS. All efficacy 
Part B will be performed using the RS. The FAS and PPS will be used for a 
REDACTED COPY Part B will be performed using the RS. The FAS and PPS will be used for a 
sensitivity analysis on the primary endpoint only. The other efficacy variables for subjects 
REDACTED COPY sensitivity analysis on the primary endpoint only. The other efficacy variables for subjects 
flare in Part B will be based on the FS
REDACTED COPY flare in Part B will be based on the FS
will be based on the SS. All safety summaries in Part B will be REDACTED COPY will be based on the SS. All safety summaries in Part B will be 
based on the SSB. The other safety variables for subjects REDACTED COPY based on the SSB. The other safety variables for subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the course of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during the course of the 
P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. art 
who have received at least 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. who have received at least 
will include all subjects from the RS who ever received a dose 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will include all subjects from the RS who ever received a dose 
for variables collected in Part A will be based on the OLS. All efficacy 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for variables collected in Part A will be based on the OLS. All efficacy 
Part B will be performed using the RS. The FAS and PPS will be used for a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B will be performed using the RS. The FAS and PPS will be used for a 
sensitivity analysis on the primary endpoint only. The other efficacy variables for subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sensitivity analysis on the primary endpoint only. The other efficacy variables for subjects 
flare in Part B will be based on the FS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B will be based on the FS
will be based on the SS. All safety summaries in Part B will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be based on the SS. All safety summaries in Part B will be 
based on the SSB. The other safety variables for subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based on the SSB. The other safety variables for subjects 
and immunogenicity 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and immunogenicity 
Treatment assignment and treatment groups
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment assignment and treatment groups
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , all subjects will receive the same treatment consisting of 3 loading doses of CZP 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , all subjects will receive the same treatment consisting of 3 loading doses of CZP 
400mg Q2W
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 400mg Q2W
all subjects will be summariz
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. all subjects will be summariz
present subjects overall as well as broken out by 
[CONTACT_122253]. present subjects overall as well as broken out by 
[CONTACT_634221] B, subjects are expected to receive their treatment as randomized (PBO, CZP 200mg 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. During Part B, subjects are expected to receive their treatment as randomized (PBO, CZP 200mg 
Q2W, CZP 200m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q2W, CZP 200m
summarie
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarie s for Part B, subjects will be summarized according to their randomized or actual 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s for Part B, subjects will be summarized according to their randomized or actual 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group. Select summary tables will also present subjects broken out by 
[CONTACT_122253]. treatment group. Select summary tables will also present subjects broken out by 
[CONTACT_634222]. subpopulation
will be summarized according to their randomized treatment group; an overall column may also 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be summarized according to their randomized treatment group; an overall column may also 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 48 of 149 3.8 Center pooling strategy 
Due to the small number of subjects expected at each center, centers will be pooled into regions 
(North America, Western Europe, Eastern Europe and Asia) for analysis purposes. The list of 
countries assigned to each region is provided in the table below. 
Table 3.4: List of countries in each region 
Region List of countries 
North America [LOCATION_003]  
Western Europe Belgium 
[LOCATION_009] 
[LOCATION_013] 
Netherlands Spain 
[LOCATION_008]
 
Eastern Europe Bulgaria 
Czech Republic Hungary 
Poland 
Romania 
Asia Turkey  
Taiwan  
 
3.9 Coding dictionaries 
Medical history and AEs will be recorded and coded using version 19.0 of the Medical 
Dictionary for Regulatory Activities (MedDRA®) criteria. Medications will be coded using the 
version from September 2015 of the World Health Organization Drug Dictionary (WHO-DD). Medical procedures will not be coded. 
3.[ADDRESS_846816] escape treatment in Part B instead of the visit in which the flare occurred. 
In addition to the protocol, a modified version for ASDAS-MI is added for sensitivity analysis of 
ASDAS- MI.  
Furthermore, analysis for IBD-Q response and IBD-Q remission using Part A Baseline and Part 
B Baseline as a reference and SF -36 PCS response and SF-36 MCS response using Part A 
Baseline as a reference are added. 
Exploratory statistical comparisons for WPS will be based on MMRM instead of nonparametric 
bootstrap-t method. REDACTED COPY Czech Republic
REDACTED COPY Czech Republic
Hungary
REDACTED COPY Hungary
Poland
REDACTED COPY Poland
Romania
REDACTED COPY Romania
REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Czech Republic
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Czech Republic
Hungary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Hungary
Poland
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Poland
Romania
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Romania
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Turkey
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Turkey
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Coding dictionaries
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Coding dictionaries
Medical history and AEs will be recorded and coded using version 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Medical history and AEs will be recorded and coded using version 
Dictionary for Regulatory Activities (MedDRA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Dictionary for Regulatory Activities (MedDRA
from September [ADDRESS_846817] escape treatment in Part B 
In addition to the protocol, a modified version for ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition to the protocol, a modified version for ASDAS
ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS
Fur
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Fur
B Baseline as a reference
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B Baseline as a reference
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 49 of 149 ASDAS-Moderate Disease changed to ASDAS-Low Disease activit y (Machado et al. 2018). 
LOCF analysis are removed from Part B efficacy tables.  
MMRM will be used instead of ANCOVA based on LOCF for   
 Total spi[INVESTIGATOR_18172] 
 Nocturnal spi[INVESTIGATOR_18172] 
 PtGADA 
 Average of Questions 5 and 6 of the BASDAI concerning morning stiffness 
 SF-36 PCS, MCS, and physical function domain 
 Fatigue NRS 
 ASQoL. 
The primary purpose of the study is to evaluate treatment options of axSpA patients after being 
in sustained remission. Hence, one of the objectives is to evaluate the PK and immunogenicity of 
these patients. The CZP plasma concentration and ADAb titer of the patients that did not reach 
sustained remission are therefore not analysed , the Pharmacokinetic Set A (PKSA) as described 
in the protocol has been removed from the SAP.  
4 STATISTICAL/ANALYTIC AL ISSUES 
4.[ADDRESS_846818] values of the stratification factors (including any corrections post randomization) will be used for the analyses.  
4.[ADDRESS_846819]-flare efficacy data (except radiographic data) for subjects experiencing a flare (in any treatment group) will be treated as missing in Part B analyses. The pattern of missingness for these variables is assumed to be missing at random (MAR). For the summaries of data collected 
at post-flare visits in subjects experiencing a flare, there will be no adjustment for missing values 
and only observed case descriptive summaries will be provided. 
For the primary efficacy variable (percentage of subjects in Part B who do not experience a 
flare), an approach based on the principles of NRI will be used to impute missing values. 
Specifically, if a subject withdraws from Part B at any point, they will be considered as having not responded to treatment. Therefore, they will be assumed to have experienced a flare during 
Part B for analysis purposes. Sensitivity analyses will be performed to assess the robustness of 
the results obtained using the NRI approach. Refer to Section  3.2.[ADDRESS_846820] values of the stratification factors (including any corrections 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the correct values of the stratification factors (including any corrections 
post randomization) will be used for the analyses
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. post randomization) will be used for the analyses
Handling of dropouts or missing data
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Handling of dropouts or missing data
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare efficacy data (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare efficacy data (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. except radiographic data) for subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. except radiographic data) for subjects 
treatment group) will be treated as missing in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group) will be treated as missing in 
these variables is assumed to be missing at random (MAR). For the summaries of data collected 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. these variables is assumed to be missing at random (MAR). For the summaries of data collected 
flare visits in subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare visits in subjects 
and only observed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and only observed 
For the primary efficacy variable (percentage of subjects in Part B who do not experience a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the primary efficacy variable (percentage of subjects in Part B who do not experience a 
flare), an approach based on the principles of NRI will be used to impute missing values.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare), an approach based on the principles of NRI will be used to impute missing values.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Specifically, if a subject wi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Specifically, if a subject wi
not responded to treatment. Therefore, they will be assumed to have experienced a flare during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. not responded to treatment. Therefore, they will be assumed to have experienced a flare during 
Part B for analysis purposes. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B for analysis purposes. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 50 of 149 flare. Similarly, sensitivity analyses will also be performed to assess the robustness of the results 
obtained using the NRI approach. Refer to Section  3.2.23  of this SAP for further details. 
For all analyses of binary endpoints (sustained remission, ASDAS-MI, ASDAS-CII, modified ASDAS- MI, ASAS20, ASAS40, ASAS5/6, ASAS PR, BASDAI50 response , IBD -Q remission, 
IBD-Q response, SF-36 PCS response, SF-36 MCS response) NRI will be used. Thus, unless 
mentioned otherwise (see Section  3.2.2  for ASAS20, ASAS40, ASAS5/6 and ASAS PR), a 
subject having missing data for the time point assessed will be conservatively counted as a non-
responder. This will be done whether the data is missing, the subject discontinued prior to the 
time point assessed, or the data is considered missing due to start of escape treatment. For the 
following continuous endpoints in Part A, imputation of missing data will be performed using 
the LOCF approach: 
 ASDAS 
 BASDAI 
 Fatigue item of BASDAI 
 BASFI 
 BASMI 
 Nocturnal spi[INVESTIGATOR_463121] 
 PtGADA 
 CRP  
In addition, ASDAS disease activity levels (ASDAS-ID, ASDAS- LD, ASDAS-HD and ASDAS-
vHD) will be imputed based on the imputed values of ASDAS. 
The LOCF imputation will be done whether the data is missing, the subject discontinued prior to 
the time point assessed, or the data is considered missing due to start of escape treatment. 
Unless otherwise stated, the following guidelines apply for the LOCF analyses: 
 For missing post-baseline Part A assessments, only carry forward earlier Part A post-
Baseline values. Screening and Part A Baseline values do not get carried forward to the Part 
A post-Baseline visits. 
 For missing post Week 48 Part B assessments,  
 if the subject did not experience a flare in Part B, only carry forward earlier Part B post-
Week 48 values,  
 if the subject experienced a flare in Part B, the assessment at Escape week [ADDRESS_846821] 48 
Part B assessments up to the week of flare (the later visit if flare was based on 2 visits), carry forward earlier Part B post-Week [ADDRESS_846822] for the assessment s 
after week 72 in Part B (76, 80, 84, 88, 92 and 96) REDACTED COPY In addition, ASDAS disease activity levels (ASDAS
REDACTED COPY In addition, ASDAS disease activity levels (ASDAS
vHD) will be imputed based on the iREDACTED COPY vHD) will be imputed based on the i mputed values of ASDAS.REDACTED COPY mputed values of ASDAS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessed will be conservatively counted as a no
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessed will be conservatively counted as a no n
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. n-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -
responder. This will be done whether the data is missing, the subject discontinued prior to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. responder. This will be done whether the data is missing, the subject discontinued prior to the 
For the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the 
rmed using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rmed using 
In addition, ASDAS disease activity levels (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, ASDAS disease activity levels (ASDAS
mputed values of ASDAS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mputed values of ASDAS.
The LOCF imputation will be done whether the data is missing, the subject discontinued prior to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The LOCF imputation will be done whether the data is missing, the subject discontinued prior to 
assessed, or the data is considered missing due to start of escape treatment.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessed, or the data is considered missing due to start of escape treatment.
Unless otherwise stated, the following guid
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Unless otherwise stated, the following guid
baseline Part A assessments, only carry forward earlier Part A post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline Part A assessments, only carry forward earlier Part A post
aseline values. Screening and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. aseline values. Screening and 
aseline visits
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. aseline visits
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For missing post Week [ADDRESS_846823] 
Week 48 values
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 48 values

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. if the subject experience
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. if the subject experience
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 51 of 149  Week [ADDRESS_846824]-Baseline visits. 
 Assessments during escape treatment will not be carried forward. 
 The following continuous endpoints in Part B will be compared between treatment groups 
using a mixed model for repeated measures (MMRM). The pattern of missingness for these variables is assumed to be MAR. Subjects who enter Part B will have already demonstrated sustained remission through [ADDRESS_846825]-flare data for subjects experiencing a flare (in any treatment group) will be treated as 
missing for the MMRM analysis. It is further assumed that most subjects who discontinue at 
this late stage in the study (i.e. during Part B) will do so as a result of reduced efficacy. 
Therefore, missing efficacy data due to either flare or study treatment discontinuation should 
be dependent on the observed efficacy scores, but independent of unobserved data. For the 
following continuous endpoints in Part B, imputation of missing data will be performed using 
the MMRM approach: 
 ASDAS 
 BASDAI 
 Average of Questions 5 and 6 of the BASDAI concerning morning stiffness 
 Fatigue item of BASDAI 
 BASFI 
 BASMI 
 Total spi[INVESTIGATOR_463121] 
 Nocturnal spi[INVESTIGATOR_463121] 
 ASQoL 
 PtGADA 
 SF-36 physical functioning score 
 SF-36 PCS 
 SF-36 MCS 
 WPS  
The below rules will be applied for imputation of partial and missing start date of medications: 
 If start day is missing, but month and year are present, start date will be replaced by [CONTACT_634223] A, if study 
medication in Part A was first administered in that month and year (exception: if in this case 
start date is after stop date, also the first day of the months will be utilized). 
 If start day and month are missing and year is present, start date will be replaced by [CONTACT_634224] A, if study medication in Part A was first administered in that year (exception: if in this case start 
date is after stop date, also the first day of January will be utilized). REDACTED COPY Average of Questions 5 and 6 of the BASDAI concerning 
REDACTED COPY Average of Questions 5 and 6 of the BASDAI concerning 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. W. Many of these subjects will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. W. Many of these subjects will be 
flare (in any treatment group) will be treated as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare (in any treatment group) will be treated as 
rther assumed that most subjects who discontinue at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rther assumed that most subjects who discontinue at 
during Part B) will do so as a result of reduced efficacy. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during Part B) will do so as a result of reduced efficacy. 
Therefore, missing efficacy data due to either flare or study treatment discontinuation should 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Therefore, missing efficacy data due to either flare or study treatment discontinuation should 
the observed efficacy scores, but independent of unobserved data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the observed efficacy scores, but independent of unobserved data.
, imputation of missing data will be performed using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , imputation of missing data will be performed using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Average of Questions [ADDRESS_846826] 
day of the month of that year or by [CONTACT_634225]. day of the month of that year or by [CONTACT_634226]   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 52 of 149  If start day, month, and year are missing, start date will be replaced by [CONTACT_634227] A or by [CONTACT_634228], if the first administration date is after the end date. 
If medications are not ongoing (stopped) and the stop date is incomplete or missing, the following rules will be applied: 
 If stop day is missing, but month and year are present, stop date will be replaced by [CONTACT_634229] B if the last 
study drug administration in Part B occurs in that months and subject did not experience a 
flare. In subjects experiencing a flare in Part B and start escape therapy, stop date will be replaced by [CONTACT_634230]. For subjects not 
randomized into Part B, stop date will be replaced by [CONTACT_634231] A if the last study drug administration in Part A 
occurs in that month. If in result of imputation, the stop date is before start date, also the last 
day of the months will be utilized. 
 If stop day and months are missing and year is present, stop date will be replaced by [CONTACT_634232] B if the 
last study drug administration in Part B was in that year and subject did not experience a 
flare. In subjects experiencing a flare in Part B and start escape therapy, stop date will be replaced by [CONTACT_634233]. For subjects 
not randomized into Part B, replacement by [CONTACT_634234] A will be performed if the last study drug administration in Part A was 
in that year. If in result of imputation, the stop date is before start date, also the last day of 
December will be utilized. 
 If stop day, months, and year are missing, stop date will be replaced by [CONTACT_634235]-blind period or by [CONTACT_634236], if the last visit in the double-blind period date is before the start date. 
The below rules will be applied for imputation of partial and missing AE start dates: 
 If start day is missing, but month and year are present, start date will be replaced by [CONTACT_634223] A, if study 
medication in Part A was first administered in that month and year (exception: if in this case start date is after stop date, also the first day of the month will be utilized). 
 If start day and month are missing and year is present, start date will be replaced by [CONTACT_634224] A, if study medication in Part A was first administered in that year (exception: if in this case start 
date is after stop date, also the first day of January will be utilized). 
 If start day, month, and year are missing, start date will be replaced by [CONTACT_634227] A or by [CONTACT_634237] t he year of the end date, if the 
first administration date is after the end date. 
The below rules will be applied for imputation of partial and missing medical history start dates: REDACTED COPY was in that year
REDACTED COPY was in that year
lare in Part B and start escape therapy, stop date will be 
REDACTED COPY lare in Part B and start escape therapy, stop date will be 
y last day of December or by [CONTACT_634238] y last day of December or by [CONTACT_634239] i
REDACTED COPY escape therapy if the last administration of escape therapy occurs i
into Part B, replacement 
REDACTED COPY into Part B, replacement by [CONTACT_634240] 
A will be performed
REDACTED COPY A will be performed
If in result of imputation,REDACTED COPY If in result of imputation,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If stop day is missing, but month and year are present, stop date will be replaced by [CONTACT_634241]. If stop day is missing, but month and year are present, stop date will be replaced by [CONTACT_634242] B occurs in that months and subject did not experience a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study drug administration in Part B occurs in that months and subject did not experience a 
flare in Part B and start escape therapy, stop date will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B and start escape therapy, stop date will be 
f the last administration of escape 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. f the last administration of escape 
therapy if the last administration of escape therapy occurs in that month. For subjects not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. therapy if the last administration of escape therapy occurs in that month. For subjects not 
randomized into Part B, stop date will be replaced by [CONTACT_634243]. randomized into Part B, stop date will be replaced by [CONTACT_634244] A if the last study drug administration in Part A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tion in Part A if the last study drug administration in Part A 
occurs in that month. If in result of imputation, the stop date is before start date, also the last 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. occurs in that month. If in result of imputation, the stop date is before start date, also the last 
top date will be replaced by [CONTACT_634245]. top date will be replaced by [CONTACT_634246] B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. study drug administration in Part B 
was in that year
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. was in that year and subject did not experience a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and subject did not experience a 
lare in Part B and start escape therapy, stop date will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. lare in Part B and start escape therapy, stop date will be 
y last day of December or by [CONTACT_634247]. y last day of December or by [CONTACT_634239] i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. escape therapy if the last administration of escape therapy occurs i
by [CONTACT_634248]. by [CONTACT_634249] 
A will be performed
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A will be performed if the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. if the 
If in result of imputation,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If in result of imputation, the
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. thestop date is before start date, also the last day of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. stop date is before start date, also the last day of 
If stop day, months, and year are missing, stop date will be replaced by [CONTACT_634250]. If stop day, months, and year are missing, stop date will be replaced by [CONTACT_634251], if the last visit in the doubl
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. blind period or by [CONTACT_634236], if the last visit in the doubl
The below rules will be applied for imputation of partial and missing AE start dates:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The below rules will be applied for imputation of partial and missing AE start dates:
If start day is missing, but month and year are present, sta
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If start day is missing, but month and year are present, sta
day of the month of that y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. day of the month of that y
medication 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medication in Part A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in Part A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date is after stop date, also the first day of the month will be utilized).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date is after stop date, also the first day of the month will be utilized).
If start day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If start day
of January of that year or by [CONTACT_634252]. of January of that year or by [CONTACT_634253]. study 
date is after 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date is after 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 53 of 149  If start day is missing, but month and year are present, start date will be replaced by [CONTACT_634223] A, if study medication in Part A was first administered in that month and year (exception: if in this case start date is after stop date, also the first day of the month will be utilized). 
 If start day and month is missing for one item diagnosis (medical history of any of the preferred terms ‘Axial Spondyloarthritis’, 'Spondyloarthropathy', 'Ankylosing spondylitis' , or 'Spondylitis' ) or symptom (medical history preferred term of ‘Back pain’, ‘Inflammatory 
pain’, ‘Spi[INVESTIGATOR_140719]’, ‘Lumbar spi[INVESTIGATOR_185775]’ ) and the year is similar, the missing month will be 
imputed by [CONTACT_634254]. 
 If only one item diagnosis or symptom is present and if start day and month are missing and year is present, start date will be replaced by [CONTACT_634255] A, if study medication in Part A was first 
administered in that year (exception: if in this case start date is after stop date, also the first 
day of January will be utilized).  
 If start day, month, and year are missing, start date will be replaced by [CONTACT_634256] A or by [CONTACT_634228], if the first administration date is after the end date. 
4.[ADDRESS_846827], and to potentially present the results at 
scientific meetings. No CSR will be written. The following assessments will not be included in 
the Interim Analysis:  
 MRI Efficacy scores (SPARCC (Sacroiliac joint), Spi[INVESTIGATOR_18241]-a in Berlin Modification 
score) 
 Work Productivity Questionnaire 
 EQ-5D- 3L 
 Fecal and serum calprotectin 
 Correlation between calprotectin and IBD, CRP 
 SF36 (domains, PCS, MCS) 
 Resource utilization 
 PK 
 ADAb  
The scope of the Interim Analysis will not be covered in a separate Analysis Plan.  REDACTED COPY Interim analyses and data monitoring
REDACTED COPY Interim analyses and data monitoring
Main focus of this interim analysis will be the efficacy and safety up to Week 48. An interim 
REDACTED COPY Main focus of this interim analysis will be the efficacy and safety up to Week 48. An interim 
once 
REDACTED COPY once all subjects have completed 
REDACTED COPY all subjects have completed 
REDACTED COPY Part A data will be reported in corresponding Part A tables and listings.
REDACTED COPY Part A data will be reported in corresponding Part A tables and listings.
remain blinded. In the disposition tables, treatment will remain blinded and be presented 
REDACTED COPY remain blinded. In the disposition tables, treatment will remain blinded and be presented 
eatment assignment for Part BREDACTED COPY eatment assignment for Part B
The purpose of the interim analysis is to check whether the assumptions REDACTED COPY The purpose of the interim analysis is to check whether the assumptions 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ‘Inflammatory 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ‘Inflammatory 
and the year is similar, the missing month will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and the year is similar, the missing month will be 
nth are missing and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nth are missing and 
year is present, start date will be replaced by [CONTACT_634257]. year is present, start date will be replaced by [CONTACT_634255] A, if study medication in Part A was first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and month of start of study medication in Part A, if study medication in Part A was first 
ase start date is after stop date, also the first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ase start date is after stop date, also the first 
If start day, month, and year are missing, start date will be replaced by [CONTACT_634258]. If start day, month, and year are missing, start date will be replaced by [CONTACT_634227] A or by [CONTACT_634259]. drug administration in Part A or by [CONTACT_634260]. Interim analyses and data monitoring
Main focus of this interim analysis will be the efficacy and safety up to Week 48. An interim 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Main focus of this interim analysis will be the efficacy and safety up to Week 48. An interim 
all subjects have completed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. all subjects have completed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A data will be reported in corresponding Part A tables and listings.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A data will be reported in corresponding Part A tables and listings.
remain blinded. In the disposition tables, treatment will remain blinded and be presented 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. remain blinded. In the disposition tables, treatment will remain blinded and be presented 
eatment assignment for Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eatment assignment for Part B
The purpose of the interim analysis is to check whether the assumptions 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The purpose of the interim analysis is to check whether the assumptions 
on efficacy of CZP made for the protocol were correct, and to potentially present the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. on efficacy of CZP made for the protocol were correct, and to potentially present the 
o CSR will be written. The following assessments will not
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. o CSR will be written. The following assessments will not
MRI Efficacy scores (SPARCC (Sacroiliac joint), Spi[INVESTIGATOR_634094]. MRI Efficacy scores (SPARCC (Sacroiliac joint), Spi[INVESTIGATOR_634094]. Work Productivity Questionnaire
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Work Productivity Questionnaire
3L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3L
Fecal and serum calprotectin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Fecal and serum calprotectin
Correlation between calprotectin and IBD, CRP
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Correlation between calprotectin and IBD, CRP
SF36 (domains, PCS, MCS)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SF36 (domains, PCS, MCS)

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 54 of 149 No specific data monitoring, steering, or evaluation committee is planned for this study. 
The following variable will be classed as unblinding during the full study. Therefore, these 
variables will be kept blinded until study unblinding after database lock: 
 Randomized treatment group 
 CRP ( Post Week 48) 
 MRI Efficacy scores (Post Week 48) 
 PK and ADAb (Post Week 48). 
4.4 Multicenter studies 
Individual center results will not be directly presented, however as discussed in Section  4.1 
geographical region is used as a covariate and some outputs will be presented by [CONTACT_101827]. Centers will be grouped in the following regions: North America, Western Europe, 
Eastern Europe and Asia. 
4.5 Multiple comparisons/multiplicity 
The statistical analysis of the primary efficacy variable will account for the testing of multiple doses by [CONTACT_2329] a fixed sequence testing procedure. The proportion of subjects who do not 
experience a flare will be compared between each CZP dose and PBO. The predefined order of 
hypotheses testing, each at a 2-sided 0.05 significance level for the comparison between the given CZP dose and PBO, will be performed in the sequence shown below: 
1. CZP 200mg Q2W vs PBO 
2. CZP 200mg Q4W vs PBO 
The second test will be performed irrespective of whether the first test is significant at the 0.[ADDRESS_846828] is significant at the 0.05 level as well. 
No adjustment for multiplicity will be considered when analysing the secondary efficacy 
variables. The p-values calculated in conjunction with those variables will be considered as 
nominal. 
4.6 Use of an efficacy subset of subjects 
The primary efficacy analysis from Part B will be repeated using the FAS and the PPS as a 
supportive analysis. 
4.7 Examination of subgroups 
The primary efficacy variable and PK variables will be summarized using the following subgroups: 
 mNY classification (mNY positive, mNY negative) 
 Geographical region (North America, Western Europe, Eastern Europe and Asia) 
 Age (<30 and ≥30 years) 
 Gender REDACTED COPY doses by [CONTACT_2329] a fixed sequence testing procedure. The proportion of subjects who do not 
REDACTED COPY doses by [CONTACT_2329] a fixed sequence testing procedure. The proportion of subjects who do not 
each CZP dose and PBO. The predefined order of 
REDACTED COPY each CZP dose and PBO. The predefined order of 
sided 0.05 significance level for the comparison between the 
REDACTED COPY sided 0.05 significance level for the comparison between the 
given CZP dose and PBO, will be performed in the sequence shown below:
REDACTED COPY given CZP dose and PBO, will be performed in the sequence shown below:
The second test will be performed irrespective of whether the first test is significant at the 0.[ADDRESS_846829] is significant at the 0.05 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section
be presented by [CONTACT_634261]. be presented by [CONTACT_634262], Western Europe, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. North America, Western Europe, 
The statistical analysis of the primary efficacy variable will account for the testing of multiple 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The statistical analysis of the primary efficacy variable will account for the testing of multiple 
doses by [CONTACT_2329] a fixed sequence testing procedure. The proportion of subjects who do not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. doses by [CONTACT_2329] a fixed sequence testing procedure. The proportion of subjects who do not 
each CZP dose and PBO. The predefined order of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. each CZP dose and PBO. The predefined order of 
sided 0.05 significance level for the comparison between the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sided 0.05 significance level for the comparison between the 
given CZP dose and PBO, will be performed in the sequence shown below:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. given CZP dose and PBO, will be performed in the sequence shown below:
The second test will be performed irrespective of whether the first test is significant at the 0.[ADDRESS_846830] is significant at the 0.05 level as well.
adjustment for multiplicity will be considered when analysing the secondary efficacy 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. adjustment for multiplicity will be considered when analysing the secondary efficacy 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values calculated in conjunction with those variables will be considered as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values calculated in conjunction with those variables will be considered as 
Use of an efficacy subset of subjects
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Use of an efficacy subset of subjects
The primary efficacy analysis f
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The primary efficacy analysis f
supportive analysis.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. supportive analysis.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The primary efficacy variable 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The primary efficacy variable 
subgroups
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subgroups

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 55 of 149  Race (white and non-white) 
 Baseline CRP level (≤ upper limit of normal  (ULN ), >ULN ) 
 ADAb status (Negative, Positive <512, Positive 512-<1024, Positive >=1024). 
These analyses will be based on descriptive statistics only. 
[ADDRESS_846831] disposition 
The number and percentage of subjects who enter ed the study, completed Part A, discontinued 
from Part A with reasons for discontinuation, were randomized in to Part B, completed Part B 
(without flare, after flare) and discontinued Part B as well as started Escape Part, completed 
Escape Part and discontinued Escape Part with reasons for discontinuation will be presented.  
Subjects who completed Week [ADDRESS_846832]  been 
moved to escape treatment via IXRS system (even if they do not receive any escape treatment). 
This summary will be based on the ES and will present subjects overall and broken out by 
[CONTACT_634184]. 
Discontinuations due to AEs will also be presented. This summary will be based on the ES and 
will present subjects overall and broken out by [CONTACT_634184]. 
The disposition of subjects screened by [CONTACT_634263], including the number of 
subjects in each analysis set will be summarized. This summary will be based on the ES and will present subjects overall (ie not broken out by [CONTACT_634184] ). 
A summary table of reasons for screen failures will be provided. 
The following listings will be produced based on the ES: 
 A listing of subject analysis sets  
 A listing of subjects who did not meet study eligibility criteria 
 A listing of subject disposition 
The following listings will be produced based on the OLS: 
 A listing of study discontinuation 
 A listing of visit dates 
 A listing of important protocol deviations (including any reasons for exclusion from the PPS) 
5.[ADDRESS_846833]’s rights, safety, 
well-being, and/or on the validity of the data for analysis will be identified during the blinded data evaluation meeting.  REDACTED COPY This summary will be based on the ES and will present subjects overall and broken out by 
[CONTACT_634264]. This summary will be based on the ES and 
REDACTED COPY Discontinuations due to AEs will also be presented. This summary will be based on the ES and 
will present subjects overall and broken out by 
[CONTACT_634265], including the number 
REDACTED COPY The disposition of subjects screened by [CONTACT_634263], including the number 
summarizedREDACTED COPY summarized
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A, discontinued 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A, discontinued 
Part B, completed Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B, completed Part B 
as well as started Escape Part, completed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as well as started Escape Part, completed 
will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be presented
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. presented
without SFU are considered as completed Part A. Subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. without SFU are considered as completed Part A. Subjects 
visit are considered as completed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. visit are considered as completed 
experienced a flare and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experienced a flare and 
(even if they do not receive any escape treatment).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (even if they do not receive any escape treatment).
This summary will be based on the ES and will present subjects overall and broken out by 
[CONTACT_122253]. This summary will be based on the ES and will present subjects overall and broken out by 
[CONTACT_634266]. This summary will be based on the ES and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Discontinuations due to AEs will also be presented. This summary will be based on the ES and 
will present subjects overall and broken out by 
[CONTACT_122253]. will present subjects overall and broken out by [CONTACT_634267] s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The disposition of subjects screened by [CONTACT_634263], including the number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The disposition of subjects screened by [CONTACT_634263], including the number 
summarized
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarized
present subjects overall (ie not broken out by 
[CONTACT_122253]. present subjects overall (ie not broken out by 
A summary table of reasons for screen failures will be provided.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A summary table of reasons for screen failures will be provided.
will be produced based on the ES:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be produced based on the ES:
A listing of subject analysis sets 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of subject analysis sets 
A listing of subjects who did not meet study eligibility criteria
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of subjects who did not meet study eligibility criteria
A listing of subject disposition
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of subject disposition
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following listings will be produced based on the OLS:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following listings will be produced based on the OLS:
A listing of study 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of study 
A listing of visit dates
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of visit dates

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 56 of 149 The identified important protocol deviations will be classified by [CONTACT_094]-specified items (e.g., 
informed consent, inclusion and exclusion criteria, IP administration/study treatment, withdrawal 
criteria, disallowed medications, procedures/tests, visit schedule, safety and other) as well as study period of occurrence (Part A, Part B) and summarized in Part A using the OLS, in Part B 
using the RS and overall using the OLS.  
All important protocol deviations will be provided in a data listing using the OLS. 
6 DEMOGRAPHICS AND OTHER BASELINE 
CHARACTERISTICS  
6.1 Demographics 
The following demographic variables will be summarized by [CONTACT_634268]. This presentation will also be produced for the RS by 
[CONTACT_1570]. 
Continuous variables: age (years), height (cm), weight (kg) and body mass index (BMI; kg/m2)  
Categorical variables: age (<30 years, ≥30 years and also ≤18, 19 to 24, 25 to 34, 35 to 44, ≥45), 
gender (male, female), racial group (American Indian/Alaskan Native, Asian, Black, Native 
Hawaiian or Other Pacific Islander, White, Other/Mixed), ethnicity (Hispanic or Latino, Not Hispanic or Latino), BMI category (<18.5, 18.5 - <25, 25 - <30, 30 - <35, 35 - <40, ≥40) and 
region and country as per Table 3.4 . 
All demographic details will be listed using the OLS. 
6.2 Other Baseline characteristics 
Lifestyle (alcohol, caffeinated beverages) and Tobacco usage at Baseline will be summarized by [CONTACT_634269].  
The responses to the 4 criteria for Modified NY Criteria for AS will be summarized by [CONTACT_634270]. This table will 
be also produced for the RS by [CONTACT_1570]. 
Similarly, the responses to the following modified ASAS classification criteria for AS will be 
summarized by [CONTACT_634271] . This table will be also produced for the RS by [CONTACT_1570]. 
 back pain of ≥[ADDRESS_846834]’s age at onset <45 years 
 inflammatory back pain 
 arthritis 
 enthesitis 
 uveitis 
 dactylitis 
 psoriasis 
 Crohn´s disease (CD)/ulcerative colitis REDACTED COPY Hawaiian or Other Pacific Islander, White, Other/Mixed
REDACTED COPY Hawaiian or Other Pacific Islander, White, Other/Mixed
<25, 25 
REDACTED COPY <25, 25 
All demographic details will be listed using the OLS.
REDACTED COPY All demographic details will be listed using the OLS.
Other Baseline characteristics
REDACTED COPY Other Baseline characteristics
Lifestyle (alcohol, caffeinated beverages) and Tobacco usage REDACTED COPY Lifestyle (alcohol, caffeinated beverages) and Tobacco usage 
and for all subjects combined using the OLS REDACTED COPY and for all subjects combined using the OLS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA subpopulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA subpopulation a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and for all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nd for all 
subjects combined using the OLS. This presentation will also be produced for the RS by 
[CONTACT_122253]. subjects combined using the OLS. This presentation will also be produced for the RS by 
[CONTACT_634272]: age (years), height (cm), weight (kg) and body mass index (BMI; kg/m2) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Continuous variables: age (years), height (cm), weight (kg) and body mass index (BMI; kg/m2) 
Categorical variables: age (<30 years, ≥30 years and also ≤18, 19 to 24, 25 to 34, 35 to 44, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Categorical variables: age (<30 years, ≥30 years and also ≤18, 19 to 24, 25 to 34, 35 to 44, 
American Indian/Alaskan Native, Asian, Black, Native 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. American Indian/Alaskan Native, Asian, Black, Native 
), ethnicity 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ), ethnicity 
<25, 25 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <25, 25 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -<30, 30 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <30, 30 
All demographic details will be listed using the OLS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All demographic details will be listed using the OLS.
Other Baseline characteristics
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Other Baseline characteristics
Lifestyle (alcohol, caffeinated beverages) and Tobacco usage 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Lifestyle (alcohol, caffeinated beverages) and Tobacco usage 
and for all subjects combined using the OLS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and for all subjects combined using the OLS
Modified NY Criteria for AS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Modified NY Criteria for AS
and for all subjects combined in frequency tables using the OLS. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and for all subjects combined in frequency tables using the OLS. 
produced for the RS by [CONTACT_1570].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. produced for the RS by [CONTACT_1570].
Similarly, the responses to th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Similarly, the responses to th e following modified ASAS classification criteria for AS will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e following modified ASAS classification criteria for AS will be 
axSpA s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA s ubpopulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ubpopulation
will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be also 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. also 
back pain of ≥3 months and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. back pain of ≥3 months and 
inflammatory back pain
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. inflammatory back pain
arthritis
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. arthritis
enthesitis
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. enthesitis

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 57 of 149  HLA -B27 
 elevated CRP 
 presence of sacroiliitis on imaging including imaging method 
History of extra-articular manifestations will be summarized by [CONTACT_634273]. This table will be also produced for the RS by 
[CONTACT_1570]. 
 History of uveitis 
 History of IBD 
 History of psoriasis 
Frequency tables by [CONTACT_634274]: 
 History of latent tuberculosis 
 Tuberculosis test 
 Chest x-ray 
 Sacroiliac joint x-ray 
All baseline characteristics described above as well as baseline extra-articular manifestations  
will be listed using the OLS. 
For subjects randomized to Part B, frequency tables by [CONTACT_634275]: 
 Geographic region 
 mNY classification 
Summaries of the randomization stratification factors will include both the original values of the 
stratification factors (ie, as used for randomization) as recorded in the IXRS and the final values 
of the stratification factors (ie, updated values in case any modifications were made after randomization). The randomization stratification factors will also be listed using the RS. 
6.3 Medical history and concomitant diseases 
Previous and ongoing medical history will be summarized by [CONTACT_61132]® system organ class 
(SOC) and preferred term (PT). 
Previous and ongoing medical history will be summarized by [CONTACT_634276] A using the SS, by [CONTACT_634277] B using the SSB, and will be listed using the SS. 
Time since diagnosis of disease and symptom duration will be summarized by [CONTACT_634278] A using the OLS , by [CONTACT_634279] B using the RS. Time since diagnosis will also be categorized into 
≤2 and >2 years, and symptom duration will be categorized into ≤3 and >3 years. 
Time since diagnosis of disease will be defined as: Date of first study medication administration 
minus earliest start date of the medical history of any of the preferred terms ‘Axial Spondyloarthritis’, 'Spondyloarthropathy', 'Ankylosing spondylitis', or 'Spondylitis' . If a subject REDACTED COPY All baseline characteristics described above as well as
REDACTED COPY All baseline characteristics described above as well as baseline ex
REDACTED COPY baseline ex
For subjects randomized to Part B, frequency tables by [CONTACT_634280] B, frequency tables by [CONTACT_634275]:
REDACTED COPY will be provided for the randomization stratification factors:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the OLS will also be provided for
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the OLS will also be provided for
baseline ex
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline ex
For subjects randomized to Part B, frequency tables by [CONTACT_634281]. For subjects randomized to Part B, frequency tables by [CONTACT_634275]:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be provided for the randomization stratification factors:
stratification 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. stratification 
stratification factors (ie, as used for randomization) as recorded in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. stratification factors (ie, as used for randomization) as recorded in
of the stratification factors (ie, updated values in case any modifications were made after 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of the stratification factors (ie, updated values in case any modifications were made after 
on). The randomization stratification factors will also be listed using the RS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. on). The randomization stratification factors will also be listed using the RS.
Medical history and concomitant diseases
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Medical history and concomitant diseases
Previous and ongoing medical history will be summarized by [CONTACT_634282]. Previous and ongoing medical history will be summarized by [CONTACT_61132]
(SOC) and preferred term (PT).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (SOC) and preferred term (PT).
Previous and ongoing medical history will be summarized by 
[CONTACT_122253]. Previous and ongoing medical history will be summarized by 
[CONTACT_634283] A using the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects combined in Part A using the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B using the SS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using the SS
Time since diagnosis of disease and symptom duration will be summarized by [CONTACT_634284]. Time since diagnosis of disease and symptom duration will be summarized by [CONTACT_634278] A using the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subpopulation and for all subjects combined in Part A using the 
UCB   [ADDRESS_846835] a history of any of the above 4 preferred terms, then the time since diagnosis of 
disease will be set equal to the symptom duration. 
Symptom duration will be calculated as: 
(Date of first study medication administration – Start date of symptoms)/365.[ADDRESS_846836] using the 
following rules (including imputation of partial dates as described for concomitant medications in Section 4.2):   
 Subjects with a medical history preferred term of ‘Back pain’, ‘Inflammatory pain’, ‘Spi[INVESTIGATOR_634121]’, ‘Lumbar spi[INVESTIGATOR_185775]’ and a start date present will use the earliest start date of these 
symptoms as the start date of symptoms. 
 Otherwise, subjects with a preferred term of ‘Axial spondyloarthritis’, 
‘Spondyloarthropathy’, ‘Ankylosing spondylitis’, or ‘Spondylitis’ will use the earliest start date of disease as the start date of symptoms 
 Otherwise, the subject’s medical history will be reviewed in the DEM meeting to determine if the subject has evidence of a start date of symptoms or primary disease. 
 If the resulting symptom duration is unknown or is below [ADDRESS_846837] medication summaries will be generated for disease-modifying antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), and anti-tumor necrosis factors 
(anti- TNFs ) by [CONTACT_2220] (ATC) code (level 3 (4-digit) decode, level 4 (5-
digit) decode, and PT). See Section  3.2.[ADDRESS_846838], prior and concomitant 
medications. 
For Part A, prior DMARDs and NSAIDs will be summarized by [CONTACT_120055]-DD ATC code (level 3 
(4-digit) decode, level 4 (5-digit) decode, and PT). No extra table for prior anti-TNFs will be 
produced due to the fact that this summary is identical to the [ADDRESS_846839] anti- TNF s. 
Summaries will be presented by [CONTACT_634285]. 
For Part A, prior medications (except DMARDs and NSAIDs) will be summarized by [CONTACT_120055]-DD 
ATC code (level 2 (3-digit) and level 3 (4-digit) decode. Summary will be presented by [CONTACT_634286]. 
For Part A, concomitant DMARDs and NSAIDs will be summarized by [CONTACT_120055]-DD ATC code 
(level 3 (4-digit) decode, level 4 (5-digit) decode, and PT). Summaries will be presented by 
[CONTACT_634285]. 
For Part A, concomitant medication (except DMARDs and NSAIDs) will be summarized by 
[CONTACT_120055]-DD ATC code (level 2 (3-digit) and level 3 (4-digit) decode. Summary will be presented 
by [CONTACT_634285]. REDACTED COPY will be set to [ADDRESS_846840] medication summaries will be generated for disease
inflammatory drugs (NSAIDs), and REDACTED COPY inflammatory drugs (NSAIDs), and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. imputation of partial dates as described for concomitant medications 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. imputation of partial dates as described for concomitant medications 
Spi[INVESTIGATOR_634122]. Spi[INVESTIGATOR_634123]. will use the earliest start date of these 
Spondylitis’ will use the earliest start 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Spondylitis’ will use the earliest start 
Otherwise, the subject’s medical history will be reviewed in the DEM meeting to determine 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Otherwise, the subject’s medical history will be reviewed in the DEM meeting to determine 
if the subject has evidence of a start date of symptoms or primary disease.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. if the subject has evidence of a start date of symptoms or primary disease.
below [ADDRESS_846841] medication summaries will be generated for disease
inflammatory drugs (NSAIDs), and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. inflammatory drugs (NSAIDs), and 
by [CONTACT_634287]. by [CONTACT_634288]. Section 3.2.29
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.29
For Part A, prior DMARDs and NSAIDs will be summarized by [CONTACT_634289]. For Part A, prior DMARDs and NSAIDs will be summarized by [CONTACT_634290]) decode, level 4 (5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. digit) decode, level 4 (5 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -digit) decode, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. digit) decode, and 
produced due to the fact that this summary is identical to the [ADDRESS_846842]
Summaries will be presented by 
[CONTACT_122253]. Summaries will be presented by 
p
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. prior medications (except DMARDs and NSAIDs) will be summarized by [CONTACT_634289]. rior medications (except DMARDs and NSAIDs) will be summarized by [CONTACT_634291] (level 2 (3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ATC code (level 2 (3
subpopulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subpopulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For Part A, concomitant DMARDs and NSAIDs will be summarized by [CONTACT_634289]. For Part A, concomitant DMARDs and NSAIDs will be summarized by [CONTACT_120055]
(level 3 (4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (level 3 (4
axSpA subpopulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA subpopulation
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 59 of 149 For Part B, prior DMARDs and NSAIDs will be summarized by [CONTACT_120055]-DD ATC code (level 3 
(4-digit) decode, level 4 (5-digit) decode, and PT). Summaries will be presented by [CONTACT_634292]. 
For Part B, prior medications (except DMARDs and NSAIDs) will be summarized by [CONTACT_120055]-DD 
ATC code (level 2 (3-digit) and level 3 (4-digit) decode. Summary will be presented by 
[CONTACT_634293]. 
For Part B, concomitant DMARDs and NSAIDs will be summarized by [CONTACT_120055]-DD ATC code 
(level 3 (4-digit) decode, level 4 (5-digit) decode, and PT). Summaries will be presented by 
[CONTACT_634293]. Additionally, in subjects experiencing a flare in Part 
B, separate summaries by [CONTACT_634294]-flare 
and post-flare concomitant medications. 
For Part B, concomitant medications (except DMARDs and NSAIDs) will be summarized by 
[CONTACT_120055]-DD ATC code (level 2 (3-digit) and level 3 (4-digit) decode. Summary will be presented 
by [CONTACT_634293]. Additionally, in subjects experiencing a flare in 
Part B, separate summaries by [CONTACT_634294]-
flare and post-flare concomitant medications. 
Prohibited medication use and date of first usage will be determined and documented during the pre-analysis review meeting prior to the database lock. 
The number and percentage of subjects who used prohibited medication will be summarized by 
[CONTACT_634295] A using the SS and by [CONTACT_634296] B using the SSB. Separate summaries in subjects experiencing a flare in Part B by [CONTACT_634297]-flare and post-flare prohibited medication. 
An overall summary of subjects who used prohibited medication in Part A or Part B will be 
provided using the SS. 
Prohibited medications will be assigned to Part A or Part B (overall, pre-flare, post-flare) using the same rules as outlined for concomitant medications in Section  3.2.[ADDRESS_846843] will utilize the number of administered syringes and compare them to the scheduled expected number of injections. The sum of the 
difference in number of syringes between the actual used and expected syringes will be 
summarized. In addition, a ratio of compliance will be further computed based on the number of actual and expected syringes. The ratio of compliance will be summarized as a continuous variable and categorically (<0.80, ≥0.80–≤1.0 and >1.0). The general formula for the compliance ratio (CR) is given as follows: 
CR = # actual syringes / # expected syringes  
The second approach defines compliance with study drug administration based upon comparing the actual day of administration with the expected day of administration. The expected day of administration will be based upon (1) the Baseline date and (2) the previous injection date. The REDACTED COPY analysis review meeting prior to the database lock.
REDACTED COPY analysis review meeting prior to the database lock.
The number and percentage of subjects who used prohibited medication will be summarized by 
[CONTACT_634298] 
A using the 
REDACTED COPY A using the 
. Separate summaries in subjects 
REDACTED COPY . Separate summaries in subjects 
group using the FS will be provided presenting
REDACTED COPY group using the FS will be provided presenting
of subjects who used prohibited medication in Part A or Part B will be 
REDACTED COPY of subjects who used prohibited medication in Part A or Part B will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ATC code 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ATC code 
). Summaries will be presented by 
[CONTACT_122253]. ). Summaries will be presented by 
[CONTACT_634299]. flare in Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part 
ill be provided presenting pre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ill be provided presenting pre flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare 
For Part B, concomitant medications (except DMARDs and NSAIDs) will be summarized by 
[CONTACT_122253]. For Part B, concomitant medications (except DMARDs and NSAIDs) will be summarized by 
[CONTACT_634300]) decode. Summary will be presented 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. digit) decode. Summary will be presented 
. Additionally, in subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . Additionally, in subjects experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a 
S will be provided presenting pre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. S will be provided presenting pre
and date of first usage will be determined and documented during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and date of first usage will be determined and documented during the 
The number and percentage of subjects who used prohibited medication will be summarized by 
[CONTACT_122253]. The number and percentage of subjects who used prohibited medication will be summarized by 
A using the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A using the SS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SS and by [CONTACT_634301]. and by [CONTACT_634302] 
. Separate summaries in subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . Separate summaries in subjects 
group using the FS will be provided presenting
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. group using the FS will be provided presenting pre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. pre
of subjects who used prohibited medication in Part A or Part B will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of subjects who used prohibited medication in Part A or Part B will be 
Prohibited medications will be assigned to Part A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Prohibited medications will be assigned to Part A
the same rules as outlined for concomitant medications in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the same rules as outlined for concomitant medications in 
medications
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medications
MEASUREMENTS OF TREA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MEASUREMENTS OF TREA
Treatment compliance will be calculated for Part A, Part B and Part B post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment compliance will be calculated for Part A, Part B and Part B post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B summaries will not consider any post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B summaries will not consider any post
approaches to calculate treatment compliance. The first will utilize the number of administered 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. approaches to calculate treatment compliance. The first will utilize the number of administered 
syringes and compare them to the scheduled expected number of injections. The sum of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. syringes and compare them to the scheduled expected number of injections. The sum of the 
difference in number of syringes be
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. difference in number of syringes be
summarized. In addition, a ratio of compliance will be further computed based on the number of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarized. In addition, a ratio of compliance will be further computed based on the number of 
actual and expected syringes. The ratio of compliance will be summarized as a continuous 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. actual and expected syringes. The ratio of compliance will be summarized as a continuous 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. variable and categor
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. variable and categor
ratio (CR) is given as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ratio (CR) is given as follows:
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 60 of 149 sum of the absolute difference in days between the actual and expected days will be summarized. 
In addition, a ratio of compliance will be computed based upon the actual and expected days for each of the 2 methods. The ratio of compliance will be summarized as a continuous variable and categorically (<0.80, ≥0.80). The general formula for the compliance ratio is given as follows: 
 Compliance Ratio (CR) = {[Exposure Duration (days)] - [Cumulative Difference (days)]}/ 
         {Exposure Duration (days)} The CR ranges between [ADDRESS_846844] listing of compliance will be provided by [CONTACT_634303].  
8 EFFICACY ANALYSES 
Efficacy summaries for variables collected in Part A will be based on the OLS. All efficacy analyses for Part B will be performed using the RS, unless otherwise mentioned (ie, the FAS and PPS will be used for a sensitivity analysis on the primary endpoint only). Efficacy summaries for subjects experiencing a flare in Part B will be performed using the FS. All efficacy endpoints will be listed using the observed case data. Furthermore, for selected analyses, statistical 
appendices will be created and included in the CSR appendix “Documentation of Statistical Methods”.  
8.1 Primary efficacy variable 
8.1.1  Primary analysis of the primary efficacy variable 
The number and percentage of subjects in Part B who do not experience a flare will be 
summarized descriptively for the RS using NRI data. The 95% CI based on the Exact Binomial 
distribution will also be presented. Summary statistics will be presented by [CONTACT_7273] B. 
The primary analysis will be based on a logistic regression model which will include factors of 
treatment group, region, and mNY classification. The final values of the randomization 
stratification factors (region, mNY classification) will be used for this analysis. The odds ratios based on the proportion of subjects who do not experience a flare will be estimated from this REDACTED COPY If no Escape Week [ADDRESS_846845] listing of compliance will be provided by [CONTACT_634304]. by [CONTACT_634305]. EFFICACY ANALYSES
Efficacy summaries for variables collected in Part A will be based on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Efficacy summaries for variables collected in Part A will be based on the 
analyses for Part B will be performed using the RS, unless otherwise mentioned (ie, the FAS and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. analyses for Part B will be performed using the RS, unless otherwise mentioned (ie, the FAS and 
PPS will be used for a sensitivity analysis on the primary endpoint only). Efficacy summaries for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PPS will be used for a sensitivity analysis on the primary endpoint only). Efficacy summaries for 
flare in Part B will
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B will
will be listed using the observed case data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be listed using the observed case data.
appendices will be created
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. appendices will be created and included in the CSR appendix “Documentation of Statistical 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and included in the CSR appendix “Documentation of Statistical 
P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Primary eff
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rimary eff
Primary analysis of the primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Primary analysis of the primary efficacy variable
The number and percentage of subjects in Part B who do not experience a flare will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in Part B who do not experience a flare will be 
summarized descriptively for the RS using NRI data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarized descriptively for the RS using NRI data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. distribution 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. distribution 
Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 61 of 149 logistic regression model and presented with 95% 2-sided CIs and p-values. This analysis will be 
conducted for the RS using NRI data. 
To avoid the problem of the monotone likelihood resulting in infinite large confidence intervals 
(eg, if one of the cell counts in the 2x2 table is equal to zero), a penalized maximum likelihood 
approach based on the modified score procedure of Firth (Heinze and Schemper, 2002) will be 
used in the logistic models. 
Each CZP dose will be compared against PBO to establish superiority over PBO and will be 
tested sequentially at an alpha of 0.05. The primary statistical analysis of the primary efficacy 
variable will account for the testing of multiple doses by [CONTACT_2329] a fixed sequence testing procedure. The predefined order of hypotheses testing, each at a 2-sided 0.05 significance level 
for the comparison between the given CZP dose and PBO, will be performed in the sequence 
shown below: 
1.  CZP 200mg Q2W vs PBO 
2.  CZP 200mg Q4W vs PBO 
The second test will be performed irrespective of whether the first test is significant at the 0.[ADDRESS_846846] is significant at the 0.05 level as well. 
8.1.2  Secondary analyses of the primary efficacy variable 
The number and percentage of subjects in Part B who do not experience a flare will be 
summarized for the following subgroups: age, gender, race, region, baseline CRP level, overall 
ADAb  status and mNY classification. Factors for subgroups and the interaction term of subgroup 
and treatment will be added to the primary model specified in Section  8.1.1 . The 95% CI based 
on the Exact Binomial distribution will also be presented. These summaries will be performed 
for the RS using NRI data and will be based on descriptive statistics only. 
8.1.3  Supportive and sensitivity analyses of the primary efficacy variable 
The number and percentage of subjects in Part B who do experience a flare will be summarized 
descriptively for the RS using NRI data, indicating the contributing event (ASDAS defined flare 
using scheduled visits only or using unscheduled visits, missing ASDAS values, premature study 
discontinuation with reason “AE or Lack of efficacy” or other reason, incorrectly ‘flared’ due to delay in data entry ).  
The flare by [CONTACT_18375], calculated flare, time to flare and reason for flare according to NRI analysis will be listed based on the RS.  
The analysis described in Section  8.1.1 will be repeated for the RS using the different approaches 
as defined in Section  3.2.22  (observed case, premature withdrawal, MMRM imputation, 
referenced-based multiple imputation ). The 95% CI based on the Exact Binomial distribution 
will also be presented.  
In addition, the analysis as described in Section 8.1.1  will also be repeated for the FAS and PPS 
using NRI data. REDACTED COPY Secondary analyses of the primary efficacy variable
REDACTED COPY Secondary analyses of the primary efficacy variable
The number and percentage of subjects in Part B who do not experience a flare will be 
REDACTED COPY The number and percentage of subjects in Part B who do not experience a flare will be 
summarized for the following subgroups: age, gender, 
REDACTED COPY summarized for the following subgroups: age, gender, 
Factors for s
REDACTED COPY Factors for s
to the primary model specified in 
REDACTED COPY to the primary model specified in 
will also be presented. REDACTED COPY will also be presented. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Each CZP dose will be compared against PBO to establish superiority over PBO and will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Each CZP dose will be compared against PBO to establish superiority over PBO and will be 
tested sequentially at an alpha of 0.05. The primary statistical analysis of the primary efficacy 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tested sequentially at an alpha of 0.05. The primary statistical analysis of the primary efficacy 
will account for the testing of multiple doses by [CONTACT_2329] a fixed sequence testing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will account for the testing of multiple doses by [CONTACT_2329] a fixed sequence testing 
sided 0.[ADDRESS_846847] will be interpreted as statis tically significant 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tically significant 
Secondary analyses of the primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Secondary analyses of the primary efficacy variable
The number and percentage of subjects in Part B who do not experience a flare will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in Part B who do not experience a flare will be 
summarized for the following subgroups: age, gender, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarized for the following subgroups: age, gender, 
Factors for s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Factors for s ubgroup
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ubgroup
to the primary model specified in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to the primary model specified in 
will also be presented. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will also be presented. 
for the RS using NRI data and will be based on descriptive statistics only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for the RS using NRI data and will be based on descriptive statistics only.
Supportive and sensitivity analyses of the primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Supportive and sensitivity analyses of the primary efficacy variable
The number and percentage of subjects in Part B who do experience a flare will be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in Part B who do experience a flare will be summarized 
descriptively for the RS using NRI data, indicating the contributing event (ASDAS defined flar
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. descriptively for the RS using NRI data, indicating the contributing event (ASDAS defined flar
using scheduled visits only or using unscheduled visits
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using scheduled visits only or using unscheduled visits
with reason “AE or Lack of efficacy” or other reason, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with reason “AE or Lack of efficacy” or other reason, 
delay in data entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. delay in data entry ).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare by [CONTACT_18375], calculated flare
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare by [CONTACT_18375], calculated flare
will be listed
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be listed based on the RS. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based on the RS. 
The analysis described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The analysis described in 
as defined in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as defined in 
refe
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. referenced
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. renced
will also be presented.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will also be presented.
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 62 of 149 8.2 Secondary efficacy variables 
8.2.1  Part A  
All summaries of secondary efficacy variables in Part A will be based on the OLS.  
[IP_ADDRESS] Percentage of subjects achieving sustained remission at Week 48 
The number and percentage of subjects achieving sustained remission at Week 48 will be 
summarized in frequency tables by [CONTACT_634306]. The 
95% CI based on the Exact Binomial distribution will also be presented. The presentation will be 
done on the observed case data and will be repeated on the imputed data using NRI. 
[IP_ADDRESS] ASDAS disease activity (ASDAS- ID, ASDAS- LD, ASDAS- HD and ASDAS-
vHD) at Week 48 
ASDAS disease activity at Week 48 will be summarized in frequency tables by [CONTACT_634307]. The number and percentage of subjects in each of 
the 4 disease activity levels will be presented.  
The presentation will be done using observed case data and will be repeated using LOCF 
imputation for the missing data.  
[IP_ADDRESS] ASDAS clinical improvement (ASDAS- MI and ASDAS-CII) at Week 48 
The number and percentage of subjects achieving ASDAS-MI and ASDAS-CII at Week 48 will 
be summarized in frequency tables by [CONTACT_634306]. The presentation will be done using observed case data and will be repeated using NRI data. 
8.2.2  Part B  
The following analyses  are not part of the multiplicity-controlled testing procedure described in 
Section  8.1. The p-values reported for these analyses will not be adjusted for multiplicity and 
will be considered nominal. All analyses and summaries of the efficacy variables in Part B will 
be based on the RS. All tables will be presented by [CONTACT_7238] B. 
[IP_ADDRESS] Time to flare 
The time to flare will be analyzed using Kaplan-Meier methods, comparing each CZP dose to 
PBO. Stratified two-sided log rank test using strata geographic region (North America, Western 
Europe, Eastern Europe and Asia) and mNY classification (mNY positive, mNY negative) will be used to evaluate between-group differences. 
Kaplan-Meier plots of the time to flare will also be produced. Kaplan-Meier estimates of 
percentages of subjects experiencing a flare by [CONTACT_10585] 52, Week 56, Week 60, Week 6 4, Week 
68, Week 72, Week 7 6, Week 8 0, Week 84, Week 88, Week 92 and Week 96 will be provided 
along with the corresponding 95% CI by [CONTACT_2939]. For the calculation of the 95% CI, the 
LOGLOG transformation will be used. 
These analyses will be repeated using the different approaches as defined in Section  3.2.23 
(observed case, premature withdrawal). REDACTED COPY ASDAS clinical improvement (ASDAS
REDACTED COPY ASDAS clinical improvement (ASDAS
The number and percentage of subjects achieving ASDAS
REDACTED COPY The number and percentage of subjects achieving ASDAS
axSpA subpopulation
REDACTED COPY axSpA subpopulation
presentation will be done using observed case data and will be repeated using NRI data.
REDACTED COPY presentation will be done using observed case data and will be repeated using NRI data.
are not part of the multiplicityREDACTED COPY are not part of the multiplicity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sentation will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sentation will be 
and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS
ASDAS disease activity at Week [ADDRESS_846848] using strata geographic region (North Americ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sided log rank test using strata geographic region (North Americ
Europe, Eastern Europe and Asia) and mNY classification (mNY positive, mNY negative) will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Europe, Eastern Europe and Asia) and mNY classification (mNY positive, mNY negative) will 
be used to evaluate between
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be used to evaluate between
Meier plots of the time to flare will also be produced. Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Meier plots of the time to flare will also be produced. Kaplan
percentages of subj
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. percentages of subj
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 72, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 72, 
along with the corresponding 95% CI by [CONTACT_2939]. For the calculation of the 95% CI, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. along with the corresponding 95% CI by [CONTACT_2939]. For the calculation of the 95% CI, the 
LOGLOG 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LOGLOG 
These analyses will be repeated using the different approaches as defined in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These analyses will be repeated using the different approaches as defined in 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 63 of 149 [IP_ADDRESS] Continuous secondary efficacy variables  
Summary statistics of observed and change from Part B Baseline to Week [ADDRESS_846849]-flare data for subjects experiencing a flare (in any treatment group) will be treated as missing in the MMRM analysis. The MMRM methods will be 
applied to all observed change from Part B Baseline data obtained from Week [ADDRESS_846850] will be 
incorporated as repeated measures (fixed term) within each subject (random term). An unstructured covariance matrix will be used and visit will be treated as a categorical predictor. 
An unstructured correlation pattern will be used to estimate the variance- covari ance of the 
within-subject repeated measures. Summary tables will present the adjusted means for PBO and 
the CZP doses, the respective differences to PBO, the corresponding p-values, and 95% CIs. 
The comparison between treatment groups using MMRM will be repeated for Part A Baseline 
with Part A Baseline score as a fixed-effect covariate, treatment group, region, mNY 
classification, and visit as fixed-effect categorical factors, and Part A Baseline-by -visit and 
treatment group- by-visit as interaction terms.  
Summary statistics of observed and change from Part B Baseline to Week 96 values for SIJ 
SPARCC and Spi[INVESTIGATOR_18241]-a in the Berlin modification scores will be presented by 
[CONTACT_1570]. These summaries will be based on observed case data. 
The changes from Part B Baseline in SIJ SPARCC and spi[INVESTIGATOR_18241]-a in the Berlin 
modification scores at Week 96 will be compared between treatment groups using an analysis of 
covariance (ANCOVA) model. The model will include Part B Baseline score, treatment group, 
region, and mNY classification. Summary tables will present the adjusted means for PBO and the CZP doses, the respective differences to PBO, the corresponding p-values, and 95% CIs. This analysis will be performed using observed case data only. 
These summary statistics will be repeated for Part A Baseline and the model includes Part A 
Baseline score, treatment group, region, and mNY classification.  
[IP_ADDRESS] Binary secondary efficacy variables 
The number and percentage of subjects in the ASDAS disease activity levels (ASDAS-ID, 
ASDAS- LD, ASDAS-HD, ASDAS-vHD) as well as the number and percentage of subjects 
achieving ASDAS clinical improvement (ASDAS-CII, ASDAS-MI), ASAS response (ASAS20, 
ASAS40, ASAS5/6, ASAS PR) and BASDAI50 response will be summarized at Week 96 by 
[CONTACT_1570]. These summaries will be based on observed case data and will be repeated using NRI data (for all variables except ASDAS disease activity level); improvement will be relative to Part A B aseline only. 
The statistical analysis of ASDAS clinical improvement (ASDAS-CII, ASDAS-MI), ASAS response (ASAS20, ASAS40, ASAS5/6, ASAS PR) and BASDAI50 response at Week [ADDRESS_846851] categorical factors
Summary statistics of observed and change from 
REDACTED COPY Summary statistics of observed and change from 
a in the Berlin modification scores will be presented by 
[CONTACT_122327] a in the Berlin modification scores will be presented by 
[CONTACT_1570]. These summaries will be based on observed case data.REDACTED COPY treatment group. These summaries will be based on observed case data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group) will be treated as missing in the MMRM analysis. The MMRM methods will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group) will be treated as missing in the MMRM analysis. The MMRM methods will be 
data obtained from Week [ADDRESS_846852] will be 
rated as repeated measures (fixed term) within each subject (random term). An 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rated as repeated measures (fixed term) within each subject (random term). An 
unstructured covariance matrix will be used and visit will be treated as a categorical predictor. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. unstructured covariance matrix will be used and visit will be treated as a categorical predictor. 
An unstructured correlation pattern will be used to estimate the variance
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. An unstructured correlation pattern will be used to estimate the variance -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -covari
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. covari
subject repeated measures. Summary tables will present the adjusted means for PBO and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subject repeated measures. Summary tables will present the adjusted means for PBO and 
the CZP doses, the respective differences to PBO, the corresponding p
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the CZP doses, the respective differences to PBO, the corresponding p
The comparison between treatment groups using MMRM will be r
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The comparison between treatment groups using MMRM will be r
effect covariate, treatment group, region, mNY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. effect covariate, treatment group, region, mNY 
effect categorical factors
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. effect categorical factors ,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ,and Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and Part 
Summary statistics of observed and change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics of observed and change from Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part 
a in the Berlin modification scores will be presented by 
[CONTACT_122253]. a in the Berlin modification scores will be presented by 
[CONTACT_1570]. These summaries will be based on observed case data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group. These summaries will be based on observed case data.
in SIJ SPARCC and spi[INVESTIGATOR_634105]. in SIJ SPARCC and spi[INVESTIGATOR_634124]. will be compared between treatment groups using an analysis of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. covariance (ANCOVA) model. The model will include 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. covariance (ANCOVA) model. The model will include 
ion, and mNY classification. Summary tables will present the adjusted means for PBO and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ion, and mNY classification. Summary tables will present the adjusted means for PBO and 
the CZP doses, the respective differences to PBO, the corresponding p
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the CZP doses, the respective differences to PBO, the corresponding p
analysis will be performed using observed case data only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. analysis will be performed using observed case data only.
statistics will be repeated for Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. statistics will be repeated for Part A Baseline
Baseline score, treatment group, region, and mNY classification
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline score, treatment group, region, and mNY classification
Binary 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Binary 
The number and percentage of subjects in the ASDAS disease activity levels (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in the ASDAS disease activity levels (ASDAS
ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -LD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LD
achieving ASDAS clinical improvement (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. achieving ASDAS clinical improvement (ASDAS
ASAS40,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS40,
treatment group. These summaries will be based on observed case data and will be repeated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group. These summaries will be based on observed case data and will be repeated 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 64 of 149 be based on a logistic regression model which will include factors of treatment group, region, 
and mNY classification. The responder rates for each treatment group and the adjusted odds 
ratios with reference to PBO will be estimated from this logistic regression model and presented with 95% 2-sided CIs and p- values. This analysis will be performed using NRI data. 
8.2.3  Subjects experiencing a flare in Part B 
All summaries will be based on observed case data and will use the FS, ie only subjects experiencing a flare based on the IXRS data will be included in these summaries. If deemed 
needed, further sensitivity analyses may be conducted excluding subjects incorrectly ‘flared’.  
[IP_ADDRESS] Continuous secondary efficacy variables 
For the continuous variables (ASDAS, BASDAI, BASFI, BASMI, SIJ SPARCC score and spi[INVESTIGATOR_634125]-a in the Berlin modification score), descriptive statistics by [CONTACT_634308]. Summary tables will include the actual results at Week 96 (or later), as well as change from Part B Baseline. 
These summary statistics will be repeated for Flare Baseline.   
[IP_ADDRESS] Binary secondary efficacy variables 
The number and percentage of subjects in the ASDAS disease activity levels (ASDAS-ID, 
ASDAS- LD, ASDAS-HD, ASDAS-vHD) as well as the number and percentage of subjects 
achieving ASDAS clinical improvement (ASDAS-CII, ASDAS-MI), and ASAS response 
(ASAS20, ASAS40, ASAS5/6, and ASAS PR) will be summarized at the Week 96 (or later) visit by [CONTACT_21964].  
8.3 Other efficacy variables 
8.3.1  Part A  
[IP_ADDRESS] ASDAS disease activity (ASDAS- ID, ASDAS -LD, ASDAS -HD and 
ASDAS -vHD) and clinical improvement (ASDAS-CII, ASDAS- MI) 
The number and percentage of subjects in each of the 4 ASDAS disease activity levels will be 
presented for each visit by [CONTACT_634306]. These summaries 
will be produced for the OLS using observed case data and will be repeated using LOCF imputation for missing data.  
The number and percentage of subjects achieving ASDAS-MI and ASDAS-CII will be 
summarized in frequency tables for each visit by [CONTACT_634306]. These summaries will be produced for the OLS using observed case data and will be 
repeated using NRI data. 
[IP_ADDRESS] ASAS20, ASAS40, ASAS5/6, and ASAS PR response 
Frequency tables will be produced to show the number and percentage of responders for each 
ASAS endpoint for each visit by [CONTACT_634306]. These 
summaries will be produced for the OLS using observed case data and will be repeated using NRI data. REDACTED COPY The number and percentage of subjects in the ASDAS disease activity levels (ASDAS
REDACTED COPY The number and percentage of subjects in the ASDAS disease activity levels (ASDAS
vHD) as well as the number and percentage of subjects 
REDACTED COPY vHD) as well as the number and percentage of subjects 
(ASDAS
REDACTED COPY (ASDAS -
REDACTED COPY -CII, ASDAS
REDACTED COPY CII, ASDAS
(ASAS20, ASAS40, ASAS5/6, and ASAS PR) will be summarized at the Week 96 (or later) visit 
REDACTED COPY (ASAS20, ASAS40, ASAS5/6, and ASAS PR) will be summarized at the Week 96 (or later) visit 
ther efficacy variables
REDACTED COPY ther efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ubjects incorrectly ‘flared’.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ubjects incorrectly ‘flared’.
For the continuous variables (ASDAS, BASDAI, BASFI, BASMI, SIJ SPARCC score and spi[INVESTIGATOR_634094]. For the continuous variables (ASDAS, BASDAI, BASFI, BASMI, SIJ SPARCC score and spi[INVESTIGATOR_634126]), descriptive statistics by [CONTACT_634309]. Berlin modification score), descriptive statistics by [CONTACT_634308]. Summary tables will include the actual results at Week 96 (or later), as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. group will be displayed. Summary tables will include the actual results at Week 96 (or later), as 
The number and percentage of subjects in the ASDAS disease activity levels (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in the ASDAS disease activity levels (ASDAS
vHD) as well as the number and percentage of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. vHD) as well as the number and percentage of subjects 
CII, ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CII, ASDAS
(ASAS20, ASAS40, ASAS5/6, and ASAS PR) will be summarized at the Week 96 (or later) visit 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (ASAS20, ASAS40, ASAS5/6, and ASAS PR) will be summarized at the Week 96 (or later) visit 
ther efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ther efficacy variables
ASDAS disease activity (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS disease activity (ASDAS
and clinical improvement (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and clinical improvement (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in each of the 4 ASDAS disease activity levels will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in each of the 4 ASDAS disease activity levels will be 
presented for each visit by 
[CONTACT_122253]. presented for each visit by [CONTACT_634310]. axSpA subpopulation
ced for the OLS using observed case data and will be repeated using LOCF 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ced for the OLS using observed case data and will be repeated using LOCF 
imputation for missing data. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. imputation for missing data. 
The number and percentage of subjects achieving ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects achieving ASDAS
summarized in frequency tables for each visit by 
[CONTACT_122253]. summarized in frequency tables for each visit by 
[CONTACT_122253]. combined. These summaries will be produced for the OLS using observed case data and will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. combined. These summaries will be produced for the OLS using observed case data and will be 
repeated using NRI data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. repeated using NRI data.
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
Frequency tables will be produced to show the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Frequency tables will be produced to show the 
ASAS endpoint
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS endpoint
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 65 of 149 [IP_ADDRESS] ASDAS, BASDAI, and BASMI 
Summary statistics of actual values and change from Part A Baseline values will used to 
summarize each  score (ASDAS, BASDAI, and BASMI) for each visit by [CONTACT_634311]. These summaries will be produced for the OLS using observed 
case data and will be repeated using LOCF imputation for missing data.  
[IP_ADDRESS] SIJ SPARCC and spi[INVESTIGATOR_634127] -a in the Berlin modification scores  
Summary statistics of the actual values and change  from Part A Baseline values will be used to 
summarize the SIJ SPARCC and Spi[INVESTIGATOR_18241]-a in the Berlin modification scores for each 
visit by [CONTACT_634306]. The analysis will use results of the 
single read assessments for Part A from the independent reviewer. These summaries will be produced for the OLS using observed case data only.   
[IP_ADDRESS] Individual ASAS core components 
Summary statistics of the actual values and change  from Part A Baseline values will be used to 
summarize the ASAS core components for each visit by [CONTACT_634312]: 
 PtGADA 
 Total spi[INVESTIGATOR_18172] (NRS) 
 BASFI 
 Average of Questions 5 and 6 of the BASDAI concerning morning stiffness 
These summaries will be produced for the OLS using observed case data and  will be repeated for 
BASFI and PtGADA using LOCF imputation for missing data. 
[IP_ADDRESS] PhGADA 
Summary statistics of the actual values and change  from Part A Baseline values will be used to 
summarize PhGADA for each visit by [CONTACT_634306]. 
These summaries will be produced for the OLS using observed case data.  
[IP_ADDRESS] Nocturnal spi[INVESTIGATOR_18172] (NRS) 
Summary statistics of the actual values and change  from Part A Baseline values will be used to 
summarize nocturnal spi[INVESTIGATOR_634128]. These summaries will be produced for the OLS using observed case data and  will be 
repeated using LOCF imputation for missing data. 
[IP_ADDRESS] Fatigue (NRS) (from BASDAI) 
Summary statistics of the actual values and change  from Part A Baseline values will be used to 
summarize fatigue item score of the BASDAI for each visit by [CONTACT_634312]. This summary will be produced for the OLS using observed case data and  
will be repeated using LOCF imputation for missing data.  
The remaining components of the BASDAI maybe analyzed as well. REDACTED COPY Average of Questions 5 and 6 of the BASDAI concerning morning stiffness
REDACTED COPY Average of Questions 5 and 6 of the BASDAI concerning morning stiffness
These summaries will be produced for the OLS using observed 
REDACTED COPY These summaries will be produced for the OLS using observed 
using LOCF imputation for missing data.REDACTED COPY using LOCF imputation for missing data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values will be used to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values will be used to 
for each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for each 
results of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. results of the 
These summaries will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summaries will be 
Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline values will be used to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values will be used to 
axSpA subpopulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA subpopulation
Average of Questions 5 and 6 of the BASDAI concerning morning stiffness
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Average of Questions 5 and 6 of the BASDAI concerning morning stiffness
These summaries will be produced for the OLS using observed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summaries will be produced for the OLS using observed 
using LOCF imputation for missing data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using LOCF imputation for missing data.
the actual values
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the actual values
summarize PhGADA for each visit by 
[CONTACT_122253]. summarize PhGADA for each visit by 
[CONTACT_634313]. These summaries will be produced for the OLS using observed 
Nocturnal spi[INVESTIGATOR_18172] (NRS)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Nocturnal spi[INVESTIGATOR_18172] (NRS)
Summary statistics of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the actual values
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the actual values
summarize nocturnal spi[INVESTIGATOR_634129]. summarize nocturnal spi[INVESTIGATOR_634130]. These summaries will be produced for the OLS using observed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. combined. These summaries will be produced for the OLS using observed 
repeated using LOCF imputation for missing data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. repeated using LOCF imputation for missing data.
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
Summary statistics of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics of 
summarize fatigue item score of the BASDAI for each visit by 
[CONTACT_122253]. summarize fatigue item score of the BASDAI for each visit by 
[CONTACT_634314].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects combined.
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 66 of 149 [IP_ADDRESS] BASDAI50 response 
Frequency tables will be produced to show the number and percentage of BASDAI50 responders 
for each visit by [CONTACT_634306]. This summary will be 
performed on the OLS using observed case data and will be repeated using NRI data. 
[IP_ADDRESS] C-reactive protein (CRP) 
Summary statistics of the actual values, change  from Part A Baseline values and the ratio of 
post-Baseline over Part A Baseline values will be used to summarize the CRP values for each 
visit by [CONTACT_634306]. This summary will be produced for 
the OLS using observed case data and  will be repeated using LOCF imputation for missing data.  
The geometric mean and the corresponding CV of the geometric mean will be computed and 
displayed for the observed values and for the ratio of post-Baseline over Part A Baseline values. 
[IP_ADDRESS] Ankylosing Spondylitis Quality of Life (ASQoL) 
Summary statistics of the actual values and change  from Part A Baseline values will be used to 
summarize the ASQoL score for each visit by [CONTACT_634315]. This summary will be produced for the OLS using observed case data. 
[IP_ADDRESS] Work Productivity Survey (WPS) 
Frequency tables will be produced to summarize the answer provided to question 1 of the WPS 
for each visit by [CONTACT_634306].  
Summary statistics of the actual values and change from Part A Baseline values will be used to summarize the answers to the question 2 to 9 of the WPS for each visit by [CONTACT_634311]. 
These summaries will be produced for the OLS using observed case. 
[IP_ADDRESS] EuroQoL Health Status Questionnaire 5 dimensions 3 levels ( EQ-5D-3L) 
Frequency tables will be produced to summarize answers provided to each of the 5 items of the 
EQ-5D- 3L for each visit by [CONTACT_634306]. 
Summary statistics of the actual values and change from Part A Baseline values will be used to summarize the EQ -5D- 3L VAS score for each visit by [CONTACT_634315]. 
These summaries will be produced for the OLS using observed case data. 
[IP_ADDRESS] Maastricht Ankylosis Spondylitis Enthesitis Score (MASES) 
Summary statistics of the actual values and change from Part A Baseline values will be used to 
summarize the MASES score for each visit by [CONTACT_634315]. This summary will be produced for the OLS using observed case data. 
[IP_ADDRESS] Swollen and tender joint counts (44 joint count) 
Summary statistics of the actual and change from Part A Baseline values will be used to 
summarize TJC and SJC for each visit by [CONTACT_634306]. 
These summaries will be produced for the OLS using observed case data. REDACTED COPY Frequency tables will be produced to summarize the answer provided to question 1 of the WPS 
REDACTED COPY Frequency tables will be produced to summarize the answer provided to question 1 of the WPS 
and for all subjects combin
REDACTED COPY and for all subjects combin
Summary statistics of the actual values and change from 
REDACTED COPY Summary statistics of the actual values and change from 
summarize the answers to the question 2 to 9 of the WPS for each visit by 
[CONTACT_634316] 2 to 9 of the WPS for each visit by 
[CONTACT_634317]. REDACTED COPY produced for the OLS using observed case.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used to summarize the CRP values for each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used to summarize the CRP values for each 
and for all subjects combined. This summary will be produced for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and for all subjects combined. This summary will be produced for 
LOCF imputation for missing data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LOCF imputation for missing data.
he geometric mean and the corresponding CV of the geometric mean will be computed and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. he geometric mean and the corresponding CV of the geometric mean will be computed and 
Baseline over Part A Baseline values.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline over Part A Baseline values.
Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline values will be used to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values will be used to 
axSpA subpopulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA subpopulation and for all subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and for all subjects 
This summary will be produced for the OLS using observed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This summary will be produced for the OLS using observed 
Frequency tables will be produced to summarize the answer provided to question 1 of the WPS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Frequency tables will be produced to summarize the answer provided to question 1 of the WPS 
and for all subjects combin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and for all subjects combin
Summary statistics of the actual values and change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics of the actual values and change from 
summarize the answers to the question 2 to 9 of the WPS for each visit by 
[CONTACT_122253]. summarize the answers to the question 2 to 9 of the WPS for each visit by 
[CONTACT_634317].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. produced for the OLS using observed case.
EuroQoL Health Status Questionnaire 5 dimensions
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. EuroQoL Health Status Questionnaire 5 dimensions
Frequency tables will be produced to summarize answers provided to each of the 5 items of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Frequency tables will be produced to summarize answers provided to each of the 5 items of the 
axSpA subpopulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA subpopulation
Summary statistics of the actual values and change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics of the actual values and change from 
5D
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 5D-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -3L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3LVAS score
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. VAS score
These summaries will be produced
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summaries will be produced
Maastricht Ankylosis Spondylitis Enthesitis Score (MASES)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maastricht Ankylosis Spondylitis Enthesitis Score (MASES)
Summary statistics of the actual values and change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics of the actual values and change from 
summarize the MASES score
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarize the MASES score
combined. This summary will be produced for the OLS using observed case data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. combined. This summary will be produced for the OLS using observed case data.
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 67 of 149 [IP_ADDRESS] Spi[INVESTIGATOR_634131] A Baseline values will be used to 
summarize spi[INVESTIGATOR_634132]. These summaries will be produced for the OLS using observed case data. 
[IP_ADDRESS] Number of uveitis flares, IBD exacerbations and psoriasis exacerbations 
Separate tables will be produced to summarize incidence of each of these events (uveitis flares, 
IBD exacerbations and psoriasis exacerbations) during Part A.  
These summary tables will display the number and percentage of subjects experiencing the 
considered event in Part A and number of event . In this style of output, “number of event ” will 
include all occurrences of the event including repeat occurrences in individual subjects, while 
“number of subjects” will count each subject only once.  
The presentation will be based on the OLS by [CONTACT_634318].  
For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations ), the 
summary table will be repeated based on the subset of subjects with a current occurrence of the event at screening. 
[IP_ADDRESS] Fecal calprotectin  
Actual fecal calprotectin levels and corresponding change from Part A Baseline values will be 
summarized by [CONTACT_634319] A using the geometric mean, 95% CI, geometric CV, arithmetic mean, 
arithmetic SD, median, minimum, and maximum. This analysis will be performed on observed 
case data only using the OLS. 
[IP_ADDRESS] Serum cal protectin 
Actual serum calprotectin levels and corresponding change from Part A Baseline values will be 
summarized by [CONTACT_634320] A using the geometric mean, 95% CI, geometric CV, arithmetic mean, 
arithmetic SD, median, minimum, and maximum. This analysis will be performed on observed case data only using the OLS. 
[IP_ADDRESS] Inflammatory Bowel Disease Questionnaire (IBD- Q) 
Summary statistics will be used to summarize each score (Global IBD-Q total score, IBD- Q 
bowel symptoms score, IBD-Q systemic symptoms score, IBD-Q emotional function score and  
IBD-Q social function score) using the actual values and change from Part A Baseline values at 
each visit by [CONTACT_634321]. These summaries will be produced for the OLS 
using observed case data. 
Frequency tables by [CONTACT_634322]-Q responders and IBD-Q remitters at each visit. These summaries will be 
produced for the OLS using observed case data and  will be repeated using NRI data. REDACTED COPY Actual fecal calprotectin levels and corresponding change from 
REDACTED COPY Actual fecal calprotectin levels and corresponding change from 
overall 
REDACTED COPY overall 
using the geometric mean, 95% CI, geometric 
REDACTED COPY using the geometric mean, 95% CI, geometric 
arithmetic SD, median, minimum, and maximum. REDACTED COPY arithmetic SD, median, minimum, and maximum. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. uveitis flares, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. uveitis flares, 
number and percentage of subjects experiencing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number and percentage of subjects experiencing the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the 
In this style of output, “number of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In this style of output, “number of event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. event
including repeat occurrences in individual subjects, while 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. including repeat occurrences in individual subjects, while 
and overall using observed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and overall using observed 
uveitis flares, IBD exacerbations and psoriasis exacerbations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. uveitis flares, IBD exacerbations and psoriasis exacerbations
ble will be repeated based on the subset of subjects with a current occurrence of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ble will be repeated based on the subset of subjects with a current occurrence of the 
Actual fecal calprotectin levels and corresponding change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Actual fecal calprotectin levels and corresponding change from 
overall 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. overall for each visit at which
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for each visit at which
using the geometric mean, 95% CI, geometric 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using the geometric mean, 95% CI, geometric 
arithmetic SD, median, minimum, and maximum. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. arithmetic SD, median, minimum, and maximum. 
protectin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. protectin
Actual serum calprotectin levels and corresponding change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Actual serum calprotectin levels and corresponding change from 
axSpA subpopulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA subpopulation
using the geometric mean, 95% CI, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using the geometric mean, 95% CI, 
arithmetic SD, median, minimum, and maximum. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. arithmetic SD, median, minimum, and maximum. 
case data only using the OLS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. case data only using the OLS.
Inflammatory Bowel Disease Questionnaire (IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Inflammatory Bowel Disease Questionnaire (IBD
Summary statistics will be used to summarize each score (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics will be used to summarize each score (
bowel symptoms score, IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. bowel symptoms score, IBD
Q social function score
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q social function score
each
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. each visit by 
[CONTACT_122253]. visit by 
[CONTACT_634323]. using observed 
Frequency tables by 
[CONTACT_122253]. Frequency tables by 
[CONTACT_18338]   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 68 of 149 [IP_ADDRESS] Correlation between fecal calprotectin, serum calprotectin, IBD-Q and CRP 
The following correlations will be summarized at Part A Baseline and Week 48 by [CONTACT_634324]: 
 fecal calprotectin and serum calprotectin 
 fecal calprotectin and global IBD-Q total score 
 serum calprotectin and global IBD-Q total score 
 fecal calprotectin and CRP 
 serum calprotectin and CRP 
 CRP and global IBD-Q total score 
For each considered correlations, number and percentage of subjects with non-missing values 
and Spearman's rank correlation coefficient along with corresponding 2-sided 95% CI will be reported at each visit. These summaries will be produced for the OLS using observed case data. 
[IP_ADDRESS] Short -Form 36-Item Health Survey (SF-36)  
Summary statistics of the actual values and change  from Part A Baseline values  will be used to 
summarize each SF-36 domain scores and the PCS and MCS scores for each visit by [CONTACT_634307]. These summaries will be produced for the OLS 
using observed case data. 
Frequency tables will be produced to show the number and percentage of SF-36 PCS and MCS 
responders for each visit by [CONTACT_634306]. This summary 
will be performed on the OLS using observed case data and will be repeated using NRI data. 
[IP_ADDRESS] Resources utilization 
Summary statistics and frequency distribution (number of subjects by [CONTACT_634325]) will be presented by [CONTACT_634326], health care provider consultations, and in-patient hospi[INVESTIGATOR_634133], including length of stay. These summaries will be produced for the OLS 
using observed case data. 
8.3.2  Part B 
The following analyses  are not part of the multiplicity-controlled testing procedure described in 
Section  8.1.1. The p-values reported for these analyses will not be adjusted for multiplicity and 
will be considered nominal. All efficacy summaries and analyses for Part B will be performed 
using the RS. 
[IP_ADDRESS] ASDAS clinical improvement (ASDAS-CII, ASDAS- MI) 
The number and percentage of subjects achieving ASDAS-MI and ASDAS-CII will be 
summarized in frequency tables by [CONTACT_105289]. This summary will be produced 
using observed case data and will be repeated using NRI data. This analysis will be performed 
using Part A Baseline as reference for the definition of ASDAS- MI and ASDAS -CII. 
The statistical analysis of ASDAS- MI and ASDAS- CII at each visit will be based on a logistic 
regression model which will include factors of treatment group, region, and mNY classification. REDACTED COPY and the PCS and MCS scores for each visit by 
[CONTACT_634327]. For each considered correlations, number and percentage of subjects with non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For each considered correlations, number and percentage of subjects with non -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -missing values 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing values 
sided 95% CI will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sided 95% CI will be 
OLS usi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. OLS usi ng
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ng
Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline
and the PCS and MCS scores for each visit by 
[CONTACT_122253]. and the PCS and MCS scores for each visit by 
[CONTACT_634328]. These summaries will be produced for the OLS 
number and percentage of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number and percentage of 
axSpA subpopulation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA subpopulation and for all subjects combined. This summary 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and for all subjects combined. This summary 
will be performed on the OLS using observed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be performed on the OLS using observed case data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. case data 
Summary statistics and frequency distribution (number of subjects by [CONTACT_634329]. Summary statistics and frequency distribution (number of subjects by [CONTACT_634330]) will be presented by 
[CONTACT_122253]. ed) will be presented by [CONTACT_634310]. axSpA subpopulation
medical procedures, health care provider consultations, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medical procedures, health care provider consultations, and 
emergency room visits, including length of stay. These summaries will be produced for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emergency room visits, including length of stay. These summaries will be produced for 
using observed case data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using observed case data.
Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B
following
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. following analyses
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. analyses
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.1.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.1.1 . The p
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . The p
will be considered nominal. All 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be considered nominal. All 
using the RS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using the RS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
The number and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and 
summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarized 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 69 of 149 The responder rates and adjusted odds ratios with reference to PBO  will be estimated from this 
logistic regression model and presented with 95% 2-sided CIs and p-values. These analyses will 
be performed using NRI data. These analyses will be performed using Part A Baseline as reference for the definition of ASDAS-MI and ASDAS- CII. 
[IP_ADDRESS] ASAS20, ASAS40, ASAS5/6, and ASAS PR response 
The number and percentage of subjects achieving each of the ASAS endpoints will be summarized in frequency tables by [CONTACT_105289]. This summary will be produced using observed case data and will be repeated using NRI data. This analysis will be performed 
using Part A Baseline as reference for the definition of the ASAS endpoints. 
The statistical analysis of ASAS20, ASAS40, ASAS5/6 and  ASAS PR at each visit will be based 
on a logistic regression model which will include factors of treatment group, region, and mNY 
classification. The responder rates and adjusted odds ratios with reference to PBO  will be 
estimated from this logistic regression model and presented with 95% 2-sided CIs and p-values. 
These analyses will be performed using NRI data. These analyses will be performed using Part A Baseline as reference for the definition of the ASAS endpoints. 
[IP_ADDRESS] ASDAS, BASDAI, BASFI and BASMI 
Summary statistics of the actual values, change from Part B Baseline values and change from Part B Baseline values for ASDAS, BASDAI, BASFI and BASMI will be presented by [CONTACT_10663]. These summaries will be produced using observed case data. These summary 
statistics will be repeated for Part A Baseline. 
The changes from Part B Baseline to each visit in Part B for ASDAS, BASDAI, BASFI and 
BASMI will be compared between treatment groups using a MMRM. The model will include 
Part B Baseline score as a fixed-effect covariate, treatment group, region, mNY classification, 
and visit as fixed-effect categorical factors, and Part B Baseline- by-visit and treatment group- by-
visit as interaction terms. The multiple visits for each subject will be incorporated as repeated 
measures (fixed term) within each subject (random term). An unstructured covariance matrix will be used and visit will be treated as a categorical predictor. Summary tables will present th e 
adjusted means for PBO and the CZP doses, the respective differences to PBO, the corresponding p-values, and 95% CIs. 
This analysis will be repeated based on change from Part A Baseline  with Part A Baseline score 
as a fixed-effect covariate, treatment group, region, mNY classification, and visit as fixed- effect 
categorical factors, and Part A Baseline- by-visit and treatment group- by-visit as interaction 
terms. 
[IP_ADDRESS] Individual ASAS core components 
Summary statistics will be used to summarize the actual values, change  from Part A Baseline 
values and change from Part B Baseline values by [CONTACT_634331] (note 
that BASFI is covered in Section  [IP_ADDRESS]):  
 PtGADA 
 Total spi[INVESTIGATOR_18172] (NRS) 
 Average of Questions [ADDRESS_846853] will be incorporated as repeated 
measures (fixed term) within each subject (random term). An unstructured covariance matrix 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. measures (fixed term) within each subject (random term). An unstructured covariance matrix 
will be used and visit will be treated as a categorical predictor. Summary tables will present th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used and visit will be treated as a categorical predictor. Summary tables will present th
adjusted means for PBO and the CZP doses, the respective differences to PBO, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. adjusted means for PBO and the CZP doses, the respective differences to PBO, the 
values, and 95% CIs.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values, and 95% CIs.
This analysis will be repeated based on change from Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This analysis will be repeated based on change from Part 
effect covariate, treatment gr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. effect covariate, treatment gr
categorical factors
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. categorical factors
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
Summary statistics will be used to summarize 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics will be used to summarize 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values and change from Part B Baseline values by [CONTACT_634332]. values and change from Part B Baseline values by [CONTACT_634333]. that BASFI is covered in 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 70 of 149 These summaries will be produced using observed case data. 
For each component, the changes from Part B Baseline to each visit in Part B will be compared 
between treatment groups using a MMRM. (see Section  [IP_ADDRESS]). This analysis will be repeated 
based on change from Part A Baseline . 
[IP_ADDRESS] Fatigue NRS 
Fatigue (NRS) will be taken from BASDAI Question 1. Summary statistics for actual values, 
change from Part A Baseline values and change from Part B Baseline values by [CONTACT_634334] B. This summary will be produced using observed case. 
Treatment group comparisons for both CZP groups vs. PBO will be performed based on the 
change from Part B Baseline to each visit in Fatigue using a MMRM. (see Section  [IP_ADDRESS]).   
This analysis will be repeated based on change from Part A Baseline . 
The remaining components of the BASDAI maybe analyzed as well. 
[IP_ADDRESS] BASDAI50 response 
Frequency tables by [CONTACT_634335]50 responders at each visit during Part B. This summary will be produced 
using observed case data and will be repeated using NRI for missing data. This analysis will be performed using Part A Baseline as reference for the definition of BASDAI50. 
The statistical analysis of BASDAI50 response at each visit will be based on a logistic regression 
model which will include factors of treatment group, region, and mNY classification. The responder rates for each treatment group and the adjusted odds ratios with reference to PBO will 
be estimated from this logistic regression model and presented with 95% 2-sided CIs and p-
values. This analysis will be performed using NRI data. This analysis will be performed using Part A Baseline as reference for the definition of BASDAI50. 
[IP_ADDRESS] ASQoL 
Summary statistics for actual values, change from Part A Baseline values and change from Part 
B Baseline values by [CONTACT_634336] B. This summary will be produced using observed case. 
Treatment group comparisons for both CZP groups vs. PBO will be performed based on the 
change from Part B Baseline to each visit in ASQoL score using MMRM (see Section  [IP_ADDRESS]).  
This analysis will be repeated based on change from Part A Baseline.  
[IP_ADDRESS] Work Productivity Survey (WPS) 
Frequency tables will be produced by [CONTACT_634337] 1 of the WPS.  
Summary statistics will be used to summarize the actual values, change from Part A Baseline 
values and change from Part B Baseline values by [CONTACT_634338] 2 to 9 of WPS. These summaries will be produced using observed case data.  
Treatment group comparisons for both CZP groups vs. PBO will be performed for the change 
from Part B Baseline  for answers to questions 2 to 9 using MMRM (see Section [IP_ADDRESS]).  REDACTED COPY percentage of BASDAI50 responders at each visit during Part B. 
REDACTED COPY percentage of BASDAI50 responders at each visit during Part B. 
using observed case data and will be repeated using 
REDACTED COPY using observed case data and will be repeated using NRI
REDACTED COPY NRI
as reference for the definition of BASDAI50.
REDACTED COPY as reference for the definition of BASDAI50.
The statistical analysis of BASDAI50 response at each
REDACTED COPY The statistical analysis of BASDAI50 response at each
model which will include factors of treatment group, region, and mNY classification. The 
REDACTED COPY model which will include factors of treatment group, region, and mNY classification. The 
responder rates for each treatment group and the adjusted odds ratios with reference to PBO will 
REDACTED COPY responder rates for each treatment group and the adjusted odds ratios with reference to PBO will 
ogistic regression model and presented with 95% 2REDACTED COPY ogistic regression model and presented with 95% 2
values. This analysis will be performed using NRI data. This analysis will be performed using REDACTED COPY values. This analysis will be performed using NRI data. This analysis will be performed using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. by [CONTACT_634339]. by [CONTACT_634340] B. This 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group will be used to summarize the fatigue scores at each visit during Part B. This 
Treatment group comparisons for both CZP groups vs. PBO will be performed based on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment group comparisons for both CZP groups vs. PBO will be performed based on the 
Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Section [IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
will be produced to show the number and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be produced to show the number and 
percentage of BASDAI50 responders at each visit during Part B. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. percentage of BASDAI50 responders at each visit during Part B. This summary will be produced 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This summary will be produced 
for missing data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for missing data.
as reference for the definition of BASDAI50.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as reference for the definition of BASDAI50.
The statistical analysis of BASDAI50 response at each
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The statistical analysis of BASDAI50 response at each visit will be based on a logistic regression 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. visit will be based on a logistic regression 
model which will include factors of treatment group, region, and mNY classification. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. model which will include factors of treatment group, region, and mNY classification. The 
responder rates for each treatment group and the adjusted odds ratios with reference to PBO will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. responder rates for each treatment group and the adjusted odds ratios with reference to PBO will 
ogistic regression model and presented with 95% 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ogistic regression model and presented with 95% 2
values. This analysis will be performed using NRI data. This analysis will be performed using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values. This analysis will be performed using NRI data. This analysis will be performed using 
as reference for the definition of BASDAI50.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as reference for the definition of BASDAI50.
Summary statistics for actual
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics for actual values, change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values, change from 
B Baseline values by [CONTACT_634341]. B Baseline values by [CONTACT_634342] B. This summary will be produced using observed case.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. at each visit during Part B. This summary will be produced using observed case.
Treatment group co
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment group co mparisons for both CZP groups vs. PBO will be performed based on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mparisons for both CZP groups vs. PBO will be performed based on the 
Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline
This analysis will be repeated based on change from Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This analysis will be repeated based on change from Part 
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Frequency tables will be produced by [CONTACT_634343]. Frequency tables will be produced by [CONTACT_634344] 1 of the WPS. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. question 1 of the WPS. 
Summary statistics will be used to summarize the actual values, change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics will be used to summarize the actual values, change from 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 71 of 149 This analysis will be repeated based on the change from Part A Baseline. 
[IP_ADDRESS] Number of uveitis flares, IBD exacerbations and psoriasis exacerbations 
Separate tables will be produced to summarize incidence of each of these events (uveitis flares, 
IBD exacerbations and psoriasis exacerbations) during Part B.  
These summary tables will display the number and percentage of subjects experiencing the 
considered event in Part B, number of event, incidence rate, event rate and 100 patient exposure 
year. Only the events occurring up to Escape Week 0 will be considered. In this style of output, 
“number of event” will include all occurrences of the event including repeat occurrences in 
individual subjects, while “number of subjects” will count each subject only once.  
The presentation will be performed by [CONTACT_634345]. 
For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations), the 
summary table will be repeated based on the subset of subjects with a history of occurrence and/or a current occurrence of the event at screening. 
[IP_ADDRESS] Correlation between fecal calprotectin, serum calprotectin, IBD-Q and CRP 
The following correlations will be summarized at Week 48 and Week 96 by [CONTACT_1570]: 
 fecal calprotectin and serum calprotectin 
 fecal calprotectin and global IBD-Q total score 
 serum calprotectin and global IBD-Q total score 
 fecal calprotectin and CRP 
 serum calprotectin and CRP 
 CRP an d global IBD-Q total score 
For each considered correlations, number and percentage of subjects with non-missing values 
and Spearman's rank correlation coefficient along with corresponding 2-sided 95% CI will be 
reported at each visit. These summaries will be produced using observed case data only. 
[IP_ADDRESS] Short -Form 36-Item Health Survey (SF-36)  
Summary statistics for actual values, change from Part A Baseline values and change from Part 
B Baseline values by [CONTACT_634346]-36 domain, 
PCS and MCS scores at each visit during Part B. This summary will be produced using observed 
case data . 
Treatment group comparisons for both CZP groups vs. PBO will be performed based on the change from Part B Baseline in the SF-36 physical function domain, PCS and MCS scores only 
at the time points of Part B using MMRM (Section [IP_ADDRESS]). This analysis will be repeated based 
on change from Part A Baseline. 
Frequency tables by [CONTACT_634347]-36 PCS and MCS responders at each visit during Part B. This summary will be 
produced using observed case data and will be repeated using NRI for missing data. This 
analysis will be performed using Part A Baseline as reference for the definition of SF-36 PCS and MCS responders. REDACTED COPY Q total score
REDACTED COPY Q total score
Q total score
REDACTED COPY Q total score
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ncidence rate, event rate and 100 patient exposure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ncidence rate, event rate and 100 patient exposure 
In this style of output, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In this style of output, 
“number of event” will include all occurrences of the event including repeat occurrences in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. “number of event” will include all occurrences of the event including repeat occurrences in 
(uveitis flares, IBD exacerbations and psoriasis exacerbations),
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (uveitis flares, IBD exacerbations and psoriasis exacerbations),
a history of occurrence 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a history of occurrence 
Correlation between fecal calprotectin, serum calprotectin, IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Correlation between fecal calprotectin, serum calprotectin, IBD
be summarized at Week 48 and Week 96 by [CONTACT_1570]:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be summarized at Week 48 and Week 96 by [CONTACT_1570]:
Q total score
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q total score
Q total score
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q total score
For each considered correlations, number and percentage of subjects with non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For each considered correlations, number and percentage of subjects with non
and Spearman's rank correlation coefficient along with corresponding 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and Spearman's rank correlation coefficient along with corresponding 2
reported at each visit. These summaries will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. reported at each visit. These summaries will 
Form 36
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Form 36
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics for actual values, change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics for actual values, change from 
B Baseline values by [CONTACT_634348] t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B Baseline values by [CONTACT_634348] t
PCS and MCS scores at each visit during Part B. This summary will be produced using observed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PCS and MCS scores at each visit during Part B. This summary will be produced using observed 
Treatment group comparisons for both CZP groups vs. PBO will be performed based on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment group comparisons for both CZP groups vs. PBO will be performed based on the 
hange from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hange from 
at the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. at the time point
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. time point
on change 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. on change 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 72 of 149 The statistical analysis of SF-36 PCS and MCS response at each visit will be based on a logistic 
regression model which will include factors of treatment group, region, and mNY classification. 
The responder rates for each treatment group and the adjusted odds ratios with reference to PBO will be estimated from this logistic regression model and presented with 95% 2-sided CIs and p-
values. This analysis will be performed using NRI data. This analysis will be performed using 
Part A Baseline as reference for the definition of SF-36 PCS and MCS response. 
[IP_ADDRESS] Descriptive summaries of other efficacy variables 
The below listed efficacy variables will be summarized descriptively by [CONTACT_634349].  
 ASDAS disease activity (ASDAS-ID, ASDAS- LD, ASDAS-HD and ASDAS-vHD) 
 Change fro m Part A Baseline and change from Part B Baseline in SIJ SPARCC and spi[INVESTIGATOR_634125]-a in the Berlin modification scores (summaries based on observed case data only) 
 Change from Part A Baseline and change from Part B Baseline in PhGADA 
 Change from Part A Baseline and change from Part B Baseline in nocturnal spi[INVESTIGATOR_18172] 
(NRS)  
 CRP (actual values, change from Part A Baseline values, change from Part B Baseline 
values, ratio of post-Baseline over Part A Baseline values, ratio of post-Baseline over Part B Baseline values) 
 Health status as assessed by [CONTACT_20367]-5D-3L: domains, VAS actual score, change from Part A Baseline and change from Part B Baseline in VAS score 
 Change from Part A Baseline and change from Part B Baseline in MASES 
 Change from Part A Baseline and change from Part B Baseline in swollen and tender joint counts (44 joint counts). The summaries for TJC will be repeated including only the subjects 
with a TJC>0 at Part A Baseline or Part B Baseline, as appropriate. Similar approach will be 
used for SJC. 
 Change from Part A Baseline and change from Part B Baseline in spi[INVESTIGATOR_634134] 
 Change from Part A Baseline and change from Part B Baseline in fecal calprotectin (summaries based on observed case data only) 
 Change from Part A Baseline and change from Part B Baseline in serum calprotectin 
(summaries based on observed case data only) 
 Change from Part A Baseline and change from Part B Baseline in the IBD-Q scores (Global 
IBD-Q total score, IBD-Q bowel symptoms score, IBD-Q systemic symptoms score, IBD- Q 
emotional function score and IBD-Q social function score) 
 Frequency of IBD-Q responders and IBD-Q remitters (NRI data will be used) using Part A 
Baseline and Part B Baseline as reference 
 Resources utilization: concomitant medical procedures, healthcare provider consultations not 
foreseen by [CONTACT_760], in-patient hospi[INVESTIGATOR_634135], change from Part B Baseline 
REDACTED COPY values, change from Part B Baseline 
Baseline over Part A Baseline values
REDACTED COPY Baseline over Part A Baseline values
3L: domains, VAS actual score, change from 
REDACTED COPY 3L: domains, VAS actual score, change from 
and change from Part B Baseline in VAS score
REDACTED COPY and change from Part B Baseline in VAS score
and change from Part B Baseline in MASES
REDACTED COPY and change from Part B Baseline in MASES
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e below listed efficacy variables will be summarized descriptively by [CONTACT_634350]. e below listed efficacy variables will be summarized descriptively by [CONTACT_634351])
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. vHD)
and change from Part B Baseline in SIJ SPARCC and spi[INVESTIGATOR_634094]. and change from Part B Baseline in SIJ SPARCC and spi[INVESTIGATOR_050] 
a in the Berlin modification scores (summaries based on observed case data only)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a in the Berlin modification scores (summaries based on observed case data only)
and change from Part B Baseline in PhGADA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and change from Part B Baseline in PhGADA
and change from Part B Baseline in nocturnal spi[INVESTIGATOR_634096]. and change from Part B Baseline in nocturnal spi[INVESTIGATOR_634136], change from Part B Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values, change from Part B Baseline 
Baseline over Part A Baseline values
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline over Part A Baseline values
3L: domains, VAS actual score, change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3L: domains, VAS actual score, change from 
and change from Part B Baseline in VAS score
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and change from Part B Baseline in VAS score
and change from Part B Baseline in MASES
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and change from Part B Baseline in MASES
and cha
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and cha nge from Part B Baseline in swollen and tender joint 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nge from Part B Baseline in swollen and tender joint 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . The summaries for TJC will be repeated including only the subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . The summaries for TJC will be repeated including only the subjects 
Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline or Part B Baseline, as appropriate. Similar approach will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. or Part B Baseline, as appropriate. Similar approach will be 
Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline
by [CONTACT_634352][INVESTIGATOR_634137]. by [CONTACT_634352][INVESTIGATOR_634138] A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline
(summaries based on observed case data only)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (summaries based on observed case data only)
Change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (summaries based on observed case data only)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (summaries based on observed case data only)
Change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from 
IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. IBD
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 73 of 149 8.3.3  Subjects experiencing a flare in Part B 
The below listed efficacy variables for subjects experiencing a flare in Part B will be 
summarized descriptively by [CONTACT_634353]. If deemed 
needed, further sensitivity analyses may be conducted excluding subjects incorrectly ‘flared’.  All summaries will be based on observed case data and will present data as collected at all 
scheduled study visits following Escape Week 0. Generally, the format of the summaries 
described here will mirror the format of summaries described in Section  8.3.2 .  
 ASDAS disease activity (ASDAS-ID, ASDAS- LD, ASDAS-HD, and ASDAS-vHD)  
 ASDAS clinical improvement (ASDAS-CII, ASDAS- MI, MI) using Flare Baseline as 
reference 
 ASAS20, ASAS40, ASAS5/6, and ASAS PR using Flare Baseline as reference  
 Change from Part B Baseline and change from Flare Baseline in ASDAS, BASDAI and 
BASMI 
 Change Part B Baseline and change from Flare Baseline in SIJ SPARCC and spi[INVESTIGATOR_18241]-a in the Berlin modification scores 
 Change from Part B Baseline and change from Flare Baseline in all individual ASAS core components: 
 PtGADA 
 Total spi[INVESTIGATOR_18172] (NRS) 
 BASFI 
 Average of questions 5 and 6 of the BASDAI concerning morning stiffness 
 Change from Part B Baseline and change from Flare Baseline in PhGADA 
 Change from Part B Baseline and change from Flare Baseline in nocturnal spi[INVESTIGATOR_18172] (NRS) 
 Change from Part B Baseline and change from Flare Baseline in Fatigue (NRS) (from 
BASDAI). The remaining components of the BASDAI maybe analyzed as well. 
 BASDAI50 response using Flare Baseline as reference  
 CRP (actual values, change from Part B Baseline values, ratio of post-Baseline over Part B Baseline values, change from Flare Baseline values, ratio of post-Baseline over Flare 
Baseline values) 
 Change from Part B Baseline and change from Flare Baseline in ASQoL 
 Change from Part B Baseline and change from Flare Baseline WPS  
 Health status as assessed by [CONTACT_20367]-5D- 3L: domains, VAS actual score, change from Part B 
Baseline and change from Flare Baseline in VAS score 
 Change from Part B Baseline and change from Flare Baseline in MAS ES 
 Change from Part B Baseline and change from Flare Baseline in spi[INVESTIGATOR_634139] 5 and 6 of the BASDAI concerning morning stiffness REDACTED COPY Average of questions 5 and 6 of the BASDAI concerning morning stiffness
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Flare Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Flare Baseline as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as 
as reference
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as reference
in ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in ASDAS , BASDAI and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , BASDAI and 
in SIJ SPARCC and spi[INVESTIGATOR_634094]. in SIJ SPARCC and spi[INVESTIGATOR_634140]. Flare Baseline
Average of questions 5 and 6 of the BASDAI concerning morning stiffness
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Average of questions 5 and 6 of the BASDAI concerning morning stiffness
Change from Part B Baseline and change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from Part B Baseline and change from 
Change from Part B Baseline and change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from Part B Baseline and change from 
nge from Part B Baseline and change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nge from Part B Baseline and change from 
The remaining components of the BASDAI maybe analyzed as well.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The remaining components of the BASDAI maybe analyzed as well.
BASDAI50 response
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI50 response
CRP (actual values, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CRP (actual values, 
Baseline values
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline values
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline values
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values
Change from Part B Baseline and change from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from Part B Baseline and change from 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from Pa
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change from Pa

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 74 of 149  Number of uveitis flares, IBD exacerbations and psoriasis exacerbations occurring post 
ASDAS-defined flare 
 Change from Part B Baseline and change from Flare Baseline in fecal calprotectin 
 Change from Part B Baseline and change from Flare Baseline in serum calprotectin 
 Change from Part B Baseline and change from Flare Baseline in the IBD-Q scores (Global 
IBD-Q total score, IBD-Q bowel symptoms score, IBD-Q systemic symptoms score, IBD- Q 
emotional function score and, IBD-Q social function score) 
 Frequency of IBD-Q responders and IBD-Q remitters using Part B Baseline and Flare 
Baseline as reference 
 Correlation between fecal calprotectin, serum calprotectin, IBD-Q and CRP 
 Change from Part B Baseline and change from Flare Baseline in all SF-36 domains, SF-36 
PCS, SF -36 MCS 
 Frequency of SF-36 PCS responders and SF -36 MCS  responders using Flare Baseline  as 
reference 
 Resources utilization: concomitant medical procedures, healthcare provider consultations not 
foreseen by [CONTACT_760], in-patient hospi[INVESTIGATOR_306134] 
9 PHARMACOKINETICS AND  PHARMACODYNAMICS  
9.1 Pharmacokinetics 
CZP plasma concentrations will be tabulated and summarized using PKS B for each visit at 
which samples were taken during Part A by [CONTACT_634354], 
95% CI, geometric CV , arithmetic mean, arithmetic SD, median, minimum, and maximum. 
Plasma concentration time curves of Part A will be plotted for all subjects and Part A treatment-emergent ADAb (Part A TE ADAb) status with titer classification (see Section 9.2).  
CZP plasma concentrations will be tabulated and summarized by [CONTACT_634355], 95% CI, 
geometric CV, arithmetic mean, arithmetic SD, median, minimum, and maximum. The table will 
be repeated for TE ADAb status with titer classification (see Section 9.2.).   
For each treatment group, plasma concentration time curves of Part B will be plotted and 
repeated for TE ADAb status with titer classification (see Section  9.2.). 
Part B figures will not include post-flare assessments. Separate figures will be produced for 
subjects experiencing a flare in Part B and start escape therapy including only the post-flare assessments. 
Spaghetti plots of CZP plasma concentrations by [CONTACT_634356] (see Section  9.2.) will be presented 
for subjects with flare and no flare per NRI approach. 
Spaghetti plots of CZP plasma concentrations by [CONTACT_634357] (see Section  9.2.). REDACTED COPY Resources utilization: concomitant medical procedures, healthcare provider consultations not 
REDACTED COPY Resources utilization: concomitant medical procedures, healthcare provider consultations not 
hospi[INVESTIGATOR_634141] A REDACTED COPY which samples were taken during Part A by [CONTACT_634358] 
, arithmetic mean, arithmetic SD, median, minimum, and maximum. REDACTED COPY , arithmetic mean, arithmetic SD, median, minimum, and maximum. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q 
Flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Flare 
Q and CRP
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q and CRP
36 domains, SF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 domains, SF
responders 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. responders using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using 
Resources utilization: concomitant medical procedures, healthcare provider consultations not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Resources utilization: concomitant medical procedures, healthcare provider consultations not 
and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and emergency room visits
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emergency room visits
PHARMACODYNAMICS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PHARMACODYNAMICS 
plasma concentrations will be tabulated and summarized using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. plasma concentrations will be tabulated and summarized using 
by [CONTACT_634359]. by [CONTACT_634184] 
, arithmetic mean, arithmetic SD, median, minimum, and maximum. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , arithmetic mean, arithmetic SD, median, minimum, and maximum. 
of Part A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of Part A 
TE ADAb) status with titer 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. TE ADAb) status with titer 
CZP plasma concentrations will be tabulated and summarized by [CONTACT_634360]. CZP plasma concentrations will be tabulated and summarized by [CONTACT_634361]. of the total study at which samples were taken using the geometric mean, 95% CI, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. at which samples were taken using the geometric mean, 95% CI, 
, arithmetic mean, arithmetic SD,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , arithmetic mean, arithmetic SD,
repeated for TE ADAb status with titer 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. repeated for TE ADAb status with titer 
For each treatment group, plasma concentration time curves 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For each treatment group, plasma concentration time curves 
repeated for TE ADAb status with titer 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. repeated for TE ADAb status with titer 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. figures
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. figures will not include post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will not include post
subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessments
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessments
Spaghetti plots of CZP plasma concentrations by 
[CONTACT_122253]. Spaghetti plots of CZP plasma concentrations by 
[CONTACT_634362]. treatment group 
UCB   [ADDRESS_846854] of CZP Concentrations/ADAb titer and ASDAS score plotted on the 
Y-axes by [CONTACT_765] (X-axis) for the full treatment period, including SFU. Flare data will be displayed 
on the days relative to Part A.  
Concentrations below the limit of quantification (BLQ) will be replaced by [CONTACT_634363] 
2 for the calculation of descriptive statistics. 
Anomalous values will be not included in summaries/analysis and will be reviewed and flag ged 
by [CONTACT_634364]. 
All CZP plasma concentration will be listed at subject-level.  
9.[ADDRESS_846855] samples: 
 An ADAb status will be confirmed as positive for any sample with an ADAb level that is 
positive screen and positive immunodepletion.  
 An ADAb status of negative will be concluded for any sample with an ADAb level that is either negative screen or positive screen and negative immunodepletion. 
Confirmed positive samples will be titrated. The dilution factor will be reported. The titer 
represents the last dilution factor of the sample’s titration series still scoring positive in the 
screening ADAb assay. ADAb titer dilution factor is presented in the listings and summaries 
excluding the minimum required dilution, i.e. reportable values are divided by 100.  
If the titer for an ADAb level that is positive screen and positive immunodepletion is missing, 
then a conservative will be used and ADAb status will be consider as positive. No imputation rules apply for the missing titer. 
If the ADAb level is positive screen but no confirmatory result could be determined, then then a 
conservative will be used and ADAb status will be consider as positive. 
Anomalous value will be not included in summaries/analysis and will be reviewed and flagged 
by [CONTACT_634364]. 
Subjects will have the following Baseline ADAb status: 
Baseline ADAb Status positive is defined as having an ADAb confirmed positive inhibition 
result at baseline, Baseline ADAb Status negative is defined as having negative inhibition result 
at baseline. 
Subjects will receive a treatment-emergent ADAb status, inclusive of Baseline and Post- Baseline 
results (including SFU), and be classified as follows based on the ADAb assay results: 
 TE ADAb status positive is defined as either (i) baseline ADAb negative subjects having at 
least one ADAb confirmed positive sample post baseline or ii) baseline ADAb positive subjects with at least one post baseline sample with ≥minimum significant ratio (MSR) -fold REDACTED COPY An ADAb status of negative will be concluded for any sample with an ADAb level that is 
REDACTED COPY An ADAb status of negative will be concluded for any sample with an ADAb level that is 
screen and negative immunodepletion.
REDACTED COPY screen and negative immunodepletion.
Confirmed positive samples will be titrated. The dilution factor will be reported. The titer 
REDACTED COPY Confirmed positive samples will be titrated. The dilution factor will be reported. The titer 
represents the last dilution factor of the sample’s titration series still scoring positive in the 
REDACTED COPY represents the last dilution factor of the sample’s titration series still scoring positive in the 
titer dilution factor is presented in the listings and summaries REDACTED COPY titer dilution factor is presented in the listings and summaries 
excluding the minimum required dilution, i.e. reportable values are divided by 100. REDACTED COPY excluding the minimum required dilution, i.e. reportable values are divided by 100. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ged
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ged
Immunogenicity will be assessed through listing of individual results by [CONTACT_634365]. Immunogenicity will be assessed through listing of individual results by [CONTACT_18464]. Immunogenicity data will be correlated with PK and efficacy readout. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tables. Immunogenicity data will be correlated with PK and efficacy readout. 
A cut point will be determined by [CONTACT_634366]. A cut point will be determined by [CONTACT_634367]. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. point will be used to determine the status of ADAb in the test sample. 
The following definitions will be applied regarding classification of test samples:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following definitions will be applied regarding classification of test samples:
An ADAb status will be confirmed as positive for any sample with an ADAb level that is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. An ADAb status will be confirmed as positive for any sample with an ADAb level that is 
An ADAb status of negative will be concluded for any sample with an ADAb level that is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. An ADAb status of negative will be concluded for any sample with an ADAb level that is 
screen and negative immunodepletion.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. screen and negative immunodepletion.
Confirmed positive samples will be titrated. The dilution factor will be reported. The titer 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Confirmed positive samples will be titrated. The dilution factor will be reported. The titer 
represents the last dilution factor of the sample’s titration series still scoring positive in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. represents the last dilution factor of the sample’s titration series still scoring positive in the 
titer dilution factor is presented in the listings and summaries 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. titer dilution factor is presented in the listings and summaries 
excluding the minimum required dilution, i.e. reportable values are divided by 100. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. excluding the minimum required dilution, i.e. reportable values are divided by 100. 
If the titer for an ADAb level that is positive screen and positive immunodepletion is missing, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the titer for an ADAb level that is positive screen and positive immunodepletion is missing, 
servative will be used and ADAb status will be consider as positive. No imputation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. servative will be used and ADAb status will be consider as positive. No imputation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rules apply for the missing titer.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rules apply for the missing titer.
If the ADAb level is positive screen but no confirmatory result could be determined, then then a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the ADAb level is positive screen but no confirmatory result could be determined, then then a 
conservative will be used and ADAb status
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. conservative will be used and ADAb status
Anomalous value will be not included in summaries/analysis and will be reviewed and flagged 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Anomalous value will be not included in summaries/analysis and will be reviewed and flagged 
by [CONTACT_634364].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. by [CONTACT_634364].
Subjects will have the following Baseline ADAb status:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subjects will have the following Baseline ADAb status:
Baseline ADAb Status positive is defined as having an A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline ADAb Status positive is defined as having an A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. result at baseline, Baseline ADAb Status negative is defined as having negative inhibition result 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. result at baseline, Baseline ADAb Status negative is defined as having negative inhibition result 
at baseline.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. at baseline.
Subjects will receive a treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subjects will receive a treatment
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 76 of 149 increase from baseline on CZP treatment. The MSR will be defined during the process of 
sample analysis and is disease-specific. 
 TE ADAb status negative is defined as having no samples either ADAb positive or with 
values ≥MSR -fold increase from baseline.  
Once determined positive, the highest titer during Part A and Part B (including Escape and SFU) 
is used to categorize the subject. 
 Positive <512,  
 Positive 512- <=1024,  
 Positive >1024. 
In addition, for some outputs also the subjects with TE ADAb status negative will be presented. 
The TE ADAb will be also defined for the different treatment periods. For each Period the SFU 
visit will be considered:  
 Part A TE ADAb status positive is defined as either (i) baseline ADAb negative subjects 
having at least one ADAb confirmed positive sample post baseline during Part A or ii) baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
from baseline on CZP treatment during Part A. Once determined positive, the highest titer 
during Part A is used to categorize the subject. 
 Part A TE ADAb status negative is defined as having no samples either ADAb positive or with values ≥MSR increase from baseline during Part A.  
 Part B TE ADAb Status positive is defined as either (i) baseline ADAb negative subjects having at least one ADAb confirmed positive sample post baseline during Part B or ii) 
baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
from baseline on CZP treatment during Part B. Once determined positive, only the highest titer during Part is used to categorize the subject. For subjects with flare in Part B, any assessments after Escape treatment are not included. 
 Part B TE ADAb Status negative is defined as having no samples either ADAb positive or with values ≥MSR increase from baseline during Part B (excluding any values up to [ADDRESS_846856] Part B dose).  
 Escape TE ADAb Status positive is defined as either (i) baseline ADAb negative subjects having at least one ADAb confirmed positive sample post baseline during Escape Part or ii) 
baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
from baseline on CZP treatment during Escape Part B. Once determined positive, only the highest titer during Escape is used to categorize the subject. 
 Escape TE ADAb Status negative is defined as having no samples either ADAb positive or 
with values ≥MSR increase from baseline during Escape Part. Once determined positive, 
only the highest titer during Escape is used to categorize the subject. 
Summaries will be done using PKSB.  REDACTED COPY ZP treatment during Part A. Once determined positive, the highest titer 
REDACTED COPY ZP treatment during Part A. Once determined positive, the highest titer 
during Part A is used to categorize the subject.
REDACTED COPY during Part A is used to categorize the subject.
Part A TE ADAb status negative is defined as having no samples either ADAb positive or 
REDACTED COPY Part A TE ADAb status negative is defined as having no samples either ADAb positive or 
with values ≥MSR increase from baseline during P
REDACTED COPY with values ≥MSR increase from baseline during P
Part B TE ADAb Status positive is defined as either (i) baseline ADAb negative subjects 
REDACTED COPY Part B TE ADAb Status positive is defined as either (i) baseline ADAb negative subjects 
having at least one ADAb confirmed positive sample post baseline during Part B or ii) REDACTED COPY having at least one ADAb confirmed positive sample post baseline during Part B or ii) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, for some outputs also the subjects with TE ADAb status negative will be presented.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, for some outputs also the subjects with TE ADAb status negative will be presented.
The TE ADAb will be also defined for the different treatment periods. For each Period the SFU 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The TE ADAb will be also defined for the different treatment periods. For each Period the SFU 
tive is defined as either (i) baseline ADAb negative subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tive is defined as either (i) baseline ADAb negative subjects 
having at least one ADAb confirmed positive sample post baseline during Part A or ii) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. having at least one ADAb confirmed positive sample post baseline during Part A or ii) 
baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
ZP treatment during Part A. Once determined positive, the highest titer 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ZP treatment during Part A. Once determined positive, the highest titer 
Part A TE ADAb status negative is defined as having no samples either ADAb positive or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A TE ADAb status negative is defined as having no samples either ADAb positive or 
with values ≥MSR increase from baseline during P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with values ≥MSR increase from baseline during P
Part B TE ADAb Status positive is defined as either (i) baseline ADAb negative subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B TE ADAb Status positive is defined as either (i) baseline ADAb negative subjects 
having at least one ADAb confirmed positive sample post baseline during Part B or ii) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. having at least one ADAb confirmed positive sample post baseline during Part B or ii) 
baseline ADAb positive subjects with at least one post baseline sample wit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline ADAb positive subjects with at least one post baseline sample wit
from baseline on CZP treatment during Part B. Once determined positive, only the highest 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from baseline on CZP treatment during Part B. Once determined positive, only the highest 
titer during Part is used to categorize the subject. For subjects with flare in Part B, any 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. titer during Part is used to categorize the subject. For subjects with flare in Part B, any 
assessments after Escape treatment are not included.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessments after Escape treatment are not included.
TE ADAb Status negative is defined as having no samples either ADAb positive or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. TE ADAb Status negative is defined as having no samples either ADAb positive or 
with values ≥MSR increase from baseline during Part B (excluding any values up to 8 weeks 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with values ≥MSR increase from baseline during Part B (excluding any values up to [ADDRESS_846857] Part B dose). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. post first Part B dose). 
Escape TE ADAb Status positive is defined as either (i) bas
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape TE ADAb Status positive is defined as either (i) bas
having at least one ADAb confirmed positive sample post baseline during Escape Part or ii) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. having at least one ADAb confirmed positive sample post baseline during Escape Part or ii) 
baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
from baseline on CZP treatment during Escape P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from baseline on CZP treatment during Escape P
highest titer during Escape is used to categorize the subject.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. highest titer during Escape is used to categorize the subject.

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape TE ADAb Status negative is defined as having no samples either ADAb positive or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape TE ADAb Status negative is defined as having no samples either ADAb positive or 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 77 of 149 Summary of shift from Baseline ADAb status with titer classification to TE ADAb Status with 
titer classification by [CONTACT_634368].  
The shift table will be repeated for  
 Part A TE ADAb status with titer classification to Part B TE ADAb status with titer 
classification by [CONTACT_634369] B.  
 Part B TE ADAb status with Part B titer classification to Escape Part TE ADAb status with Escape titer classification by [CONTACT_634370]. 
The time to achieving TE ADAb for all subjects will be analyzed based on Kaplan-Meier methods. Subjects will be considered to have an event at the time where treatment-emergent 
ADAb positive is first achieved during treatment period excluding Baseline/pre-treatment. 
Subjects classified as treatment-emergent ADAb negative will be censored at the time of last available ADAb result. The median and 95% CI based on the Kaplan-Meier estimation will also be presented. A plot of time to first ADAb positivity will be presented. 
Number and percentage of subjects with ADAb titer above the specified cut point 
(“categorized”) at any visit during the treatment period, separated by [CONTACT_2058]. 
A summary of flare responder during Part B (NRI) and ASDAS MI responder at Week 96 (NRI) 
by [CONTACT_634371] (“categorized”) per subject will be presented 
during Part A and Part B (excluding Escape). This table will be repeated for Part B (excluding 
Escape). 
A scatter plot of CZP Plasma Concentration and ADAb titer during Part A for all subjects will be 
presented. The scatter plot will be repeated for Part B by [CONTACT_1570]. 
Spaghetti plots of ADAb titer on a loglog scale by [CONTACT_634372]/titer classification will be presented for subjects with flare and no flare per NRI approach. 
All individual ADAb results will be listed at subject level. 
10 SAFETY ANALYSES 
10.1 Extent of exposure 
10.1.1 Part A  
Exposure to study medication in Part A will be evaluated by [CONTACT_634373], the total amount of CZP received in mg, the total drug exposure duration in days, the patient time at risk and the total patient years at risk. Summaries will be based on the SS and 
presented by [CONTACT_634321].  
Duration of exposure to study medication in Part A will be calculated (in days) as:  
 The date of the last Part A injection – date of first Part A injection + [ADDRESS_846858] of these events. REDACTED COPY A summary of flare responder during Part B (NRI) and ASDAS MI responder at Week 96 (NRI) 
REDACTED COPY A summary of flare responder during Part B (NRI) and ASDAS MI responder at Week 96 (NRI) 
titer (“categorized”) per subject will be presented 
REDACTED COPY titer (“categorized”) per subject will be presented 
during Part A and Part B (excluding Escape). This table will be repeated for Part B (excluding 
REDACTED COPY during Part A and Part B (excluding Escape). This table will be repeated for Part B (excluding 
A scatter plot of CZP Plasma Concentration and ADAb titer during Part A for all subjects will be 
REDACTED COPY A scatter plot of CZP Plasma Concentration and ADAb titer during Part A for all subjects will be 
esented. The scatter plot will be repeated for Part B by [CONTACT_1570]. REDACTED COPY esented. The scatter plot will be repeated for Part B by [CONTACT_1570].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B TE ADAb status with Part B titer classification to Escape Part TE ADAb status with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B TE ADAb status with Part B titer classification to Escape Part TE ADAb status with 
Escape titer classification by [CONTACT_634370].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape titer classification by [CONTACT_634370].
Meier 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Meier 
methods. Subjects will be considered to have an event at the time where treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. methods. Subjects will be considered to have an event at the time where treatment -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -emergent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emergent 
ADAb positive is first achieved during treatment period excluding Baseline/pre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb positive is first achieved during treatment period excluding Baseline/pre -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -treatment. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment. 
l be censored at the time of last 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. l be censored at the time of last 
Meier estimation will also 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Meier estimation will also 
be presented. A plot of time to first ADAb positivity will be presented.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be presented. A plot of time to first ADAb positivity will be presented.
he specified cut point 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. he specified cut point 
(“categorized”) at any visit during the treatment period, separated by [CONTACT_634374]. (“categorized”) at any visit during the treatment period, separated by [CONTACT_634375] 
A summary of flare responder during Part B (NRI) and ASDAS MI responder at Week 96 (NRI) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A summary of flare responder during Part B (NRI) and ASDAS MI responder at Week 96 (NRI) 
titer (“categorized”) per subject will be presented 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. titer (“categorized”) per subject will be presented 
during Part A and Part B (excluding Escape). This table will be repeated for Part B (excluding 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. during Part A and Part B (excluding Escape). This table will be repeated for Part B (excluding 
A scatter plot of CZP Plasma Concentration and ADAb titer during Part A for all subjects will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A scatter plot of CZP Plasma Concentration and ADAb titer during Part A for all subjects will be 
esented. The scatter plot will be repeated for Part B by [CONTACT_1570].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. esented. The scatter plot will be repeated for Part B by [CONTACT_1570].
Spaghetti plots of ADAb titer on a loglog scale by [CONTACT_634376]. Spaghetti plots of ADAb titer on a loglog scale by [CONTACT_634372]/titer classification will be presented for subjects with
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and TE ADAb status/titer classification will be presented for subjects with
and no flare per NRI approach.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and no flare per NRI approach.
All individual ADAb results will be listed at subject level.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All individual ADAb results will be listed at subject level.
SAFETY ANALYSES
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SAFETY ANALYSES
Extent of exposure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Extent of exposure
Part A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A
Exposure to study medication in Part A will be evaluated by [CONTACT_634377]. Exposure to study medication in Part A will be evaluated by [CONTACT_634377]. CZP injections, the to
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP injections, the to
the patient time at risk and the total patient years at risk. Summaries will be based on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the patient time at risk and the total patient years at risk. Summaries will be based on the 
presented by 
[CONTACT_122253]. presented by 
[CONTACT_634378]. Duration of exposure to study med
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 78 of 149 Patient time at risk in Part A will be calculated (in days) as: 
 The date of the last injection in Part A – date of first injection in Part A + [ADDRESS_846859] 
of these events. 
Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in 
days) divided by 365.25. 
10.1.2 Part B  
[IP_ADDRESS] All subjects in SSB – Prior to Flare 
Exposure to study medication in Part B will be evaluated by [CONTACT_634379], the total number of CZP injections, the total amount of CZP received in 
mg, the total drug exposure duration in days, the patient time at risk and the total patient years at risk. Summaries will be based on the SSB and presented by [CONTACT_1570]. 
Duration of exposure to study medication in Part B will be calculated (in days) for subjects who 
do not experience a flare as: 
 The date of the last CZP 200mg or PBO Part B injection – date of Week 48 injection + 14 
days for subjects in the 200mg CZP Q2W and PBO groups [1] 
 The date of the last CZP 200mg Part B injection – date of Week 48 injection + 28 days for 
subjects in the 200mg CZP Q4W group [2] 
Duration of exposure to study medication in Part B will be calculated (in days) for subjects who 
do experience a flare as: 
 The date of the last CZP 200mg or PBO Part B injection prior to start of escape full-dose 
CZP – date of Week 48 injection + 14 days for subjects in the 200mg CZP Q2W and PBO 
groups [3] 
 The date of the last CZP 200mg Part B injection prior to start of escape full-dose CZP – date of Week 48 injection + 28 days for subjects in the 200mg CZP Q4W group [4] 
If the final contact [CONTACT_634380] 14- day period for [1] or 
prior to the completion of the 28-day period for [2], exposure to study medication in Part B will 
be censored at the earliest of these events. If the start of escape full-dose CZP occurs prior to the 
completion of the 14-day period for [3] or prior to the completion of the 28-day period for [4], 
exposure to study medication in Part B will be censored at the date of this event. 
Patient time at risk in Part B will be calculated (in days) for subjects who do not experience a 
flare as: 
 The date of the last CZP 200mg or PBO Part B injection – date of Week 48 injection + 70 
days for subjects in the 200mg CZP Q2W and PBO groups [1] 
 The date of the last CZP 200mg Part B injection – date of Week 48 injection + 70 days for subjects in the 200mg CZP Q4W group [2] REDACTED COPY The date of the last CZP 200mg or PBO Part B injection
REDACTED COPY The date of the last CZP 200mg or PBO Part B injection
days for subjects in the 200mg CZP Q2W and PBO groups 
REDACTED COPY days for subjects in the 200mg CZP Q2W and PBO groups 
The date of the last CZP 200mg Part B injection 
REDACTED COPY The date of the last CZP 200mg Part B injection 
subjects in the 200mg CZP Q4W group [2]
REDACTED COPY subjects in the 200mg CZP Q4W group [2]
REDACTED COPY Duration of exposure to study medication in Part B will be calculated (in days) for subjects who 
REDACTED COPY Duration of exposure to study medication in Part B will be calculated (in days) for subjects who 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. lculated as the sum of all the relevant patient time at risk (in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. lculated as the sum of all the relevant patient time at risk (in 
Exposure to study medication in Part B will be evaluated by [CONTACT_634377]. Exposure to study medication in Part B will be evaluated by [CONTACT_634381], the total amount of CZP received in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tal number of CZP injections, the total amount of CZP received in 
mg, the total drug exposure duration in days, the patient time at risk and the total patient years at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. mg, the total drug exposure duration in days, the patient time at risk and the total patient years at 
and presented by [CONTACT_1570].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and presented by [CONTACT_1570].
xposure to study medication in Part B will be calculated (in days) for subjects who 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. xposure to study medication in Part B will be calculated (in days) for subjects who 
The date of the last CZP 200mg or PBO Part B injection
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The date of the last CZP 200mg or PBO Part B injection –
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. –date of Week 48 injection + 14 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of Week 48 injection + [ADDRESS_846860] CZP 200mg Part B injection –
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. –date of Week 48 injection + 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of Week 48 injection + 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Duration of exposure to study medication in Part B will be calculated (in days) for subjects who 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Duration of exposure to study medication in Part B will be calculated (in days) for subjects who 
The date of the last CZP 200mg or PBO Part B injection prior to start of escape full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The date of the last CZP 200mg or PBO Part B injection prior to start of escape full
date of Week 48 injection + 14 days for subjects in the 200mg CZP Q2W and PBO 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of Week 48 injection + [ADDRESS_846861] CZP 200mg Part B injection prior to start of escape full
of Week 48 injection + 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of Week 48 injection + [ADDRESS_846862] of these events. If the start 
completion of the 14
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. completion of the 14
exposure to study medication in Part B will be censored at the date of this event.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. exposure to study medication in Part B will be censored at the date of this event.
Patient time at risk in Part B will be calculated (in days) for subjects who do not experience a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Patient time at risk in Part B will be calculated (in days) for subjects who do not experience a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare as:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare as:

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 79 of 149 Patient time at risk in Part B will be calculated (in days) for subjects who do experience a flare 
as: 
 The date of the last CZP 200mg or PBO Part B injection prior to start of escape full-dose CZP – date of Week 48 injection + 70 days for subjects in the 200mg CZP Q2W and PBO 
groups [3]  
 The date of the last CZP 200mg Part B injection prior to start of escape full-dose CZP – date of Week 48 injection + 70 days for subjects in the 200mg CZP Q4W group [3] 
If the final contact [CONTACT_634380] 70-day period for [1] or [2], patient time at risk in Part B will be censored at the earliest of these events. If the start of escape full-dose CZP occurs prior to the completion of the 70-day period for [3] and [4], patient 
time at risk in Part B will be censored at the date of this event. 
Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in 
days) divided by 365.25. 
[IP_ADDRESS] After flare 
Exposure to study medication in Part B after flare and escape to full-dose CZP will be evaluated 
by [CONTACT_634382], the total number of CZP injections, the total amount of CZP received in mg, the total drug exposure duration in days, the patient time 
at risk and the total patient years at risk. Summaries will be based on the ETS and presented by 
[CONTACT_1570]. 
Duration of exposure to study medication in Part B after escape to full-dose CZP will be 
calculated (in days) as: 
 The date of the last escape full-dose CZP injection – date of first escape full-dose CZP 
injection + [ADDRESS_846863] or death occurs prior to the completion of the 14–day period, the exposure 
duration will be censored at the date of the earliest event. 
Patient time at risk in Part B after escape to full-dose CZP will be calculated (in days) as: 
 The date of the last escape full-dose CZP injection – date of first escape full-dose CZP 
injection + [ADDRESS_846864] or death occurs prior to the completion of the 70–day period, the patient time at 
risk will be censored at the date of the earliest event. 
Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in 
days) divided by 365.25. 
[IP_ADDRESS] Full-dose CZP in Part B 
Exposure to full-dose CZP in Part B will be evaluated by [CONTACT_634383], the total amount of CZP received in mg, the total drug exposure duration in days, the patient time at risk and the total patient years at risk. Summaries will be based on the FDS. These 
summaries will be produced presenting a single column “CZP full-dose in Part B (CZP 200mg 
Q2W )”. REDACTED COPY the total amount of CZP received in mg, the total drug exposure duration in days, the patient time 
REDACTED COPY the total amount of CZP received in mg, the total drug exposure duration in days, the patient time 
e total patient years at risk. Summaries will be based on the 
REDACTED COPY e total patient years at risk. Summaries will be based on the 
Duration of exposure to study medication in Part B after escape to full
REDACTED COPY Duration of exposure to study medication in Part B after escape to full
REDACTED COPY dose CZP REDACTED COPY dose CZP 
injection + 14 days for all subjectsREDACTED COPY injection + 14 days for all subjects
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date 
day period for [1]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. day period for [1] or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. or 
, patient time at risk in Part B will be censored at the earliest of these events. If the start 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , patient time at risk in Part B will be censored at the earliest of these events. If the start of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of 
and [4]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and [4] , patient
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , patient
Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in 
re and escape to full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. re and escape to full -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -dose CZP will be evaluated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose CZP will be evaluated 
by [CONTACT_634382], the total number of CZP injections, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. by [CONTACT_634382], the total number of CZP injections, 
the total amount of CZP received in mg, the total drug exposure duration in days, the patient time 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the total amount of CZP received in mg, the total drug exposure duration in days, the patient time 
e total patient years at risk. Summaries will be based on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e total patient years at risk. Summaries will be based on the 
Duration of exposure to study medication in Part B after escape to full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Duration of exposure to study medication in Part B after escape to full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose CZP 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose CZP injection
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injection
injection + 14 days for all subjects
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injection + [ADDRESS_846865] escape full
injection + 70 days for all subjects
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injection + [ADDRESS_846866] or death occurs prior to the 
will be censored 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be censored 
Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in 
days) divided by 365.25.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. days) divided by 365.25.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
Exp
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Exp
injections, the total amount of CZP received in mg, the total drug exposure duration in days, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injections, the total amount of CZP received in mg, the total drug exposure duration in days, the 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 80 of 149 Duration of exposure to full-dose CZP in Part B as double-blind or as escape treatment will be 
calculated (in days) as:  
 The date of the last escape full-dose CZP injection – date of the first escape full-dose CZP 
injection + 14 days for subjects in the 200mg CZP Q4W and PBO groups who escape to full-
dose CZP therapy 
 The date of the last escape full-dose CZP injection – date of Week 48 injection + 14 days for subjects in the 200mg CZP Q2W group experiencing a flared 
 The date of the last Part B injection – date of Week 48 injection + [ADDRESS_846867] or death occurs prior to the completion of the 14–day period, the exposure 
duration will be censored at the date of the earliest event. 
Patient time at risk in Part B under full-dose CZP therapy will be calculated (in days) as: 
 The date of the last escape full-dose CZP injection – date of the first escape full-dose CZP 
injection + 70 days for subjects in the 200mg CZP Q4W and PBO groups who escape to full-
dose CZP therapy 
 The date of the last escape full-dose CZP injection – date of Week 48 injection + 70 days for subjects in the 200mg CZP Q2W group experiencing a flared 
 The date of the last Part B injection – date of Week 48 injection + [ADDRESS_846868] or death occurs prior to the completion of the 70–day period, the patient time at 
risk will be censored at the date of the earliest event. 
Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in 
days) divided by 365.25. 
10.1.3 Part A and Part B full-dose CZP therapy 
Exposure to full-dose CZP therapy in Part A and/or Part B will be evaluated by [CONTACT_634384], the total amount of CZP received in mg, the total drug exposure 
duration in days, the patient time at risk and the total patient years at risk. Summaries will be 
based on the SS. These summaries will be produced presenting a single column “CZP full-dose 
in Part A and/or Part B (CZP 200mg Q2W)”.  
Duration of exposure to full-dose CZP therapy in Part A and/or Part B will be calculated (in 
days)  as: 
 The date of the last Part A full-dose CZP injection – date of first Part A full-dose CZP injection + [ADDRESS_846869] of the following events if any of these events occur prior to 
the completion of the 14-day period: final contact [CONTACT_634385]. 
 The date of the last Part A full-dose CZP injection – date of first Part A full-dose CZP injection + [ADDRESS_846870] of the following events if any of these events REDACTED COPY dose CZP injection 
REDACTED COPY dose CZP injection –
REDACTED COPY –
experiencing a 
REDACTED COPY experiencing a 
date of Week 48 injection + 70 days for subjects in the 
REDACTED COPY date of Week 48 injection + [ADDRESS_846871] event.
Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in REDACTED COPY Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. k 48 injection + 14 days for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. k 48 injection + 14 days for 
date of Week 48 injection + 14 days for subjects in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of Week 48 injection + 14 days for subjects in the 
day period, the exposure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. day period, the exposure 
will be calculated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be calculated (in days) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (in days) 
date of the first escape full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of the first escape full
injection + 70 days for subjects in the 200mg CZP Q4W and PBO groups who escape to full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injection + 70 days for subjects in the 200mg CZP Q4W and PBO groups who escape to full
date of Week 48 injection + 70 days for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of Week 48 injection + 70 days for 
experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a flared
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flared
date of Week 48 injection + 70 days for subjects in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of Week 48 injection + [ADDRESS_846872] event.
Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in 
and Part B full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and Part B full
dose CZP therapy in Part A and/or Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose CZP therapy in Part A and/or Part B
total number of CZP injections, the total amount of CZP received in mg, the total drug exposure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. total number of CZP injections, the total amount of CZP received in mg, the total drug exposure 
duration in days, the patient time at risk and the total patient 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. duration in days, the patient time at risk and the total patient 
. These summaries will be produced presenting a single column “CZP full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . These summaries will be produced presenting a single column “CZP full
in Part A and/or Part B (CZP 200mg Q2W)”.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in Part A and/or Part B (CZP 200mg Q2W)”.
Duration of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Duration of exposure to full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. exposure to full
as:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as:
The date of the last Part A full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The date of the last Part A full
injection + 14 days for subjects not randomized into Part B. Duration of exposure will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injection + [ADDRESS_846873] of the following events if any
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 81 of 149 occur prior to the completion of the 14-day period (first study medication administration in 
Part B, final contact [CONTACT_634385]). 
 The sum of (date of the last Part A full-dose CZP injection – date of first Part A full-dose 
CZP injection + 14 days) [1] and (date of the last escape full-dose CZP injection – date of 
first escape full-dose CZP injection + 14 days) [2] for subjects randomized into Part B to the PBO or CZP 200mg Q4W arms who do experience a flare and do escape to CZP full-dose 
therapy. If first study medication administration in Part B occurs prior to the completion of 
the 14 day period for [1], [1] will be censored at the date of this event. If final contact [CONTACT_634386] 14-day period for [2], [2] will be censored at the date of the earliest event. 
 The date of the last Part B injection – date of first Part A full-dose CZP injection + [ADDRESS_846874] event. 
Patient time at risk in Part A and or Part B under full-dose CZP therapy will be calculated (in 
days)  as: 
 The date of the last Part A full-dose CZP injection – date of first Part A full-dose CZP injection + [ADDRESS_846875] of the following events if any of these events occur prior to the completion of the 70-day period: final contact [CONTACT_634385]. 
 The date of the last Part A full-dose CZP injection – date of first Part A full-dose CZP injection + [ADDRESS_846876] of the following events if any of these events 
occur prior to the completion of the 70-day period (first study medication administration in Part B, final contact [CONTACT_634385]). 
 The sum of (date of the last Part A full-dose CZP injection – date of first Part A full-dose CZP injection + 70 days) [1] and (date of the last escape full-dose CZP injection – date of 
first escape full-dose CZP injection + 70 days) [2] for subjects randomized into Part B to the PBO or CZP 200mg Q4W arms who do experience a flare and do escape to CZP full-dose 
therapy. If first study medication administration in Part B occurs prior to the completion of the 70-day period for [1], [1] will be censored at the date of this event. If final contact [CONTACT_634386] 70-day period for [2], [2] will be censored at the 
date of the earliest event. 
 The date of the last Part B injection – date of first Part A full-dose CZP injection + [ADDRESS_846877] event. 
Total patient years at risk will be calculated as the sum of all the relevant patient time at risk (in days) divided by 365.25. 
Exposure data will be listed. REDACTED COPY ed into Part B. 
REDACTED COPY ed into Part B. 
censored at the date of earliest of the following events if any of these events occur prior to 
REDACTED COPY censored at the date of earliest of the following events if any of these events occur prior to 
day period: final contact [CONTACT_634385].
REDACTED COPY day period: final contact [CONTACT_634385].
dose CZP injection 
REDACTED COPY dose CZP injection 
injection + 70 days for subjects randomized into Part B to the PBO or CZP 200mg Q4W 
REDACTED COPY injection + 70 days for subjects randomized into Part B to the PBO or CZP 200mg Q4W 
arms who do not experience a flare and do not escape to CZP fullREDACTED COPY arms who do not experience a flare and do not escape to CZP full
will be censored at the date of earlie REDACTED COPY will be censored at the date of earlie
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ompletion of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ompletion of 
the 14 day period for [1], [1] will be censored at the date of this event. If final contact [CONTACT_634387]. the 14 day period for [1], [1] will be censored at the date of this event. If final contact [CONTACT_634388] [2], [2] will be censored at the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. day period for [2], [2] will be censored at the 
dose CZP injection + 14 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose CZP injection + [ADDRESS_846878] of the following events if any of these events occur prior to 
day period: final contact [CONTACT_634385].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. day period: final contact [CONTACT_634385].
dose CZP injection 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose CZP injection 
injection + 70 days for subjects randomized into Part B to the PBO or CZP 200mg Q4W 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injection + [ADDRESS_846879] or death).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B, final contact [CONTACT_634385]).
The sum of (date of the last Part A full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The sum of (date of the last Part A full
CZP injection + 70 days) [1] and (date of the last escape full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP injection + 70 days) [1] and (date of the last escape full
dose CZP injection + 70 days) [2] for subjects randomized into Part B to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose CZP injection + 70 days) [2] for subjects randomized into Part B to the 
PBO or CZP 200mg Q4W arms who do experience a flare and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PBO or CZP 200mg Q4W arms who do experience a flare and 
therapy. If first study medication administration in Part B occurs prior to the completion of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. therapy. If first study medication administration in Part B occurs prior to the completion of 
day period for [1], [1] will be censored at the date of this event. If final contact [CONTACT_634387]. day period for [1], [1] will be censored at the date of this event. If final contact [CONTACT_634389]. death occurs prior to the completion of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of the earliest event.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of the earliest event.
The date of the last Part B injection 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The date of the last Part B injection 
for subjects randomized into Part B to CZP 200mg Q2W arm. If final contact [CONTACT_634387]. for subjects randomized into Part B to CZP 200mg Q2W arm. If final contact [CONTACT_634390] [ADDRESS_846880]-treatment AEs. No tabular summaries of these events will be produced 
although they will be included in listings. 
Treatment -Emergent AEs (TEAEs) 
Treatment emergent AEs (TEAEs) will be defined and summarized in four different ways: 
[1] TEAEs in Part A: will be defined as all AEs starting on or after the date of first study 
medication in Part A and up to [ADDRESS_846881] study medication in Part B if any.  
[2] TEAEs in Part B prior to flare: will be defined as all AEs starting on or after the date of first 
study medication in Part B and up to [ADDRESS_846882]-flare will be excluded from any summary tables of TEAEs in Part B prior to flare. 
[3] TEAEs in Part B in subjects experiencing a flare: Pre-flare TEAEs in Part B will be defined 
as any TEAEs in Part B with an onset date before the start date of escape therapy. Post-flare 
TEAEs in Part B will be defined as any TEAEs in Part B with an onset date on or after the start 
date of escape therapy. 
[4] TEAEs in Part B under CZP full-dose therapy: These will be defined for subjects in the FDS 
who ever received a dose of CZP 200mg Q2W during Part B as double-blind or as escape treatment.  
TEAEs in Part B under CZP full-dose therapy will be defined as follows: 
 In subjects randomized into Part B to the PBO or CZP 200mg Q4W arm who do experience a 
flare and do escape to CZP full-dose therapy, TEAEs under CZP full-dose therapy will include all post-flare TEAEs in Part B 
 In subjects randomized into Part B to CZP 200mg Q2W arm, TEAEs under CZP full-dose 
therapy will include all TEAEs in Part B 
Data Handling Rules for AEs 
Duration of AEs will not be calculated if there is missing stop date information.  
If the intensity of an AE is unknown, it will be considered as severe. If the relationship to study 
drug is missing, it will be considered as related. 
For relatedness, AEs determined to be ‘not related’ or ‘unlikely related’ to study drug will map 
to ‘not related’, while all other values will map to ‘related’. REDACTED COPY AEs occurring more than [ADDRESS_846883] administration of study medication will 
Treatment emergent AEs (TEAEs) will be defined and summarized in four different ways:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment emergent AEs (TEAEs) will be defined and summarized in four different ways:
[1] TEAEs in Part A: will be defined as all AEs starting on or after the date of first study 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [1] TEAEs in Part A: will be defined as all AEs starting on or after the date of first study 
medication in Part A and up to [ADDRESS_846884] dose of study medication in Part A and 
TEAEs in Part B prior to flare: will be defined as all AEs starting on or after the date of first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. TEAEs in Part B prior to flare: will be defined as all AEs starting on or after the date of first 
study medication in Part B and up to [ADDRESS_846885] dose in Part B will not be considered treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will not be considered treatment 
emergent, regardless of whether this occurs during the SFU period, or after a treatment gap of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emergent, regardless of whether this occurs during the SFU period, or after a treatment gap of 
flare will be excluded from any summary tables of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare will be excluded from any summary tables of 
experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a flare: Pre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare: Pre
as any TEAEs in Part B with an onset date before the start date of escape therapy. Post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as any TEAEs in Part B with an onset date before the start date of escape therapy. Post
TEAEs in Part B will be defined as any TEAEs in Part B with an onset da
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. TEAEs in Part B will be defined as any TEAEs in Part B with an onset da
[4] TEAEs in Part B under CZP full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [4] TEAEs in Part B under CZP full -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -dose therapy: These will be defined for subjects in the FDS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose therapy: These will be defined for subjects in the FDS 
ever received a dose of CZP 200mg Q2W during Part B as double
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ever received a dose of CZP 200mg Q2W during Part B as double
under CZP full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. under CZP full
In subjects randomized into Part B to the PBO or CZP 200mg Q4W arm who do experience a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In subjects randomized into Part B to the PBO or CZP 200mg Q4W arm who do experience a 
flare and do escape to CZP full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare and do escape to CZP full
include all post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. include all post
In subjects randomized into Part B to CZP 200mg Q2W arm, TEAEs under CZP full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In subjects randomized into Part B to CZP 200mg Q2W arm, TEAEs under CZP full
therapy will include all TEAEs in Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. therapy will include all TEAEs in Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Data Handling Rules for AEs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Data Handling Rules for AEs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Duration of AEs will not be calculated if there is missing stop date information. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Duration of AEs will not be calculated if there is missing stop date information. 
If the in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the in
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 83 of 149 AE Summaries 
All AE summary tables described in this Section will be produced four ways, ie for each of the 
following types of AEs: 
a. TEAEs in Part A, based on the SS 
b. TEAEs in Part B prior to flare, based on the SSB 
c. TEAEs in Part B for subjects experiencing a flare, based on the ETS 
d. TEAEs in Part B under CZP full-dose therapy, based on the FD 
SAEs will be classified by [CONTACT_2946], High Level Term (HLT), and PT according to MedDRA®. The 
latest version available to the sponsor at the time of coding will be used. Summary tables will 
display the number and percentage of subjects experiencing the TEAEs and number of TEAEs. 
In this style of output, “number of TEAEs” will include all occurrences of a TEAE including 
repeat occurrences in individual subjects, while “number of subjects” will count each subject 
only once.  
Overall summaries of AEs will be produced to present the number of events and number and 
percentage of subjects with: 
 Any TEAE 
 Any serious TEAE 
 Any TEAE leading to study discontinuation 
 Permanent withdrawal of study medication due to TEAEs 
 Any drug-related TEAE 
 Any severe TEAE 
 All Deaths (AEs leading to death) 
 Deaths (TEAE leading to death) 
In addition, the following AE summaries will be presented: 
 All TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d) 
 All serious TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d) 
 All TEAEs leading to permanent discontinuation of study drug by [CONTACT_148274], HLT, and 
PT (for the Parts/Analysis sets a, b, c, d) 
 All TEAEs leading to death by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, 
c) 
 All TEAEs by [CONTACT_148274], PT, and maximum intensity (for the Parts/Analysis sets a, b, c, d) 
 All TEAEs by [CONTACT_148274], PT, and maximum relationship (for the Parts/Analysis sets a, b, 
c, d) REDACTED COPY to study discontinuation
REDACTED COPY to study discontinuation
Permanent withdrawal of study medication due to TEAEs
REDACTED COPY Permanent withdrawal of study medication due to TEAEs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AEs will be classified by [CONTACT_2946], High Level Term (HLT), and PT according to MedDRA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AEs will be classified by [CONTACT_2946], High Level Term (HLT), and PT according to MedDRA®
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ®
onsor at the time of coding will be used. Summary tables will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. onsor at the time of coding will be used. Summary tables will 
display the number and percentage of subjects experiencing the TEAEs and number of TEAEs.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. display the number and percentage of subjects experiencing the TEAEs and number of TEAEs.
In this style of output, “number of TEAEs” will include all occurrences of a TEAE including 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In this style of output, “number of TEAEs” will include all occurrences of a TEAE including 
rences in individual subjects, while “number of subjects” will count each subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rences in individual subjects, while “number of subjects” will count each subject 
Overall summaries of AEs will be produced to present the number of events and number and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Overall summaries of AEs will be produced to present the number of events and number and 
Permanent withdrawal of study medication due to TEAEs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Permanent withdrawal of study medication due to TEAEs
All Deaths (AEs leading to death)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All Deaths (AEs leading to death)
Deaths (TEAE leading to death)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Deaths (TEAE leading to death)
In addition, the following AE summaries will be presented:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, the following AE summaries will be presented:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. primary SOC, HLT, and PT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. primary SOC, HLT, and PT
All serious TEAEs by [CONTACT_148274], HLT, and PT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All serious TEAEs by [CONTACT_148274], HLT, and PT
All TEAEs leading to permanent discontinuation of study drug by [CONTACT_148274], HLT, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs leading to permanent discontinuation of study drug by [CONTACT_148274], HLT, and 
(for the Parts
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (for the Parts
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs leading to death by [CONTACT_148274], HLT, and PT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs leading to death by [CONTACT_148274], HLT, and PT
c)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. c)

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 84 of 149  All serious TEAEs by [CONTACT_148274], PT and maximum relationship (for the Parts/Analysis 
sets a, b, c, d) 
 All TEAEs above reporting threshold of 5% by [CONTACT_183008] (for the Parts/Analysis sets a, b, c, d) 
 All non-serious TEAEs above reporting threshold of 5% by [CONTACT_183008] (for the 
Parts/Analysis sets a, b, c) 
 All injection related TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d) 
AE summary tables will also be produced to display the exposure adjusted incidence rate (EAIR) 
with associated 95% CI, and the exposure adjusted event rate (EAER): 
 All TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d) 
 All serious TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d) 
For EAIR, the numerator will be the total number of subjects experiencing the AE of interest in 
the corresponding period. The denominator will be 100 patient-years; that is, the total summation of individual patient- years at risk up to the first occurrence of the AE of interest for subjects with 
that AE, and the total patient-years at risk for those subjects not experiencing that AE, divided by 100. EAIRs will be presented with a 95% exact CI based upon the Chi-Square distribution (Ulm, 1990).  
For EAERs, the numerator will be the number of AEs including repeat occurrences in individual 
subjects; the denominator will be 100 patient-years. That is, the total summation of individual patient-years at risk divided by 100. No CI will be computed for EAER. 
The TEAE summary table will be presented by [CONTACT_634391] ( Prior to becoming ADAb Positive>=1024 , After becoming ADAb 
Positive>=1024 , Subjects Who Never Became ADAb Positive>=102 4) based on PKSB.) 
The following AEs of interest will be summarized: 
1. Serious infections, including opportunistic infections 
2. Malignancies, including lymphoma 
3. Serious cardiovascular events (i.e. Major adverse cardiac events or MACE)  
4. Congestive heart failure 
5. Demyelinating-like disorders 
6. Aplastic anemia, pancytopenia, thrombocytopenia, neutropenia, and leucopenia 
7. Serious bleeding events 
8. Lupus and lupus-like illness 
9. Serious skin reactions (eg, Stevens Johnson Syndrome, toxic epi[INVESTIGATOR_59373], and 
erythema multiforme) 
Serious infections (1) will be summarized using the previously described serious TEAEs tables. No separate tables will be produced. In addition, summary tables will be produced for REDACTED COPY years at risk for those subjects not experiencing that AE, divided by 
[CONTACT_634392], divided by 
100. EAIRs will be presented with a 95% exact CI based upon the Chi
REDACTED COPY 100. EAIRs will be presented with a 95% exact CI based upon the Chi
For EAERs, the numerator will be the number of AEs including repeat occurrences in individual 
REDACTED COPY For EAERs, the numerator will be the number of AEs including repeat occurrences in individual 
subjects; the denominator will be 100 patient
REDACTED COPY subjects; the denominator will be 100 patient -
REDACTED COPY -years. That is, the total summation of individual 
REDACTED COPY years. That is, the total summation of individual 
years at risk divided by 100. No C
REDACTED COPY years at risk divided by 100. No C I will be computed for EAER.
REDACTED COPY I will be computed for EAER.
presenteREDACTED COPY presente
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (for the Parts/Analysis sets a, b, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (for the Parts/Analysis sets a, b, 
to display the exposure adjusted incidence
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to display the exposure adjusted incidence rate (EAIR) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rate (EAIR) 
for the Parts/Analysis sets a, b, c, d
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for the Parts/Analysis sets a, b, c, d
the Parts/Analysis sets a, b, c, d
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the Parts/Analysis sets a, b, c, d
For EAIR, the numerator will be the total number of subjects experiencing the AE of interest in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For EAIR, the numerator will be the total number of subjects experiencing the AE of interest in 
years; that is, the total summation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. years; that is, the total summation 
s at risk up to the first occurrence of the AE of interest for subjects with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s at risk up to the first occurrence of the AE of interest for subjects with 
years at risk for those subjects not experiencing that AE, divided by 
[CONTACT_122253]. years at risk for those subjects not experiencing that AE, divided by 
100. EAIRs will be presented with a 95% exact CI based upon the Chi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 100. EAIRs will be presented with a 95% exact CI based upon the Chi
For EAERs, the numerator will be the number of AEs including repeat occurrences in individual 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For EAERs, the numerator will be the number of AEs including repeat occurrences in individual 
years. That is, the total summation of individual 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. years. That is, the total summation of individual 
I will be computed for EAER.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. I will be computed for EAER.
presente
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. presente d 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. d by 
[CONTACT_122253]. by 
[CONTACT_634393]>=1024
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Prior to becoming ADAb Positive>=1024
Subjects Who Never Became ADAb Positive>=102
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subjects Who Never Became ADAb Positive>=[ADDRESS_846886] will be summarized:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following AEs of interest will be summarized:
including opportunistic infections
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. including opportunistic infections
including lymphoma
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. including lymphoma
Serious cardiovascular events
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Serious cardiovascular events
Congestive heart failure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Congestive heart failure
Demyelinating
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Demyelinating
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Aplastic anemia, pancytopenia, thrombocytopenia, neutropenia, and leucopenia
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Aplastic anemia, pancytopenia, thrombocytopenia, neutropenia, and leucopenia
7.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 7.Serious bleeding events
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Serious bleeding events
8.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8.
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 85 of 149 opportunistic infections (including tuberculosis). Identification of opportunistic infections 
(including tuberculosis) will be performed using UCB-defined search criteria based on a two step 
process using identification via predefined list of PTs in addition to identification via manual review by [CONTACT_5989]. 
(2) will be presented in two set of summary tables using the criteria standard MedDRA
® query 
(SMQ) = “Malignant or unspecified tumours” and SMQ=”Malignant tumours”, respectively.  The 
SMQ search will include all TEAEs which code to a PT included in the Scope=Narrow group 
within each SMQ. Corresponding summary tables will also include incidence of “Any 
malignancy (including unspecified, excluding non-melanomic skin cancers)” or “Any 
malignancy (excluding non-melanomic skin cancers)” depending on the table. 
(3) will be presented in a stand-alone table and will be identified using the following UCB-
defined search criteria: 
 All serious TEAEs which code to a PT included in the search=Broad and or Narrow  scope of 
the following SMQs:  Haemorrhagic central nervous system vascular conditions (SMQ) 
 Ischaemic central nervous system vascular conditions (SMQ) except events coding to PT 
“Transient ischaemic attack” 
 All serious TEAEs which code to a PT included in the HLT “Ischaemic coronary artery disorders” except events coding to PT “Chest Pain” or “Chest discomfort” 
 All serious TEAEs which code to a PT included in any of the following HLTs: “Heart Failures NEC”, “Left Ventricular Failures”, or “Right Ventricular Failures” and which also 
code to the SOC of “Cardiac Disorders” as Primary SOC. 
(4) will be manually identified by [CONTACT_634394]. No separate tables will be produced. 
(5) will be presented in a stand- alone table which is based on the SMQ = “Demyelinat ion”. The 
SMQ search should include all TEAEs which code to a PT included in Scope=Narrow group  
within the SMQ. TEAEs which code to a PT included in the Scope=Broad group within the 
SMQ should be excluded from the search. 
(6) will be presented in tables using the criteria SMQ = “Haematopoietic cytopenias” in the 
subset of Serious TEAEs. The SMQ search will include all serious TEAEs which code to a PT 
included in the  Scope=Broad and/or Scope=Narrow groups within the SMQ.  
(7) will be presented in tables using the criteria SMQ = “Haemorrhage terms (excl laboratory 
terms)” in the subset of serious TEAEs. The SMQ search will include all serious TEAEs which 
code to a PT included in the SMQ. Note that there is only a Narrow scope defined for this SMQ. 
(8) will be manually identified by [CONTACT_634394]. No separate tables will be produced. 
(9) will be manually identified by [CONTACT_634395]. No separate tables will be produced. 
In addition, while not considered to be AEs of interest, following types of events will also be 
summarized:  REDACTED COPY All serious TEAEs which code to a PT included in 
REDACTED COPY All serious TEAEs which code to a PT included in 
disorders” except events coding to PT “Chest Pain” or “Chest discomfort”
REDACTED COPY disorders” except events coding to PT “Chest Pain” or “Chest discomfort”
All serious TEAEs which code to a PT included in any of the following HLTs: “Heart 
REDACTED COPY All serious TEAEs which code to a PT included in any of the following HLTs: “Heart 
Failures NEC”, “Left Ventricular Failures”, or “Right Ventricular
REDACTED COPY Failures NEC”, “Left Ventricular Failures”, or “Right Ventricular
code to the SOC of “Cardiac Disorders” as Primary SOC.REDACTED COPY code to the SOC of “Cardiac Disorders” as Primary SOC.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The 
all TEAEs which code to a PT included in the Scope=Narrow group 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. all TEAEs which code to a PT included in the Scope=Narrow group 
alone table and will be identified using the following UCB
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. alone table and will be identified using the following UCB
All serious TEAEs which code to a PT included in the search=Broad and or Narrow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All serious TEAEs which code to a PT included in the search=Broad and or Narrow
Haemorrhagic central nervous system vascular conditions (SMQ)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Haemorrhagic central nervous system vascular conditions (SMQ)
Ischaemic central nervous system vascular conditions (SMQ)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ischaemic central nervous system vascular conditions (SMQ)
the HLT “Ischaemic coronary artery 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the HLT “Ischaemic coronary artery 
disorders” except events coding to PT “Chest Pain” or “Chest discomfort”
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. disorders” except events coding to PT “Chest Pain” or “Chest discomfort”
All serious TEAEs which code to a PT included in any of the following HLTs: “Heart 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All serious TEAEs which code to a PT included in any of the following HLTs: “Heart 
Failures NEC”, “Left Ventricular Failures”, or “Right Ventricular
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Failures NEC”, “Left Ventricular Failures”, or “Right Ventricular
code to the SOC of “Cardiac Disorders” as Primary SOC.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. code to the SOC of “Cardiac Disorders” as Primary SOC.
) will be manually identified by [CONTACT_634396]. ) will be manually identified by [CONTACT_634397]
. No separate tables will be produced.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . No separate tables will be produced.
will be presented in a stand
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be presented in a stand -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -alone table which is based on the SMQ = “Demyelinat
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. alone table which is based on the SMQ = “Demyelinat
SMQ search should include all TEAEs which code to a PT included in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SMQ search should include all TEAEs which code to a PT included in 
within the SMQ. TEAEs which code to a PT included in the Scope=Broad group within the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. within the SMQ. TEAEs which code to a PT included in the Scope=Broad group within the 
SMQ should be excluded from the search
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SMQ should be excluded from the search
presented in t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. presented in t
subset of Serious TEAEs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subset of Serious TEAEs
included in th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. included in th e
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eScope=Broad and/or Scope=Narrow groups within the SMQ. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Scope=Broad and/or Scope=Narrow groups within the SMQ. 
) will be presented 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ) will be presented 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. erms)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. erms) ” in the subset of serious TEAEs.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ” in the subset of serious TEAEs.
code to a PT included in the SMQ. Note that there is only a Narrow scope defined for this SMQ.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. code to a PT included in the SMQ. Note that there is only a Narrow scope defined for this SMQ.
(
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (8
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 8) will be manually identified by [CONTACT_634398]. ) will be manually identified by [CONTACT_634394]. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tables. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 86 of 149  Hepatic events 
 Hypersensitivity reactions and anaphylactic reactions 
Hepatic events will be identified in the set of all TEAEs using following SMQs: 
 Cholestasis and jaundice of hepatic origin (SMQ);  
 Hepatic failure, fibrosis, and cirrhosis and other liver damage-related conditions (SMQ);  
 Hepatitis, non-infectious (SMQ);  
 Liver-related investigations, signs and symptoms (SMQ);  
 Liver-related coagulation and bleeding disturbances (SMQ)  
Hypersensitivity reactions and anaphylactic reactions will be summarized together. 
Corresponding set of tables will include incidence of following types of events: 
 Any hypersensitivity and anaphylactic reactions 
 Any hypersensitivity reactions 
 Any anaphylactic reactions 
All TEAEs that emerge within one day of when a study medication injection reaction was 
received which code to the following PTs will be considered to be a hypersensitivity reaction and included in the summary tables: 
 Administration site hypersensitivity 
 Documented hypersensitivity to administered product 
 Drug hypersensitivity 
 Hypersensitivity 
 Hypersensitivity vasculitis 
 Infusion site hypersensitivity 
 Injection site hypersensitivity 
 Medical device site hypersensitivity 
 Type II hypersensitivity 
 Type IV hypersensitivity reaction 
Injection reactions are identified by [CONTACT_69861]. 
An algorithmic approach will be used to identify TEAEs that are considered to be anaphylactic 
reactions. PTs are separated into the [ADDRESS_846887] categories (A, B, C, D) prior to the algorithmic 
approach being applied.  
All TEAEs that emerge within one day of when a study medication injection reaction was 
received , and which fulfill any of the following 3 criteria will be included in the summary tables: 
 If a subject reports any TEAE which codes to a PT included in Category A, then the event 
will be flagged as an anaphylactic reaction and summarized as such in the tables. REDACTED COPY All TEAEs that emerge within one day of when a study medication injection reaction was 
REDACTED COPY All TEAEs that emerge within one day of when a study medication injection reaction was 
received which code to the following PTs will be considered to be a hypersensitivity reaction an
REDACTED COPY received which code to the following PTs will be considered to be a hypersensitivity reaction an
Documented hypersensitivity to administered product
REDACTED COPY Documented hypersensitivity to administered product
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Hypersensitivity reactions and anaphylactic reactions will be summarized together. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Hypersensitivity reactions and anaphylactic reactions will be summarized together. 
Corresponding set of tables will include incidence of following types of events:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Corresponding set of tables will include incidence of following types of events:
All TEAEs that emerge within one day of when a study medication injection reaction was 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs that emerge within one day of when a study medication injection reaction was 
received which code to the following PTs will be considered to be a hypersensitivity reaction an
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. received which code to the following PTs will be considered to be a hypersensitivity reaction an
Documented hypersensitivity to administered product
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Documented hypersensitivity to administered product
Infusion site hypersensitivity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Infusion site hypersensitivity
Injection site hypersensitivity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Injection site hypersensitivity
ical device site hypersensitivity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ical device site hypersensitivity
Type II hypersensitivity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Type II hypersensitivity
Type IV hypersensitivity reaction
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Type IV hypersensitivity reaction
Injection reactions
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Injection reactions
An algorithmic approach will be used to identify TEAEs that are considered to be anaphylactic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. An algorithmic approach will be used to identify TEAEs that are considered to be anaphylactic 
r
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. reactions. PTs are separated into the [ADDRESS_846888] categories (A, B, C, D) prior to the algorithmic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eactions. PTs are separated into the [ADDRESS_846889] categories (A, B, C, D) prior to the algorithmic 
approach being applied. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. approach being applied. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 87 of 149  If a subject reports any TEAE which codes to a PT included in Category B and reports any 
TEAE which codes to a PT included in Category C, and both TEAEs have the same start date, then both events will be flagged as anaphylactic reactions and summarized as such in the tables.  
 If a subject reports any TEAE which codes to a PT included in Category D and reports 
(either a TEAE which codes to a PT included in Category B or a TEAE which codes to a PT included in Category C), and both TEAEs have the same start date, then both events will be flagged as anaphylactic reactions and summarized as such in the tables. 
Category A consists of the following PTs which are included in the SMQ = Anaphylactic reaction (SMQ): 
 Anaphylactic reaction 
 Anaphylactic shock  
 Anaphylactic transfusion reaction  
 Anaphylactoid reaction  
 Anaphylactoid shock 
 Circulartory collapse 
 Dialysis membrane reaction 
 Kounis syndrome 
 Shock 
 Shock symptom 
 Type I hypersensitivity 
Category B consists of the following PTs: 
 Acute respi[INVESTIGATOR_1399] 
 Asthma 
 Bronchial oedema 
 Bronchospasm 
 Cardio-respi[INVESTIGATOR_1506] 
 Chest discomfort 
 Chocking 
 Chocking sensation 
 Circumoral oedema 
 Cough 
 Cyanosis REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. included in Category C), and both TEAEs have the same start date, then both events will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. included in Category C), and both TEAEs have the same start date, then both events will be 
Category A consists of the following PTs which are included in the SMQ = Anaphylactic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Category A consists of the following PTs which are included in the SMQ = Anaphylactic 
Category B consists of the following PTs:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Category B consists of the following PTs:
Acute respi[INVESTIGATOR_634142]. Acute respi[INVESTIGATOR_634143]. Bronchial oedema
Bronchospas
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Bronchospas m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. m
-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -respi[INVESTIGATOR_634144]. respi[INVESTIGATOR_634145]. Chest discomfort
Chocking
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Chocking

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 88 of 149  Dyspnoea 
 Hyperventilation 
 Irregular breathing 
 Laryngeal dyspnea 
 Laryngeal oedema 
 Laryngospasm 
 Lyngotracheal oedema 
 Mouth swelling 
 Nasal obstruction 
 Oedema mouth 
 Oropharyngeal spasm  
 Oropharyngeal swelling 
 Respi[INVESTIGATOR_13374] 
 Respi[INVESTIGATOR_1506]  
 Respi[INVESTIGATOR_634146] 
 Respi[INVESTIGATOR_1399] 
 Reversible airways obstruction 
 Sensation of foreign body 
 Sneezing 
 Stridor 
 Swollen tongue 
 Tachypnoea 
 Throat tightness 
 Tongue oedema 
 Tracheal obstruction 
 Tracheal oedema  
 Upper airway obstruction 
 Wheezing 
Category C consists of the following PTs: 
 Allergic oedema 
 Angioedema REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Throat tightnes
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Throat tightnes s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s
Tongue oedema
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Tongue oedema
Tracheal obstruction
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Tracheal obstruction
Tracheal oedema
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Tracheal oedema

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Upper airway obstruction
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Upper airway obstruction

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 89 of 149  Erythema 
 Eye oedema  
 Eye prutitus 
 Eye swelling 
 Eyelid oedema 
 Face oedema  
 Flushing 
 Generalised erythema 
 Injection site urticarial 
 Lip oedema 
 Lip swelling 
 Nodular rash 
 Ocular hyperaemia 
 Oedema 
 Periorbital oedema 
 Pruritus 
 Pruritus allergic 
 Pruritus generalized 
 Rash  
 Rash erythematous 
 Rash generalized 
 Rash pruritic 
 Skin swelling 
 Swelling 
 Swelling face 
 Urticaria 
 Urticaria papular 
Category D consists of the following PTs: 
 Blood pressure decreased 
 Blood pressure diastolic decreased  
 Blood pressure systolic decreased REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Skin swelling
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Skin swelling
Swelling face
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Swelling face
U
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Urticaria
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rticaria

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Urticaria papular
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Urticaria papular
Category D consists of the following PTs:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Category D consists of the following PTs:
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 90 of 149  Cardiac arrest 
 Cardio-respi[INVESTIGATOR_13374] 
 Cardiovascular insufficiency 
 Diastolic hypotension 
 Hypotension 
The following AE summary tables (for the Parts/Analysis sets a, b, c, d) will be used as the basis 
for presentation of AEs of interest as well as for hepatic events, hypersensitivity reactions and anaphylactic reactions: 
 All TEAEs by [CONTACT_148274], HLT, and PT (applies to opportunistic infections [ 1], [2], 
hepatic events, hypersensitivity reactions and anaphylactic reactions) 
 All serious TEAEs by [CONTACT_148274], HLT, and PT (applies to [ 3], [5], [6] and [ 7]) 
EAIR and EAER will be calculated and included in these summary tables of AEs of interest.  
Finally, a summary of all TEAEs which emerged at any time during the study (Part A or Part B) 
while on CZP 200mg Q2W will be produced. This summary will include all subjects in the SS 
and all subjects in the SSB who received CZP 200mg Q2W during Part B (either as randomized treatment or as escape treatment). EAIR and EAER will be calculated and included in this summary table. 
TEAEs which emerged at any time during the study while on CZP 200mg Q2W will be defined 
as follows: 
 In subjects not randomized into Part B, TEAEs under CZP full-dose therapy will be defined 
as all AEs starting on or after the date of first CZP full-dose therapy in Part A and up to [ADDRESS_846890] dose of study medication in Part A. 
 In subjects randomized into Part B to the PBO or CZP 200mg Q4W arm who do not 
experience a flare and do not escape to CZP full-dose therapy, TEAEs under CZP full-dose 
therapy will be defined as all AEs starting on or after the date of first study medication in 
Part A and up to [ADDRESS_846891] study medication in Part B. 
 In subjects randomized into Part B to the PBO or CZP 200mg Q4W arm who do experience a flare and do escape to CZP full-dose therapy, TEAEs under CZP full-dose therapy will include all post-flare TEAEs in Part B. 
 In subjects randomized into Part B to CZP 200mg Q2W arm, TEAEs under CZP full-dose therapy will include all TEAEs in Part A and Part B. 
AE data will be listed. A glossary for the AE listing will detail the verbatim terms that are coded 
to each SOC, HLT, and PT. 
10.3 Clinical laboratory evaluations 
Testing for hepatitis B surface antigen and antibodies to hepatitis C and HIV will be performed 
at Screening. HLA-B27 will be performed at Screening only. These data will be listed only. REDACTED COPY who received CZP 200mg Q2W during Part B (either as randomized 
REDACTED COPY who received CZP 200mg Q2W during Part B (either as randomized 
EAIR and EAER will be calculated and 
REDACTED COPY EAIR and EAER will be calculated and 
which emerged at any time during the study while on CZP 200mg Q2W
REDACTED COPY which emerged at any time during the study while on CZP 200mg Q2W
In subjects not randomized into Part B, TEAEs under CZP full
REDACTED COPY In subjects not randomized into Part B, TEAEs under CZP full
e date of first CZP fullREDACTED COPY e date of first CZP full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used as the basis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used as the basis 
as well as for hepatic events, hypersensitivity reactions and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as well as for hepatic events, hypersensitivity reactions and 
SOC, HLT, and PT (applies to opportunistic infections
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SOC, HLT, and PT (applies to opportunistic infections [
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ][
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [
], 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ], [
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 6]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ]and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and 
EAIR and EAER will be calculated and included in these summary tables of AEs of interest. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. EAIR and EAER will be calculated and included in these summary tables of AEs of interest. 
Finally, a summary of all TEAEs which emerged at any time during the study (Part A or Part B) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Finally, a summary of all TEAEs which emerged at any time during the study (Part A or Part B) 
while on CZP 200mg Q2W will be produced. This summary will include all subjects in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. while on CZP 200mg Q2W will be produced. This summary will include all subjects in the 
who received CZP 200mg Q2W during Part B (either as randomized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. who received CZP 200mg Q2W during Part B (either as randomized 
EAIR and EAER will be calculated and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. EAIR and EAER will be calculated and 
which emerged at any time during the study while on CZP 200mg Q2W
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. which emerged at any time during the study while on CZP 200mg Q2W
In subjects not randomized into Part B, TEAEs under CZP full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In subjects not randomized into Part B, TEAEs under CZP full
e date of first CZP full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e date of first CZP full
days after the last dose of study medication in Part A.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. days after the last dose of study medication in Part A.
In subjects randomized into Part B to the PBO or CZP 200mg Q4W arm who do not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In subjects randomized into Part B to the PBO or CZP 200mg Q4W arm who do not 
experience a flare and do not escape to CZP full
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experience a flare and do not escape to CZP full
therapy will be defined as all AEs starting on or after the date of first study medication in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. therapy will be defined as all AEs starting on or after the date of first study medication in 
Part A and up to [ADDRESS_846892]
In subjects randomized into Part B to CZP 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In subjects randomized into Part B to CZP 
therapy will include all TEAEs in Part A and Part B.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. therapy will include all TEAEs in Part A and Part B.
AE data will be listed. A glossary for the AE listing will detail the verbatim terms that are coded 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AE data will be listed. A glossary for the AE listing will detail the verbatim terms that are coded 
to each SOC, HLT, and PT.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to each SOC, HLT, and PT.
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 91 of 149 Descriptive statistics for observed values and change from Part A Baselin e will be presented for 
each scheduled visit for the following parameters:  
 Hematology: red blood cells, hemoglobin, hematocrit, platelets, white blood cells, 
neutrophils, lymphocytes, monocytes, eosinophils, and basophils 
 Biochemistry: sodium, potassium, chloride, bicarbonate, total calcium, inorganic phosphorus, 
creatine phosphokinase (CPK), glucose, creatinine, urate, urea nitrogen, total protein, 
albumin, alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, total cholesterol 
Values reported BLQ will be replaced by [CONTACT_31806]-half the limit of quantification when reporting summary statistics. 
Summaries for Part A will be presented by [CONTACT_634399]. 
Summaries for Part B will be presented by [CONTACT_634400]-flare 
assessments in the subset of subjects experiencing a flare in Part B and start escape therapy. For 
the subset of subjects experiencing a flare in Part B and start escape therapy, separate summaries 
will be produced using the ETS and will present only the post-flare assessments by [CONTACT_6490].  
For the continuous laboratory parameters, last value (end of treatment), minimum value during 
treatment, and maximum value during treatment, will be derived. Derivations will be performed for each treatment period separately. The derivations will only use post-baseline assessments in 
the corresponding treatment period and will exclude any assessment performed at the SFU visit. 
In Part B, derivations will be done excluding all assessments performed after the start of escape therapy in subjects experiencing a flare in Part B and start escape therapy. Additional derivations 
will be performed for the subset of subjects experiencing a flare in Part B and start escape 
therapy using the ETS and including only the assessments performed after the start of escape 
therapy.  
The calculations for end of treatment, minimum and maximum values will be performed for each parameter separately. 
A by-subject listing of all laboratory data will be provided. This listing will be presented by 
[CONTACT_1570], results (with abnormal values flagged) and unit. In the listing for biochemistry 
also Glomerular Filtration Rate will be added. 
All laboratory values, for which a normal range is available, will be classified into low (L) 
normal (N), and high (H) according to the respective normal range. Values falling outside of the 
normal limits will be classified as H or L and values within the range with N. In case no lower 
(upper) limit is given, the classification L (H) is not applicable.  
A summary of shift from Baseline to  the maximum, minimum and end of treatment value will be 
provided for hematology and biochemistry parameters for each treatment period separately (Part 
A, Part B pre-flare, Part B post-flare). 
Presentations in Part A will be performed by [CONTACT_634399]. 
Presentations in Part B pre-flare will be performed by [CONTACT_634401]. Presentations 
in Part B post-flare data will be performed by [CONTACT_634402]. REDACTED COPY For the continuous laboratory parameters, last value (end of treatment), minimum value during 
REDACTED COPY For the continuous laboratory parameters, last value (end of treatment), minimum value during 
treatment, and maximum value during treatment, will be derived. Derivations will be performed 
REDACTED COPY treatment, and maximum value during treatment, will be derived. Derivations will be performed 
. The derivations will only use 
REDACTED COPY . The derivations will only use 
the corresponding treatment period and will exclude any assessment performed at the SFU visit
REDACTED COPY the corresponding treatment period and will exclude any assessment performed at the SFU visit
In Part B, derivations will be done excluding all assessments
REDACTED COPY In Part B, derivations will be done excluding all assessments
flare in Part B
REDACTED COPY flare in Part B
will be performed for the subset of subjects REDACTED COPY will be performed for the subset of subjects 
and including only the assessments REDACTED COPY and including only the assessments
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. half the limit of quantification when reporting 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. half the limit of quantification when reporting 
and overall in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and overall in the SS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SS
excluding any post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. excluding any post
flare in Part B and start escape therapy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B and start escape therapy
and start escape therapy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and start escape therapy
flare assessments
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare assessments
For the continuous laboratory parameters, last value (end of treatment), minimum value during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the continuous laboratory parameters, last value (end of treatment), minimum value during 
treatment, and maximum value during treatment, will be derived. Derivations will be performed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment, and maximum value during treatment, will be derived. Derivations will be performed 
. The derivations will only use 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . The derivations will only use 
the corresponding treatment period and will exclude any assessment performed at the SFU visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the corresponding treatment period and will exclude any assessment performed at the SFU visit
In Part B, derivations will be done excluding all assessments
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In Part B, derivations will be done excluding all assessments
flare in Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B and start escape therapy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and start escape therapy
will be performed for the subset of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be performed for the subset of subjects experiencing a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experiencing a 
and including only the assessments
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and including only the assessments
The calculations for end of treatment, minimum and maximum values will be performed for each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The calculations for end of treatment, minimum and maximum values will be performed for each 
subject listing of all laboratory data will be provided. This listing will be presented by 
[CONTACT_122253]. subject listing of all laboratory data will be provided. This listing will be presented by 
[CONTACT_634403]. result s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s(with abnormal values flagged) and unit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (with abnormal values flagged) and unit.
Glomerular Filtration Rate
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Glomerular Filtration Rate
All laboratory values, for which a normal range is available, will be classified into low (L) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All laboratory values, for which a normal range is available, will be classified into low (L) 
normal (N), and high (H) according to the
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. normal (N), and high (H) according to the
normal limits will be classified as H or L and values within the range with N. In case no lower 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. normal limits will be classified as H or L and values within the range with N. In case no lower 
(upper) limit is given, the classification L (H) is not applicable. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (upper) limit is given, the classification L (H) is not applicable. 
A summary of shift from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A summary of shift from Baseline
provided for
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. provided for
A, Part B pre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A, Part B pre
UCB   [ADDRESS_846893]-Baseline visit will be defined as laboratory values graded 
3 or 4 according to the Rheumatology Common Toxicity Criteria (RCTC). Values fulfilling the 
criteria will be classified as marked abnormal high (MH) or marked abnormal low (ML). In case no lower (upper) limit is given the classification ML (MH) is not applicable.  
Definitions of markedly abnormal values are given in the below Table 10.1  and Table 10.2 . 
Table 10.1: Definitions of Markedly Abnormal Hematology Values 
Parameter (SI units)  Markedly Abnormal Definition  
Low  High  
Hemoglobin (g/L)  <Lower Limit of Normal  
AND decrease from 
Baseline >20 N/Aa 
Hemoglobin (g/L)  <80 N/A 
Leukocytes (total x 1000)  <2.0 N/A 
Lymphocytes (x 1000)  <0.5 N/A 
Neutrophils (x 1000)  <1.0 N/A 
Platelets (x 1000)  <50 N/A 
a N/A= not applicable. 
Table 10.2: Definitions of Markedly Abnormal Biochemistry Values 
Parameter (SI units)  Markedly Abnormal Definition  
Low  High  
AP N/Aa >[ADDRESS_846894]  
ALT  N/A >[ADDRESS_846895]  N/A >[ADDRESS_846896]  
Calcium (mmol/L)  <1.75  >3.125  
CPK  N/A >[ADDRESS_846897]  
Creatinine  N/A >1.[ADDRESS_846898]  
Glucose (mmol/L)  <2.22  >13.89  
Potassium (mmol/L)  <3.0 >6.4 
Sodium (mmol/L)  <125  N/A 
Total bilirubin  N/A ≥[ADDRESS_846899]  
Uric acid  N/A ≥[ADDRESS_846900]  
a N/A= not applicable, ALT=alanine aminotransferase, AP=alkaline phosphatase , AST= aspartate aminotransferase , 
CPK= creatine phospho kinase . REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY Definitions of Markedly Abnormal Biochemistry Values
REDACTED COPY Definitions of Markedly Abnormal Biochemistry Values
Markedly Abnormal DefinitionREDACTED COPY Markedly Abnormal DefinitionREDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. N/A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. N/A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. N/A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. N/A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. N/A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. N/A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Definitions of Markedly Abnormal Biochemistry Values
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Definitions of Markedly Abnormal Biochemistry Values
Markedly Abnormal Definition
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Markedly Abnormal Definition
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Low 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Low 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. N/A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. N/Aa
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. N/A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. N/A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Calcium (mmol/L)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Calcium (mmol/L)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Creatinine
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Creatinine
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Glucose (mmol/L)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Glucose (mmol/L)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Potassium (mmol/L)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Potassium (mmol/L)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Sodium (mmol/L)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Sodium (mmol/L)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 93 of 149 The number and percent age of subjects with markedly abnormal hematology or biochemistry 
values will be summarized by [CONTACT_634404] (excluding the SFU visit) separately for each 
treatment period. Subject numbers for subjects with any markedly abnormal hematology or 
biochemistry value will be tabulated.  
Summaries for Part A will be presented by [CONTACT_634399]. 
Summaries for Part B will be presented by [CONTACT_634400]-flare 
assessments in the subset of subjects experiencing a flare in Part B and start escape therapy. For 
the subset of subjects experiencing a flare in Part B and start escape therapy, separate summaries 
will be produced using the ETS and will present only the post-flare assessments by [CONTACT_1570].  
For the derivation of the number and percentage of subjects with markedly abnormal hematology 
or biochemistry at any visit within a treatment period, only post-baseline assessments within the 
corresponding treatment period will be considered (excluding the SFU visit). In Part B, 
derivations will be done excluding all assessments performed after the start of escape therapy in 
subjects experiencing a flare in Part B and start escape therapy. In the subset of subjects experiencing a flare in Part B and start escape therapy, derivations will be done including only 
the assessments performed after the start of escape therapy. 
A by-subject listing of markedly abnormal values will be provided separately.  
The number and percentage of post-baseline liver function test evaluations will be summarized 
by [CONTACT_634405], AP, AST and total bilirubin separately for each 
treatment period, using same derivation as described previously. Presentations in Part A will be performed by [CONTACT_634285]. Presentations in Part B will be 
performed by [CONTACT_634406]. For the subset of subjects experiencing a flare in Part B and do start escape therapy, presentations will be performed by [CONTACT_634407].  
The varied parameter criteria will be:  
 ≥2x, 3x, 5x, 10x, 20x ULN elevation of AST 
 ≥2x, 3x, 5x, 10x, 20x ULN elevation of ALT 
 ≥2x, 3x, 5x, 10x, 20x ULN elevation of AST or ALT 
 ≥1x, 1.5x ULN elevation of Bilirubin 
 ≥1.5x ULN elevation of AP 
 ≥2x ULN elevation of Bilirubin and 3x ULN elevation of either ALT or AST 
In order to meet the last above criteria, a subject must experience the elevation in bilirubin and 
ALT or AST at the same visit. For example, a subject who experiences a ≥2x ULN elevation of 
bilirubin at one visit and a 3x ULN elevation in ALT (or AST) at a subsequent visit has not 
fulfilled the Hy’s law criteria. 
A by-subject listing for any subject with at least one post-baseline elevated test data will be provided. The listing includes all liver function test laboratory values for this subject.  
Samples and results for additional laboratory tests (hepatitis B surface antigen and antibodies to 
hepatitis C and HIV, Genomics Laboratory Data , HLA -B27) will be listed separately. REDACTED COPY arkedly abnormal values will be 
REDACTED COPY arkedly abnormal values will be 
baseline liver function test evaluati
REDACTED COPY baseline liver function test evaluati
by [CONTACT_634405], AP, AST and total bilirubin
REDACTED COPY by [CONTACT_634405], AP, AST and total bilirubin
treatment period, using same derivation as described previously
REDACTED COPY treatment period, using same derivation as described previously
and overall u
REDACTED COPY and overall u
performed by [CONTACT_634408]. flare in Part B and start escape therapy. For 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B and start escape therapy. For 
flare in Part B and start escape therapy, separate summaries 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B and start escape therapy, separate summaries 
flare assessments by [CONTACT_455614]. flare assessments by [CONTACT_634409]. rivation of the number and percentage of subjects with markedly abnormal hematology
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hematology
baseline assessments within the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline assessments within the 
corresponding treatment period will be considered (excluding the SFU visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. corresponding treatment period will be considered (excluding the SFU visit ). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ). In Part B, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In Part B, 
derivations will be done excluding all assessments performed after the start of escape therapy in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. derivations will be done excluding all assessments performed after the start of escape therapy in 
flare in Part B and start escape therapy. In the subset of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B and start escape therapy. In the subset of subjects 
apy, derivations will be done including only 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. apy, derivations will be done including only 
provided
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. provided
baseline liver function test evaluati
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline liver function test evaluati
by [CONTACT_634405], AP, AST and total bilirubin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. by [CONTACT_634405], AP, AST and total bilirubin
treatment period, using same derivation as described previously
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment period, using same derivation as described previously
and overall u
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and overall u sing the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sing the 
B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B. For the subset of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. . For the subset of subjects 
presentations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. presentations
The varied parameter criteria will be: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The varied parameter criteria will be: 
≥2x, 3x, 5x, 10x, 20x ULN elevation of AST
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥2x, 3x, 5x, 10x, 20x ULN elevation of AST
≥2x, 3x, 5x, 10x, 20x ULN elevation of ALT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥2x, 3x, 5x, 10x, 20x ULN elevation of ALT
≥2x, 3x, 5x, 10x, 20x ULN elevation of AST or ALT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥2x, 3x, 5x, 10x, 20x ULN elevation of AST or ALT
≥1x, 1.5x ULN elevation of Bilirubin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥1x, 1.5x ULN elevation of Bilirubin
≥1.5x ULN elevation of AP
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥1.5x ULN elevation of AP
≥2x ULN elevation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≥2x ULN elevation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In order to meet the last above criteria, a subject must experience the elevation in bilirubin and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In order to meet the last above criteria, a subject must experience the elevation in bilirubin and 
ALT or AST at the same visit. For example, a subject who experiences a ≥2x ULN elevation of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ALT or AST at the same visit. For example, a subject who experiences a ≥2x ULN elevation of 
bilirubin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. bilirubin
fulfilled 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. fulfilled 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 94 of 149 The urinalysis data will be listed only. 
10.4 Vital signs, physical findings, and other observations related to 
safety 
10.4.1 Vital signs 
Vital signs, including temperature, will be measured at all on-site visits (except at the 3 to 5 days 
prior to Week 48 Visit) including the SFU visit and also at all home-nurse visits in Part B. In 
subjects experiencing a flare in Part B, vital signs will be measured at escape Weeks 0, 2, 4, 12 and every 12 weeks thereafter. Respi[INVESTIGATOR_634147]; and in addition at subsequent visits, if a subject experiences an AE. 
Descriptive statistics for observed values and change from Part A Baseline will be presented for 
each scheduled visit for each vital sign parameter.  
Vital signs will be presented for Part A and Part B separately. Part A summaries will be done by 
[CONTACT_634285]. Part B summaries will be done by [CONTACT_634410]. Part B summaries will not include post-flare assessments. For the subset of subjects experiencing a flare in Part B and start escape therapy, summaries will be produced 
using the ETS including only the post-flare assessments. Vital signs assessments will be listed. 
10.4.2 Other safety variables 
The following presentations will be based on the SS for Part A and on the SSB for Part B, unless 
otherwise mentioned.  
[IP_ADDRESS] Pregnancy testing 
Pregnancy testing must be carried out for women of childbearing potential and will consist of 
serum testing at Screening and SFU, and urine testing at Baseline and Week 96/withdrawal Visit. 
Pregnancy test results (i.e. Choriogonadotropin Beta) will be listed only. 
[IP_ADDRESS] Physical assessments 
Physical examination will be performed at Screening, Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 
96/withdrawal, and at the SFU visit ([ADDRESS_846901] dose). In subjects experiencing a flare in Part B, physical examination will be performed at escape Weeks 0, 2, 4, 12 and every 12 weeks thereafter. Clinically important abnormal changes in subsequent physical examinations will be recorded as AEs. Physical examination results will be listed. 
Weight is to be measured at Screening, Baseline, Week 48, and at completion at Week 
96/withdrawal Visit. Height will be measured at the Baseline Visit only. Summary statistics will 
be provided by [CONTACT_634411] A using the SS and by [CONTACT_7239] B using the SSB by [CONTACT_634412] A Baseline for 
weight, height and BMI, as applicable. The summary for Part B will not include post-flare 
assessments. For the subset of subjects experiencing a flare in Part B and start escape therapy, a 
summary by [CONTACT_634413]-flare 
assessments. These data will also be listed. REDACTED COPY SS 
REDACTED COPY SS for Part A and on
REDACTED COPY for Part A and on
Pregnancy testing must be carried out for women of childbearing potential and will consist of 
REDACTED COPY Pregnancy testing must be carried out for women of childbearing potential and will consist of 
serum testing at Screening and SFU, and urine testing at Baseline and REDACTED COPY serum testing at Screening and SFU, and urine testing at Baseline and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (except at the 3 to 5 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (except at the 3 to 5 days 
subjects experiencing a flare in Part B, vital signs will be measured at escape Weeks 0, 2, 4, 12 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects experiencing a flare in Part B, vital signs will be measured at escape Weeks 0, 2, 4, 12 
and every 12 weeks thereafter. Respi[INVESTIGATOR_634147]; 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and every 12 weeks thereafter. Respi[INVESTIGATOR_634147]; 
Baseline will be presented for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline will be presented for 
eparately. Part A summaries will be done by 
[CONTACT_122253]. eparately. Part A summaries will be done by 
. Part B summaries will be done by [CONTACT_455614]. . Part B summaries will be done by [CONTACT_634414]. For the subset of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessments. For the subset of 
, summaries will be produced 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , summaries will be produced 
flare assessments. Vital signs assessments will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare assessments. Vital signs assessments will be listed.
for Part A and on
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for Part A and on
Pregnancy testing must be carried out for women of childbearing potential and will consist of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pregnancy testing must be carried out for women of childbearing potential and will consist of 
serum testing at Screening and SFU, and urine testing at Baseline and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. serum testing at Screening and SFU, and urine testing at Baseline and 
Choriogonadotropin Beta
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Choriogonadotropin Beta
Physical assessments
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Physical assessments
Physical examination will be performed at Screening, Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Physical examination will be performed at Screening, Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 
96/withdrawal, and at the SFU 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 96/withdrawal, and at the SFU v
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. v
flare in Part B, physical examination will be performed at escape Weeks 0, 2, 4, 12 and every 12 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B, physical examination will be performed at escape Weeks 0, 2, 4, 12 and every 12 
weeks thereafter. Clinically important abnormal changes in subsequent physical examinations 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. weeks thereafter. Clinically important abnormal changes in subsequent physical examinations 
will be recorded as AEs. Physical
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be recorded as AEs. Physical
Weight is to be measured at Screening, Baseline, Week 48, and at completion at Week 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Weight is to be measured at Screening, Baseline, Week 48, and at completion at Week 
withdrawal Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. withdrawal Visit
be provided by 
[CONTACT_122253]. be provided by 
[INVESTIGATOR_313517] B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using the SSB 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using the SSB 
weight, height and BMI, as applicable. The summary for Part B will not include 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. weight, height and BMI, as applicable. The summary for Part B will not include 
assessments. For
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessments. For
summar
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summar
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 95 of 149 [IP_ADDRESS] Tuberculosis assessments 
During the conduct of the study, the tuberculosis ( TB) assessment by [CONTACT_18406] (QuantiFERON TB 
GOLD In Tube test or Elispot, if QuantiFERON TB GOLD In Tube test is not available locally), 
will be repeated at Week 48 and Week 96/withdrawal Visit for all subjects .  
Tuberculosis testing results will be listed. 
A plain posteroanterior chest x-ray (or, if done, computed axial tomography of the chest) must be 
done within [ADDRESS_846902] was confirmed positive or any further evidence is suggestive of potential TB infection (eg, exposure).  
Chest x-ray results will be listed.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ray (or, if done, computed axial tomography of the chest) must be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ray (or, if done, computed axial tomography of the chest) must be 
ray should be repeated only if the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ray should be repeated only if the 
confirmed positive or any further evidence is suggestive of potential TB infection 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. confirmed positive or any further evidence is suggestive of potential TB infection 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 96 of 149 11 REFERENCES  
Guyatt G, Mitchell A, Irvine E J, Singer J, Williams N, Goodacre R, Tompkins C. A new 
measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989 Mar; 96(3) 804-10. 
Heinze, G. and Schemper, M. A Solution to the Problem of Separation in Logistic Regression. 
Statistics in Medicine, 2002; 21, 2409–2419. 
Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van der Tempel H, Mielants 
H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003; 62:127-32. 
Machado PM, Landewé R, van der Heijde D, Assessment of SpondyloArthritis international 
Society (ASAS). Letter. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update 
of the nomenclature for disease activity states. Ann Rheum Dis. 2018; 77:1539-40. 
Mallinckrodt C.H. Preventing and Treating Missing Data in Longitudinal Clinical Trials. A 
Practical Guide. Cambridge University Press, 2013. 
Siddiqui O, Hung HMJ, O’Neill R. MMRM vs. LOCF: A comprehensive comparison based on 
simulation study and 25 NDA datasets. J Biopharm Stat. 2009; 19: 227-246. 
Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio. 
American Journal of Epi[INVESTIGATOR_623] 1990;131(2):373-375. 
REDACTED COPY calculate the confidence interval of a standardized mortality ratio. 
REDACTED COPY calculate the confidence interval of a standardized mortality ratio. 
REDACTED COPY American Journal of Epi[INVESTIGATOR_623] 1990;131(2):373
REDACTED COPY American Journal of Epi[INVESTIGATOR_623] 1990;131(2):373 -
REDACTED COPY -375.
REDACTED COPY 375.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van der Tempel H, Mielants 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van der Tempel H, Mielants 
62:127
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 62:127 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -32.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 32.
international 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. international 
Society (ASAS). Letter. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Society (ASAS). Letter. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update 
77:1539
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 77:1539 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -40.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 40.
l Clinical Trials. A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. l Clinical Trials. A 
Siddiqui O, Hung HMJ, O’Neill R. MMRM vs. LOCF: A comprehensive comparison based on 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Siddiqui O, Hung HMJ, O’Neill R. MMRM vs. LOCF: A comprehensive comparison based on 
simulation study and 25 NDA datasets. J Biopharm Stat. 2009; 19: 227
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. simulation study and 25 NDA datasets. J Biopharm Stat. 2009; 19: 227
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. calculate the confidence interval of a standardized mortality ratio. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. calculate the confidence interval of a standardized mortality ratio. 
375.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 375.
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 97 of 149 12 APPENDICES 
12.1 Rules for medical resource utilization 
12.1.1 Healthcare Resource Utilization 
Study-specific modules will be used to capture the following data regarding healthcare resource 
utilization during the study: 
 Concomitant medical procedures 
 Health care provider consultations not foreseen by [CONTACT_760] 
 In-patient hospi[INVESTIGATOR_306134] (including length of stay) 
In addition to the above categories, the duration of hospi[INVESTIGATOR_634148]. 
12.1.2 Counting rules 
[IP_ADDRESS] In-patient hospi[INVESTIGATOR_94947] 
1. In case of complete admission and discharge dates, for the same subject only one 
hospi[INVESTIGATOR_634118] “start date of the second hospi[INVESTIGATOR_059] - end date of the first hospi[INVESTIGATOR_059]≤1”. 
2. In case the discharge date for a hospi[INVESTIGATOR_634149] (regardless of the discharge check value), 
 if there is a subsequent hospi[INVESTIGATOR_059], 
 if the initial entry point and relationship are the same between the [ADDRESS_846903] hospi[INVESTIGATOR_634150] 
(1) if the discharge date of the second hospi[INVESTIGATOR_634151]-missing, then 
length = second hospi[INVESTIGATOR_634152] – first hospi[INVESTIGATOR_175992] +1; 
(2) else,  
length = last non missing visit date – first hospi[INVESTIGATOR_175992] +1 . 
 otherwise, if either the entry point or the relationship of the [ADDRESS_846904] hospi[INVESTIGATOR_634153]:  
length = (second hospi[INVESTIGATOR_175992] – 1) – first hospi[INVESTIGATOR_634154] + 1 = second hospi[INVESTIGATOR_634155] – first 
hospi[INVESTIGATOR_175992]. 
 in case there is no subsequent hospi[INVESTIGATOR_059], then the length of the hospi[INVESTIGATOR_634156] = last non missing visit date – hospi[INVESTIGATOR_175992] +1. 
 REDACTED COPY In case the discharge date for a hospi[INVESTIGATOR_634149] (regardless of the discharge check 
REDACTED COPY In case the discharge date for a hospi[INVESTIGATOR_634149] (regardless of the discharge check 
tial entry point and relationship are the same between the [ADDRESS_846905] hospi[INVESTIGATOR_634150]
(1) if the discharge date of the second hospi[INVESTIGATOR_634157] (1) if the discharge date of the second hospi[INVESTIGATOR_634158]. addition to the above categories, the duration of hospi[INVESTIGATOR_634148].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. addition to the above categories, the duration of hospi[INVESTIGATOR_634148].
hospi[INVESTIGATOR_634159]. hospi[INVESTIGATOR_634160], for the same subject only one 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In case of complete admission and discharge dates, for the same subject only one 
considered if “start date of the second hospi[INVESTIGATOR_634161]. considered if “start date of the second hospi[INVESTIGATOR_634162] a hospi[INVESTIGATOR_634149] (regardless of the discharge check 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In case the discharge date for a hospi[INVESTIGATOR_634149] (regardless of the discharge check 
tial entry point and relationship are the same between the [ADDRESS_846906] hospi[INVESTIGATOR_634150]
(1) if the discharge date of the second hospi[INVESTIGATOR_634158]. (1) if the discharge date of the second hospi[INVESTIGATOR_634163] = second hospi[INVESTIGATOR_634164]. length = second hospi[INVESTIGATOR_634165] +1;
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. admission date +1;
length = last non missing visit date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. length = last non missing visit date 
otherwise, if either the entry point or the relationship of the [ADDRESS_846907] 
hospi[INVESTIGATOR_634153]: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. hospi[INVESTIGATOR_634153]: 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in case there is no subsequent hospi[INVESTIGATOR_059], then the length of the hospi[INVESTIGATOR_634166]. in case there is no subsequent hospi[INVESTIGATOR_059], then the length of the hospi[INVESTIGATOR_634167]   [ADDRESS_846908] visit date is before the start date, then the discharge date for a hospi[INVESTIGATOR_634168] 
1. 
[IP_ADDRESS] Healthcare provider consultations not foreseen by [CONTACT_634415], count only once for the same subject, same consultation 
date, same location, and same provider. 
[IP_ADDRESS] Concomitant medical procedures 
If the procedure name, start date, and relationship are the same, then only [ADDRESS_846909]/several procedures are counted. 
12.2 Compliance ratio calculation 
The general formula for treatment compliance is given as follows: 
 Compliance Ratio (CR)= {[Exposur e Duration (days)] - [Cumulative Difference (days)]}/ 
             {Exposure Duration (days)} There are 2 methods to determine the CR. CR(1) is based upon scheduled days which reference 
the Baseline Visits. CR(2) is based upon scheduled days which reference the previous dosing 
administration date. CR(1) and CR(2) each will be computed separately. The definition of exposure duration and cumulative difference varies for the [ADDRESS_846910] be set to 0. Specific details for each calculation follow. 
 
CR(1):  
 Exposure Duration (days) = Last Visit date – Baseline date + 14 
            Cumulative Difference (days)=∑
i ABS(AD i – SD i),       where i=Week 0, 2, 4, 6,  … , XX 
   where AD i = Actual day of administration,  for Week i=0 to XX by 2 
     SD i = (i/2) x 14,            for Week i=0 to XX by 2 
 
   Note: XX represents the last completed visit in which study drug 
        should have been administered. If subject is still in the study but AD i 
        is missing, then ABS[AD i – SD i]=14 for the missed Visit i.  
 
CR(2):  
 Exposure Duration (days) = Last Visit date – Baseline date +14 
        
 Cumulative Difference (days)=∑ i ABS(AD i – SD i), where i= Week 0, 2, 4, 6,  … , XX 
   where AD i = Actual day of administration,  for Week i=0 to XX by 2 
     SD i =  {0,        for Week i=0  } REDACTED COPY There are 2 methods to determine the CR. CR(1) is based upon scheduled days which reference 
REDACTED COPY There are 2 methods to determine the CR. CR(1) is based upon scheduled days which reference 
s. CR(2) is based upon scheduled days which referenc
REDACTED COPY s. CR(2) is based upon scheduled days which referenc
administration date. CR(1) and CR(2) each will be computed separately. The definition of 
REDACTED COPY administration date. CR(1) and CR(2) each will be computed separately. The definition of 
exposure duration and cumulative difference varies for the [ADDRESS_846911] 1 variable among procedure name, start date, or relationship is different, 
[Cumulative Difference (days)]}/
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [Cumulative Difference (days)]}/
There are 2 methods to determine the CR. CR(1) is based upon scheduled days which reference 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. There are 2 methods to determine the CR. CR(1) is based upon scheduled days which reference 
s. CR(2) is based upon scheduled days which referenc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s. CR(2) is based upon scheduled days which referenc
administration date. CR(1) and CR(2) each will be computed separately. The definition of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. administration date. CR(1) and CR(2) each will be computed separately. The definition of 
exposure duration and cumulative difference varies for the [ADDRESS_846912] be set to 0. Specific details for each calculation follow.
Exposure Duration (days) = Last 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Exposure Duration (days) = Last V
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. V
Cumulative Difference (days)=∑
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Cumulative Difference (days)=∑
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. i= Actual day of administration, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. = Actual day of administration, 
SD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SD i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. i= (i/2) x 14, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. = (i/2) x 14, 
Note: XX represents the last completed visit in which study drug
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note: XX represents the last completed visit in which study drug
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CR(2):
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CR(2):
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 99 of 149        {14 + AD i-2,     for Week i=2 to XX by 2 } 
 
   Note: XX represents the last completed visit in which study drug         should have been administered. If subject is still in the study but AD
i 
        is missing, then ABS(AD i – SD i)=14 for the missed Visit i.  
Table 12.1: Example 
Week  Scheduled  
day (1)  Scheduled  
day (2)  Actual day  ABS Diff (1)  ABS Diff (2)  
0 0 0 0 0 0 
2 14 14 13 1 1 
4 28 27 29 1 2 
6 42 43 - 14 14 
8 56 57 55 1 2 
10 70 69 69 1 0 
Total  - - - 18 19 
CR    66/84 =0.79  65/84 =0.77  
Note that this example is for a 12 week study. 
In case the actual day of administration is missing, the maximum deviation to the scheduled visit 
date will be assumed (ie 14 days). If for a scheduled visit date with 2 planned injections, the 
syringes were administered on 2 different days, the maximum day difference of the 2 actual dates to the scheduled visit date will be utilized. 
For the measurement of treatment compliance in Part A, the exposure duration in Part A, 
identified as “Exposure Duration [a]”, will use the last of the open label injection visit dates: 
 Exposure Duration [a] (days) = week 46 Visit/last injection date – Baseline date + 14  
The cumulative difference will be calculated for all visits from Week 0 (Baseline) to week 46. 
For the measurement of treatment compliance in Part B, the exposure duration in Part B, 
identified as “Exposure Duration [b]”, will use the last of the double-blind injection visit dates: 
 Exposure Duration [b] (days) = week 94 Visit/last injection date – Week 48 injection/ Week 
48 Visit date + [ADDRESS_846913]-flare exposure 
duration, identified as “Exposure Duration [f]”, will use the last of the injection escape Visit 
dates: 
 Exposure Duration [f] (days) = last escape visit/last injection date – first Escape Week 0 
injection /Escape Week 0 Visit date + 14 REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY Note that this example is for a 12 week study.
REDACTED COPY Note that this example is for a 12 week study.
In case the actual day of administration is missing, the maximum deviation to the scheduled visit 
REDACTED COPY In case the actual day of administration is missing, the maximum deviation to the scheduled visit 
date will be assumed (ie 14 days). If for a 
REDACTED COPY date will be assumed (ie 14 days). If for a scheduled visit date with 2 planned injections, the 
REDACTED COPY scheduled visit date with 2 planned injections, the 
syringes were administered on 2 different days, the maximum day difference of the 2 actual dates REDACTED COPY syringes were administered on 2 different days, the maximum day difference of the 2 actual dates 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ABS Diff (2)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ABS Diff (2)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 14
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 14
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In case the actual day of administration is missing, the maximum deviation to the scheduled visit 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In case the actual day of administration is missing, the maximum deviation to the scheduled visit 
scheduled visit date with 2 planned injections, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scheduled visit date with 2 planned injections, the 
syringes were administered on 2 different days, the maximum day difference of the 2 actual dates 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. syringes were administered on 2 different days, the maximum day difference of the 2 actual dates 
to the scheduled visit date will be utilized.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to the scheduled visit date will be utilized.
measurement of treatment compliance in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. measurement of treatment compliance in
“Exposure Duration [a]”, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. “Exposure Duration [a]”, 
Exposure Duration [a] (days) = week 46 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Exposure Duration [a] (days) = week 46 
The cumulative difference will be calculated
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The cumulative difference will be calculated
For the measurement of treatment compliance in Part B, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the measurement of treatment compliance in Part B, the 
“Exposure Duration [b]”, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. “Exposure Duration [b]”, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Exposure Duration
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Exposure Duration
48 Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 48 Visit date + 14
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date + [ADDRESS_846914] Escape 
visit. 
12.3 SAP Amendment 1 
Rationale for the amendment 
The main purpose of this amendment is to implement the updates of Protocol Amendment 2 where the current assay for measuring ADAb in plasma was replaced by a new method in order to align with current regulatory guidelines. 
In line with the Protocol of the study, the Safety Set changed to include the subjects in open-label 
Part A as well. The previous defined Safety Set was changed to Safety Set Part B (SSB). There is also the possibility to report one unscheduled ASDAS between two scheduled ASDAS 
assessments, the censoring time point changed and additional instruction for analysis are added.   
Moreover, scores which should present an improvement (ASDAS-CII, ASDAS-MI, ASAS20, 
ASAS40, ASAS5/6, SF-36 PCS response and SF-36 MCS response) are not analyzed using Part 
B Baseline as reference . 
A modified version of ASDAS-MI was added as sensitivity analysis for ASDAS- MI.  
Analyses for time since diagnosis of disease and symptom duration were added to medical 
history. 
Modifications and changes 
Global changes  
The following changes were made throughout the SAP:  
 In the summary tables for Part A, the axSpA subpopulation is used instead of mNY 
classification, since the data is presented for AS and nr- axSPA  in the corresponding outputs. 
The term mNY classification is kept when it is presented or used as stratification factor. 
 In safety outputs for Part A, SS is used instead of OLS and in safety outputs for Part B SSB 
is used instead of SS.  
 Censoring point changed from week 92 to week 94. 
 Analyses for ASDAS-CII, ASDAS-MI, ASAS20, ASAS40, ASAS5/6, SF-[ADDRESS_846915] been made (formats as missing spaces or redundant spaces are not listed): 
Change #[ADDRESS_846916] of abbreviation 
The following abbreviations were added: 
Nab Neutralizing antibody 
SSB  Safety Set Part B REDACTED COPY ime since diagnosis of disease and symptom duration
REDACTED COPY ime since diagnosis of disease and symptom duration
The following changes were made throughout the SAP: 
REDACTED COPY The following changes were made throughout the SAP: 
the axSpA subpopulation REDACTED COPY the axSpA subpopulation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in order 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in order 
in open
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in open label 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. label 
Part B (SSB).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B (SSB).
There is also the possibility to report one unscheduled ASDAS between two scheduled ASDAS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. There is also the possibility to report one unscheduled ASDAS between two scheduled ASDAS 
, the censoring time point changed and additional instruction for analysis are added.  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , the censoring time point changed and additional instruction for analysis are added.  
CII, ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CII, ASDAS
are not analyzed using Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. are not analyzed using Part 
as sensitivity analysis for ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as sensitivity analysis for ASDAS
ime since diagnosis of disease and symptom duration
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ime since diagnosis of disease and symptom duration
The following changes were made throughout the SAP: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following changes were made throughout the SAP: 
the axSpA subpopulation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the axSpA subpopulation 
classification, since the data is presented for AS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. classification, since the data is presented for AS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. classification is
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. classification is kept
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. kept
In safety outputs for Part A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In safety outputs for Part A ,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ,SS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SS 
Censoring point changed from week 92 to week 94.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Censoring point changed from week 92 to week 94.
Analyses for ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Analyses for ASDAS
36 MCS response referring to Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 MCS response referring to Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. cific changes
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. cific changes
In addition 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition 
missing spaces or redundant spaces are not listed):
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing spaces or redundant spaces are not listed):
Change #1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #1
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 101 of 149 ADAb  anti-CZP antibody 
Change #2 
1 Introduction 
The following protocol version was added: 
 Protocol Amendment 2 dated 24 Jan 2018 
 Protocol Amendment 2.1 (Taiwan) dated 27 Feb 18 
 Protocol Amendment 2.2  ([LOCATION_006]) dated 27 Feb 18 
Change #3 
[IP_ADDRESS].2 Other efficacy variables for subjects entering Part B 
 ASDAS clinical improvement (ASDAS-CII, ASDAS-MI) using Part A Baseline and Part B 
Baseline as a reference 
 ASAS20, ASAS40, ASAS5/6, and ASAS PR response using Part A Baseline Baseline and Part B Baseline as a reference 
 BASDAI50 response using Part A Baseline and Part B Baseline as a reference 
 SF-36 PCS response and SF-36 response using Part A Baseline and Part B Baseline as a 
reference 
Has been changed to: 
 ASDAS clinical improvement (ASDAS-CII, ASDAS- MI) using Part A Baseline as a 
reference 
 ASAS20, ASAS40, ASAS5/6, and ASAS PR response using Part A Baseline as a reference 
 BASDAI50 response using Part A Baseline as a reference 
 SF-36 PCS response and SF-36 MCS response using Part A Baseline as a reference 
Change #4 
[IP_ADDRESS].3 Other efficacy variables for subjects who experience a flare in Part B 
 ASDAS clinical improvement (ASDAS-CII, ASDAS-MI) using Part B Baseline and Flare 
Baseline as reference 
 ASAS20, ASAS40, ASAS5/6, and ASAS PR response using Part B Baseline and Flare 
Baseline as reference 
 BASDAI50 response using Part B Baseline and Flare Baseline as reference 
 SF-36 PCS response and SF-36 response using Part B Baseline and Flare Baseline as a 
reference 
Has been changed to: 
 ASDAS clinical improvement (ASDAS-CII, ASDAS- MI) using Flare Baseline as reference 
 ASAS20, ASAS40, ASAS5/6, and ASAS PR response using Flare Baseline as reference REDACTED COPY BASDAI50 response using Part A Baseline and Part B Baseline as a reference
REDACTED COPY BASDAI50 response using Part A Baseline and Part B Baseline as a reference
36 response using Part A Baseline and Part B Baseline as a 
REDACTED COPY 36 response using Part A Baseline and Part B Baseline as a 
clinical improvement (ASDAS
REDACTED COPY clinical improvement (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MI) using Part A Baseline and Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MI) using Part A Baseline and Part B 
ASAS20, ASAS40, ASAS5/6, and ASAS PR response using Part A Baseline Baseline and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS20, ASAS40, ASAS5/6, and ASAS PR response using Part A Baseline Baseline and 
BASDAI50 response using Part A Baseline and Part B Baseline as a reference
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI50 response using Part A Baseline and Part B Baseline as a reference
36 response using Part A Baseline and Part B Baseline as a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 response using Part A Baseline and Part B Baseline as a 
CII, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CII, ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS
ASAS20, ASAS40, ASAS5/6, and ASAS PR response
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS20, ASAS40, ASAS5/6, and ASAS PR response
BASDAI50 response using Part A Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI50 response using Part A Baseline
36 PCS response and SF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 PCS response and SF -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 
[IP_ADDRESS].3 Other efficacy variables for subjects who experience a flare in Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS].3 Other efficacy variables for subjects who experience a flare in Part B
ASDAS clinical improvement (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS clinical improvement (ASDAS
as reference
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as reference
ASAS20, ASAS40, ASAS5/6, and ASAS PR response using Pa
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS20, ASAS40, ASAS5/6, and ASAS PR response using Pa
Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline
BASDAI50 response using Part B Baseline and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI50 response using Part B Baseline and 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 102 of 149  BASDAI50 response using Flare Baseline as reference  
 SF-36 PCS response and SF-36 MCS response using Flare Baseline as a reference 
Change #5 
[IP_ADDRESS] Immunogenicity variables 
The number and percentage of subjects with anti-CZP Ab levels above 2.4 units/mL will be 
reported as follows: 
 Number and % of subjects with Ab >2.4 units/mL at the time of each visit 
 Number and % of subjects with Ab >2.4 units/mL at any visit during treatment (not including 
the safety follow-up (SFU) visit) 
 Number and % of subjects with Ab >2.4 units/mL at any visit including the SFU visit 
For the subgroup of subjects with at least 1 anti-CZP Ab >2.4 units/mL, the time point of occurrence of the first finding will also be displayed. 
Has been changed to: 
Anti-CZP antibody (ADA b) levels will be assessed at Baseline and subsequent time points as 
described in the protocol. 
Determination of ADAb will be done using a validated screening, confirmation, and titration 
ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) 
assay. The immunogenicity data will be processed according to dedicated Bioanalytical Analysis 
plans. 
Change #6 
3.2.4 MRI assessments 
MRI will be assessed centrally and scoring will be done by 2 independent readers, who are 
blinded to both the order of the scans and to the treatment group, using a previously reported scoring system. Two different MRI scores will be used for analysis. 
Has been changed to: 
Magnetic resonance imaging of the spi[INVESTIGATOR_634169], Week 48, Week 96, or WD Visit if MRI was performed more than 12 weeks prior to WD. MRI will be assessed centrally and scoring will be done by 2 independent readers, who are blinded to 
both the order of the scans and to the treatment group, using a previously reported scoring 
system. In addition, a single reader assessment will be performed for change from Baseline 
(Week 48) evaluation in the MRI scores for all subjects that entered Part A. Two different MRI scores will be used for analysis. 
Change #7 
3.2.7 Ankylosing Spondylitis Disease Activity Score (ASDAS) 
0.579 × (natural logarithm of the CRP [mg/L] + 1) 
Has been changed to: REDACTED COPY termination of ADAb will be done using a validated screening, confirmation, and titration 
REDACTED COPY termination of ADAb will be done using a validated screening, confirmation, and titration 
ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) 
REDACTED COPY ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) 
assay. The immunogenicity data will be processed according to dedicated 
REDACTED COPY assay. The immunogenicity data will be processed according to dedicated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number and % of subjects with Ab >2.4 units/mL at any visit during treatment (not including 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number and % of subjects with Ab >2.4 units/mL at any visit during treatment (not including 
Number and % of subjects with Ab >2.4 units/mL at any visit including the SFU visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number and % of subjects with Ab >2.4 units/mL at any visit including the SFU visit
CZP Ab >2.4 units/mL, the time point of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP Ab >2.4 units/mL, the time point of 
b) levels will be assessed at Baseline and subsequent time points as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. b) levels will be assessed at Baseline and subsequent time points as 
termination of ADAb will be done using a validated screening, confirmation, and titration 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. termination of ADAb will be done using a validated screening, confirmation, and titration 
ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) 
assay. The immunogenicity data will be processed according to dedicated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assay. The immunogenicity data will be processed according to dedicated 
MRI will be assessed centrally and scoring will be done by 2 independent readers, who are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MRI will be assessed centrally and scoring will be done by 2 independent readers, who are 
blinded to both the order of the scans and to the treatment group, using a previously reported 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. blinded to both the order of the scans and to the treatment group, using a previously reported 
ystem. Two different MRI scores will be used for analysis.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ystem. Two different MRI scores will be used for analysis.
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
Magnetic resonance imaging of the spi[INVESTIGATOR_634169], 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Magnetic resonance imaging of the spi[INVESTIGATOR_634169], 
Week 48, Week 96, or WD Visit if MRI was performed more than 12 weeks prior to WD.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 48, Week 96, or WD Visit if MRI was performed more than 12 weeks prior to WD.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be assessed centrally and scoring will be done by 2 independent readers, who are blinded to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be assessed centrally and scoring will be done by 2 independent readers, who are blinded to 
both the order of the scans and to the treatment group, using a previously reported scoring 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. both the order of the scans and to the treatment group, using a previously reported scoring 
system. In addition, a single reader assessment will be perfor
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. system. In addition, a single reader assessment will be perfor
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (Week 48) evaluation in the MRI scores for all subjects that entered Part A. Two different MRI 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (Week 48) evaluation in the MRI scores for all subjects that entered Part A. Two different MRI 
scores will be used for analysis.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores will be used for analysis.
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 103 of 149 0.579 × (natural logarithm of the (CRP [mg/L] + 1)) 
Change #8 
3.2.7 Ankylosing Spondylitis Disease Activity Score (ASDAS) 
 ASDAS-MI: ASDAS reduction (improvement) of ≥2.0 relative to Baseline. 
Has been changed to: 
 ASDAS-MI: ASDAS reduction (improvement) of ≥2.0 relative to Baseline. As a sensitivity 
analysis, ASDAS-MI analyses will be repeated using a Modified ASDAS- MI: ASDAS 
reduction (improvement) of >=2.[ADDRESS_846917] -
baseline (i.e. when CRP<LLOQ and all other components are 0, then the minimum ASDAS 
score is 0.636 to 3 decimal places). 
Change #9 
3.2.22 Flare 
The following part has been added: 
(in case of an unscheduled ASDAS visit at Week 94). 
Change #10 
3.2.22 Flare The following part has been added: 
There is also the possibility to report one unscheduled ASDAS between two scheduled ASDAS 
assessments. The same rules as for the scheduled ASDAS apply for the unscheduled ASDAS. 
The unscheduled ASDAS will be taken into account for flare calculation for two consecutive 
visits if there are more than [ADDRESS_846918] experienced a flare. 
Change #11 
3.2.23 Time to flare 
The following part has been added:  
 If the assessments were not performed on the same day, a conservative approach will be used 
and the latest day will be taken as calculated ASDAS day.  
Change #12  
3.2.23 Time to flare 
 For subjects who complete the study without meeting the criteria for flare, the censored date 
will be the date of Week 12 visit. 
Has been changed to: REDACTED COPY There is also the possibility to report one unscheduled ASDAS between two scheduled ASDAS 
REDACTED COPY There is also the possibility to report one unscheduled ASDAS between two scheduled ASDAS 
assessments. The same rules as for the scheduled ASDAS apply for the unscheduled ASDAS.
REDACTED COPY assessments. The same rules as for the scheduled ASDAS apply for the unscheduled ASDAS.
The unscheduled ASDAS will be taken into acREDACTED COPY The unscheduled ASDAS will be taken into ac
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. As a sensitivity 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. As a sensitivity 
ASDAS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS 
reduction (improvement) of >=2.[ADDRESS_846919]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. reduction (improvement) of >=2.[ADDRESS_846920]
baseline (i.e. when CRP<LLOQ and all other components are 0, then the minimum ASDAS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline (i.e. when CRP<LLOQ and all other components are 0, then the minimum ASDAS 
There is also the possibility to report one unscheduled ASDAS between two scheduled ASDAS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. There is also the possibility to report one unscheduled ASDAS between two scheduled ASDAS 
assessments. The same rules as for the scheduled ASDAS apply for the unscheduled ASDAS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessments. The same rules as for the scheduled ASDAS apply for the unscheduled ASDAS.
The unscheduled ASDAS will be taken into ac
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The unscheduled ASDAS will be taken into ac
visits if there are more than [ADDRESS_846921] experienced a 
Time to flare
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Time to flare
The following part has been added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following part has been added:
If the assessments were not performed on the same day, a conservative approach will be used 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the assessments were not performed on the same day, a conservative approach will be used 
and the latest 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and the latest 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
3.2.23
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.23
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 104 of 149  For subjects who complete the study without meeting the criteria for flare, the censored date 
will be the last possible date of the event, i.e. Week 92 for scheduled ASDAS and Week 94 if 
an unscheduled ASDAS was performed at Week 94. 
Change #13  
3.2.26 Anti-CZP antibody status 
The anti-CZP Ab status is positive (Ab+) at a given visit if the Ab level is >2.4 units/mL. The 
anti-CZP Ab status is negative (Ab-) at a given visit if the Ab level is ≤2.4 units/mL.  
A subject has an overall positive anti-CZP Ab status if the Ab level is >2.4 units/mL on at least [ADDRESS_846922] has an overall negative anti-CZP Ab 
status if the Ab level is ≤2.4 units/mL at all visits during treatment, excluding the SFU visit. 
Has been changed to: 
Determination of ADAb will be done using a validated screening, confirmation, and titration ADAb bridging assay, with potential further characterization by a NAb assay. The immunogenicity data will be processed according to dedicated Bioanalytical Analysis plans. 
Change #14  
3.2.27 Modified [LOCATION_001] criteria 
The following part has been added : 
The mNY classification will determined at Screening. MRI will be assessed centrally and by 2 
independent readers. If the results from the readers are different, then the result of the adjudicator will be used. 
Change #[ADDRESS_846923] been added: 
  If a subject does not have a Week 96/withdrawal Visit, then safety and efficacy data recorded at 
either the date of the last scheduled or unscheduled visit during the treatment Period, whichever is later, will be included in summaries “Last/Withdrawal” visit. 
… 
If a subject does not have a Withdrawal Visit, then safety and efficacy data recorded at either the 
date of the last scheduled or unscheduled visit during the Escape Period or the date of last known 
dose during the Escape Period, whichever is later, will be included in summaries 
“Last/Withdrawal” visit. 
Change #16  
3.6 Analysis sets 
There will be 10 analysis sets used within this study   
Has been changed to: 
There will be 11 analysis sets used within this study   REDACTED COPY at Screening. MRI will be assessed centrally and by 2 
REDACTED COPY at Screening. MRI will be assessed centrally and by 2 
. If the results from the readers are different, then the result of the adj
REDACTED COPY . If the results from the readers are different, then the result of the adj
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP Ab status is positive (Ab+) at a given visit if the Ab level is >2.4 units/mL. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP Ab status is positive (Ab+) at a given visit if the Ab level is >2.4 units/mL. The 
ts/mL on at least 1 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ts/mL on at least [ADDRESS_846924] has an overall negative anti -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -CZP Ab 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP Ab 
status if the Ab level is ≤2.4 units/mL at all visits during treatment, excluding the SFU visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. status if the Ab level is ≤2.4 units/mL at all visits during treatment, excluding the SFU visit.
will be done using a validated screening, confirmation, and titration 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be done using a validated screening, confirmation, and titration 
ADAb bridging assay, with potential further characterization by a NAb assay. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb bridging assay, with potential further characterization by a NAb assay. The 
immunogenicity data will be processed according to dedicated Bioanalytical Analysis plans.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. immunogenicity data will be processed according to dedicated Bioanalytical Analysis plans.
at Screening. MRI will be assessed centrally and by [ADDRESS_846925] been added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following parts have been added:
If a subject does not have a Week 96/withdrawal Visit, then safety and efficacy data recorded at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If a subject does not have a Week 96/withdrawal Visit, then safety and efficacy data recorded at 
either the date of the last scheduled or unscheduled visit du
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. either the date of the last scheduled or unscheduled visit du
is later, will be included in summaries “Last/Withdrawal” visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is later, will be included in summaries “Last/Withdrawal” visit.
If a subject does not have a Withdrawal Visit, then safety and efficacy data recorded at either the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If a subject does not have a Withdrawal Visit, then safety and efficacy data recorded at either the 
date of the last scheduled or unscheduled visit duri
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date of the last scheduled or unscheduled visit duri
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose during the Escape Period, whichever is later, will be included in summaries 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. dose during the Escape Period, whichever is later, will be included in summaries 
“Last/Withdrawal” visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. “Last/Withdrawal” visit.
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
3.6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.6
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 105 of 149 Change #17  
3.6.4 Safety Set  
The Safety Set (SS) will consist of all subjects in the RS who have received at least 1 dose of 
study medication in the Double-Blind Period of the study (Part B). 
Has been changed to: 
The Safety Set (SS) will consist of all subjects in the ES who have received at least 1 dose of study medication. 
Change #18 
The following section has been added: 
3.6.5 Safety Set Part B 
The Safety Set Part B (SSB) will consist of all subjects in the RS who have received at least 1 
dose of study medication in the Double-Blind Period of the study (Part B). 
Change #19  
3.6.7 Pharmacokinetic Set A 
The Pharmacokinetic Set A (PKSA) will consist of all subjects from the OLS who provide at least 1 PK sample during Part A. 
Has been changed to: 
3.6.8 Pharmacokinetic Set A 
The Pharmacokinetic Set A (PKSA) will consist of all subjects from the SS who provide at least 1 PK sample during Part A. 
Change #20  
3.6.8 Pharmacokinetic Set B 
The Pharmacokinetic Set B (PKSB) will consist of all subjects from the SS who provide at least 1 PK sample during Part B. 
Has been changed to: 
3.6.9 Pharmacokinetic Set B 
The Pharmacokinetic Set B (PKSB) will consist of all subjects from the SSB who provide at 
least 1 PK sample during Part B. 
Change #21 
The following section was added: 
3.6.13 General use of the Analysis Sets 
Efficacy summaries for variables collected in Part A will be based on the OLS. All efficacy 
analyses for Part B will be performed using the RS. The FAS and PPS will be used for a 
sensitivity analysis on the primary endpoint only. The other efficacy variables for subjects who experience a flare in Part B will be based on the FS.  REDACTED COPY The Pharmacokinetic Set A (PKSA) will consist of all subjects from the OLS who provide at 
REDACTED COPY The Pharmacokinetic Set A (PKSA) will consist of all subjects from the OLS who provide at 
The Pharmacokinetic Set A (PKSA) will consist of all subjects from the SS who provide at least REDACTED COPY The Pharmacokinetic Set A (PKSA) will consist of all subjects from the SS who provide at least 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Safety Set (SS) will consist of all subjects in the ES who have received at least 1 dose of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Safety Set (SS) will consist of all subjects in the ES who have received at least [ADDRESS_846926] 1 
Blind Period of the study (Part B).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Blind Period of the study (Part B).
The Pharmacokinetic Set A (PKSA) will consist of all subjects from the OLS who provide at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Pharmacokinetic Set A (PKSA) will consist of all subjects from the OLS who provide at 
The Pharmacokinetic Set A (PKSA) will consist of all subjects from the SS who provide at least 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Pharmacokinetic Set A (PKSA) will consist of all subjects from the SS who provide at least 
Pharmacokinetic Set B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic Set B
B (PKSB) will consist of all subjects from the SS who provide at least 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B (PKSB) will consist of all subjects from the SS who provide at least 
1 PK sample during Part B.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1 PK sample during Part B.
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
Pharmacokinetic Set B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic Set B
The Pharmacokinetic Set B (PKSB) will consist of all subjects from the SSB who provide at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Pharmacokinetic Set B (PKSB) will consist of all subjects from the SSB who provide at 
least [ADDRESS_846927] 1 PK sample d
Change #2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #2
The following section was added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following section was added:
3.6.13
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.6.13
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 106 of 149 All safety summaries in Part A will be based on the SS. All safety summaries in Part B will be 
based on the SSB. The other safety variables for subjects who experience a flare in Part B will be 
based on the ETS.  
Pharmacokinetic summaries will be based on to Part A/ Part B corresponding set. 
Change #22  
3.8 Center pooling strategy: Italy was removed in the list of countries in Table 3-3. 
Change #[ADDRESS_846928] 1 dose 
of study medication in the Double-Blind Period of the study (Part B). The rational for the 
modification of this definition is that using the protocol definition, the SS would be identical to the OLS. 
Has been changed to: 
The protocol defines the censor date for time flare as week 96. The censor date in the SAP is defined as the last possible visit of event, i.e. week 94. 
In addition to the protocol, a modified version for ASDAS-MI is added. 
Change #24 
4.2 Handling of dropouts or missing data The following part has been added: 
Specifically, if a subject withdraws from Part B at any point, they will be considered as having 
not responded to treatment. Therefore, they will be assumed to have experienced a flare during Part B for analysis purposes. 
Change #25 
4.2 Handling of dropouts or missing data 
For all analyses of binary endpoints (sustained remission, ASDAS-MI, ASDAS-CII, ASAS20, 
ASAS40, ASAS5/6, ASAS PR,  BASDAI50 response, IBD-Q remission, IBD-Q response, SF-
36 PCS response, SF-36 MCS response) NRI will be used. Thus, unless mentioned otherwise 
(see Section 3.2.2 for ASAS20, ASAS40, ASAS5/6 and ASAS PR), a subject having missing 
data for the time point assessed will be conservatively counted as a non-responder. This will be done whether the data is missing, the subject discontinued prior to the time point assessed, or the data is considered missing due to start of escape treatment. 
Has been changed to: 
For all analyses of binary endpoints (sustained remission, ASDAS-MI, ASDAS-CII, modified ASDAS- MI, ASAS20, ASAS40, ASAS5/6, ASAS PR, BASDAI50 response, IBD-Q remission, REDACTED COPY The protocol defines the censor date for time flare as week 96. The censor date in the SAP is 
REDACTED COPY The protocol defines the censor date for time flare as week 96. The censor date in the SAP is 
defined as the last possible visit of event, i.e. week 94.
REDACTED COPY defined as the last possible visit of event, i.e. week 94.
tion to the protocol, a modified version for ASDAS
REDACTED COPY tion to the protocol, a modified version for ASDAS
Handling of dropouts or missing dataREDACTED COPY Handling of dropouts or missing data
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The protocol defines the SS as all subjects in the ES who have received at least [ADDRESS_846929] 1 dose 
Blind Period of the study (Part B). The rational for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Blind Period of the study (Part B). The rational for the 
that using the protocol definition, the SS would be identical to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. that using the protocol definition, the SS would be identical to 
The protocol defines the censor date for time flare as week 96. The censor date in the SAP is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The protocol defines the censor date for time flare as week 96. The censor date in the SAP is 
defined as the last possible visit of event, i.e. week 94.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. defined as the last possible visit of event, i.e. week 94.
tion to the protocol, a modified version for ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tion to the protocol, a modified version for ASDAS
Handling of dropouts or missing data
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Handling of dropouts or missing data
The following part has been added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following part has been added:
Specifically, if a subject withdraws from Part B at any point, they will be considered as having 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Specifically, if a subject withdraws from Part B at any point, they will be considered as having 
responded to treatment. Therefore, they will be assumed to have experienced a flare during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. responded to treatment. Therefore, they will be assumed to have experienced a flare during 
Part B for analysis purposes.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B for analysis purposes.
Handling of dropouts or missing data
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Handling of dropouts or missing data
For all analyses of binary endpoints (sustained 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For all analyses of binary endpoints (sustained 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS40, ASAS5/6, ASAS PR,  BASDAI50 response, IBD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS40, ASAS5/6, ASAS PR,  BASDAI50 response, IBD
36 PCS response, SF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 PCS response, SF
(see Section 3.2.2 for ASAS20, ASAS40, ASAS5/6 and ASAS PR), a subject having mis
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (see Section 3.2.2 for ASAS20, ASAS40, ASAS5/6 and ASAS PR), a subject having mis
data for the time point assessed will be conservatively counted as a non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. data for the time point assessed will be conservatively counted as a non
done whether the data is missing, the subject discontinued prior to the time point assessed, or the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. done whether the data is missing, the subject discontinued prior to the time point assessed, or the 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 107 of 149 IBD-Q response, SF-36 PCS response, SF-36 MCS response) NRI will be used. Thus, unless 
mentioned otherwise (see Section  3.2.2 for ASAS20, ASAS40, ASAS5/6 and ASAS PR), a 
subject having missing data for the time point assessed will be conservatively counted as a non-
responder. This will be done whether the data is missing, the subject discontinued prior to the time point assessed, or the data is considered missing due to start of escape treatment. 
Change #26 
4.2 Handling of dropouts or missing data 
 For missing post Week [ADDRESS_846930]-baseline visits 
Has been changed to: 
 For missing post Week 48 Part B assessments,  
 if the subject did not experience a flare in Part B, only carry forward earlier Part B post-
Week 48 values,  
 if the subject did experience a flare in Part B, the assessment at escape week [ADDRESS_846931] 48 
Part B assessments up to the week of flare (the later visit if flare was based on 2 visits), carry forward earlier Part B post-Week [ADDRESS_846932] for the assessments 
after week 72 in Part B (76, 80, 84, 88, 92 and 96) 
Week [ADDRESS_846933]-baseline visits. 
 Assessments during escape treatment will not be carried forward. 
Change #27 
A database lock may be performed and an interim study report may be written, if required. The 
scope of an Interim Analysis will be covered in a separate Analysis Plan. 
Has been changed to: 
4.[ADDRESS_846934] completed Week 48 of Part A. 
Part A data will be reported in corresponding Part A tables and listings. All blinded data will 
remain blinded. In the disposition tables, treatment will remain blinded and be presented 
according to a dummy treatment assignment for Part B. For the listing only open-label data from 
Part A will be included. No CSR will be written. The following assessments will not be included 
in the Interim Analysis:  REDACTED COPY treated as the last assessment in Part B prior to escape treatment. For any missing post [ADDRESS_846935] 48 
Part B assessments up to the week of flare (the later visit if flare was based on 2 visits), 
REDACTED COPY Part B assessments up to the week of flare (the later visit if flare was based on 2 visits), 
Week [ADDRESS_846936] experienced a flare at 
week 72 then the Escape week 0 assessme
REDACTED COPY week 72 then the Escape week 0 assessme
after week 72 in Part B (76, 80, 84, 88, 92 and 96)REDACTED COPY after week 72 in Part B (76, 80, 84, 88, 92 and 96)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For missing post Week [ADDRESS_846937] 48 
Part B assessments up to the week of flare (the later visit if flare was based on 2 visits), 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B assessments up to the week of flare (the later visit if flare was based on 2 visits), 
values. Assessments whilst on escape 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values. Assessments whilst on escape 
treatment are not to be used, therefore the assessment at escape week [ADDRESS_846938] for the assessments 
after week 72 in Part B (76, 80, 84, 88, 92 and 96)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. after week 72 in Part B (76, 80, 84, 88, 92 and 96)
Week [ADDRESS_846939]
database lock may be performed and an interim study report may be written, if required. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. database lock may be performed and an interim study report may be written, if required. The 
scope of an Interim Analysis will be covered in a separate Analysis Plan.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scope of an Interim Analysis will be covered in a separate Analysis Plan.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
Interim analyses and data monitoring
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Interim analyses and data monitoring
The purpose of the interim a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The purpose of the interim a
made for the protocol were correct, and to potentially present the results at scientific meetings. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. made for the protocol were correct, and to potentially present the results at scientific meetings. 
Main focus of this interim analysis will be the efficacy and safety up to Week 48. An interim 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Main focus of this interim analysis will be the efficacy and safety up to Week 48. An interim 
freeze of the database will be performed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. freeze of the database will be performed 
Part A data will be reported in corresponding Part A tables and listings.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A data will be reported in corresponding Part A tables and listings.
remain blinded. In the disposition tables, treatment will remain bl
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. remain blinded. In the disposition tables, treatment will remain bl
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 108 of 149  MRI Efficacy scores (SPARCC (Sacroiliac joint), Spi[INVESTIGATOR_18241]-a in Berlin Modification 
score) 
 Work Productivity Questionnaire 
 EQ-5D- 3L 
 Fecal and serum calprotectin 
 Correlation between calprotectin and IBD, CRP 
 SF36 (domains, PCS, MCS) 
 Resource utilization 
 PK 
 ADAb  
The scope of the Interim Analysis will not be covered in a separate Analysis Plan.  
Change #28 
4.7 Examination of subgroups 
 Overall anti-CZP Ab status (Ab-, Ab+) 
Has been changed to: 
 ADAb status 
Change #29  
5.2 Protocol deviations 
blinded data review meeting 
Has been changed to: 
blinded data evaluation meeting 
Change #30 
The following part  has been added : 
Time since diagnosis of disease and symptom duration will be summarized by [CONTACT_634278] A using the SS, by [CONTACT_634279] B using the SSB. Time since diagnosis will also be categorized into 
≤2 and >2 years, and symptom duration will be categorized into ≤3 and >3 years. 
Time since diagnosis of disease will be defined as: Earliest start date of the medical history of 
any of the preferred terms ‘Axial Spondyloarthritis’,  'Spondyloarthropathy' , 'Ankylosing 
spondylitis' , or 'Spondylitis' minus date of first study medication administration.  If a subject does not have a history of any of the above 4 preferred terms, then the time since diagnosis of disease will be set equal to the symptom duration. 
Symptom duration will be calculated as: 
Date of first study medication administration – Start date of symptoms REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The scope of the Interim Analysis will not be covered in a separate Analysis Plan. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The scope of the Interim Analysis will not be covered in a separate Analysis Plan. 
blinded data evaluation meeting
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. blinded data evaluation meeting
ha
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. has
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sbeen added
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. been added
Time since diagnosis of disease and symptom duration will be summarized by [CONTACT_634284]. Time since diagnosis of disease and symptom duration will be summarized by [CONTACT_634278] A using t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subpopulation and for all subjects combined in Part A using t
all subjects combined in Part B using the SSB. Time since diagnosis will also be categorized into 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. all subjects combined in Part B using the SSB. Time since diagnosis will also be categorized into 
≤2 and >2 years, and symptom duration will be categorized into ≤3 and >3 years.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ≤2 and >2 years, and symptom duration will be categorized into ≤3 and >3 years.
Time since diagnosis of disease will be defi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Time since diagnosis of disease will be defi
any of the preferred terms ‘Axial Spondyloarthritis’, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. any of the preferred terms ‘Axial Spondyloarthritis’, 
spondylitis' , or 'Spondylitis' minus date of first study medication administration.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. spondylitis' , or 'Spondylitis' minus date of first study medication administration.
UCB   [ADDRESS_846940] using the 
following rules (including imputation of partial dates as described for concomitant medications 
in Section 4.2):   
 Subjects with a medical history preferred term of ‘Back pain’, ‘Inflammatory pain’, ‘Spi[INVESTIGATOR_634121]’, ‘Lumbar spi[INVESTIGATOR_185775]’ will use the earliest start date of these symptoms as the start date 
of symptoms. 
 Otherwise, subjects with a preferred term of ‘Axial spondyloarthritis’, 
‘Spondyloarthropathy’, ‘Ankylosing spondylitis’, or ‘Spondylitis’ will use the earliest start 
date of disease as the start date of symptoms 
 Otherwise, the subject’s medical history will be reviewed in the DEM meeting to determine if the subject has evidence of a start date of symptoms or primary disease. 
If the resulting symptom duration is unknown or is below 3 months, the imputed start date will 
be set to 3 months and 1 day prior to the start of treatment so that the symptom duration is 
imputed as 3 months. 
Change #31 
[IP_ADDRESS] Number of uveitis flares, IBD exacerbations and psoriasis exacerbations  
For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations), the 
summary table will be repeated based on the subset of subjects with a current occurrence of the 
event at screening. 
Has been changed to: 
For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations), the summary table will be repeated based on the subset of subjects with a history of occurrence and/or a current occurrence of the event at screening. 
Change #32 
9.2 Immunogenicity 
The number and percentage of subjects with anti-CZP Ab levels above 2.4 units/mL will be 
reported as follows: 
• Number and % of subjects with Ab >2.4 units/mL at the time of each visit 
• Number and % of subjects with Ab >2.4 units/mL at any visit during treatment (not including 
the SFU visit) 
• Number and % of subjects with Ab >2.4 units/mL at any visit including the SFU visit 
Summaries will be done separately in Part A by [CONTACT_634416] B by 
[CONTACT_634417].  Part B summary will not include post-flare assessments. Separate 
summary by [CONTACT_634418] a flare in Part B and 
start escape therapy including only the post- flare assessments.  
For the subgroup of subjects with at least 1 anti-CZP Ab >2.4 units/mL, the time point of occurrence of the first finding will also be displayed. 
Has been changed to: REDACTED COPY For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations), the 
REDACTED COPY For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations), the 
summary table will be repeated based on the subset of subjects with a current occurrence o
REDACTED COPY summary table will be repeated based on the subset of subjects with a current occurrence o
For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations), the 
REDACTED COPY For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations), the 
summary table will be repeated based on the subset of subjects with a history of occurrence REDACTED COPY summary table will be repeated based on the subset of subjects with a history of occurrence 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ‘Ankylosing spondylitis’, or ‘Spondylitis’ will use the earliest start 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ‘Ankylosing spondylitis’, or ‘Spondylitis’ will use the earliest start 
Otherwise, the subject’s medical history will be reviewed in the DEM meeting to determine 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Otherwise, the subject’s medical history will be reviewed in the DEM meeting to determine 
If the resulting symptom duration is unknown or is below 3 months, the imputed start date will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the resulting symptom duration is unknown or is below 3 months, the imputed start date will 
be set to 3 months and 1 day prior to the start of treatment so that the symptom duration is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be set to 3 months and 1 day prior to the start of treatment so that the symptom duration is 
umber of uveitis flares, IBD exacerbations and psoriasis exacerbations 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. umber of uveitis flares, IBD exacerbations and psoriasis exacerbations 
For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations), the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations), the 
summary table will be repeated based on the subset of subjects with a current occurrence o
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summary table will be repeated based on the subset of subjects with a current occurrence o
For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations), the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For each of these events (uveitis flares, IBD exacerbations and psoriasis exacerbations), the 
summary table will be repeated based on the subset of subjects with a history of occurrence 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summary table will be repeated based on the subset of subjects with a history of occurrence 
ence of the event at screening.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ence of the event at screening.
The number and percentage of subjects with anti
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects with anti
Number and % of subjects with Ab >2.4 units/mL at the time of each visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number and % of subjects with Ab >2.4 units/mL at the time of each visit
and % of subjects with Ab >2.4 units/mL at any visit during treatment (not including 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and % of subjects with Ab >2.4 units/mL at any visit during treatment (not including 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the SFU visit)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the SFU visit)
Number and % of subjects with Ab >2.4 units/mL at any visit including the SFU visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number and % of subjects with Ab >2.4 units/mL at any visit including the SFU visit
Summaries will be done separately in Part A by [CONTACT_634419] P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summaries will be done separately in Part A by [CONTACT_634419] P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group using PKSB.  Part B summary will not include post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group using PKSB.  Part B summary will not include post
summary by [CONTACT_634420]. summary by [CONTACT_634421]   [ADDRESS_846941] sample as above the cut point 
(ACP) or below the cut point (BCP). For any ADAb test samples with results that are ACP, a further confirmatory assay will be performed, the results of which will be determined as either ‘confirmed positive’ (CP) or ‘not confirmed positive’ (NCP). 
The following definitions will be applied regarding classification of test samples:. 
 An ADAb status will be confirmed as positive for any sample with an ADAb level that is 
ACP and CP. 
 An ADAb status of negative will be concluded for any sample with an ADAb level that is either BCP or ACP and NCP. 
Confirmed positive samples will be titrated. The dilution factor will be reported. The titer represents the last dilution factor of the sample’s titration series still scoring positive in the screening ADAb assay.. 
Subjects will receive an overall classification, inclusive of Baseline and Post-Baseline results, 
and be classified as follows based on the ADAb assay results:. 
 ADAb negative: no confirmed positive ADAb samples at any of the sampling time points. 
ADAb positive: confirmed positive ADAb samples at one or more sampling time points. 
Summaries will be done separately in Part A by [CONTACT_634422] B by [CONTACT_634417].  Part B summary will not include post-flare 
assessments. Separate summary by [CONTACT_634418] a flare in Part B and start escape therapy including only the post-flare assessments.  
Change #33 
10.2 Adverse events 
(5) will be manually identified by [CONTACT_634394]. No separate tables will be produced. 
Has been changed to: 
(5) will be presented in a stand- alone table which is based on the SMQ = “Demyelination”. The 
SMQ search should include all TEAEs which code to a PT included in Scope=Narrow group within the SMQ. TEAEs which code to a PT included in the Scope=Broad group within the SMQ should be excluded from the search. 
Change #34 
10.2 Adverse events 
 All serious TEAEs by [CONTACT_148274], HLT, and PT (applies to [3], [6] and [7]) 
Has been changed to: REDACTED COPY Subjects will receive an overall classification, inclusive of Baseline and Post
REDACTED COPY Subjects will receive an overall classification, inclusive of Baseline and Post
and be classified as follows based on the ADAb assa
REDACTED COPY and be classified as follows based on the ADAb assa y results:.
REDACTED COPY y results:.
ADAb negative: no confirmed positive ADAb samples at any of the sampling time points.
REDACTED COPY ADAb negative: no confirmed positive ADAb samples at any of the sampling time points.
ADAb positive: confirmed positive ADAb samples at one or more sampling time points.
REDACTED COPY ADAb positive: confirmed positive ADAb samples at one or more sampling time points.
Summaries will be done separately in Part A by [CONTACT_634423] A by [CONTACT_634424] B by [CONTACT_634417].  Part B summary will not include post REDACTED COPY and in Part B by [CONTACT_634417].  Part B summary will not include post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sults of which will be determined as either 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sults of which will be determined as either 
n ADAb level that is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. n ADAb level that is 
An ADAb status of negative will be concluded for any sample with an ADAb level th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. An ADAb status of negative will be concluded for any sample with an ADAb level th
Confirmed positive samples will be titrated. The dilution factor will be reported. The titer 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Confirmed positive samples will be titrated. The dilution factor will be reported. The titer 
last dilution factor of the sample’s titration series still scoring positive in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. last dilution factor of the sample’s titration series still scoring positive in the 
Subjects will receive an overall classification, inclusive of Baseline and Post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subjects will receive an overall classification, inclusive of Baseline and Post
y results:.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. y results:.
ADAb negative: no confirmed positive ADAb samples at any of the sampling time points.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb negative: no confirmed positive ADAb samples at any of the sampling time points.
ADAb positive: confirmed positive ADAb samples at one or more sampling time points.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb positive: confirmed positive ADAb samples at one or more sampling time points.
Summaries will be done separately in Part A by [CONTACT_634425]. Summaries will be done separately in Part A by [CONTACT_634424] B by [CONTACT_634417].  Part B summary will not include post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and in Part B by [CONTACT_634417].  Part B summary will not include post
assessments. Separate summary by [CONTACT_634426]. assessments. Separate summary by [CONTACT_634427] B and start escape therapy including only
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in Part B and start escape therapy including only
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (5) will be manually identified by [CONTACT_634398]. (5) will be manually identified by [CONTACT_634394]. No separate tables will be produced.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tables. No separate tables will be produced.
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
(5) will be presented in a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (5) will be presented in a 
SMQ search should include all TEAEs which code to a PT included in Scope=Narrow group 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SMQ search should include all TEAEs which code to a PT included in Scope=Narrow group 
within the SMQ. TEAEs which code to a PT included in the Scope=Broad group within the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. within the SMQ. TEAEs which code to a PT included in the Scope=Broad group within the 
SMQ should be exc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SMQ should be exc
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 111 of 149  All serious TEAEs by [CONTACT_148274], HLT, and PT (applies to [3], [5], [6] and [7]) 
Change #35 
[IP_ADDRESS] In-patient hospi[INVESTIGATOR_634170]:  
 In case the last visit date is before the start date, then the discharge date for a hospi[INVESTIGATOR_634168] 1. 
12.4 SAP Amendment 2 
Rationale for the amendment 
The main purpose of this amendment is to specify the ADAb  analysis.  The CZP plasma 
concentration and ADAb titer of the patients that did not reach sustained remission are not analyzed , the PKSA as described in the protocol will be removed from the SAP. 
In line with the charter with medical imaging for MRI reads the Section 3.2.4 was updated.  
Further specification for the analysis of flare and time to flare are added (Subject with incorrectly 
identified flared in Part B, seeds for referenced based multiple imputation of ASDAS). The “Last/Withdrawal” visit and the “Last” visit for Escape Part were renamed to 
“Last/Withdrawal Escape” visit and “Last Visit (Week 96 Termination)” for clarification and to indicated that summary statistics consist of different data.   
Definition of Part B Baseline changed and further specification in all baseline definitions were 
added. 
Scoring software for SF-36 was updated calculate all subjects with the same software.  
The model for MMRM was specified for changes to Part A and Part B Baseline. 
Imputation rules for medical history were specified 
Modifications and changes 
Global changes  
The following changes were made throughout the SAP:  
 Censoring point changed from week 94 to week 96 in accordance with the protocol 
 ASDAS-Moderate Disease changed to ASDAS-Low Disease activity (Machado et al. 2018). 
 LOCF analysis are removed from Part B efficacy tables and for selected Part A efficacy 
tables.  
 MMRM will be used instead of ANCOVA based on LOCF for   
 Total spi[INVESTIGATOR_18172] 
 Nocturnal spi[INVESTIGATOR_18172] 
 PtGA DA REDACTED COPY eferenced based multiple imputation 
REDACTED COPY eferenced based multiple imputation 
for Escape Part 
REDACTED COPY for Escape Part 
Last Visit (Week 96 Termination)
REDACTED COPY Last Visit (Week 96 Termination)
indicated that summary statistics consist of different data.
REDACTED COPY indicated that summary statistics consist of different data.
tion of Part B Baseline changed and further specification in all baseline definitions were 
REDACTED COPY tion of Part B Baseline changed and further specification in all baseline definitions were 
[ADDRESS_846942] visit date is before the start date, then the discharge date for a hospi[INVESTIGATOR_634171]. hospi[INVESTIGATOR_634172]. The CZP plasma 
concentration and ADAb titer of the patients that did not reach sustained remission are not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. concentration and ADAb titer of the patients that did not reach sustained remission are not 
, the PKSA as described in the protocol will be removed from the SAP.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , the PKSA as described in the protocol will be removed from the SAP.
In line with the charter with medical imaging for MRI reads the Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In line with the charter with medical imaging for MRI reads the Section 3.2.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.4
Further specification for the analysis of flare and time to flare are added (S
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Further specification for the analysis of flare and time to flare are added (S
eferenced based multiple imputation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eferenced based multiple imputation 
for Escape Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for Escape Part 
Last Visit (Week 96 Termination)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Last Visit (Week 96 Termination)
indicated that summary statistics consist of different data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. indicated that summary statistics consist of different data.
tion of Part B Baseline changed and further specification in all baseline definitions were 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tion of Part B Baseline changed and further specification in all baseline definitions were 
36 was updated
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36 was updated
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. calculate all subjects with the same software. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. calculate all subjects with the same software. 
The model for MMRM was specified for changes to Part A and Part B Basel
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The model for MMRM was specified for changes to Part A and Part B Basel
medical history were specified
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. medical history were specified
Modifications and changes
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Modifications and changes
The following changes were made throughout the SAP: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following changes were made throughout the SAP: 
Censoring point changed from week 9
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Censoring point changed from week 9
ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Moderate Disease c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Moderate Disease c
LOCF analysis are removed from Part B efficacy tables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LOCF analysis are removed from Part B efficacy tables
tables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tables

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 112 of 149  Average of Questions 5 and 6 of the BASDAI concerning morning stiffness 
 SF-36 PCS, MCS, and physical function domain 
 Fatigue NRS 
 ASQoL  
 Exploratory statistical comparisons for WPS will be based on MMRM instead of 
nonparametric bootstrap-t method. 
 List of efficacy variables in section 2.2.[ADDRESS_846943].  
 In addition, for the primary variables and selected outputs the 95% confidence interval (CI) based on the Exact Binomial distribution will be added. 
 Wording from “subject who flare” changed to “subjects who experiencing a flare ”. 
 Subsections in Section 3.2.22 added to provide a better overview about the different imputation methods for sensitivity analysis of the primary endpoint.  
 Selected baseline characteristic tables based on the Open- Label  Set will be repeated for the 
Randomized Set 
Specific changes 
In addition to  the global changes, the following specific changes have been made (formats as 
missing spaces or redundant spaces are not listed, typos ): 
Change #[ADDRESS_846944] of abbreviation 
ASAS Assessment of SpondyloArthritis International Society 
ASAS20, 40 Assessment of SpondyloArthritis International Society 20%, 40% response 
criteria 
AS Ankylosing Spondylitis 
ASDAS- MD Ankylosing Spondylitis Disease Activity Score – Moderate Disease 
ASspI[CONTACT_9268]-a Ankylosing Spondylitis spi[INVESTIGATOR_634173] C hemical  
CPK  Creatine Phosphokinase 
DMARD Disease-modifying antirheumatic drug 
EAIR  Exposure adjusted incidence rate 
EAER Exposure adjusted event rate 
IXRS Interactive voice or web response system 
NRS Numeric R ating Scale REDACTED COPY s based on the
REDACTED COPY s based on the Open
REDACTED COPY Open
REDACTED COPY the global changes, the following specific changes have been made (formats as 
REDACTED COPY the global changes, the following specific changes have been made (formats as 
missing spaces or redundant spaces are not listed
REDACTED COPY missing spaces or redundant spaces are not listed
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and the 
Q remission using Part A Baseline and Part B Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Q remission using Part A Baseline and Part B Baseline 
are removed fr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. are removed fr om the list. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. om the list. 
In addition, for the primary variables and selected outputs the 95% confidence interval (CI) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, for the primary variables and selected outputs the 95% confidence interval (CI) 
subjects who experiencing a flare
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects who experiencing a flare
provide a better overview about the different 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. provide a better overview about the different 
imputation methods for sensitivity analysis of the primary endpoint. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. imputation methods for sensitivity analysis of the primary endpoint. 
Open
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Open -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -Label
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Label
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the global changes, the following specific changes have been made (formats as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the global changes, the following specific changes have been made (formats as 
missing spaces or redundant spaces are not listed
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing spaces or redundant spaces are not listed , typos
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. , typos
Assessment of SpondyloArthritis International Society
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Assessment of SpondyloArthritis International Society
Assessment of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Assessment of 
A
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ankylosing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nkylosing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ankylosing Spondylitis Disease Activity Score 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ankylosing Spondylitis Disease Activity Score 
a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a
CPK
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CPK
DMARD
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. DMARD
EAIR
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. EAIR
UCB   [ADDRESS_846945] 
Has been changed to: 
ASAS Assessment of SpondyloArthritis international Society 
ASAS20, 40 Assessment of SpondyloArthritis international Society 20%, 40% response 
criteria 
AS ankylosing spondylitis 
ASDAS- LD Ankylosing Spondylitis Disease Activity Score – Low Disease activity 
ASspi[CONTACT_9268]-a Ankylosing Spondylitis spi[INVESTIGATOR_634174]-modifying antirheumatic drug 
EAIR  exposure adjusted incidence rate 
EAER exposure adjusted event rate 
IXRS interactive voice or web response system 
NRS numeric rating scale 
WHO- DD World Health Organization Drug Dictionary 
The following abbreviation has been added: 
ANCOVA  analysis of covariance 
BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50% response criteria 
CI confidence interval eCRF  electronic Case Report Form 
FS Flared Set 
H high 
HIV human immunodeficiency virus 
HLA -B27 human leukocyte antigen B27 
HLT  High Level Term 
IGRA interferon-gamma release assay 
L low 
MAR missing at random 
MSR minimum significant ratio 
N normal 
NA not applicable 
PK pharmacokinetics REDACTED COPY interactive voice or web response system
REDACTED COPY interactive voice or web response system
World Health Organization Drug Dictionary
REDACTED COPY World Health Organization Drug Dictionary
The following abbreviation has been added:
REDACTED COPY The following abbreviation has been added:
analysis of covariance
REDACTED COPY analysis of covariance
Bath Ankylosing SpondylitREDACTED COPY Bath Ankylosing Spondylit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Low Disease activity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Low Disease activity
interactive voice or web response system
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. interactive voice or web response system
World Health Organization Drug Dictionary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. World Health Organization Drug Dictionary
Bath Ankylosing Spondylit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Bath Ankylosing Spondylit
confidence interval
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. confidence interval
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eCRF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eCRF
human immunodeficiency virus
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. human immunodeficiency virus
human leukocyte antigen B27
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. human leukocyte antigen B27
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MAR
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MAR
MSR
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MSR
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 114 of 149 PBO  placebo 
PR partial remission 
PT preferred term 
Q2W every 2 weeks 
Q4W every 4 weeks 
r-axSpA  radiographic axial spondyloarthritis 
SOC system organ class 
STIR  short-tau-inversion recovery 
TB tuberculosis 
TE treatment- emergent  
[LOCATION_006] [LOCATION_008] 
VU vertebral units 
The following abbreviation has been removed: 
Ab antibody 
LLN  lower limit of normal  
Change #2 
2.2.2 Pharmacokinetic immunogenicity variables 
[IP_ADDRESS] Pharmacokinetic variables 
Plasma concentrations of CZP will be measured at Baseline and subsequent time points as 
described in Table 5.1 and Table 5.2 of the protocol. These plasma samples may be used 
additionally for analyses of CZP and its constituent moieties using alternative methods.  
[IP_ADDRESS] Immunogenicity variables 
Anti-CZP antibody (ADAb) levels will be assessed at Baseline and subsequent time points as 
described in the protocol. 
Determination of ADAb will be done using a validated screening, confirmation, and titration 
ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) 
assay. The immunogenicity data will be processed according to dedicated Bioanalytical Analysis 
plans. 
Has been changed to: 
2.2.2 Pharmacokinetic, pharmacogenomic and immunogenicity variables 
[IP_ADDRESS] Pharmacokinetic variables 
Plasma concentrations of CZP will be measured at Part A Baseline and subsequent time points as 
described in Table 5.1 and Table 5.2 of the protocol only for subjects randomized into Part B 
(see Section 3.10). These plasma samples may be used additionally for analyses of CZP and its 
constituent moieties using alternative methods.  REDACTED COPY Pharmacokinetic immunogenicity variables
REDACTED COPY Pharmacokinetic immunogenicity variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic immunogenicity variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pharmacokinetic immunogenicity variables
Plasma concentrations of CZP will be measured at Baseline and subsequent time points as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Plasma concentrations of CZP will be measured at Baseline and subsequent time points as 
described in Table 5.1 and Table 5.2 of the protocol. These plasma samples may be used 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. described in Table 5.1 and Table 5.2 of the protocol. These plasma samples may be used 
additionally for analyses of CZP and its constituent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. additionally for analyses of CZP and its constituent 
Immunogenicity variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Immunogenicity variables
CZP antibody (ADAb) levels will be assessed at Baseline and subsequent time points as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP antibody (ADAb) levels will be assessed at Baseline and subsequent time points as 
described in the protocol.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. described in the protocol.
Determination of ADAb will be done using a validated screening, conf
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Determination of ADAb will be done using a validated screening, conf
ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) 
assay. The immunogenicity data will be processed according to dedicated Bioanalytical Analysis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assay. The immunogenicity data will be processed according to dedicated Bioanalytical Analysis 
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
2.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2.2.2
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 115 of 149 [IP_ADDRESS] Biomarkers 
Any a nalysis for the biomarker will be described in a separate document.  
[IP_ADDRESS] Pharmacogenomic variables Analysis for the pharmacogenomic will be described in a separate document. [IP_ADDRESS] Immunogenicity variables 
Anti-CZP antibody (ADAb) levels will be assessed at Part A Baseline and subsequent time 
points as described in the protocol. 
Determination of ADAb will be done using a validated screening, confirmation, and titration 
ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) assay. The NAb will be not part of the CSR. The immunogenicity samples will be processed 
according to dedicated Bioanalytical Analysis plans. 
Change #3 
3.1 General presentation of summaries and analyses 
The following parts ha ve been added: 
In addition, for the primary variables and selected outputs the 95% confidence interval (CI) 
based on the Exact Binomial distribution will be presented. 
… 
The study design has three different periods: Part A, Part B and Escape Part. The outputs will be 
presented for each period. Summaries for Part A will be presented by [CONTACT_634184]. 
Summaries for Part B will be presented by [CONTACT_634185]-flare assessments 
in the subset of subjects who experiencing a flare in Part B and start escape therapy. For the subset of subjects who experiencing a flare in Part B and start escape therapy, separate summaries will be produced for the Escape Part. 
Change #4 
3.2.2 ASAS20, ASAS40, ASAS 5/6 response, and ASAS Partial Remission 
The following part has been added:  
The lateral lumbar flexion value is taken as the mean of left and right assessment values and 
improvement is a ≥20% increase. Improvement in CRP is a ≥20% decrease.  
Change #5 
3.2.4 MRI assessments 
Magnetic resonance imaging of the spi[INVESTIGATOR_634169], 
Week 48, Week 96, or WD Visit if MRI was performed more than 12 weeks prior to WD. MRI will be assessed centrally and scoring will be done by 2 independent readers, who are blinded to 
both the order of the scans and to the treatment group, using a previously reported scoring 
system. In addition, a single reader assessment will be performed for change from Baseline (Week 48) evaluation in the MRI scores for all subjects that entered Part A. Two different MRI scores will be used for analysis. REDACTED COPY In addition, for the primary variables and selected outputs the 95% confide
REDACTED COPY In addition, for the primary variables and selected outputs the 95% confide
based on the Exact Binomial distribution will be presented.
REDACTED COPY based on the Exact Binomial distribution will be presented.
The study design has three different periods: Part A, Part B and Escape Part. The outputs will be 
REDACTED COPY The study design has three different periods: Part A, Part B and Escape Part. The outputs will be 
presented for each period. Summaries for Part A will be presented by [CONTACT_634428]. Summaries for Part A will be presented by [CONTACT_634429] B will be presented by [CONTACT_634186] B will be presented by [CONTACT_634430] a flare in Part B and start escape therapy. For the REDACTED COPY in the subset of subjects who experiencing a flare in Part B and start escape therapy. For the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Determination of ADAb will be done using a validated screening, confirmation, and titration 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Determination of ADAb will be done using a validated screening, confirmation, and titration 
ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb bridging assay, with potential further characterization by a neutralizing antibody (NAb) 
ity samples will be processed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ity samples will be processed 
In addition, for the primary variables and selected outputs the 95% confide
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, for the primary variables and selected outputs the 95% confide
based on the Exact Binomial distribution will be presented.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based on the Exact Binomial distribution will be presented.
The study design has three different periods: Part A, Part B and Escape Part. The outputs will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The study design has three different periods: Part A, Part B and Escape Part. The outputs will be 
presented for each period. Summaries for Part A will be presented by [CONTACT_634431]. presented for each period. Summaries for Part A will be presented by [CONTACT_634429] B will be presented by [CONTACT_634188]. Summaries for Part B will be presented by [CONTACT_634430] a flare in Part B and start escape therapy. For the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in the subset of subjects who experiencing a flare in Part B and start escape therapy. For the 
subset of subjects who experiencing a flare in Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subset of subjects who experiencing a flare in Part B 
summaries will be produced for the Escape Part.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summaries will be produced for the Escape Part.
ASAS20, ASAS40, ASAS 5/6 response, and ASAS Partial Remission
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS20, ASAS40, ASAS 5/6 response, and ASAS Partial Remission
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following part has been added
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following part has been added
The lateral lumbar flexion value is taken as the mean of left and right assessment values and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The lateral lumbar flexion value is taken as the mean of left and right assessment values and 
improvement is a ≥20% increase. Improvement in CRP is a ≥20% decrease. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. improvement is a ≥20% increase. Improvement in CRP is a ≥20% decrease. 
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change # 5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 5
MRI assessments
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MRI assessments
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Magnetic resonance imaging of the spi[INVESTIGATOR_634175]. Magnetic resonance imaging of the spi[INVESTIGATOR_634176] 48, Week 96, or WD Visit if MRI was performed more than 12 weeks prior to WD. MRI 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 48, Week 96, or WD Visit if MRI was performed more than 12 weeks prior to WD. MRI 
will be assessed centrally and scoring will be done by 2 independent readers, who are blinded to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be assessed centrally and scoring will be done by 2 independent readers, who are blinded to 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 116 of 149 The SPARCC scoring method for lesions found on the MRI is based on an abnormal increased 
signal on the short- tau-inversion recovery (STIR) sequence, representing bone marrow edema 
(defined as an increased signal in bone marrow on a T2-weighted sequence, reflecting an 
increased concentration of “free water” related to a bone lesion). Each SIJ is divided into 4 
quadrants: upper iliac, lower iliac, upper sacral, and lower sacral. The presence of increased 
signal on STIR in each of these 4 q uadrants are scored on a dichotomous basis, where 1 = 
increased signal and 0 = normal signal. Joints that include a lesion exhibiting intense signal are 
each given an additional score of 1 per slice that demonstrated this feature. Similarly, each joint 
that included a lesion demonstrating continuous increased signal of depth greater or equal 1 cm from the articular surface is also given an additional score of 1. The scoring is repeated in each of 6 consecutive coronal slices. Total SIJ SPARCC scores can range from 0 to 72. 
The Berlin modification of the ASspi[CONTACT_9268]-a is a scoring system with a concentration on STIR 
sequences without other fat saturation techniques. This scoring method quantifies active changes 
in 23 vertebral units (VU) of the spi[INVESTIGATOR_050] (from C2 to S1). A VU is defined as the region between [ADDRESS_846946] level of inflammation in a particular VU. Total spi[INVESTIGATOR_18241]-a score in 
the Berlin modification can range from 0 to 69. 
… 
In case of out of window images/scores regarding the visit schedule, the following rules will 
apply: 
Has been changed to: 
Magnetic resonance imaging of the spi[INVESTIGATOR_634169], Week 48, Week 96, or WD Visit if the previous MRI was performed more than 12 weeks prior to WD. In the Escape Part it will be also performed at Escape Week 0 and 12. MRI will be assessed 
centrally and scoring will be done according to the imaging charter by 2 independent readers, 
who are blinded to both the order of the scans and to the treatment group, using a previously reported scoring system. A single reader assessment will be performed for change from Baseline 
(Week 48) evaluation in the MRI scores for all subjects that entered Part A. A double reader 
assessment will be performed for subjects entering Part B. The analysis will use the average of the scores from the [ADDRESS_846947] independent review. 
Whenever an adjudication, is present the average score across all 3 reviewers will be used for analysis. In addition, a single reader assessment will be performed for change from Baseline 
(Week 48) evaluation in the MRI scores for all subjects that entered Part A. Two different MRI 
scores will be used for analysis (SPARCC, Berlin modification of the ASspi[CONTACT_9268]-a). 
The SPARCC scoring method for lesions found on the MRI is based on an abnormal increased 
signal on the short- tau-inversion recovery (STIR) sequence, representing bone marrow edema 
(defined as an increased signal in bone marrow on a T2-weighted sequence, reflecting an 
increased concentration of “free water” related to a bone lesion). Each SIJ is divided into 4 
quadrants and will be assessed for left and right: upper iliac, lower iliac, upper sacral, and lower 
sacral. The presence of increased signal on STIR in each of these 4 quadrants are scored on a dichotomous basis, where 1 = increased signal and 0 = normal signal. Joints that include a lesion REDACTED COPY In case of out of window images/scores regarding the visit 
REDACTED COPY In case of out of window images/scores regarding the visit 
esonance imaging of the spi[INVESTIGATOR_634169], REDACTED COPY esonance imaging of the spi[INVESTIGATOR_634169], 
Week 48, Week 96, or WD Visit if the previous MRI was performed more than 12 weeks prior to REDACTED COPY Week 48, Week 96, or WD Visit if the previous MRI was performed more than 12 weeks prior to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. increased signal and 0 = normal signal. Joints that include a lesion exhibiting intense signal are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. increased signal and 0 = normal signal. Joints that include a lesion exhibiting intense signal are 
each given an additional score of 1 per slice that demonstrated this feature. Similarly, each joint 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. each given an additional score of 1 per slice that demonstrated this feature. Similarly, each joint 
t included a lesion demonstrating continuous increased signal of depth greater or equal 1 cm 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. t included a lesion demonstrating continuous increased signal of depth greater or equal 1 cm 
from the articular surface is also given an additional score of 1. The scoring is repeated in each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from the articular surface is also given an additional score of 1. The scoring is repeated in each 
a is a scoring system with a concentration on STIR 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a is a scoring system with a concentration on STIR 
sequences without other fat saturation techniques. This scoring method quantifies active changes 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sequences without other fat saturation techniques. This scoring method quantifies active changes 
S1). A VU is defined as the region between 2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. S1). A VU is defined as the region between 2 
virtual lines through the middle of each vertebra. Active inflammation is scored by [CONTACT_634432]. virtual lines through the middle of each vertebra. Active inflammation is scored by [CONTACT_634433] 0 to 3 in 1 dimension on 1 or more consecutive slices that 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. degree of bone marrow edema from 0 to 3 in 1 dimension on 1 or more consecutive slices that 
level of inflammation in a particular VU. Total spi[INVESTIGATOR_634105]. level of inflammation in a particular VU. Total spi[INVESTIGATOR_634177]/scores regarding the visit 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In case of out of window images/scores regarding the visit schedule
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. schedule
esonance imaging of the spi[INVESTIGATOR_634169], 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. esonance imaging of the spi[INVESTIGATOR_634169], 
Week 48, Week 96, or WD Visit if the previous MRI was performed more than 12 weeks prior to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 48, Week 96, or WD Visit if the previous MRI was performed more than 12 weeks prior to 
WD. In the Escape Part it will be also performed at Escape Week 0 and 12. MRI wi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. WD. In the Escape Part it will be also performed at Escape Week 0 and 12. MRI wi
centrally and scoring will be done according to the imaging charter by 2 independent readers, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. centrally and scoring will be done according to the imaging charter by 2 independent readers, 
who are blinded to both the order of the scans and to the treatment group, using a previously 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. who are blinded to both the order of the scans and to the treatment group, using a previously 
reported scoring system. A single reader assessment w
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. reported scoring system. A single reader assessment w
(Week 48) evaluation in the MRI scores for all subjects that entered Part A. A double reader 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (Week 48) evaluation in the MRI scores for all subjects that entered Part A. A double reader 
assessment will be performed for subjects entering Part B. The analysis will use the average of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessment will be performed for subjects entering Part B. The analysis will use the average of 
the scores from the [ADDRESS_846948] independent review. 
Whenever an adjudication, is present the average score across all 3 reviewers will be us
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Whenever an adjudication, is present the average score across all 3 reviewers will be us
analysis. In addition, a single reader assessment will be performed for change from Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. analysis. In addition, a single reader assessment will be performed for change from Baseline 
(Week 48) evaluation in the MRI scores for all subjects that entered Part A. Two different MRI 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (Week 48) evaluation in the MRI scores for all subjects that entered Part A. Two different MRI 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores will be used for analysis (SPARCC, Berlin modification
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scores will be used for analysis (SPARCC, Berlin modification
The SPARCC scoring method for lesions found on the MRI is based on an abnormal increased 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The SPARCC scoring method for lesions found on the MRI is based on an abnormal increased 
signal on the short
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. signal on the short
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 117 of 149 exhibiting intense signal are each given an additional score of 1 per slice that demonstrated this 
feature. Similarly, each joint that included a lesion demonstrating continuous increased signal of 
depth greater or equal 1 cm from the articular surface is also given an additional score of 1. The scoring is repeated in each of 6 consecutive coronal slices. Total SIJ SPARCC scores can range from 0 to 72. 
The Berlin modification of the ASspi[CONTACT_9268]-a is a scoring system with a concentration on STIR 
sequences without other fat saturation techniques. This scoring method quantifies active changes 
in 23 vertebral units (VU) of the spi[INVESTIGATOR_050] (from C2 to S1) or 24 VUs if transitional vertebra is 
present. If a transitional vertebra is present L5/L6 and L6/SI will be assessed instead L5/SI. A VU is defined as the region between [ADDRESS_846949] level of inflammation in a particular 
VU.  
Total spi[INVESTIGATOR_18241]-a score in the Berlin modification can range from 0 to 69. This score will 
increase if there are transitional vertebrae. 
… In case of out of window images/scores regarding the visit date, the following rules will apply: 
Change #6 
3.2.7 Ankylosing Spondylitis Disease Activity Score (ASDAS) The following part has been added:  
For Part A Baseline derivation of the ASDAS score the latest value prior to treatment will be 
used for each component. It will be not required that all components are measured at the same 
visit, e.g. PtGADA is available only at screening while the other components are available at 
Baseline then the ASDAS score will be derived combining the screening value of PtGADA and the baseline value of the other components.  
For Part B Baseline derivation of the ASDAS score the latest value prior to randomization will 
be used for each component. It will be not required that all components are measured at the same visit. 
For Flare Baseline derivation of the ASDAS score the latest value prior to first injection in 
Escape Part will be used for each component. It will be not required that all components are 
measured at the same visit. 
Change #7 
3.2.11 Short-Form 36-item Health Survey (SF-36) 
For the calculation of the SF-36 domain scores and the component summaries PCS and MCS, the scoring software QualityMetric Health Outcomes(tm) Scoring Software 4.5 will be used. The norm-based scores (based on the US general population) will be utilized for analysis. 
Has been changed to: REDACTED COPY Ankylosing Spondylitis Disease Activity
REDACTED COPY Ankylosing Spondylitis Disease Activity Score (ASDAS)
REDACTED COPY Score (ASDAS)
For Part A Baseline derivation of the ASDAS score the latest value prior to treatment will be 
REDACTED COPY For Part A Baseline derivation of the ASDAS score the latest value prior to treatment will be 
used for each component. It will be not required that all components are measured at the same REDACTED COPY used for each component. It will be not required that all components are measured at the same 
A is available only at screening while the other components are available at REDACTED COPY A is available only at screening while the other components are available at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sequences without other fat saturation techniques. This scoring method quantifies active changes 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sequences without other fat saturation techniques. This scoring method quantifies active changes 
ebral units (VU) of the spi[INVESTIGATOR_050] (from C2 to S1) or 24 VUs if transitional vertebra is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ebral units (VU) of the spi[INVESTIGATOR_050] (from C2 to S1) or 24 VUs if transitional vertebra is 
present. If a transitional vertebra is present L5/L6 and L6/SI will be assessed instead L5/SI. A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. present. If a transitional vertebra is present L5/L6 and L6/SI will be assessed instead L5/SI. A 
ach vertebra. Active 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ach vertebra. Active 
inflammation is scored by [CONTACT_634434] [ADDRESS_846950] level of inflammation in a particular 
in modification can range from 0 to 69. This score will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in modification can range from 0 to 69. This score will 
In case of out of window images/scores regarding the visit date, the following rules will apply:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In case of out of window images/scores regarding the visit date, the following rules will apply:
Score (ASDAS)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Score (ASDAS)
For Part A Baseline derivation of the ASDAS score the latest value prior to treatment will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For Part A Baseline derivation of the ASDAS score the latest value prior to treatment will be 
used for each component. It will be not required that all components are measured at the same 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. used for each component. It will be not required that all components are measured at the same 
A is available only at screening while the other components are available at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A is available only at screening while the other components are available at 
Baseline then the ASDAS score will be derived combining the screening value of PtGADA and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline then the ASDAS score will be derived combining the screening value of PtGADA and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the baseline value of the other components. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the baseline value of the other components. 
For Part B Baseline derivation of the ASDAS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For Part B Baseline derivation of the ASDAS 
be used for each component. It will be not required that all components are measured at the same 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be used for each component. It will be not required that all components are measured at the same 
Baseline derivation of the ASDAS score the latest value prior to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline derivation of the ASDAS score the latest value prior to 
will be used for each component. It will be not required that all components are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used for each component. It will be not required that all components are 
measured at the same visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. measured at the same visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #7
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #7
3.2.11
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 3.2.11 Short
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Short
For the calculation of the SF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For the calculation of the SF
scoring software QualityMetric Health Outcomes(tm) Scoring Software 4.5 will be used. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. scoring software QualityMetric Health Outcomes(tm) Scoring Software 4.5 will be used. The 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 118 of 149 For the calculation of the SF-36 domain scores and the component summaries PCS and MCS, the 
scoring software Optum’s PRO CoRE will be used. The norm-based scores (based on the US 
2009 general population) will be utilized for analysis.  
Change #8 
3.2.22 Flare 
The following part has been added:  
If a subject was incorrectly identified as flared in Part B at any point in Part B due the to late data 
entry in IXRS aand went to escape Part B, then the subject will be considered to have 
experienced a flare.  
Change #9 
Multiple imputation of ASDAS 
Has been changed to: 
[IP_ADDRESS] Referenced based multiple imputation of ASDAS 
Change #10  
[IP_ADDRESS] Referenced based multiple imputation of ASDAS 
The following seeds have been added: 
(seed will be 221). (seeds will be 51, 52, 53, 54, 55, 56, 57, 58, 59, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 
520, 221). 
Change #11  
3.2.23 Time to flare 
The following parts ha ve been added: 
 Subjects who discontinue the study without Withdrawal Visit will be treated as having 
experienced a flare at the next planned ASDAS visit. The final available ASDAS score date + 32 (4 Weeks + visit window) will be used as flare date. If Week [ADDRESS_846951] 
ASDAS visits, Week 48/Week 50 ASDAS date + 18. (2 weeks + visit window) will be used 
as flare date. 
  …, if the last ASDAS visit date is not equal with the withdrawal date. If the withdrawal date 
is equal with the with the last ASDAS visit date, the same approach as for subject without 
Withdrawal Visit will be used for deriving the flare date. 
… 
 If the date of the second missing ASDAS visit is available, the date of the visit will be used.  
 If the date of the second missing ASDAS visit is not available, the last ASDAS date + 60 (8 weeks +visit window) will be used as flare date. If Week [ADDRESS_846952] ASDAS visits, Week 48 ASDAS date + 32. (4 weeks + visit window) will be used as flare date. If Week REDACTED COPY Referenced based multiple imputation of ASDAS
REDACTED COPY Referenced based multiple imputation of ASDAS
(seeds will be 51, 52, 53, 54, 55, 56, 57, 58, 59, 510, 511, 512, 513, 
REDACTED COPY (seeds will be 51, 52, 53, 54, 55, 56, 57, 58, 59, 510, 511, 512, 513, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to late data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. to late data 
Referenced based multiple imputation of ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Referenced based multiple imputation of ASDAS
(seeds will be 51, 52, 53, 54, 55, 56, 57, 58, 59, 510, 511, 512, 513, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (seeds will be 51, 52, 53, 54, 55, 56, 57, 58, 59, 510, 511, 512, 513, 
been added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. been added:
Subjects who discontinue the study without Withdrawal Visit will be treated as having 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subjects who discontinue the study without Withdrawal Visit will be treated as having 
experienced a flare at the next planned ASDAS visit. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. experienced a flare at the next planned ASDAS visit. The 
+ 32 (4 Weeks + visit window) will be used as flare date. If Week [ADDRESS_846953] 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. + 32 (4 Weeks + visit window) will be used as flare date. If Week [ADDRESS_846954] 
ASDAS visits, Week 48/Week 50 ASDAS date + 18. (2 weeks + visit window) will be used 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS visits, Week 48/Week 50 ASDAS date + 18. (2 weeks + visit window) will be used 
as flare date.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as flare date.
…, if the last ASDAS visit date i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. …, if the last ASDAS visit date i
is equal with the with the last ASDAS visit date, the same approach as for subject without 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is equal with the with the last ASDAS visit date, the same approach as for subject without 
Withdrawal Visit will be used for deriving the flare date.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Withdrawal Visit will be used for deriving the flare date.
…
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. …
UCB   [ADDRESS_846955] ASDAS visits, Week 50 ASDAS date + 46. (6 weeks + visit window) will 
be used as flare date. 
Change #12  
3.2.23 Time to flare 
The following overview has been added: 
Overview of different approaches for flare definition:  
Table 12.2 Flare Definition and Time to Flare 
Reason for flare Event/Censoring 
day Non-
responder 
imputation  Observed 
Case Alternative handling of 
premature 
withdrawal 
ASDAS >=2.1 at 2 consecutive visits Day of 2nd ASDAS  Event Event Event 
ASDAS >3.[ADDRESS_846956] discontinued study during Part B due to other 
reason Day of 
discontinuation not 
equal ASDAS visit Event Censored Censored 
No Flare (completed Part B) Week 96 Censored Censored Censored 
Incorrectly ‘flared’ due to delay in data entry 2nd ASDAS visit or 
planned date for the 
2nd ASDAS visit if 
missing  Event Censored Censored 
Change #13  
3.2.26 Anti-CZP antibody status 
Determination of ADAb will be done using a validated screening, confirmation, and titration 
ADAb bridging assay. The immunogenicity data will be analyzed according to dedicated 
Bioanalytical Analysis plans. 
Has been changed to: 
Determination of ADAb will be done using a validated screening, confirmation, and titration ADAb bridging assay, with potential further characterization by a NAb assay. The immunogenicity data will be processed analyzed according to dedicated Bioanalytical Analysis plans. REDACTED COPY Event
REDACTED COPY Event
REDACTED COPY discontinuation not 
REDACTED COPY discontinuation not 
equal ASDAS visit
REDACTED COPY equal ASDAS visit
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY discontinuation not REDACTED COPY discontinuation not REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Alternative 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Alternative 
handling of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. handling of 
premature 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. premature 
withdrawal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. withdrawal
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Censored
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Censored
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. equal ASDAS visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. equal ASDAS visitEvent
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. discontinuation not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. discontinuation not 
equal ASDAS visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. equal ASDAS visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 96
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 96
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2nd ASDAS visit 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 2nd ASDAS visit 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change # 13
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 13
Anti
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Anti-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -CZP antibody status
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP antibody status
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Determination of ADAb will be done using a validated screening, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Determination of ADAb will be done using a validated screening, 
ADAb bridging assay. The immunogenicity data will be analyzed according to dedicated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb bridging assay. The immunogenicity data will be analyzed according to dedicated 
Bioanalytical Analysis plans.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Bioanalytical Analysis plans.
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 120 of 149 Change #14 
3.2.27 Modified [LOCATION_001] criteria 
Subjects will be defined as having AS or non-radiographic axial spondyloarthritis (nr-axSpA) in 
this study based solely on the radiologic criterion. If a subject has sacroiliitis grade ≥[ADDRESS_846957] AS/be 
modified [LOCATION_001] (mNY) positive, otherwise they will be considered to have nr-axSPA/be mNY negative. 
The mNY classification will determined at Screening. MRI will be assessed centrally and by 2 
independent readers. If the results from the readers are different, then the result of the adjudicator will be used. 
Has been changed to: 
3.2.27 Modified [LOCATION_001] criteria 
Subjects will be defined as having radiographic axial spondyloarthritis (r-axSpA) or non-
radiographic axial spondyloarthritis (nr-axSpA) in this study based solely on the radiologic 
criterion. For simplification, r-axSpA will be referred to AS in the SAP and statistical outputs. If 
a subject has sacroiliitis grade ≥[ADDRESS_846958] AS/be modified [LOCATION_001] (mNY) positive, otherwise they will be considered to have nr-axSPA/be mNY negative. 
The mNY classification will be determined at Screening. MRI will be assessed centrally and by 2 
independent readers. If the results from the readers are different, then the result of the adjudicator will be used as the adjudicator's decision was considered final for the inclusion of the subject in 
the study. If the modified NY criteria data recorded in the ‘Modified NY Criteria for Ankylosing 
Spondylitis’ eCRF differs from the MRI result reported by [CONTACT_9559], the result from central review will be used in summary table instead of the result reported in the eCRF.  
Change #15 
The following section has been added: 
3.2.28 Modified ASAS Classification Criteria  
If the results for CRP, human leukocyte antigen B27 ( HLA -B27) or MRI on the ‘Modified 
ASAS Classification Criteria for AS’ eCRF differ from central laboratory results and/or the MRI 
result from central review, respectively, the result of the central laboratory and/or central review of MRI will be used in the summary table for modified ASAS classification criteria 
Change #[ADDRESS_846959] been added: 
If a subject withdraws early during Part A but does not have a Withdrawal Visit in Part A, safety 
and efficacy data recorded at either the date of the last scheduled or unscheduled visit during the 
treatment Period, whichever is later, will be included in summaries of “Early Withdrawal” visit. 
Only post Part A Baseline assessments will be included in the “Early Withdrawal” visit. 
… REDACTED COPY the subject will be considered to have AS/be modified [LOCATION_001] (mNY) positive, otherwise 
REDACTED COPY the subject will be considered to have AS/be modified [LOCATION_001] (mNY) positive, otherwise 
axSPA/be mNY negative.
REDACTED COPY axSPA/be mNY negative.
The mNY classification will be determined at Screening. MRI will be assessed centrally and by 2 
REDACTED COPY The mNY classification will be determined at Screening. MRI will be assessed centrally and by 2 
readers. If the results from the readers are different, then the result of the adjudicator 
REDACTED COPY readers. If the results from the readers are different, then the result of the adjudicator 
will be used as the adjudicator's decision was considered final for the inclusion of the subject in 
REDACTED COPY will be used as the adjudicator's decision was considered final for the inclusion of the subject in 
the study. If the modified NY criteria data recorded in the ‘Modi
REDACTED COPY the study. If the modified NY criteria data recorded in the ‘Modi
Spondylitis’ eCRF differs from the MRI result reported by [CONTACT_9559], the result from central REDACTED COPY Spondylitis’ eCRF differs from the MRI result reported by [CONTACT_9559], the result from central 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The mNY classification will determined at Screening. MRI will be assessed centrally and by 2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The mNY classification will determined at Screening. MRI will be assessed centrally and by 2 
eaders are different, then the result of the adjudicator 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. eaders are different, then the result of the adjudicator 
Subjects will be defined as having radiographic axial spondyloarthritis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subjects will be defined as having radiographic axial spondyloarthritis (r
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (r-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -axSpA) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA) 
axSpA) in this study based solely on the radiologic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA) in this study based solely on the radiologic 
axSpA will be referred to AS in the SAP and statistical outputs. If 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSpA will be referred to AS in the SAP and statistical outputs. If 
a subject has sacroiliitis grade ≥[ADDRESS_846960] has sacroiliitis grade ≥[ADDRESS_846961] AS/be modified [LOCATION_001] (mNY) positive, otherwise 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the subject will be considered to have AS/be modified [LOCATION_001] (mNY) positive, otherwise 
axSPA/be mNY negative.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axSPA/be mNY negative.
The mNY classification will be determined at Screening. MRI will be assessed centrally and by 2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The mNY classification will be determined at Screening. MRI will be assessed centrally and by 2 
readers. If the results from the readers are different, then the result of the adjudicator 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. readers. If the results from the readers are different, then the result of the adjudicator 
will be used as the adjudicator's decision was considered final for the inclusion of the subject in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used as the adjudicator's decision was considered final for the inclusion of the subject in 
the study. If the modified NY criteria data recorded in the ‘Modi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the study. If the modified NY criteria data recorded in the ‘Modi
Spondylitis’ eCRF differs from the MRI result reported by [CONTACT_9559], the result from central 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Spondylitis’ eCRF differs from the MRI result reported by [CONTACT_9559], the result from central 
review will be used in summary table instead of the result reported in the eCRF. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. review will be used in summary table instead of the result reported in the eCRF. 
The following section has been 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following section has been added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. added:
Modified ASAS Classification Criteria 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Modified ASAS Classification Criteria 
If the results for CRP, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the results for CRP, human leukocyte antigen B27
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. human leukocyte antigen B27
ASAS Classification Criteria for AS’ eCRF differ from central laboratory results and/or the MRI 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASAS Classification Criteria for AS’ eCRF differ from central laboratory results and/or the MRI 
result from central r
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. result from central r
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of MRI will be used in the summary table for modified ASAS classification criteria
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. of MRI will be used in the summary table for modified ASAS classification criteria
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change # [ADDRESS_846962] been added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following parts have been added:
UCB   [ADDRESS_846963] visit prior to escape medication (e.g. Escape Week 0) 
will be included in the summaries of the “Last/Withdrawal Visit”. Only post Part B Baseline 
assessments will be included in the “Last/Withdrawal Visit”.  
… Only post Flare baseline assessments will be included in the “Last/Withdrawal Escape” visit. 
… 
PK and ADA 
For ADA data the same approach as for the efficacy analysis will be used, i.e for withdrawals to 
assign the withdrawal value to the next scheduled visit for the assessment. However, for PK analysis the withdrawal PK result will be only included in summaries of “Withdrawal” and the 
“Withdrawal Escape” and not assigned to the next scheduled visit. Furthermore, the Withdrawal 
summaries visit will not summarize any last visit assessments.  
In addition, in the case that a sample is collected one or more days following the scheduled visit 
date, in which the drug was administered, the PK results for that sample will not be summarized 
as part of that visit. 
Change #[ADDRESS_846964] been added: 
If a Part A Baseline measurement is missing or not collected, and a Screening value is available, 
the Screening value will be utilized as Part A Baseline instead. If no measurement is available 
prior to receiving study medication in Part A, the Part A Baseline value is treated as missing.  
… 
If a Part B Baseline measurement is missing or not collected, and a post-Baseline Part A value is 
available, the post-Baseline Part A value will be utilized as Part B Baseline instead. If no post-
Baseline Part A measurement is available prior to randomization date, the Part B Baseline value 
is treated as missing. If a subject does not receive study medication in Part B, the last available 
post-Baseline Part A measurement will be used as Part B Baseline.    
… 
If a Flare Baseline measurement is missing or not collected, and a post-Baseline Part B value is 
available, the post-Baseline Part B value will be utilized as Flare Baseline instead. If no post-
Baseline Part B measurement is available prior to receiving study medication in Escape Part, the 
Flare Baseline value is treated as missing. If a subject does not receive study medication in 
Escape Part, the last available post-Baseline Part B measurement will be used as Flare Baseline.    
… 
When the date of first dose is derived, it should be based on the first injection of study treatment, 
regardless of whether it is an active treatment. 
Change #18 
3.4 Definition of Baseline values REDACTED COPY ment is missing or not collected, and a Screening value is available, 
REDACTED COPY ment is missing or not collected, and a Screening value is available, 
the Screening value will be utilized as Part A Baseline instead. If no measurement is available 
REDACTED COPY the Screening value will be utilized as Part A Baseline instead. If no measurement is available 
prior to receiving study medication in Part A, the Part A Baseline value is treated as misREDACTED COPY prior to receiving study medication in Part A, the Part A Baseline value is treated as mis
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For ADA data the same approach as for the efficacy analysis will be used, i.e for withdrawals to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For ADA data the same approach as for the efficacy analysis will be used, i.e for withdrawals to 
assign the withdrawal value to the next scheduled visit for the assessment. However, for PK 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assign the withdrawal value to the next scheduled visit for the assessment. However, for PK 
s of “Withdrawal” and the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. s of “Withdrawal” and the 
“Withdrawal Escape” and not assigned to the next scheduled visit. Furthermore, the Withdrawal 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. “Withdrawal Escape” and not assigned to the next scheduled visit. Furthermore, the Withdrawal 
lowing the scheduled visit 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. lowing the scheduled visit 
date, in which the drug was administered, the PK results for that sample will not be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. date, in which the drug was administered, the PK results for that sample will not be summarized 
ment is missing or not collected, and a Screening value is available, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ment is missing or not collected, and a Screening value is available, 
the Screening value will be utilized as Part A Baseline instead. If no measurement is available 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the Screening value will be utilized as Part A Baseline instead. If no measurement is available 
prior to receiving study medication in Part A, the Part A Baseline value is treated as mis
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. prior to receiving study medication in Part A, the Part A Baseline value is treated as mis
If a Part B Baseline measurement is missing or not collected, and a post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If a Part B Baseline measurement is missing or not collected, and a post
Baseline Part A value will be utilized as Part B Baseline instead. If no post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline Part A value will be utilized as Part B Baseline instead. If no post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline Part A measurement is available prior to r
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline Part A measurement is available prior to r
is treated as missing. If a subject does not receive study medication in Part B, the last available 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is treated as missing. If a subject does not receive study medication in Part B, the last available 
Baseline Part A measurement will be used as Part B Baseline.   
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline Part A measurement will be used as Part B Baseline.   
If a Flare Baseline measurement is missi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If a Flare Baseline measurement is missi
available, the post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. available, the post
Baseline Part B measurement is available prior to receiving study medication in Escape Part, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline Part B measurement is available prior to receiving study medication in Escape Part, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Flare
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Flare
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline value is treated as missing. If a subject does not receive study medication in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline value is treated as missing. If a subject does not receive study medication in 
Escape Part, the last available post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape Part, the last available post
…
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. …
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 122 of 149 For subjects randomized into Part B, a “Part B Baseline” will be defined as the latest 
measurement for that subject up to and including the day of administration of first study 
medication in Part B, unless otherwise stated 
Has been changed to: 
For subjects randomized into Part B, a “Part B Baseline” will be defined as the latest measurement for that subject up to and including the day of randomization, unless otherwise stated. 
Change #19 
The following Section has been removed: 
3.6.8 Pharmacokinetic Set A 
The Pharmacokinetic Set A (PKSA) will consist of all subjects from the SS who provide at least 
1 PK sample during Part A. 
Change #20 
3.6.9 Flared Set 
The Flared Set (FS) will consist of all subjects from the RS experiencing a flare in Part B. Since 
IXRS will be used to determine whether flare criteria are met during the course of the study, the 
population will be based on the IXRS data. 
Has been changed to: 
The Flared Set (FS) will consist of all subjects from the RS experiencing a flare (ASDAS>3.5 
once or >2.1 on 2 consecutive visits, or ASDAS missing on 2 consecutive visits) in Part B. Since 
IXRS will be used to determine whether flare criteria are met during the course of the study, the 
population will be based on the IXRS data and whether they enter the Escape Part according to 
IXRS. Change # 21 
3.8 Center pooling strategy 
The following country has been removed from Table 3.4: Canada . 
Change #[ADDRESS_846965] possible visit of event (i.e. Week 92, or Week 94 if unscheduled occurred). 
In addition to the protocol, a modified version for ASDAS-MI is added for sensitivity analysis of 
ASDAS- MI.  
Has been changed to: 
The SAP specifies which Baseline value is applicable for each analysis. The Flare Baseline is defined as the latest measurement for that subject up to and including the day of administration of first escape treatment in Part B instead of the visit in which the flare occurred. 
In addition to the protocol, a modified version for ASDAS-MI is added for sensitivity analysis of ASDAS- MI.  REDACTED COPY The Flared Set (FS) will consist of all subjects from the RS experiencing a flare in Part B. 
REDACTED COPY The Flared Set (FS) will consist of all subjects from the RS experiencing a flare in Part B. 
IXRS will be used to determine whether flare criteria are met during the course of the study, the 
REDACTED COPY IXRS will be used to determine whether flare criteria are met during the course of the study, the 
The Flared Set (FS) will consist of all subjects from the RS experiencing a flare (ASDAS
REDACTED COPY The Flared Set (FS) will consist of all subjects from the RS experiencing a flare (ASDAS
once or >2.1 on 2 consecutive visits, or ASDAS missing on 2 consecutive visits) in Part B. Since 
REDACTED COPY once or >2.1 on 2 consecutive visits, or ASDAS missing on 2 consecutive visits) in Part B. Since 
IXRS will be used to determine whether flare criteria are met during the course of the study, the REDACTED COPY IXRS will be used to determine whether flare criteria are met during the course of the study, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Pharmacokinetic Set A (PKSA) will consist of all subjects from the SS who provide at least 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Pharmacokinetic Set A (PKSA) will consist of all subjects from the SS who provide at least 
The Flared Set (FS) will consist of all subjects from the RS experiencing a flare in Part B. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Flared Set (FS) will consist of all subjects from the RS experiencing a flare in Part B. 
IXRS will be used to determine whether flare criteria are met during the course of the study, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. IXRS will be used to determine whether flare criteria are met during the course of the study, the 
The Flared Set (FS) will consist of all subjects from the RS experiencing a flare (ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The Flared Set (FS) will consist of all subjects from the RS experiencing a flare (ASDAS
once or >2.1 on 2 consecutive visits, or ASDAS missing on 2 consecutive visits) in Part B. Since 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. once or >2.1 on 2 consecutive visits, or ASDAS missing on 2 consecutive visits) in Part B. Since 
IXRS will be used to determine whether flare criteria are met during the course of the study, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. IXRS will be used to determine whether flare criteria are met during the course of the study, the 
population will be based on the IXRS data and whether th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. population will be based on the IXRS data and whether th
The following country has been removed from Table 3.4: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following country has been removed from Table 3.4: 
Changes to protocol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Changes to protocol
The protocol defines the censor date for time to flare as
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The protocol defines the censor date for time to flare as
defined as the last possible visit of event (i.e. Week 92, or Week 94 if unscheduled occurred).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. defined as the last possible visit of event (i.e. Week 92, or Week 94 if unscheduled occurred).
In addition to the protocol, a modified version for ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition to the protocol, a modified version for ASDAS
ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been ch
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been ch
The SAP specifies which Baseline value is applicable for each analysis. The Flare Baseline is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The SAP specifies which Baseline value is applicable for each analysis. The Flare Baseline is 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 123 of 149 Furthermore, analysis for IBD-Q response and IBD-Q remission using Part A Baseline and Part 
B Baseline as a reference and SF-36 PCS response and SF-36 MCS response using Part A 
Baseline as a reference are added. 
Exploratory statistical comparisons for WPS will be based on MMRM instead of nonparametric 
bootstrap-t method. 
ASDAS-Moderate Disease changed to ASDAS-Low Disease activity (Machado et al. 2018). 
LOCF analysis are removed from Part B efficacy tables.  
MMRM will be used instead of ANCOVA based on LOCF for   
• Total spi[INVESTIGATOR_18172] 
• Nocturnal spi[INVESTIGATOR_18172] 
• PtGADA 
• Average of Questions 5 and 6 of the BASDAI concerning morning stiffness 
• SF-36 PCS, MCS, and physical function domain 
• Fatigue NRS 
• ASQoL. 
The primary purpose of the study is to evaluate treatment options of axSpA patients after being 
in sustained remission. Hence, one of the objectives is to evaluate the PK and immunogenicity of 
these patients. The CZP plasma concentration and ADAb titer of the patients that did not reach sustained remission are therefore not analysed, the Pharmacokinetic Set A (PKSA) as described 
in the protocol has been removed from the SAP.  
Change #23  
4.2 Handling of dropouts or missing data. 
The following part has been removed: 
If the Part A Baseline value is missing, carry forward the Screening value as far as Part A 
Baseline but no further. 
Change #24  
4.2 Handling of dropouts or missing data. 
The following parts ha ve been added: 
The following continuous endpoints in Part B will be compared between treatment groups using 
a mixed model for repeated measures (MMRM). The pattern of missingness for these variables is 
assumed to be MAR. Subjects who enter Part B will have already demonstrated sustained 
remission through 48 weeks on CZP 200mg Q2W. Many of these subjects will be randomized to receive placebo and will, therefore, be more likely to experience a flare. Postflare data for 
subjects who experience a flare (in any treatment group) will be treated as missing for the 
MMRM analysis. It is further assumed that most subjects who discontinue at this late stage in the study (ie, during Part B) will do so as a result of reduced efficacy. Therefore, missing efficacy REDACTED COPY The primary purpose of the study is to evaluate treatment options of axSpA patients after being 
REDACTED COPY The primary purpose of the study is to evaluate treatment options of axSpA patients after being 
in sustained remission. Hence, one of the objectives is to evaluate the 
REDACTED COPY in sustained remission. Hence, one of the objectives is to evaluate the 
these patients. The CZP plasma concentration and ADAb titer of the patients that did not reach 
REDACTED COPY these patients. The CZP plasma concentration and ADAb titer of the patients that did not reach 
sustained remission are therefore not analysed, the 
REDACTED COPY sustained remission are therefore not analysed, the 
removed from the 
REDACTED COPY removed from the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. morning stiffness
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. morning stiffness
The primary purpose of the study is to evaluate treatment options of axSpA patients after being 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The primary purpose of the study is to evaluate treatment options of axSpA patients after being 
in sustained remission. Hence, one of the objectives is to evaluate the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in sustained remission. Hence, one of the objectives is to evaluate the 
these patients. The CZP plasma concentration and ADAb titer of the patients that did not reach 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. these patients. The CZP plasma concentration and ADAb titer of the patients that did not reach 
sustained remission are therefore not analysed, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sustained remission are therefore not analysed, the 
removed from the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. removed from the SAP. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. SAP. 
Handling of dropouts or missing data
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Handling of dropouts or missing data
The following part has been removed:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following part has been removed:
If the Part A Baseline value is missing, carry forward the Screening value as far as Part A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the Part A Baseline value is missing, carry forward the Screening value as far as Part A 
Baseline but no further.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline but no further.
Handling of dropouts or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Handling of dropouts or 
The following part
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following part
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following continuous endpoints in Part B will be compared between treatment groups using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following continuous endpoints in Part B will be compared between treatment groups using 
a mixed model for repeated measures (MMRM). The pattern of missingness for these variables is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. a mixed model for repeated measures (MMRM). The pattern of missingness for these variables is 
assumed to be MAR.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assumed to be MAR.
remission through 48 weeks on CZP 200mg Q2W. Many of these subjects will be randomized to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. remission through 48 weeks on CZP 200mg Q2W. Many of these subjects will be randomized to 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 124 of 149 data due to either flare or study treatment discontinuation should be dependent on the observed 
efficacy scores, but independent of unobserved data. ASDAS 
 BASDAI 
 Average of Questions 5 and 6 of the BASDAI concerning morning stiffness 
 Fatigue item of BASDAI 
 BASFI 
 BASMI 
 Total spi[INVESTIGATOR_463121] 
 Nocturnal spi[INVESTIGATOR_463121] 
 ASQoL 
 PtGADA 
 SF-36 physical functioning score 
 SF-36 PCS 
 SF-36 MCS 
 WPS  
… 
The below rules will be applied for imputation of partial and missing medical history start dates: 
 If start day is missing, but month and year are present, start date will be replaced by [CONTACT_634223] A, if study 
medication in Part A was first administered in that month and year (exception: if in this case 
start date is after stop date, also the first day of the month will be utilized). 
 If start day and month is missing for one item diagnosis (medical history of any of the preferred terms ‘Axial Spondyloarthritis’, 'Spondyloarthropathy', 'Ankylosing spondylitis' , or 'Spondylitis') or symptom (medical history preferred term of ‘Back pain’, ‘Inflammatory 
pain’, ‘Spi[INVESTIGATOR_140719]’, ‘Lumbar spi[INVESTIGATOR_185775]’) and the year is similar, the missing month will be 
imputed by [CONTACT_634254]. 
 If only one item diagnosis or symptom is present and if start day and month are missing and year is present, start date will be replaced by [CONTACT_634255] A, if study medication in Part A was first 
administered in that year (exception: if in this case start date is after stop date, also the first day of January will be utilized).  
 If start day, month, and year are missing, start date will be replaced by [CONTACT_634256] A or by [CONTACT_634228], if the first administration date is after the end date. 
Change #[ADDRESS_846966] day of the month will be utilized).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. start date is after stop date, also the first day of the month will be utilized).
If start day and month is missing for one item diagnosis (medical history of any of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If start day and month is missing for one item diagnosis (medical history of any of the 
preferred terms ‘Axial Spondyloarthritis’, 'Spon
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. preferred terms ‘Axial Spondyloarthritis’, 'Spon
or 'Spondylitis') or symptom (medical history preferred term of ‘Back pain’, ‘Inflammatory 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. or 'Spondylitis') or symptom (medical history preferred term of ‘Back pain’, ‘Inflammatory 
pain’, ‘Spi[INVESTIGATOR_140719]’, ‘Lumbar spi[INVESTIGATOR_185775]’) and the year is similar, the missing month will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. pain’, ‘Spi[INVESTIGATOR_140719]’, ‘Lumbar spi[INVESTIGATOR_185775]’) and the year is similar, the missing month will be 
imputed by [CONTACT_634435]. imputed by [CONTACT_634436]. If only one item diagnosis or symptom is present and if start day and month are missing and 
year is present, start date will be replaced by [CONTACT_634257]. year is present, start date will be replaced by [CONTACT_634257]. and month of start of study medication in Part A, if s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and month of start of study medication in Part A, if s
administered in that year (exception: if in this case start date is after stop date, also the first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. administered in that year (exception: if in this case start date is after stop date, also the first 
day of January will be utilized). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. day of January will be utilized). 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 125 of 149 The following part has been added:  
The following variable will be classed as unblinding during the full study. Therefore, these 
variables will be kept blinded until study unblinding after database lock: 
 Randomized treatment group 
 CRP (Post Week 48) 
 MRI Efficacy scores (Post Week 48) 
 PK and ADA (Post Week 48). 
Change #26 
4.7 Examination of subgroups 
 Baseline CRP level (≤15 mg/L, >15 mg/L) 
 ADAb status 
Has been changed to: 
 Baseline CRP level (≤ ULN , >ULN ) 
 ADAb status (Negative, Positive <512, Positive 512- <1024, Positive >=1024).  
Change #[ADDRESS_846967] disposition 
The number and percentage of subjects who entered the study, completed Part A, discontinued 
from Part A with reasons for discontinuation, were randomized into Part B, completed Part B 
(without flare, after flare) and discontinued Part B with reasons for discontinuation will be 
presented. 
… 
 A listing of reasons for exclusion from the PPS 
Has been changed to: 
The number and percentage of subjects who entered the study, completed Part A, discontinued 
from Part A with reasons for discontinuation, were randomized into Part B, completed Part B 
(without flare, after flare) and discontinued Part B as well as started Escape Part, completed 
Escape Part and discontinued Escape Part with reasons for discontinuation will be presented.  
… 
 A listing of important protocol deviations (reasons for exclusion from the PPS) 
Change #[ADDRESS_846968] disposition 
The following part has been added:  REDACTED COPY egative, Positive <512, Positive 512
REDACTED COPY egative, Positive <512, Positive 512 -
REDACTED COPY -
The number and percentage of subjects who entered the study, completed Part A, discontinued 
REDACTED COPY The number and percentage of subjects who entered the study, completed Part A, discontinued 
from Part A with reasons for discontinuation, were randomized into Part B, completed Part B 
REDACTED COPY from Part A with reasons for discontinuation, were randomized into Part B, completed Part B 
(without flare, after flare) and discontinued Part B with re REDACTED COPY (without flare, after flare) and discontinued Part B with re
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <1024, Positive >=1024).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. <1024, Positive >=1024).
The number and percentage of subjects who entered the study, completed Part A, discontinued 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects who entered the study, completed Part A, discontinued 
from Part A with reasons for discontinuation, were randomized into Part B, completed Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from Part A with reasons for discontinuation, were randomized into Part B, completed Part B 
(without flare, after flare) and discontinued Part B with re
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (without flare, after flare) and discontinued Part B with re
A listing of reasons for exclusion from the PPS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of reasons for exclusion from the PPS
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
The number and percentage of subjects who entered the study, completed Part A, discontinued 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects who entered the study, completed Part A, discontinued 
from Part A with reasons for discontinuation, were randomized into Part B, completed Part B 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from Part A with reasons for discontinuation, were randomized into Part B, completed Part B 
(without flare, after flare) and discontinued Part B as well as started 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (without flare, after flare) and discontinued Part B as well as started 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape Part and discontinued Escape Part with reasons for discontinuation will be presented. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape Part and discontinued Escape Part with reasons for discontinuation will be presented. 
A listing of important protocol deviations (reasons for exclusion from the PPS)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A listing of important protocol deviations (reasons for exclusion from the PPS)
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
UCB   [ADDRESS_846969] been 
moved to escape treatment via IXRS system (even if they do not receive any escape treatment). 
… 
The following listings will be produced based on the OLS 
Change #29  
6.1 Demographics 
The following part has been added: 
and region and country as per Table 3‒4 
Change #30  
6.3 Medical history and concomitant diseases 
Time since diagnosis of disease will be defined as: Earliest start date of the medical history of 
any of the preferred terms ‘Axial Spondyloarthritis’,  'Spondyloarthropathy' , 'Ankylosing spondylitis' , or 'Spondylitis' minus date of first study medication administration. 
… 
Date of first study medication administration – Start date of symptoms 
Has been changed to: 
Time since diagnosis of disease will be defined as: Date of first study medication administration 
minus earliest start date of the medical history of any of the preferred terms ‘Axial Spondyloarthritis’, 'Spondyloarthropathy', 'Ankylosing spondylitis', or 'Spondylitis'. 
… 
(Date of first study medication administration – Start date of symptoms)/365.25 
Change #[ADDRESS_846970]-flare using the ETS. 
Has been changed to: 
The CR ranges between [ADDRESS_846971] REDACTED COPY rms ‘Axial Spondyloarthritis’,  'Spondyloarthropathy' , 'Ankylosing 
REDACTED COPY rms ‘Axial Spondyloarthritis’,  'Spondyloarthropathy' , 'Ankylosing 
spondylitis' , or 'Spondylitis' minus date of first study medication administration.
REDACTED COPY spondylitis' , or 'Spondylitis' minus date of first study medication administration.
Date of first study medication administration 
REDACTED COPY Date of first study medication administration –
REDACTED COPY –
since diagnosis of disease will be defined as: Date of first study medication administration REDACTED COPY since diagnosis of disease will be defined as: Date of first study medication administration 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Time since diagnosis of disease will be defined as: Earliest start date of the medical history of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Time since diagnosis of disease will be defined as: Earliest start date of the medical history of 
rms ‘Axial Spondyloarthritis’,  'Spondyloarthropathy' , 'Ankylosing 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rms ‘Axial Spondyloarthritis’,  'Spondyloarthropathy' , 'Ankylosing 
spondylitis' , or 'Spondylitis' minus date of first study medication administration.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. spondylitis' , or 'Spondylitis' minus date of first study medication administration.
Start date of symptoms
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Start date of symptoms
since diagnosis of disease will be defined as: Date of first study medication administration 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. since diagnosis of disease will be defined as: Date of first study medication administration 
minus earliest start date of the medical history of any of the preferred terms ‘Axial 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. minus earliest start date of the medical history of any of the preferred terms ‘Axial 
Spondyloarthritis’, 'Spondyloarthropathy', 'Ankylosing spondylitis', or 'Spon
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Spondyloarthritis’, 'Spondyloarthropathy', 'Ankylosing spondylitis', or 'Spon
(Date of first study medication administration 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (Date of first study medication administration 
MEASUREMENTS OF TREATMENT COMPLIANCE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. MEASUREMENTS OF TREATMENT COMPLIANCE
The CR ranges between [ADDRESS_846972] -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -flare using the ETS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare using the ETS.
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
UCB   [ADDRESS_846973] of abbreviation 
Change #32 
8 EFFICACY ANALYSES 
The following part has been added: 
Furthermore, for selected analyses, statistical appendices will be created and included in the CSR 
appendix “Documentation of Statistical Methods”. 
Change #323 
8.1.1 Primary analysis of the primary efficacy variable 
The number and percentage of subjects in Part B who do not experience a flare will be 
summarized descriptively for the RS using NRI data. Summary statistics will be presented by 
[CONTACT_634321]. 
Has been changed to: 
The 95% CI based on the Exact Binomial will also be presented. Summary statistics will be presented by [CONTACT_7238] B. 
Change #34  
8.1.1 Primary analysis of the primary efficacy variable 
The following part has been added: 
To avoid the problem of the monotone likelihood resulting in infinite large confidence intervals 
(eg, if one of the cell counts in the 2x2 table is equal to zero), a penalized maximum likelihood 
approach based on the modified score procedure of Firth (eg, Heinze and Schemper, 2002) w ill 
be used in the logistic models. 
Change #35  
8.1.2 Secondary analyses of the primary efficacy variable 
The following part has been added: REDACTED COPY Furthermore, for selected analyses, statistical appendices will be created and included in the CSR 
REDACTED COPY Furthermore, for selected analyses, statistical appendices will be created and included in the CSR 
efficacy variable
REDACTED COPY efficacy variable
The number and percentage of subjects in Part B who do not experience a flare will be 
REDACTED COPY The number and percentage of subjects in Part B who do not experience a flare will be 
summarized descriptively for the RS using NRI data. Summary statistics will be presented by [CONTACT_634437]. Summary statistics will be presented by 
[CONTACT_122253]. If no Escape Week [ADDRESS_846974] listing of compliance will be provided by [CONTACT_634438], for selected analyses, statistical appendices will be created and included in the CSR 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Furthermore, for selected analyses, statistical appendices will be created and included in the CSR 
efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. efficacy variable
The number and percentage of subjects in Part B who do not experience a flare will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in Part B who do not experience a flare will be 
summarized descriptively for the RS using NRI data. Summary statistics will be presented by 
[CONTACT_122253]. summarized descriptively for the RS using NRI data. Summary statistics will be presented by 
95% CI based on the Exact Binomial will also be presented. Summary statistics will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 95% CI based on the Exact Binomial will also be presented. Summary statistics will be 
presented by [CONTACT_7238] B.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. presented by [CONTACT_7238] B.
Primary analysis of the primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Primary analysis of the primary efficacy variable
The following part has been added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following part has been added:
To avoid the problem of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. To avoid the problem of the 
(eg, if one of the cell counts in the 2x2 table is equal to zero), a penalized maximum likelihood 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (eg, if one of the cell counts in the 2x2 table is equal to zero), a penalized maximum likelihood 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. approach based on the modified score procedure of Firth (eg, Heinze and Schemper, 2002) w
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. approach based on the modified score procedure of Firth (eg, Heinze and Schemper, 2002) w
be used in the logistic models.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be used in the logistic models.
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 128 of 149 Factors for subgroups and the interaction term of subgroup and treatment will be added to the 
primary model specified in Section 8.1.1. The 95% CI based on the Exact Binomial distribution 
will also be presented. 
The following part has been removed: 
The region- by-treatment interaction will be tested by [CONTACT_634439] 8.1.1. If the region- by-treatment interaction is found to be significant (α=0.10), further 
analyses will be conducted to determine which region or regions may be the source of the 
interaction. This will be done by [CONTACT_397162] (including the interaction 
term) where each region will be systematically removed from the model. The impact of a given region will be based on the change in the interaction p-value when that region is removed. The 
region or regions that appear to be driving the significant interaction effect will then be removed 
from the primary efficacy model to verify that conclusions remain the same with or without the 
influential region(s). Separately, a similar testing approach will be conducted to assess the mNY 
classification- by-treatment interaction. These analyses will not be part of the TFLs included in 
the CSR; however it will be included in the CSR appendix “Documentation of Statistical 
Method”. 
Change #36  
8.1.3 Supportive and sensitivity analyses of the primary efficacy variable 
The number and percentage of subjects in Part B who do experience a flare will be summarized 
descriptively for the RS using NRI data, indicating the contributing event (ASDAS defined flare, 
missing ASDAS values, premature study discontinuation).  
The analysis described in Section 8.1.1 will be repeated for the RS using the different approaches 
as defined in Section 3.2.22 (observed case, handling of premature withdrawal, MMRM 
imputation, multiple imputation). 
In addition, the analysis as described in Section 8.1.1 will also be repeated for the FAS and PPS 
using NRI data. 
Has been changed to: 
The number and percentage of subjects in Part B who do experience a flare will be summarized descriptively for the RS using NRI data, indicating the contributing event (ASDAS defined flare using scheduled visits only or using unscheduled visits, missing ASDAS values, premature study 
discontinuation with reason “AE or Lack of efficacy” or other reason, incorrectly ‘flared’ due to 
delay in data entry).  
The flare by [CONTACT_18375], calculated flare, time to flare and reason for flare according to NRI analysis 
will be listed based on the RS.  
The analysis described in Section 8.1.1 will be repeated for the RS using the different approaches 
as defined in Section 3.2.22 (observed case, premature withdrawal, MMRM imputation, 
referenced-based multiple imputation). The 95% CI based on the Exact Binomial distribution 
will also be presented.  
In addition, the analysis as described in Section 8.1.1 will also be repeated for the FAS and PP S 
using NRI data. REDACTED COPY Supportive and sensitivity analyses of the primary efficacy var
REDACTED COPY Supportive and sensitivity analyses of the primary efficacy var
The number and percentage of subjects in Part B who do experience a flare will be summarized 
REDACTED COPY The number and percentage of subjects in Part B who do experience a flare will be summarized 
descriptively for the RS using NRI data, indicating the contributing event (ASDAS defined flare, 
REDACTED COPY descriptively for the RS using NRI data, indicating the contributing event (ASDAS defined flare, 
missing ASDAS values, premature study discontinuation). 
REDACTED COPY missing ASDAS values, premature study discontinuation). 
analysis described in Section 8.1.1 will be repeated for the RS using the different approaches 
REDACTED COPY analysis described in Section 8.1.1 will be repeated for the RS using the different approaches 
as defined in Section 3.2.22 (observed case, handling of premature withdrawal, MMRM REDACTED COPY as defined in Section 3.2.22 (observed case, handling of premature withdrawal, MMRM 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e interaction 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e interaction 
term) where each region will be systematically removed from the model. The impact of a given 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. term) where each region will be systematically removed from the model. The impact of a given 
value when that region is removed. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. value when that region is removed. The 
icant interaction effect will then be removed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. icant interaction effect will then be removed 
from the primary efficacy model to verify that conclusions remain the same with or without the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from the primary efficacy model to verify that conclusions remain the same with or without the 
influential region(s). Separately, a similar testing approach will be conducted to assess the mNY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. influential region(s). Separately, a similar testing approach will be conducted to assess the mNY 
treatment interaction. These analyses will not be part of the TFLs included in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment interaction. These analyses will not be part of the TFLs included in 
the CSR; however it will be included in the CSR appendix “Documentation of Statistical 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the CSR; however it will be included in the CSR appendix “Documentation of Statistical 
Supportive and sensitivity analyses of the primary efficacy var
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Supportive and sensitivity analyses of the primary efficacy var
The number and percentage of subjects in Part B who do experience a flare will be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in Part B who do experience a flare will be summarized 
descriptively for the RS using NRI data, indicating the contributing event (ASDAS defined flare, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. descriptively for the RS using NRI data, indicating the contributing event (ASDAS defined flare, 
missing ASDAS values, premature study discontinuation). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. missing ASDAS values, premature study discontinuation). 
analysis described in Section 8.1.1 will be repeated for the RS using the different approaches 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. analysis described in Section 8.1.1 will be repeated for the RS using the different approaches 
as defined in Section 3.2.22 (observed case, handling of premature withdrawal, MMRM 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as defined in Section 3.2.22 (observed case, handling of premature withdrawal, MMRM 
In addition, the analysis as described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, the analysis as described in 
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
The number and percentage of subjects in Part B who do experience a flare will be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The number and percentage of subjects in Part B who do experience a flare will be summarized 
descriptively for the RS using NRI data, indicating the contributing e
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. descriptively for the RS using NRI data, indicating the contributing e
using scheduled visits only or using unscheduled visits, missing ASDAS values, premature study 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. using scheduled visits only or using unscheduled visits, missing ASDAS values, premature study 
discontinuation with reason “AE or Lack of efficacy” or other reason, i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. discontinuation with reason “AE or Lack of efficacy” or other reason, i
delay in data entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. delay in data entry
The flare by I
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The flare by I
will be listed based on the RS. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be listed based on the RS. 
The analysis described in Section 8.1.1 will be repeated for the RS using the different approaches 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The analysis described in Section 8.1.1 will be repeated for the RS using the different approaches 
as defined in Section 3.2.22 (observed c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. as defined in Section 3.2.22 (observed c
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 129 of 149 Change #37  
[IP_ADDRESS] Percentage of subjects achieving sustained remission at Week 48 
The following part has been added: 
The 95% CI based on the Exact Binomial distribution will also be presented. 
Change #38  
8.2.2 Part B 
All tables will be presented for all subjects combined as well as broken out by [CONTACT_634220]. 
Has been changed to 
All tables will be presented by [CONTACT_7238] B. 
Change #39  
[IP_ADDRESS] Time to flare 
Kaplan-Meier plots of the time to flare will also be produced. Kaplan-Meier estimates of 
percentages of subjects who flare by [CONTACT_10585] 60, Week 72, Week 84 and Week 92 will be provided along with the corresponding 95% CI by [CONTACT_2939]. For the calculation of the 95% CI, the LOGLOG transformation will be used. 
These analyses will be repeated using the different approaches as defined in Section  3.2.23 
(observed case, handling of premature withdrawal). 
Has been changed to: 
Kaplan-Meier plots of the time to flare will also be produced. Kaplan-Meier estimates of 
percentages of subjects who experience a experiencing a flare by [CONTACT_10585] 52, Week 56, Week 60, 
Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92 and Week 96 will be provided along with the corresponding 95% CI by [CONTACT_2939]. For the calculation of the 95% CI, the LOGLOG transformation will be used. 
These analyses will be repeated using the different approaches as defined in Section 3.2.23 
(observed case, premature withdrawal). 
Change #40  
[IP_ADDRESS] Continuous secondary efficacy variables 
Summary statistics of observed and change from Part A Baseline to Week 96 values for ASDAS, 
BASDAI, BASFI, and BASMI will be presented by [CONTACT_1570]. These summaries will be 
based on observed case data and will be repeated using LOCF data. 
The changes from Part A Baseline to Week 96 in ASDAS, BASDAI, BASFI and BASMI will be 
compared between treatment groups using a MMRM. The pattern of missingness for these 
variables is assumed to be missing at random (MAR). Post-flare data for subjects who experience a flare (in any treatment group) will be treated as missing in the MMRM analysis. 
The MMRM methods will be applied to all observed change from Part A Baseline (Week 0) data 
obtained from Week 48 up to Week 96.  REDACTED COPY percentages of subjects who flare by [CONTACT_10585] 60, Week 72, Week 84 and Week 92 will be provided 
REDACTED COPY percentages of subjects who flare by [CONTACT_10585] 60, Week 72, Week 84 and Week 92 will be provided 
along with the corresponding 95% CI by [CONTACT_2939]. For the calculation of the 95% CI, the 
REDACTED COPY along with the corresponding 95% CI by [CONTACT_2939]. For the calculation of the 95% CI, the 
alyses will be repeated using the different approaches as defined in 
REDACTED COPY alyses will be repeated using the different approaches as defined in 
(observed case, handling of premature withdrawal).
REDACTED COPY (observed case, handling of premature withdrawal).
Meier plots of the time to flare will also be produced. Kaplan REDACTED COPY Meier plots of the time to flare will also be produced. Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Kaplan
percentages of subjects who flare by [CONTACT_10585] 60, Week 72, Week 84 and Week 92 will be provided 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. percentages of subjects who flare by [CONTACT_10585] 60, Week 72, Week 84 and Week 92 will be provided 
along with the corresponding 95% CI by [CONTACT_2939]. For the calculation of the 95% CI, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. along with the corresponding 95% CI by [CONTACT_2939]. For the calculation of the 95% CI, the 
alyses will be repeated using the different approaches as defined in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. alyses will be repeated using the different approaches as defined in 
(observed case, handling of premature withdrawal).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (observed case, handling of premature withdrawal).
Meier plots of the time to flare will also be produced. Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Meier plots of the time to flare will also be produced. Kaplan
percentages of subjects who experience a experiencing a flare by [CONTACT_10585] 52, Week 56, Week 60, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. percentages of subjects who experience a experiencing a flare by [CONTACT_10585] 52, Week 56, Week 60, 
Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 
will be provided along with the corresponding 95% CI by [CONTACT_2939]. For the calculation of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be provided along with the corresponding 95% CI by [CONTACT_2939]. For the calculation of 
the 95% CI, the LOGLOG transformation will be used.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the 95% CI, the LOGLOG transformation will be used.
These analyses will be repeated using the different approaches as defined in Section 3.2.23 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These analyses will be repeated using the different approaches as defined in Section 3.2.23 
served case, premature withdrawal).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. served case, premature withdrawal).
Continuous secondary efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Continuous secondary efficacy variables
Summary statistics of observed and change from Part A Baseline to Week 96 values for ASDAS, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics of observed and change from Part A Baseline to Week 96 values for ASDAS, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI, BASFI, and BASMI will be presented by [CONTACT_1570]. These 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. BASDAI, BASFI, and BASMI will be presented by [CONTACT_1570]. These 
based on observed case data and will be repeated using LOCF data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based on observed case data and will be repeated using LOCF data.
The changes from Part A Baseline to Week 96 in ASDAS, BASDAI, BASFI and BASMI will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The changes from Part A Baseline to Week 96 in ASDAS, BASDAI, BASFI and BASMI will be 
compared between treatment groups using a MMRM. The pattern of missingness for these 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. compared between treatment groups using a MMRM. The pattern of missingness for these 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 130 of 149 … 
Summary statistics of observed and change from Part A Baseline to Week 96 values for SIJ 
SPARCC and Spi[INVESTIGATOR_18241]-a in the Berlin modification scores will be presented by [CONTACT_1570].  
The changes from Part A Baseline in SIJ SPARCC and spi[INVESTIGATOR_18241]-a in the Berlin 
modification scores at Week 96 will be compared between treatment groups using an analysis of covariance (ANCOVA) model. The model will include Part B Baseline score, treatment group, 
region, and mNY classification. Summary tables will present the adjusted means for PBO and 
the CZP doses, the respective differences to PBO, the corresponding p-values, and 95% CIs. This 
analysis will be performed using observed case data only. 
Has been changed to: 
Summary statistics of observed and change from Part B Baseline to Week 96 values for ASDAS, BASDAI, BASFI, and BASMI will be presented by [CONTACT_1570]. These summary statistics will be repeated for Part A Baseline.  
The changes from Part B Baseline to Week 96 in ASDAS, BASDAI, BASFI and BASMI will be 
compared between treatment groups using a MMRM. The pattern of missingness for these 
variables is assumed to be missing at random (MAR). Post-flare data for subjects experiencing a 
flare (in any treatment group) will be treated as missing in the MMRM analysis. The MMRM 
methods will be applied to all observed change from Part B Baseline data obtained from Week 48 up to Week 96.  
… 
The comparison between treatment groups using MMRM will be repeated for Part A Baseline 
with Part A Baseline score as a fixed-effect covariate, treatment group, region, mNY 
classification, and visit as fixed-effect categorical factors, and Part A Baseline-by -visit and 
treatment group- by-visit as interaction terms.  
Summary statistics of observed and change from Part B Baseline to Week 96 values for SIJ 
SPARCC and Spi[INVESTIGATOR_18241]-a in the Berlin modification scores will be presented by [CONTACT_1570]. These summaries will be based on observed case data. 
The changes from Part B Bas eline in SIJ SPARCC and spi[INVESTIGATOR_18241]-a in the Berlin 
modification scores at Week 96 will be compared between treatment groups using an analysis of 
covariance (ANCOVA) model. The model will include Part B Baseline score, treatment group, 
region, and mNY classification. Summary tables will present the adjusted means for PBO and 
the CZP doses, the respective differences to PBO, the corresponding p-values, and 95% CIs. This 
analysis will be performed using observed case data only. 
These summary statistics will be repeated for Part A Baseline and the model includes Part A 
Baseline score, treatment group, region, and mNY classification.  
Change #41  
[IP_ADDRESS] Binary secondary efficacy variables REDACTED COPY variables is assumed to be missing at random (MAR). Post
REDACTED COPY variables is assumed to be missing at random (MAR). Post
ent group) will be treated as missing in the MMRM analysis. The MMRM 
REDACTED COPY ent group) will be treated as missing in the MMRM analysis. The MMRM 
methods will be applied to all observed change from Part 
REDACTED COPY methods will be applied to all observed change from Part 
The comparison between treatment groups using MMRM will be repeated for Pa
REDACTED COPY The comparison between treatment groups using MMRM will be repeated for Pa
Baseline score as a fixed REDACTED COPY Baseline score as a fixed -REDACTED COPY -effect covariate, treatment group, region, mNY REDACTED COPY effect covariate, treatment group, region, mNY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. modification scores at Week 96 will be compared between treatment groups using an analysis of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. modification scores at Week 96 will be compared between treatment groups using an analysis of 
covariance (ANCOVA) model. The model will include Part B Baseline score, treatment group, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. covariance (ANCOVA) model. The model will include Part B Baseline score, treatment group, 
on, and mNY classification. Summary tables will present the adjusted means for PBO and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. on, and mNY classification. Summary tables will present the adjusted means for PBO and 
values, and 95% CIs. This 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values, and 95% CIs. This 
Baseline to Week 96 values for ASDAS, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline to Week 96 values for ASDAS, 
These summary statistics 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summary statistics 
e to Week 96 in ASDAS, BASDAI, BASFI and BASMI will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e to Week 96 in ASDAS, BASDAI, BASFI and BASMI will be 
compared between treatment groups using a MMRM. The pattern of missingness for these 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. compared between treatment groups using a MMRM. The pattern of missingness for these 
flare data for subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare data for subjects 
ent group) will be treated as missing in the MMRM analysis. The MMRM 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ent group) will be treated as missing in the MMRM analysis. The MMRM 
methods will be applied to all observed change from Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. methods will be applied to all observed change from Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B
The comparison between treatment groups using MMRM will be repeated for Pa
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The comparison between treatment groups using MMRM will be repeated for Pa
effect covariate, treatment group, region, mNY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. effect covariate, treatment group, region, mNY 
effect categorical factors
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. effect categorical factors
visit as interaction terms
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. visit as interaction terms
stics of observed and change from Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. stics of observed and change from Part 
SPARCC and Spi[INVESTIGATOR_634105]. SPARCC and Spi[INVESTIGATOR_18241] a in the Berlin modification scores will be presented by 
[CONTACT_122253]. a in the Berlin modification scores will be presented by 
[CONTACT_1570]. These summaries will be based on observed case data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group. These summaries will be based on observed case data.
The changes from Part 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The changes from Part B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B
modification scores at Week 96 will be compared between treatment groups using an analysis of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. modification scores at Week 96 will be compared between treatment groups using an analysis of 
covariance (ANCOVA) model. The model will include Part B Baseline score, treatment group, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. covariance (ANCOVA) model. The model will include Part B Baseline score, treatment group, 
region, and mNY c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. region, and mNY c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the CZP doses, the respective differences to PBO, the corresponding p
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the CZP doses, the respective differences to PBO, the corresponding p
analysis will be performed using observed case data only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. analysis will be performed using observed case data only.
These summary statistics wil
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summary statistics wil
Baseline score, treatment group, region, and mNY classification
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline score, treatment group, region, and mNY classification
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 131 of 149 These summaries will be based on observed case data and will be repeated using LOCF data (for 
ASDAS disease activity levels only) and using NRI data (for all other variables); improvement 
will be relative to Part A baseline only. 
Has been changed to: 
These summaries will be based on observed case data and will be repeated using NRI data (for all variables except ASDAS disease activity level); improvement will be relative to Part A Baseline only 
Change #42 
8.2.3 Subjects experiencing a flare in Part B 
8.3.3 Subjects experiencing a flare in Part B 
The following part has been added:  
If deemed needed, further sensitivity analyses may be conducted excluding subjects incorrectly ‘flared’. 
Change #43 
[IP_ADDRESS] Continuous secondary efficacy variables 
The following part has been added: 
These summary statistics will be repeated for Flare Baseline. List of abbreviation. 
Change #44 
[IP_ADDRESS] Binary secondary efficacy variables The following part has been removed: 
For comparative purposes, the tables will also include the responder number and percentages at 
the visit where flare criteria were met. 
Change #45 
[IP_ADDRESS] SIJ SPARCC and spi[INVESTIGATOR_18241]-a in the Berlin modification scores  
Summary statistics of the actual values and change from Part A Baseline values will be used to 
summarize the SIJ SPARCC and Spi[INVESTIGATOR_18241]-a in the Berlin modification scores for each 
visit by [CONTACT_634306]. The analysis will use the average of 
the scores from the 2 independent reviewers. Additionally, agreement between readers will be 
assessed by [CONTACT_634440]. These summaries will be produced 
for the OLS using observed case data only. 
Has been changed to: 
Summary statistics of the actual values and change from Part A Baseline values will be used to 
summarize the SIJ SPARCC and Spi[INVESTIGATOR_18241]-a in the Berlin modification scores for each 
visit by [CONTACT_634306]. The analysis will use results of the single read assessments for Part A from the independent reviewer. These summaries will be produced for the OLS using observed case data only. REDACTED COPY These summary statistics will be repeated for Flare Baseline. 
REDACTED COPY These summary statistics will be repeated for Flare Baseline. 
Binary secondary efficacy variables
REDACTED COPY Binary secondary efficacy variables
The following part has been removed: REDACTED COPY The following part has been removed:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If deemed needed, further sensitivity analyses may be conducted excluding subjects incorrectly 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If deemed needed, further sensitivity analyses may be conducted excluding subjects incorrectly 
These summary statistics will be repeated for Flare Baseline. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summary statistics will be repeated for Flare Baseline. 
Binary secondary efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Binary secondary efficacy variables
For comparative purposes, the tables will also include the responder number and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For comparative purposes, the tables will also include the responder number and 
the visit where flare criteria were met.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the visit where flare criteria were met.
SIJ SPARCC and spi[INVESTIGATOR_634105]. SIJ SPARCC and spi[INVESTIGATOR_634178] A Baseline values will be used to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics of the actual values and change from Part A Baseline values will be used to 
summarize the SIJ S
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. summarize the SIJ S PARCC and Spi[INVESTIGATOR_634105]. PARCC and Spi[INVESTIGATOR_634179]. The analysis will use the average of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. visit by [CONTACT_634306]. The analysis will use the average of 
the scores from the 2 independent reviewers. Additionally, agreement between readers will
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the scores from the 2 independent reviewers. Additionally, agreement between readers will
assessed by [CONTACT_634440]. These summaries will be produced 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessed by [CONTACT_634440]. These summaries will be produced 
for the OLS using observed case data only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for the OLS using observed case data only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
Summary statistics of the actual values and change from Part A Baseline values will be used
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics of the actual values and change from Part A Baseline values will be used
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 132 of 149 Change #46 
[IP_ADDRESS] Individual ASAS core components 
These summaries will be produced for the OLS using observed case data and will be repeated 
using LOCF imputation for missing data. 
Has been changed to: 
These summaries will be produced for the OLS using observed case data and will be repeated for BASFI and PtGADA using LOCF imputation for missing data. 
Change #47 
The following part has been updated for all the below sub sections.  
[IP_ADDRESS] PhGADA 
[IP_ADDRESS] Ankylosing Spondylitis Quality of Life (ASQoL) 
[IP_ADDRESS] Work Productivity Survey (WPS) 
[IP_ADDRESS] EuroQoL Health Status Questionnaire 5 dimensions 3 levels (EQ-5D- 3L) 
[IP_ADDRESS] Maastricht Ankylosis Spondylitis Enthesitis Score (MASES) [IP_ADDRESS] Swollen and tender joint counts (44 joint count) [IP_ADDRESS] Spi[INVESTIGATOR_18171] 
[IP_ADDRESS] Short-Form 36-Item Health Survey (SF-36) 
These summaries will be produced for the OLS using observed case data and will be repeated 
using LOCF imputation for missing data.  
Has been changed to: 
These summaries will be produced for the OLS using observed case data. 
Change #48 
[IP_ADDRESS] Swollen and tender joint counts (44 joint count) 
The following part has been removed: 
In addition, the summaries for TJC will be repeated including only the subjects with a TJC>0 at 
Part A Baseline. Similarly, the summaries for SJC will be repeated including only the subjects with a SJC>0 at Part A Baseline. 
Change #49 
[IP_ADDRESS] ASDAS, BASDAI, BASFI and BASMI 
Summary statistics of the actual values, change from Part A Baseline values and change from 
Part B Baseline values for ASDAS, BASDAI, BASFI and BASMI will be presented by [CONTACT_3232]. These summaries will be produced using observed case data and will be repeated using LOCF imputation for missing data. 
The changes from Part A Baseline to each visit in Part B for ASDAS, BASDAI, BASFI and BASMI will be compared between treatment groups using a MMRM.  REDACTED COPY Maastricht Ankylosis Spondylitis Enthesitis Score (MASES)
REDACTED COPY Maastricht Ankylosis Spondylitis Enthesitis Score (MASES)
Swollen and tender joint counts (44 joint count)
REDACTED COPY Swollen and tender joint counts (44 joint count)
Item Health Survey (SF
REDACTED COPY Item Health Survey (SF
These summaries will be produced for the OLS using observed case data and will be repeated 
REDACTED COPY These summaries will be produced for the OLS using observed case data and will be repeated 
g data. REDACTED COPY g data. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summaries will be produced for the OLS using observed case data and will be repeated for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summaries will be produced for the OLS using observed case data and will be repeated for 
EuroQoL Health Status Questionnaire 5 dimensions 3 levels (EQ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. EuroQoL Health Status Questionnaire 5 dimensions 3 levels (EQ
Maastricht Ankylosis Spondylitis Enthesitis Score (MASES)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Maastricht Ankylosis Spondylitis Enthesitis Score (MASES)
Swollen and tender joint counts (44 joint count)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Swollen and tender joint counts (44 joint count)
Item Health Survey (SF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Item Health Survey (SF -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -36)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 36)
These summaries will be produced for the OLS using observed case data and will be repeated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summaries will be produced for the OLS using observed case data and will be repeated 
g data. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. g data. 
These summaries will be produced for the OLS using observed case data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summaries will be produced for the OLS using observed case data.
Swollen and tender joint counts (44 joint count)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Swollen and tender joint counts (44 joint count)
The following part has been removed:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following part has been removed:
In addition, the summaries for TJC will be repeat
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. In addition, the summaries for TJC will be repeat
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline. Similarly, the summaries for SJC will be repeated including only the subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A Baseline. Similarly, the summaries for SJC will be repeated including only the subjects 
with a SJC>0 at Part A Baseline.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with a SJC>0 at Part A Baseline.
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
Summary statistics of the actua
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics of the actua
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 133 of 149 This analysis will be repeated based on change from Part B Baseline. 
Has been changed to: 
Summary statistics of the actual values, change from Part B Baseline values and change from 
Part B Baseline values for ASDAS, BASDAI, BASFI and BASMI will be presented by [CONTACT_10663]. These summaries will be produced using observed case data. These summary 
statistics will be repeated for Part A Baseline. 
The changes from Part B Baseline to each visit in Part B for ASDAS, BASDAI, BASFI and 
BASMI will be compared between treatment groups using a MMRM.  
… 
This analysis will be repeated based on change from Part A Baseline with Part A Baseline score 
as a fixed-effect covariate, treatment group, region, mNY classification, and visit as fixed- effect 
categorical factors, and Part A Baseline- by-visit and treatment group- by-visit as interaction 
terms. 
Change #50  
[IP_ADDRESS] Individual ASAS core components 
These summaries will be produced using observed case data and will be repeated using LOCF 
imputation for missing data. 
For each component, the changes from Part B Baseline to each visit in Part B will be compared 
between treatment groups using a MMRM. (see Section [IP_ADDRESS]). treatment group comparisons 
for both CZP groups vs. PBO will be performed based on the change from Part A Baseline 
values at the time points of Part B using an ANCOVA model including terms for Part B Baseline 
value, treatment group, region, and mNY classification. Tables will present the adjusted means 
for PBO and the CZP doses, the respective differences to PBO, the corresponding p-values, and 95% CIs. This analysis will be performed using LOCF imputation for missing data. This analysis will be repeated based on change from Part B A Baseline. 
Has been changed to: 
These summaries will be produced using observed case data. 
For each component, the changes from Part B Baseline to each visit in Part B will be compared 
between treatment groups using a MMRM. (see Section [IP_ADDRESS]). This analysis will be repeated based on change from Part A Baseline. 
Change #51 
The following part has been updated for all the below sub sections. 
[IP_ADDRESS] Fatigue NRS [IP_ADDRESS] ASQoL 
[IP_ADDRESS] Work Productivity Survey (WPS) 
[IP_ADDRESS] Short-Form 36-Item Health Survey (SF-36) REDACTED COPY These summaries will be produced using observed case data and will be repeated using LOCF 
REDACTED COPY These summaries will be produced using observed case data and will be repeated using LOCF 
For each component, the changes from Part B Baseline to each visit in Part
REDACTED COPY For each component, the changes from Part B Baseline to each visit in Part
between treatment groups using a MMRM. (see Section [IP_ADDRESS]). treatment group comparisons 
REDACTED COPY between treatment groups using a MMRM. (see Section [IP_ADDRESS]). treatment group comparisons 
for both CZP groups vs. PBO will be performed based on the change from Part A Baseline 
REDACTED COPY for both CZP groups vs. PBO will be performed based on the change from Part A Baseline 
values at the time points of Part B using an ANCOVA model i
REDACTED COPY values at the time points of Part B using an ANCOVA model i
value, treatment group, region, and mNY classification. Tables will present the adjusted means REDACTED COPY value, treatment group, region, and mNY classification. Tables will present the adjusted means 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The changes from Part B Baseline to each visit in Part B for ASDAS, BASDAI, BASFI and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The changes from Part B Baseline to each visit in Part B for ASDAS, BASDAI, BASFI and 
ed based on change from Part A Baseline with Part A Baseline score 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ed based on change from Part A Baseline with Part A Baseline score 
effect covariate, treatment group, region, mNY classification, and visit as fixed
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. effect covariate, treatment group, region, mNY classification, and visit as fixed
visit as interac
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. visit as interac
These summaries will be produced using observed case data and will be repeated using LOCF 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summaries will be produced using observed case data and will be repeated using LOCF 
For each component, the changes from Part B Baseline to each visit in Part
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For each component, the changes from Part B Baseline to each visit in Part
between treatment groups using a MMRM. (see Section [IP_ADDRESS]). treatment group comparisons 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. between treatment groups using a MMRM. (see Section [IP_ADDRESS]). treatment group comparisons 
for both CZP groups vs. PBO will be performed based on the change from Part A Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for both CZP groups vs. PBO will be performed based on the change from Part A Baseline 
values at the time points of Part B using an ANCOVA model i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values at the time points of Part B using an ANCOVA model i
value, treatment group, region, and mNY classification. Tables will present the adjusted means 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. value, treatment group, region, and mNY classification. Tables will present the adjusted means 
for PBO and the CZP doses, the respective differences to PBO, the corresponding p
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for PBO and the CZP doses, the respective differences to PBO, the corresponding p
erformed using LOCF imputation for missing data. This analysis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. erformed using LOCF imputation for missing data. This analysis 
will be repeated based on change from Part B A Baseline.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be repeated based on change from Part B A Baseline.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
These summaries will be produced using observed case data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summaries will be produced using observed case data.
For each component, the changes from Part B Baseline to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. For each component, the changes from Part B Baseline to 
between treatment groups using a MMRM. (see Section [IP_ADDRESS]). This analysis will be repeated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. between treatment groups using a MMRM. (see Section [IP_ADDRESS]). This analysis will be repeated 
based on change from Part A Baseline.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. based on change from Part A Baseline.
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change # 5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 1
The following part has been updated for all the below sub sections.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following part has been updated for all the below sub sections.
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
[IP_ADDRESS]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. [IP_ADDRESS]
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 134 of 149 This summary will be produced using observed case data and will be repeated using LOCF 
imputation for missing data. 
Treatment group comparisons for both CZP groups vs. PBO will be performed based on the 
change from Part A Baseline in Fatigue using an ANCOVA model including terms for Part B 
Baseline score, treatment group, region, and mNY classification. Tables will present the adjusted 
means for PBO and the CZP doses, the respective differences to PBO, the corresponding p-
values, and 95% CIs. This analysis will be performed using LOCF imputation for missing data. This analysis will be repeated based on change from Part B Baseline. 
Has been changed to: 
This summary will be produced using observed case. 
Treatment group comparisons for both CZP groups vs. PBO will be performed based on the 
change from Part B Baseline to each visit in Fatigue using a MMRM. (see Section [IP_ADDRESS]).   This analysis will be repeated based on change from Part A Baseline. 
Change #52 
[IP_ADDRESS] Fatigue NRS 
The following part has been added: 
The remaining components of the BASDAI maybe analyzed as well. 
Change #53 
[IP_ADDRESS] Work Productivity Survey (WPS) 
These summaries will be produced using observed case data and will be repeated using LOCF 
imputation for missing data. 
Change #54 
[IP_ADDRESS] Number of uveitis flares, IBD exacerbations and psoriasis exacerbations 
These summary tables will display the number and percentage of subjects experiencing the 
considered event in Part B and number of event. Only the events occurring prior to ASDAS-
defined flare, if ASDAS-defined flare occurred, will be considered. In this style of output, 
“number of event” will include all occurrences of the event including repeat occurrences in individual subjects, while “number of subjects” will count each subject only once. 
Has been changed to: 
These summary tables will display the number and percentage of subjects experiencing the 
considered event in Part B, and number of event, incidence rate, event rate and 100 patient 
exposure year. Only the events occurring prior to up to Escape Week 0 ASDAS-defined flare, if ASDAS-defined flare occurred, will be considered. In this style of output, “number of event” 
will include all occurrences of the event including repeat occurrences in individual subjects, 
while “number of subjects” will count each subject only once. 
Change #55 
[IP_ADDRESS] Short-Form 36-Item Health Survey (SF-36) REDACTED COPY The remaining components of the BASDAI maybe analyzed as well.
REDACTED COPY The remaining components of the BASDAI maybe analyzed as well.
duced using observed case data and will be repeated using LOCF 
REDACTED COPY duced using observed case data and will be repeated using LOCF 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values, and 95% CIs. This analysis will be performed using LOCF imputation for missing data. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. values, and 95% CIs. This analysis will be performed using LOCF imputation for missing data. 
Treatment group comparisons for both CZP groups vs. PBO will be performed based on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Treatment group comparisons for both CZP groups vs. PBO will be performed based on the 
change from Part B Baseline to each visit in Fatigue using a MMRM. (see Section [IP_ADDRESS]).   
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. change from Part B Baseline to each visit in Fatigue using a MMRM. (see Section [IP_ADDRESS]).   
The remaining components of the BASDAI maybe analyzed as well.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The remaining components of the BASDAI maybe analyzed as well.
duced using observed case data and will be repeated using LOCF 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. duced using observed case data and will be repeated using LOCF 
Number of uveitis flares, IBD exacerbations and psoriasis exacerbations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number of uveitis flares, IBD exacerbations and psoriasis exacerbations
These summary tables will display the number and percentage of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summary tables will display the number and percentage of subjects 
considered event in Part B and number of event. Only the events occurring prior to ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. considered event in Part B and number of event. Only the events occurring prior to ASDAS
defined flare, if ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. defined flare, if ASDAS -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -defined flare occurred, will be considered. In this style of output, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. defined flare occurred, will be considered. In this style of output, 
“number of event” will include all occurrences of the eve
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. “number of event” will include all occurrences of the eve
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. individual subjects, while “number of subjects” will count each subject only once.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. individual subjects, while “number of subjects” will count each subject only once.
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
These summary tables will display the number and percentage of subjects experiencing the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. These summary tables will display the number and percentage of subjects experiencing the 
considered event in Part B, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. considered event in Part B, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. exposure year. Only the events occurring prior to
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. exposure year. Only the events occurring prior to
ASDAS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ASDAS
will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 135 of 149 This analysis will be performed using Part A Baseline as reference for the definition of SF-36 
PCS and MCS response and will be repeated using Part B Baseline as reference. 
Has been changed to: 
This analysis will be performed using Part A Baseline as reference for the definition of SF-36 PCS and MCS response. 
Change #56 
[IP_ADDRESS] Descriptive summaries of other efficacy variables 
The below listed efficacy variables will be summarized descriptively by [CONTACT_634441]: 
The below listed efficacy variables will be summarized descriptively by [CONTACT_634442] #57 
9.1 Pharmacokinetics 
CZP plasma concentrations will be tabulated and summarized using PKSA (overall and by 
[CONTACT_634443]-CZP Ab status) for each visit at which samples were taken during Part A using the geometric mean, 95% CI, geometric CV, arithmetic mean, arithmetic SD, median, minimum, and 
maximum. Plasma concentration time curves will be plotted overall, and by [CONTACT_634443]-CZP Ab 
status. 
CZP plasma concentrations will be tabulated and summarized by [CONTACT_634417] 
(overall and by [CONTACT_634443]-CZP Ab status.) for each visit at which samples were taken during 
Part B using the geometric mean, 95% CI, geometric CV, arithmetic mean, arithmetic SD, median, minimum, and maximum. For each treatment group, plasma concentration time curves will be plotted overall, and by [CONTACT_634443]-CZP Ab status. 
Part B summaries will not include post-flare assessments. Separate summaries will be produced 
for subjects who flare in Part B and start escape therapy including only the post-flare 
assessments. Concentrations below the limit of quantification (BLQ) will be replaced by [CONTACT_634444] 2 for the calculation of descriptive statistics. 
Subgroup analyses based on age, gender, race, region, CRP level and mNY classification will be 
performed. 
Has been changed to: 
CZP plasma concentrations will be tabulated and summarized using PKSB for each visit at 
which samples were taken during Part A by [CONTACT_634354], 
95% CI, geometric CV, arithmetic mean, arithmetic SD, median, minimum, and maximum. Plasma concentration time curves of Part A will be plotted for all subjects and Part A treatment-
emergent ADAb (Part A TE ADAb) status with titer classification (see Section 9.2). 
CZP plasma concentrations will be tabulated and summarized by [CONTACT_634445], 95% CI, REDACTED COPY CZP plasma concentrations will be tabulated and summarized using PKSA (overall and by 
[CONTACT_634446] (overall and by 
[CONTACT_634447]) for each visit at which samples were taken during Part A using the 
REDACTED COPY CZP Ab status) for each visit at which samples were taken during Part A using the 
geometric mean, 95% CI, geometric CV, arithmetic mean, arithmetic SD, medi
REDACTED COPY geometric mean, 95% CI, geometric CV, arithmetic mean, arithmetic SD, medi
maximum. Plasma concentration time curves will be plotted overall, and by [CONTACT_634448]. Plasma concentration time curves will be plotted overall, and by [CONTACT_634449]. The below listed efficacy variables will be summarized descriptively by [CONTACT_634350]. The below listed efficacy variables will be summarized descriptively by [CONTACT_634450] u
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. group as applicable using observed case and LOCF imputed data based on the RS u nless 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nless 
The below listed efficacy variables will be summarized descriptively by [CONTACT_634350]. The below listed efficacy variables will be summarized descriptively by [CONTACT_634451]. group as applicable using observed case based on the RS unless otherwise specified
CZP plasma concentrations will be tabulated and summarized using PKSA (overall and by 
[CONTACT_122253]. CZP plasma concentrations will be tabulated and summarized using PKSA (overall and by 
[CONTACT_634447]) for each visit at which samples were taken during Part A using the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP Ab status) for each visit at which samples were taken during Part A using the 
geometric mean, 95% CI, geometric CV, arithmetic mean, arithmetic SD, medi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. geometric mean, 95% CI, geometric CV, arithmetic mean, arithmetic SD, medi
maximum. Plasma concentration time curves will be plotted overall, and by [CONTACT_634452]. maximum. Plasma concentration time curves will be plotted overall, and by [CONTACT_634453]. CZP plasma concentrations will be tabulated and summarized by [CONTACT_634454].) for
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP Ab status.) for
Part B using the geometric mean, 95% CI, geometric CV, arithmetic mean, arithmetic SD, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B using the geometric mean, 95% CI, geometric CV, arithmetic mean, arithmetic SD, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. median, minimum, and maximum. For each treatment group, plasma concentration time curves 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. median, minimum, and maximum. For each treatment group, plasma concentration time curves 
will be plotted overall, and by o
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be plotted overall, and by o verall anti
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. verall anti
Part B summaries will not include post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B summaries will not include post
for subjects who flare in Part B and start escape therapy including only the post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for subjects who flare in Part B and start escape therapy including only the post
Concentrations below the limit of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Concentrations below the limit of 
LLOQ divided by 2 for the calculation of descriptive statistics.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. LLOQ divided by 2 for the calculation of descriptive statistics.
Subgroup analyses based on age, gender, race, region, CRP level and mNY classification will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subgroup analyses based on age, gender, race, region, CRP level and mNY classification will be 
performed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. performed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
CZP plasma concentr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. CZP plasma concentr
which samples were taken during Part A by [CONTACT_634354], 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. which samples were taken during Part A by [CONTACT_634354], 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 136 of 149 geometric CV, arithmetic mean, arithmetic SD, median, minimum, and maximum. The table will 
be repeated for TE ADAb status with titer classification (see Section 9.2).  
For each treatment group, plasma concentration time curves of Part B will be plotted and 
repeated for TE ADAb status with titer classification (see Section 9.2). 
Part B figures will not include post-flare assessments. Separate figures will be produced for 
subjects who experience a experiencing a flare in Part B and start escape therapy including only the post-flare assessments. 
Spaghetti plots of CZP plasma concentrations by [CONTACT_634455] (see Section 9.2) will be presented for subjects with flare and no flare per NRI approach. 
Spaghetti plots of CZP plasma concentrations by [CONTACT_634357] (see Section 9.2). 
Individual plots by [CONTACT_634456]/ADAb titer and ASDAS score plotted on the 
Y-axes by [CONTACT_765] (X-axis) for the full treatment period, including SFU. Flare data will be displayed 
on the days relative to Part A.  
Concentrations below the limit of quantification (BLQ) will be replaced by [CONTACT_634363] 
2 for the calculation of descriptive statistics. 
Anomalous values will be not included in summaries/analysis and will be reviewed and flagged 
by [CONTACT_634364]. 
All CZP plasma concentration will be listed at subject-level. 
Change #[ADDRESS_846975] sample as above the cut point 
(ACP) or below the cut point (BCP). For any ADAb test samples with results that are ACP, a 
further confirmatory assay will be performed, the results of which will be determined as either ‘confirmed positive’ (CP) or ‘not confirmed positive’ (NCP). 
The following definitions will be applied regarding classification of test samples :. 
 An ADAb status will be confirmed as positive for any sample with an ADAb level that is 
ACP and CP. 
 An ADAb status of negative will be concluded for any sample with an ADAb level that is either BCP or ACP and NCP. 
Confirmed positive samples will be titrated. The dilution factor will be reported. The titer 
represents the last dilution factor of the sample’s titration series still scoring positive in the REDACTED COPY Concentrations below the limit of quantification (BLQ) will be replaced by [CONTACT_634457] (BLQ) will be replaced by [CONTACT_634458]/analysis and will be r
REDACTED COPY Anomalous values will be not included in summaries/analysis and will be r
All CZP plasma concentration will be listed at subject
REDACTED COPY All CZP plasma concentration will be listed at subject
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects who experience a experiencing a flare in Part B and start escape therapy including only 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. subjects who experience a experiencing a flare in Part B and start escape therapy including only 
Spaghetti plots of CZP plasma concentrations by [CONTACT_634376]. Spaghetti plots of CZP plasma concentrations by [CONTACT_634459] 
d titer classification (see Section 9.2) will be presented 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. d titer classification (see Section 9.2) will be presented 
Spaghetti plots of CZP plasma concentrations by [CONTACT_634376]. Spaghetti plots of CZP plasma concentrations by [CONTACT_634460]. per NRI by [CONTACT_634461]/ADAb titer and ASDAS score plotted on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Individual plots by [CONTACT_634456]/ADAb titer and ASDAS score plotted on the 
axis) for the full treatment period, including SFU. Flare data will be disp
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. axis) for the full treatment period, including SFU. Flare data will be disp
Concentrations below the limit of quantification (BLQ) will be replaced by [CONTACT_634462]. Concentrations below the limit of quantification (BLQ) will be replaced by [CONTACT_634458]/analysis and will be r
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Anomalous values will be not included in summaries/analysis and will be r
All CZP plasma concentration will be listed at subject
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All CZP plasma concentration will be listed at subject
Immunogenicity will be assessed through listing of individual results by [CONTACT_634365]. Immunogenicity will be assessed through listing of individual results by [CONTACT_18464]. Immunogenicity data will be correlated with PK and efficacy readout. In addition, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tables. Immunogenicity data will be correlated with PK and efficacy readout. In addition, 
immunogenicity will be correlated with possible safety findings. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. immunogenicity will be correlated with possible safety findings. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. oint will be determined by [CONTACT_634463]. This 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. oint will be determined by [CONTACT_634463]. This 
cutpoint will be used to determine the status of ADAb in the test sample as above the cut point 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. cutpoint will be used to determine the status of ADAb in the test sample as above the cut point 
(ACP) or below the cut point (BCP). For any ADAb test samples with results
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (ACP) or below the cut point (BCP). For any ADAb test samples with results
further confirmatory assay will be performed, the results of which will be determined as either 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. further confirmatory assay will be performed, the results of which will be determined as either 
‘confirmed positive’ (CP) or ‘not confirmed positive’ (NCP).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ‘confirmed positive’ (CP) or ‘not confirmed positive’ (NCP).
The following definitions will be applied regarding classification of test samples
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following definitions will be applied regarding classification of test samples
An ADAb status will be confirmed as positive for any sample with an ADAb level that is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. An ADAb status will be confirmed as positive for any sample with an ADAb level that is 
ACP and CP.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ACP and CP.
UCB   [ADDRESS_846976]- Baseline results, and be classified as follows based on the ADAb assay results:. 
 ADAb negative: no confirmed positive ADAb samples at any of the sampling time points. 
 ADAb positive: confirmed positive ADAb samples at one or more sampling time points.  
Summaries will be done separately in Part A by [CONTACT_634464] B by [CONTACT_634417].  Part B summary will not include post-flare assessments. Separate summary by [CONTACT_634465] B and start escape therapy including only the post-flare assessments. 
Has been changed to: 
Immunogenicity will be assessed through listing of individual results by [CONTACT_18464]. Immunogenicity data will be correlated with PK and efficacy readout.  
A cut point will be determined by [CONTACT_634463]. This cut 
point will be used to determine the status of ADAb in the test sample.  
The following definitions will be applied regarding classification of test samples: 
 An ADAb status will be confirmed as positive for any sample with an ADAb level that is 
positive screen and positive immunodepletion.  
 An ADAb status of negative will be concluded for any sample with an ADAb level that is either negative screen or positive screen and negative immunodpepletion. 
Confirmed positive samples will be titrated. The dilution factor will be reported. The titer 
represents the last dilution factor of the sample’s titration series still scoring positive in the 
screening ADAb assay. ADAb titer dilution factor is presented in the listings and summaries 
excluding the minimum required dilution (MRD), i.e. reportable values are divided by 100.  
If the titer for an ADAb level that is positive screen and positive immunodepletion is missing, then a conservative will be used and ADAb status will be consider as positive. No imputation rules apply for the missing titer. 
If the ADAb level is positive screen but no confirmatory result could be determined, then then a 
conservative will be used and ADAb status will be consider as positive. 
Anomalous value will be not included in summaries/analysis and will be reviewed and flagged 
by [CONTACT_634364]. 
Subjects will have the following Baseline ADAb status: 
Baseline ADAb Status positive is defined as having an ADAb confirmed positive inhibition 
result at baseline, Baseline ADAb Status negative is defined as having negative inhibition result 
at baseline. 
Subjects will receive a treatment-emergent ADAb status, inclusive of Baseline and Post- Baseline 
results (including SFU), and be classified as follows based on the ADAb assay results: 
 TE ADAb status positive is defined as either (i) baseline ADAb negative subjects having at 
least one ADAb confirmed positive sample post baseline or ii) baseline ADAb positive subjects with at least one post baseline sample with ≥minimum significant ratio (MSR) - fold REDACTED COPY An ADAb status of negative will be concluded for any sample with an ADAb level that is 
REDACTED COPY An ADAb status of negative will be concluded for any sample with an ADAb level that is 
either negative screen or positive screen and negative immunodpepletion.
REDACTED COPY either negative screen or positive screen and negative immunodpepletion.
Confirmed positive samples will be titrated. The d
REDACTED COPY Confirmed positive samples will be titrated. The d
represents the last dilution factor of the sample’s titration series still scoring positive in the 
REDACTED COPY represents the last dilution factor of the sample’s titration series still scoring positive in the 
screening ADAb assay. ADAb titer dilution factor is presented in the listings and summaries REDACTED COPY screening ADAb assay. ADAb titer dilution factor is presented in the listings and summaries 
required dilution (MRD), i.e. reportable values are divided by 100. REDACTED COPY required dilution (MRD), i.e. reportable values are divided by 100. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. flare in 
Immunogenicity will be assessed through listing of individual results by [CONTACT_634365]. Immunogenicity will be assessed through listing of individual results by [CONTACT_18464]. Immunogenicity data will be correlated with PK and efficacy readout. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. tables. Immunogenicity data will be correlated with PK and efficacy readout. 
A cut point will be determined by [CONTACT_634366]. A cut point will be determined by [CONTACT_634466]. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. will be used to determine the status of ADAb in the test sample. 
The following definitions will be applied regarding classification of test samples:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following definitions will be applied regarding classification of test samples:
An ADAb status will be confirmed as positive for any sample with an ADAb level that is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. An ADAb status will be confirmed as positive for any sample with an ADAb level that is 
An ADAb status of negative will be concluded for any sample with an ADAb level that is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. An ADAb status of negative will be concluded for any sample with an ADAb level that is 
either negative screen or positive screen and negative immunodpepletion.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. either negative screen or positive screen and negative immunodpepletion.
Confirmed positive samples will be titrated. The d
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Confirmed positive samples will be titrated. The d ilution factor will be reported. The titer 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ilution factor will be reported. The titer 
represents the last dilution factor of the sample’s titration series still scoring positive in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. represents the last dilution factor of the sample’s titration series still scoring positive in the 
screening ADAb assay. ADAb titer dilution factor is presented in the listings and summaries 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. screening ADAb assay. ADAb titer dilution factor is presented in the listings and summaries 
required dilution (MRD), i.e. reportable values are divided by 100. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. required dilution (MRD), i.e. reportable values are divided by 100. 
If the titer for an ADAb level that is positive screen and positive immunodepletion is missing, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the titer for an ADAb level that is positive screen and positive immunodepletion is missing, 
then a conservative will be used and ADAb status will be consider as positive. No imputatio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. then a conservative will be used and ADAb status will be consider as positive. No imputatio
rules apply for the missing titer.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rules apply for the missing titer.
If the ADAb level is positive screen but no confirmatory result could be determined, then then a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If the ADAb level is positive screen but no confirmatory result could be determined, then then a 
conservative will be used and ADAb status will be consider as positive.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. conservative will be used and ADAb status will be consider as positive.
Anomalous value will be not included in summaries/
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Anomalous value will be not included in summaries/
by [CONTACT_634467]. by [CONTACT_634468]:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subjects will have the following Baseline ADAb status:
Baseline ADAb Status positive is defined as having an ADAb confirmed positive inhibition 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Baseline ADAb Status positive is defined as having an ADAb confirmed positive inhibition 
result at baseline, Baseline ADAb Status negati
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. result at baseline, Baseline ADAb Status negati
at baseline.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. at baseline.
Subjects will receive a treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Subjects will receive a treatment
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 138 of 149 increase from baseline on CZP treatment. The MSR will be defined during the process of 
sample analysis and is disease-specific. 
 TE ADAb status negative is defined as having no samples either ADAb positive or with 
values ≥MSR -fold increase from baseline.  
Once determined positive, the highest titer during Part A and Part B (including Escape and SFU) 
is used to categorize the subject. 
 Positive <512,  
 Positive 512- <=1024,  
 Positive >1024. 
In addition, for some outputs also the subjects with TE ADAb status negative will be presented. 
The TE ADAb will be also defined for the different treatment periods. For each Period the SFU 
visit will be considered:  
 Part A TE ADAb status positive is defined as either (i) baseline ADAb negative subjects 
having at least one ADAb confirmed positive sample post baseline during Part A or ii) baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
from baseline on CZP treatment during Part A. Once determined positive, the highest titer 
during Part A is used to categorize the subject. 
 Part A TE ADAb status negative is defined as having no samples either ADAb positive or with values ≥MSR increase from baseline during Part A.  
 Part B TE ADAb Status positive is defined as either (i) baseline ADAb negative subjects having at least one ADAb confirmed positive sample post baseline during Part B or ii) 
baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
from baseline on CZP treatment during Part B. Once determined positive, only the highest titer during Part is used to categorize the subject. For subjects with flare in Part B, any assessments after Escape treatment are not included. 
 Part B TE ADAb Status negative is defined as having no samples either ADAb positive or with values ≥MSR increase from baseline during Part B (excluding any values up to [ADDRESS_846977] Part B dose).  
 Escape TE ADAb Status positive is defined as either (i) baseline ADAb negative subjects having at least one ADAb confirmed positive sample post baseline during Escape Part or ii) 
baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
from baseline on CZP treatment during Escape Part B. Once determined positive, only the highest titer during Escape is used to categorize the subject. 
 Escape TE ADAb Status negative is defined as having no samples either ADAb positive or 
with values ≥MSR increase from baseline during Escape Part. Once determined positive, 
only the highest titer during Escape is used to categorize the subject. 
Summaries will be done using PKSB.  REDACTED COPY from baseline on CZP treatment during Part A. Once determined positive, the highest titer 
REDACTED COPY from baseline on CZP treatment during Part A. Once determined positive, the highest titer 
rt A is used to categorize the subject.
REDACTED COPY rt A is used to categorize the subject.
Part A TE ADAb status negative is defined as having no samples either ADAb positive or 
REDACTED COPY Part A TE ADAb status negative is defined as having no samples either ADAb positive or 
with values ≥MSR increase from baseline during Part A. 
REDACTED COPY with values ≥MSR increase from baseline during Part A. 
Part B TE ADAb Status positive is defined as either (i) baseline ADAb neg
REDACTED COPY Part B TE ADAb Status positive is defined as either (i) baseline ADAb neg
having at least one ADAb confirmed positive sample post baseline during Part B or ii) REDACTED COPY having at least one ADAb confirmed positive sample post baseline during Part B or ii) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. negative will be presented.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. negative will be presented.
The TE ADAb will be also defined for the different treatment periods. For each Period the SFU 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The TE ADAb will be also defined for the different treatment periods. For each Period the SFU 
Part A TE ADAb status positive is defined as either (i) baseline ADAb negative subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A TE ADAb status positive is defined as either (i) baseline ADAb negative subjects 
ADAb confirmed positive sample post baseline during Part A or ii) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb confirmed positive sample post baseline during Part A or ii) 
baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
from baseline on CZP treatment during Part A. Once determined positive, the highest titer 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from baseline on CZP treatment during Part A. Once determined positive, the highest titer 
Part A TE ADAb status negative is defined as having no samples either ADAb positive or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part A TE ADAb status negative is defined as having no samples either ADAb positive or 
with values ≥MSR increase from baseline during Part A. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with values ≥MSR increase from baseline during Part A. 
Part B TE ADAb Status positive is defined as either (i) baseline ADAb neg
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B TE ADAb Status positive is defined as either (i) baseline ADAb neg
having at least one ADAb confirmed positive sample post baseline during Part B or ii) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. having at least one ADAb confirmed positive sample post baseline during Part B or ii) 
baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
from baseline on CZP treatment during Part B. Once determined pos
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from baseline on CZP treatment during Part B. Once determined pos
titer during Part is used to categorize the subject. For subjects with flare in Part B, any 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. titer during Part is used to categorize the subject. For subjects with flare in Part B, any 
assessments after Escape treatment are not included.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. assessments after Escape treatment are not included.
Part B TE ADAb Status negative is defined as having no samples either ADAb positive or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Part B TE ADAb Status negative is defined as having no samples either ADAb positive or 
with values ≥MSR increase from baseline during Part B (excluding any values up to 8 weeks 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with values ≥MSR increase from baseline during Part B (excluding any values up to [ADDRESS_846978] Part B dose). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. post first Part B dose). 
Escape TE ADAb Status positive is defined as either (i) baseline ADAb negative subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape TE ADAb Status positive is defined as either (i) baseline ADAb negative subjects 
having at least one ADAb confirmed positive sample p
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. having at least one ADAb confirmed positive sample p
baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. baseline ADAb positive subjects with at least one post baseline sample with ≥MSR increase 
from baseline on CZP treatment during Escape Part B. Once determined positive, only the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from baseline on CZP treatment during Escape Part B. Once determined positive, only the 
highest titer during Escape is used to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. highest titer during Escape is used to 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape TE ADAb Status negative is defined as having no samples either ADAb positive or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape TE ADAb Status negative is defined as having no samples either ADAb positive or 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 139 of 149 Summary of shift from Baseline ADAb status with titer classification to TE ADAb Status with 
titer classification by [CONTACT_634368].  
The shift table will be repeated for  
 Part A TE ADAb status with titer classification to Part B TE ADAb status with titer 
classification by [CONTACT_634369] B.  
 Part B TE ADAb status with Part B titer classification to Escape Part TE ADAb status with Escape titer classification by [CONTACT_634370]. 
The time to achieving TE ADAb for all subjects will be analyzed based on Kaplan-Meier methods. Subjects will be considered to have an event at the time where treatment-emergent 
ADAb positive is first achieved during treatment period excluding Baseline/pre-treatment. 
Subjects classified as treatment-emergent ADAb negative will be censored at the time of last available ADAb result. The median and 95% CI based on the Kaplan-Meier estimation will also be presented. A plot of time to first ADAb positivity will be presented. 
Number and percentage of subjects with ADAb titer above the specified cut point 
(“categorized”) at any visit during the treatment period, separated by [CONTACT_2058]. 
A summary of flare responder during Part B (NRI) and ASDAS MI responder at Week 96 (NRI) 
by [CONTACT_634371] (“categorized”) per subject will be presented 
during Part A and Part B (excluding Escape). This table will be repeated for Part B (excluding 
Escape). 
A scatter plot of CZP Plasma Concentration and ADAb titer during Part A for all subjects will be 
presented. The scatter plot will be repeated for Part B by [CONTACT_1570]. 
Spaghet ti plots of ADAb titer on a loglog scale by [CONTACT_634372]/titer classification will be presented for subjects with flare 
and no flare per NRI approach. 
All individual ADAb results will be listed at subject level. 
Change #59 
[IP_ADDRESS] All subjects in SSB – Prior to Flare 
Exposure to study medication in Part B will be evaluated by [CONTACT_634469], the total number of CZP or PBO injections, the total number of CZP injections, 
the total amount of CZP received in mg, the total drug exposure duration in days, the patient time 
at risk and the total patient years at risk. Summaries will be based on the SSB and presented by [CONTACT_1570]. 
Has been changed to: 
Exposure to study medication in Part B will be evaluated by [CONTACT_634379], the total number of CZP injections, the total amount of CZP received in 
mg, the total drug exposure duration in days, the patient time at risk and the total patient years at risk. Summaries will be based on the SSB and presented by [CONTACT_1570]. REDACTED COPY A summary of flare responder during Part B (NRI) and ASDAS MI responder at Week 96 (NRI) 
REDACTED COPY A summary of flare responder during Part B (NRI) and ASDAS MI responder at Week 96 (NRI) 
by [CONTACT_634371] (“categorized”) per subject will be presented 
REDACTED COPY by [CONTACT_634371] (“categorized”) per subject will be presented 
cluding Escape). This table will be repeated for Part B (excluding 
REDACTED COPY cluding Escape). This table will be repeated for Part B (excluding 
A scatter plot of CZP Plasma Concentration and ADAb titer during Part A for all subjects will be 
REDACTED COPY A scatter plot of CZP Plasma Concentration and ADAb titer during Part A for all subjects will be 
presented. The scatter plot will be repeated for Part B by [CONTACT_1570]. REDACTED COPY presented. The scatter plot will be repeated for Part B by [CONTACT_1570].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb status with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb status with 
Escape titer classification by [CONTACT_634370].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Escape titer classification by [CONTACT_634370].
Meier 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Meier 
where treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. where treatment -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -emergent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emergent 
ADAb positive is first achieved during treatment period excluding Baseline/pre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ADAb positive is first achieved during treatment period excluding Baseline/pre -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -treatment. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment. 
emergent ADAb negative will be censored at the time of last 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. emergent ADAb negative will be censored at the time of last 
Meier estimation will also 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Meier estimation will also 
be presented. A plot of time to first ADAb positivity will be presented.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. be presented. A plot of time to first ADAb positivity will be presented.
Number and percentage of subjects with ADAb titer above the specified cut point 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Number and percentage of subjects with ADAb titer above the specified cut point 
separated by [CONTACT_634374]. separated by [CONTACT_634375] 
A summary of flare responder during Part B (NRI) and ASDAS MI responder at Week 96 (NRI) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A summary of flare responder during Part B (NRI) and ASDAS MI responder at Week 96 (NRI) 
by [CONTACT_634371] (“categorized”) per subject will be presented 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. by [CONTACT_634371] (“categorized”) per subject will be presented 
cluding Escape). This table will be repeated for Part B (excluding 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. cluding Escape). This table will be repeated for Part B (excluding 
A scatter plot of CZP Plasma Concentration and ADAb titer during Part A for all subjects will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A scatter plot of CZP Plasma Concentration and ADAb titer during Part A for all subjects will be 
presented. The scatter plot will be repeated for Part B by [CONTACT_1570].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. presented. The scatter plot will be repeated for Part B by [CONTACT_1570].
ti plots of ADAb titer on a loglog scale by [CONTACT_634376]. ti plots of ADAb titer on a loglog scale by [CONTACT_634372]/titer classification will be presented for subjects with flare 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group and TE ADAb status/titer classification will be presented for subjects with flare 
and no flare per NRI approach.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and no flare per NRI approach.
All individual ADAb results will be listed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All individual ADAb results will be listed 
All subjects in SSB 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All subjects in SSB 
Exposure to study medication in Part B will be evaluated by [CONTACT_634377]. Exposure to study medication in Part B will be evaluated by [CONTACT_634469], the total number of CZP or PBO injections, the total number of CZP inject
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. PBO injections, the total number of CZP or PBO injections, the total number of CZP inject
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the total amount of CZP received in mg, the total drug exposure duration in days, the patient time 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the total amount of CZP received in mg, the total drug exposure duration in days, the patient time 
at risk and the total patient years at risk. Summaries will be based on the SSB and presented by 
[CONTACT_122253]. at risk and the total patient years at risk. Summaries will be based on the SSB and presented by 
[CONTACT_1570].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment group.
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been changed to:
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 140 of 149 Change #60  
10.2 Adverse events 
Overall summaries of AEs will be produced to present the number of events and number and 
percentage of subjects with: 
• Any TEAE 
• Any serious TEAE 
• Any TEAE leading to study discontinuation • Any drug-related TEAE 
• Any severe TEAE 
• Deaths (TEAE leading to death) 
In addition, the following AE summaries will be presented: 
• All TEAEs by [CONTACT_148274], HLT, and PT 
• All serious TEAEs by [CONTACT_148274], HLT, and PT • All non-serious TEAEs by [CONTACT_148274], HLT, and PT 
• All TEAEs leading to permanent discontinuation of study drug by [CONTACT_148274], HLT, and 
PT 
• All TEAEs leading to death by [CONTACT_148274], HLT, and PT 
• All TEAEs by [CONTACT_148274], PT, and maximum intensity 
• All TEAEs by [CONTACT_148274], PT, and maximum relationship 
• All serious TEAEs by [CONTACT_148274], PT and maximum relationship 
• All non-serious TEAEs by [CONTACT_148274], PT and maximum relationship 
• All TEAEs above reporting threshold of 5% by [CONTACT_183008] • All non-serious TEAEs above reporting threshold of 5% by [CONTACT_183008]  
• All non-serious TEAEs above reporting threshold of 5% by [CONTACT_148274], PT and maximum 
relationship 
• All injection related TEAEs by [CONTACT_148274], HLT, and PT 
AE summary tables will also be produced to display the exposure adjusted incidence rate (EAIR) 
with associated 95% CI, and the exposure adjusted event rate (EAER): 
• All TEAEs by [CONTACT_148274], HLT, and PT 
• All serious TEAEs by [CONTACT_148274], HLT, and PT 
Has been changed to: 
Overall summaries of AEs will be produced to present the number of events and number and 
percentage of subjects with: 
 Any TEAE REDACTED COPY serious TEAEs by [CONTACT_148274], HLT, and PT
REDACTED COPY serious TEAEs by [CONTACT_148274], HLT, and PT
All TEAEs leading to permanent discontinuation of study drug by [CONTACT_148274], HLT, and 
REDACTED COPY All TEAEs leading to permanent discontinuation of study drug by [CONTACT_148274], HLT, and 
All TEAEs leading to death by [CONTACT_148274], HLT, and PT
REDACTED COPY All TEAEs leading to death by [CONTACT_148274], HLT, and PT
T, and maximum intensity
REDACTED COPY T, and maximum intensity
All TEAEs by [CONTACT_148274], PT, and maximum relationship REDACTED COPY All TEAEs by [CONTACT_148274], PT, and maximum relationship
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs leading to permanent discontinuation of study drug by [CONTACT_148274], HLT, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs leading to permanent discontinuation of study drug by [CONTACT_148274], HLT, and 
All TEAEs leading to death by [CONTACT_148274], HLT, and PT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs leading to death by [CONTACT_148274], HLT, and PT
T, and maximum intensity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. T, and maximum intensity
All TEAEs by [CONTACT_148274], PT, and maximum relationship
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs by [CONTACT_148274], PT, and maximum relationship
All serious TEAEs by [CONTACT_148274], PT and maximum relationship
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All serious TEAEs by [CONTACT_148274], PT and maximum relationship
serious TEAEs by [CONTACT_148274], PT and maximum relationship
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. serious TEAEs by [CONTACT_148274], PT and maximum relationship
All TEAEs above reporting threshold of 5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs above reporting threshold of 5
serious TEAEs above reporting threshold of 5% by [CONTACT_634470]. serious TEAEs above reporting threshold of 5% by [CONTACT_634471] 5% by [CONTACT_148274], PT and maximum 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. serious TEAEs above reporting threshold of 5% by [CONTACT_148274], PT and maximum 
All injection related TEAEs by [CONTACT_148274], HLT, an
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All injection related TEAEs by [CONTACT_148274], HLT, an
AE summary tables will also be produced to display the exposure adjusted incidence rate (EAIR) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AE summary tables will also be produced to display the exposure adjusted incidence rate (EAIR) 
with associated 95% CI, and the exposure adjusted event rate (EAER):
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with associated 95% CI, and the exposure adjusted event rate (EAER):
All TEAEs by [CONTACT_148274], HLT, and PT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs by [CONTACT_148274], HLT, and PT
•
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. •
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 141 of 149  Any serious TEAE 
 Any TEAE leading to study discontinuation 
 Permanent withdrawal of study medication due to TEAEs 
 Any drug-related TEAE 
 Any severe TEAE 
 All Deaths (AEs leading to death) 
 Deaths (TEAE leading to death) 
In addition, the following AE summaries will be presented: 
 All TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d) 
 All serious TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d) 
 All TEAEs leading to permanent discontinuation of study drug by [CONTACT_148274], HLT, and 
PT (for the Parts/Analysis sets a, b, c, d) 
 All TEAEs leading to death by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, 
c) 
 All TEAEs by [CONTACT_148274], PT, and maximum intensity (for the Parts/Analysis sets a, b, c, 
d) 
 All TEAEs by [CONTACT_148274], PT, and maximum relationship (for the Parts/Analysis sets a, b, c, d) 
 All serious TEAEs by [CONTACT_148274], PT and maximum relationship (for the Parts/Analysis sets a, b, c, d) 
 All TEAEs above reporting threshold of 5% by [CONTACT_183008] (for the Parts/Analysis sets a, b, c, d) 
 All non-serious TEAEs above reporting threshold of 5% by [CONTACT_183008] (for the 
Parts/Analysis sets a, b, c) 
 All injection related TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, 
c, d) 
AE summary tables will also be produced to display the exposure adjusted incidence rate (EAIR) 
with associated 95% CI, and the exposure adjusted event rate (EAER): 
 All TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d) 
 All serious TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d) 
Change #61 
10.2 Adverse events 
For EAERs, the numerator will be the number of AEs including repeat occurrences in individual 
subjects; the denominator will be 100 patient-years. That is, the total summation of individual patient-years at risk divided by 100. No CI will be computed for EAER. REDACTED COPY All TEAEs by [CONTACT_148274], PT, and maximum intensity (for the Parts/Analysis sets a, b, c, 
REDACTED COPY All TEAEs by [CONTACT_148274], PT, and maximum intensity (for the Parts/Analysis sets a, b, c, 
All TEAEs by [CONTACT_148274], PT, and maximum relationship (for the Parts/Analysis sets a, b, 
REDACTED COPY All TEAEs by [CONTACT_148274], PT, and maximum relationship (for the Parts/Analysis sets a, b, 
rimary SOC, PT and maximum relationship (for the Parts/Analysis REDACTED COPY rimary SOC, PT and maximum relationship (for the Parts/Analysis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d)
us TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. us TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, c, d)
All TEAEs leading to permanent discontinuation of study drug by [CONTACT_148274], HLT, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs leading to permanent discontinuation of study drug by [CONTACT_148274], HLT, and 
and PT (for the Parts/Analysis sets a, b, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and PT (for the Parts/Analysis sets a, b, 
All TEAEs by [CONTACT_148274], PT, and maximum intensity (for the Parts/Analysis sets a, b, c, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs by [CONTACT_148274], PT, and maximum intensity (for the Parts/Analysis sets a, b, c, 
All TEAEs by [CONTACT_148274], PT, and maximum relationship (for the Parts/Analysis sets a, b, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs by [CONTACT_148274], PT, and maximum relationship (for the Parts/Analysis sets a, b, 
rimary SOC, PT and maximum relationship (for the Parts/Analysis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. rimary SOC, PT and maximum relationship (for the Parts/Analysis 
All TEAEs above reporting threshold of 5% by [CONTACT_183008] (for the Parts/Analysis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs above reporting threshold of 5% by [CONTACT_183008] (for the Parts/Analysis 
serious TEAEs above reporting threshold of 5% by [CONTACT_148274] a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. serious TEAEs above reporting threshold of 5% by [CONTACT_148274] a
Parts/Analysis sets a, b, c)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Parts/Analysis sets a, b, c)
All injection related TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All injection related TEAEs by [CONTACT_148274], HLT, and PT (for the Parts/Analysis sets a, b, 
AE summary tables will also be produced to display the exposure adjusted incidence
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. AE summary tables will also be produced to display the exposure adjusted incidence
with associated 95% 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with associated 95% 
All TEAEs by [CONTACT_148274], HLT, and PT 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All TEAEs by [CONTACT_148274], HLT, and PT 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All serious TEAEs by [CONTACT_148274], HLT, and PT 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. All serious TEAEs by [CONTACT_148274], HLT, and PT 
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 142 of 149 The following AE summary tables will be repeated by [CONTACT_634443]-CZP Ab status 
(positive/negative): 
 Overall summary of AEs 
 All TEAEs by [CONTACT_148274], HLT, and PT  
 All serious TEAEs by [CONTACT_148274], HLT, and PT 
The following AEs of interest will be summarized: 
1. Serious infections, including opportunistic infections 
2. Malignancies, including lymphoma 
3. Serious cardiovascular events 
Has been changed to: 
The TEAE summary table will be presented by [CONTACT_634391] (Prior to becoming ADAb Positive>=1024, After becoming ADAb 
Positive>=1024, Subjects Who Never Became ADAb Positive>=1024) based on PKSB.)  
The following AEs of interest will be summarized: 
1. Serious infections, including opportunistic infections 
2. Malignancies, including lymphoma 
3. Serious cardiovascular events (i.e. Major adverse cardiac events or MACE) 
Change #62 
10.2 Adverse events 
 Ischaemic central nervous system vascular conditions (SMQ)  
Has been changed to: 
 Ischaemic central nervous system vascular conditions (SMQ) except events coding to PT 
“Transient ischaemic attack” 
Change #63 
10.2 Adverse events 
The following part has been added: 
Injection reactions are identified by [CONTACT_69861]. 
The following Category C consists of the following PTs has been added: 
 Rash erythematous 
Change #[ADDRESS_846979] as 
well as for hepatic events, hypersensitivity reactions and anaphylactic reactions: REDACTED COPY Serious infections, including opportunistic infections
REDACTED COPY Serious infections, including opportunistic infections
Serious cardiovascular events (i.e. Major adverse cardiac events or MACE)
REDACTED COPY Serious cardiovascular events (i.e. Major adverse cardiac events or MACE)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The TEAE summary table will be presented by [CONTACT_634472]. The TEAE summary table will be presented by [CONTACT_634473]>=1024, After becoming ADAb 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. becoming ADAb Positive>=1024, After becoming ADAb 
Positive>=1024, Subjects Who Never Became ADAb Positive>=1024) based on PKSB.)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Positive>=1024, Subjects Who Never Became ADAb Positive>=1024) based on PKSB.)
Serious cardiovascular events (i.e. Major adverse cardiac events or MACE)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Serious cardiovascular events (i.e. Major adverse cardiac events or MACE)
Ischaemic central nervous system vascular conditions (SMQ) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ischaemic central nervous system vascular conditions (SMQ) 
Ischaemic central nervous system vascular conditio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Ischaemic central nervous system vascular conditio
“Transient ischaemic attack”
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. “Transient ischaemic attack”
Adverse events
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Adverse events
The following part has been added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following part has been added:
Injection reactions are identified by [CONTACT_69861].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Injection reactions are identified by [CONTACT_69861].
The following 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Rash erythematous
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Rash erythematous
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 143 of 149 Has been changed to: 
The following AE summary tables (for the Parts/Analysis sets a, b, c, d) will be used as the basis 
for presentation of AEs of interest as well as for hepatic events, hypersensitivity reactions and anaphylactic reactions: 
Change #65 
10.3 Clinical laboratory evaluations 
Testing for hepatitis B surface antigen and antibodies to hepatitis C and HIV will be performed at Screening. Screening for HLA-B27 will be performed at Baseline only. These data will be listed only. 
Has been changed to: 
Testing for hepatitis B surface antigen and antibodies to hepatitis C and HIV will be performed at Screening. HLA-B27 will be performed at Baseline only. These data will be listed only. 
Change #66 
10.3 Clinical laboratory evaluations 
Descriptive statistics for observed values and change from Baseline will be presented for each scheduled visit for the following parameters:  
… 
 Biochemistry: sodium, potassium, chloride, bicarbonate, total calcium, inorganic phosphorus, 
creatine phosphokinase (CPK), glucose, creatinine, uric acid, urea, total protein, albumin, 
alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), bilirubin, total cholesterol 
Has been changed to: 
Descriptive statistics for observed values and change from Part A Baseline will be presented for each scheduled visit for the following parameters:  
… 
 Biochemistry: sodium, potassium, chloride, bicarbonate, total calcium, inorganic phosphorus, 
creatine phosphokinase (CPK), glucose, creatinine, uric acidurate, urea nitrogen, total 
protein, albumin, alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), bilirubin, total cholesterol 
Change #[ADDRESS_846980] been added: 
A by-subject listing of all laboratory data will be provided. This listing will be presented by 
[CONTACT_1570], results (with abnormal values flagged) and unit. In the listing for biochemistry also Glomerular Filtration Rate will be added. 
… REDACTED COPY erved values and change from Baseline will be presented for each 
REDACTED COPY erved values and change from Baseline will be presented for each 
Biochemistry: sodium, potassium, chloride, bicarbonate, total calcium, inorganic phosphorus, 
REDACTED COPY Biochemistry: sodium, potassium, chloride, bicarbonate, total calcium, inorganic phosphorus, 
creatine phosphokinase (CPK), glucose, creatinine
REDACTED COPY creatine phosphokinase (CPK), glucose, creatinine
alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase 
REDACTED COPY alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), bilirubin, total cholesterol REDACTED COPY (ALT), bilirubin, total cholesterol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Testing for hepatitis B surface antigen and antibodies to hepatitis C and HIV will be performed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Testing for hepatitis B surface antigen and antibodies to hepatitis C and HIV will be performed 
B27 will be performed at Baseline only. These data will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B27 will be performed at Baseline only. These data will be 
for hepatitis B surface antigen and antibodies to hepatitis C and HIV will be performed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. for hepatitis B surface antigen and antibodies to hepatitis C and HIV will be performed 
B27 will be performed at Baseline only. These data will be listed only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. B27 will be performed at Baseline only. These data will be listed only.
erved values and change from Baseline will be presented for each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. erved values and change from Baseline will be presented for each 
Biochemistry: sodium, potassium, chloride, bicarbonate, total calcium, inorganic phosphorus, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Biochemistry: sodium, potassium, chloride, bicarbonate, total calcium, inorganic phosphorus, 
creatine phosphokinase (CPK), glucose, creatinine
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. creatine phosphokinase (CPK), glucose, creatinine
alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase 
Descriptive statistics for observed values and change from Part A Base
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Descriptive statistics for observed values and change from Part A Base
each scheduled visit for the following parameters: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. each scheduled visit for the following parameters: 
Biochemistry: sodium, potassium, chloride, bicarbonate, total calcium, inorganic phosphorus, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Biochemistry: sodium, potassium, chloride, bicarbonate, total calcium, inorganic phosphorus, 
creatine phosphokinase (CPK), glucose, creatinine, uric acidurate, urea nitrogen, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. creatine phosphokinase (CPK), glucose, creatinine, uric acidurate, urea nitrogen, 
protein, albumin, alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. protein, albumin, alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), bilirubin, total cholesterol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. aminotransferase (ALT), bilirubin, total cholesterol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change # [ADDRESS_846981] been added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following parts have been added:
A by
[CONTACT_122253]. A by
[CONTACT_18338]   [ADDRESS_846982] listing of markedly abnormal values will be provided separately. 
… 
A by-subject listing for any subject with at least one post-baseline elevated test data will be 
provided. The listing includes all liver function test laboratory values for this subject.  
Samples and results for additional laboratory tests (hepatitis B surface antigen and antibodies to 
hepatitis C and HIV, Genomics Laboratory Data) will be listed separately. 
Change #68 
10.4.1 Vital signs 
Descriptive statistics for observed values and change from Baseline will be presented for each 
scheduled visit for each vital sign parameter. 
Has been changed to: 
Descriptive statistics for observed values and change from Part A Baseline will be presented for 
each scheduled visit for each vital sign parameter. 
Change #69 
[IP_ADDRESS] Pregnancy testing 
Pregnancy testing must be carried out for women of childbearing potential and will consist of 
serum testing at Screening and SFU, and urine testing at Baseline and Week 96/withdrawal Visit. Pregnancy test results will be listed only. 
Has been changed to: 
Pregnancy testing must be carried out for women of childbearing potential and will consist of serum testing at Screening and SFU, and urine testing at Baseline and Week 96/withdrawal Visit. Pregnancy test results (i.e. Choriogonadotropin Beta) will be listed only. 
Change #70  
[IP_ADDRESS] Physical assessments 
Summary statistics will be provided by [CONTACT_634295] A using the SS and by [CONTACT_7238] B using the SSB by [CONTACT_634474], height and BMI, as applicable.  
Has been changed to: 
Summary statistics will be provided by [CONTACT_634295] A using the SS 
and by [CONTACT_7238] B using the SSB by [CONTACT_634475] A Baseline for weight, height and BMI, as applicable. 
Change #71 
11 REFERENCES 
The following reference has been added: REDACTED COPY Pregnancy testing must be carried out for women of childbearing potential and will consist of 
REDACTED COPY Pregnancy testing must be carried out for women of childbearing potential and will consist of 
serum testing at Screening and SFU, and urine testing at Baseline and Week 96/withdrawal Visit. 
REDACTED COPY serum testing at Screening and SFU, and urine testing at Baseline and Week 96/withdrawal Visit. 
Pregnancy testing must be carried out for women of childbearing potential and will consist of REDACTED COPY Pregnancy testing must be carried out for women of childbearing potential and will consist of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. presented for each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. presented for each 
Descriptive statistics for observed values and change from Part A Baseline will be presented for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Descriptive statistics for observed values and change from Part A Baseline will be presented for 
Pregnancy testing must be carried out for women of childbearing potential and will consist of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pregnancy testing must be carried out for women of childbearing potential and will consist of 
serum testing at Screening and SFU, and urine testing at Baseline and Week 96/withdrawal Visit. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. serum testing at Screening and SFU, and urine testing at Baseline and Week 96/withdrawal Visit. 
Pregnancy testing must be carried out for women of childbearing potential and will consist of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pregnancy testing must be carried out for women of childbearing potential and will consist of 
serum testing at Screening and SFU, and urine testing at Baseline and Week 96/withdrawal Visit. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. serum testing at Screening and SFU, and urine testing at Baseline and Week 96/withdrawal Visit. 
Pregnancy test results (i.e. Choriogonadotropin B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Pregnancy test results (i.e. Choriogonadotropin B
Physical assessments
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Physical assessments
Summary statistics will be provided by [CONTACT_634295] A using the SS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics will be provided by [CONTACT_634295] A using the SS 
and by [CONTACT_7238] B using the SSB by [CONTACT_634476]. and by [CONTACT_7238] B using the SSB by [CONTACT_634477], height and BMI, as applicable. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from Baseline for weight, height and BMI, as applicable. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been ch
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Has been ch anged to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. anged to:
Summary statistics will be provided by [CONTACT_634295] A using the SS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Summary statistics will be provided by [CONTACT_634295] A using the SS 
and by [CONTACT_7238] B using the SSB by [CONTACT_634476]. and by [CONTACT_7238] B using the SSB by [CONTACT_634476]. from Part A Baseline for weight, height and BMI, as applica
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from Part A Baseline for weight, height and BMI, as applica
Change #
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Change #
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 145 of 149 Machado PM, Landewé R, van der Heijde D, Assessment of SpondyloArthritis international 
Society (ASAS). Letter. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update 
of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77:1539-40. 
The following reference has been removed: 
Ware J.E., Jr., Kosinski M., Bjorner J.B., Turner-Bowker, D.M., Gandek, B. and Maruish, M.E. 
(2007) User's Manual for the SF-36v2TM Health Survey (2nd Ed). Lincoln, RI, QualityMetric Incorporated. 
Change #[ADDRESS_846983] distributions (Barber and 
Thompson, 2000). Standard non-parametric tests (that compare the overall shape of 
distributions) or log transformation to normalize data (that compare geometric means) are not always suitable because for cost data the analysis needs to focus on the arithmetic mean costs 
rather than the overall differences in the shape of the distribution, the medians, or the geometric 
means. The relevance of the arithmetic mean is that it can be used to calculate the total costs of treatment, which is needed to inform health economic policy decision makers. The non-
normality of cost distributions also means that standard parametric comparisons of means based 
on the normal distribution (ANOVA and two-sample t-tests) may not be suitable. In such cases, 
bootstrap techniques can be recommended when making inferences about arithmetic means for 
moderately sized samples of highly skewed data such as healthcare costs. The cost data approach 
will be applied to the WPS.  
The Bootstrap principle 
The bootstrap is a data based simulation method that is useful for deriving confidence intervals 
and hypothesis testing when the sampling distribution of an estimator is not known or cannot be defined mathematically.  
A balanced bootstrap resampling method (Gleason, 1988) is used to increase the precision of the 
bootstrap bias and the standard error (SE), where each observation occurs a total of B times in the collection of B bootstrap samples. This does not force each bootstrap sample to contain all 
observations; the first observation may occur twice in the first bootstrap sample and not at all in 
the second, while the second observation may occur once in each sample.  
Samples of the same size as the original sample used are drawn separately from each treatment 
group by [CONTACT_634478]. For each resample the statistic of 
interest (mean or difference in means) is calculated. The distribution of these B (where B = number of bootstrap samples) values provides an approximation of its population sampling 
distribution and can be used to estimate confidence intervals and to conduct hypothesis tests. 
Typi[INVESTIGATOR_897], a large number of bootstrap resamples are calculated ([ZIP_CODE] resamples in this analysis). REDACTED COPY l differences in the shape of the distribution, the medians, or the geometric 
REDACTED COPY l differences in the shape of the distribution, the medians, or the geometric 
means. The relevance of the arithmetic mean is that it can be used to calculate the total costs of 
REDACTED COPY means. The relevance of the arithmetic mean is that it can be used to calculate the total costs of 
treatment, which is needed to inform health economic policy decision makers. Th
REDACTED COPY treatment, which is needed to inform health economic policy decision makers. Th
normality of cost distributions also means that standard parametric comparisons of means based 
REDACTED COPY normality of cost distributions also means that standard parametric comparisons of means based 
on the normal distribution (ANOVA and two
REDACTED COPY on the normal distribution (ANOVA and two -
REDACTED COPY -sample t
REDACTED COPY sample t
bootstrap techniques can be recommended when making inference
REDACTED COPY bootstrap techniques can be recommended when making inference
moderately sized samples of highly skewed data such as healthcare costs. The cost data approach REDACTED COPY moderately sized samples of highly skewed data such as healthcare costs. The cost data approach 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following Section has been removed and the following Sections receive a new number. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The following Section has been removed and the following Sections receive a new number. 
em in the analysis of cost data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. em in the analysis of cost data 
from clinical trials to provide comparisons and inferences regarding the total costs associated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from clinical trials to provide comparisons and inferences regarding the total costs associated 
with each treatment group, in the presence of highly skewed cost distributions (Barber and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. with each treatment group, in the presence of highly skewed cost distributions (Barber and 
ric tests (that compare the overall shape of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ric tests (that compare the overall shape of 
distributions) or log transformation to normalize data (that compare geometric means) are not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. distributions) or log transformation to normalize data (that compare geometric means) are not 
always suitable because for cost data the analysis needs to focus on the arithmetic mean costs 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. always suitable because for cost data the analysis needs to focus on the arithmetic mean costs 
l differences in the shape of the distribution, the medians, or the geometric 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. l differences in the shape of the distribution, the medians, or the geometric 
means. The relevance of the arithmetic mean is that it can be used to calculate the total costs of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. means. The relevance of the arithmetic mean is that it can be used to calculate the total costs of 
treatment, which is needed to inform health economic policy decision makers. Th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. treatment, which is needed to inform health economic policy decision makers. Th
normality of cost distributions also means that standard parametric comparisons of means based 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. normality of cost distributions also means that standard parametric comparisons of means based 
sample t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. sample t
bootstrap techniques can be recommended when making inference
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. bootstrap techniques can be recommended when making inference
moderately sized samples of highly skewed data such as healthcare costs. The cost data approach 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. moderately sized samples of highly skewed data such as healthcare costs. The cost data approach 
The bootstrap is a data based simulation method that is useful for deriving co
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. The bootstrap is a data based simulation method that is useful for deriving co
and hypothesis testing when the sampling distribution of an estimator is not known or cannot be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. and hypothesis testing when the sampling distribution of an estimator is not known or cannot be 
defined mathematically. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. defined mathematically. 
A balanced bootstrap resampling method (Gleason, 1988) is used to increase the precision of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. A balanced bootstrap resampling method (Gleason, 1988) is used to increase the precision of the 
bootstrap bias and t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. bootstrap bias and t he standard error (SE), where each observation occurs a total of B times in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. he standard error (SE), where each observation occurs a total of B times in 
the collection of B bootstrap samples. This does not force each bootstrap sample to contain all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the collection of B bootstrap samples. This does not force each bootstrap sample to contain all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. observations; the first observation may occur twice in the first bootstrap sample an
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. observations; the first observation may occur twice in the first bootstrap sample an
the second, while the second observation may occur once in each sample. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. the second, while the second observation may occur once in each sample. 
Samples of the same size as the original sample used are drawn separately from each treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Samples of the same size as the original sample used are drawn separately from each treatment 
group by [CONTACT_634478]. For each resam
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. group by [CONTACT_634478]. For each resam
interest (mean or difference in means) is calculated. The distribution of these B (where B = 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. interest (mean or difference in means) is calculated. The distribution of these B (where B = 
number of bootstrap samples) values provides an approximation of its population sampling 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number of bootstrap samples) values provides an approximation of its population sampling 
UCB   [ADDRESS_846984] error. This is calculated for each bootstrap resample as: 
 
where M
b* is the difference in bootstrap means between treatment groups, M the observed 
difference in means between treatment groups, and SEb* the standard error of the bootstrap 
difference in means between treatment groups. 
The standard error of the difference in means is calculated using the same method as for a t- test 
with unequal variances: 
SEb* = sqrt [ ((SD Yb*)2/m) + ((SD Zb*)2/n) ] 
 
where SD Yb* and SD Zb* are the observed standard deviations of the bootstrap samples Y b* and 
Zb* in each treatment group (group Y with sample size m and group Z with sample size n). 
Note that in some rare cases SEb*=0. When SEb* and are both equal to 0, then 
 is considered to be 0. When SEb*=[ADDRESS_846985] t-distribution to obtain the approximate two-sided p-value: 
P-value       = #{|t b*| ≥|t obs|} / B, 
where tobs is the observed value of the test statistics. If the distribution of bootstrap-t values is close to the standard t-distribution then the p-value from the usual t-test and that from the 
bootstrap-t will be similar.  
It is recognized that the bootstrap-t test performs best on a variance-stabilized scale where the 
difference in means and its standard error are independent. This independence can be assessed 
from a plot of the bootstrap values (ie differences in means M
b*) against their corresponding 
standard errors ( SEb*). If there is a strong relationship between these, the test should be carried 
out after a variance stabilizing transformation. 
The current analysis will be conducted after a variance stabilizing transformation of the bootstrap 
values. (See details on the variance stabilizing transformation in Section 12.1.4)  
12.1.3 Bootstrap confidence intervals  *
b*
b*
b M)/SE (M T
M) (M*
b
*
b*
b*
b M)/SE (M T M) (M*
b
*
b*
b*
b M)/SE (M T
bootPˆREDACTED COPY are the observed standard deviations of the bootstrap samples 
REDACTED COPY are the observed standard deviations of the bootstrap samples 
in each treatment group (group Y with sample size m and group Z with sample size n).
REDACTED COPY in each treatment group (group Y with sample size m and group Z with sample size n).
Note that in some rare cases SEb*=0. When SEb* and 
REDACTED COPY Note that in some rare cases SEb*=0. When SEb* and 
is considered to be 0. When SEb*=0 and 
REDACTED COPY is considered to be 0. When SEb*=[ADDRESS_846986] error of the difference in means is calculated using the same method as for a t
/n) ]
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. /n) ]
are the observed standard deviations of the bootstrap samples 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. are the observed standard deviations of the bootstrap samples 
in each treatment group (group Y with sample size m and group Z with sample size n).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. in each treatment group (group Y with sample size m and group Z with sample size n).
Note that in some rare cases SEb*=0. When SEb* and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Note that in some rare cases SEb*=0. When SEb* and 
is considered to be 0. When SEb*=0 and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is considered to be 0. When SEb*=[ADDRESS_846987] error are independent. This independence can be assessed 
from a plot of the bootstrap values (ie differences in means 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. from a plot of the bootstrap values (ie differences in means 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. standard errors (
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. standard errors (
out after a variance stabilizing transformation.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. out after a variance stabilizing transformation.(M
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (M
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 147 of 149 To estimate a 100(1−α)per cent confidence interval, the 100(α/2)per cent and 100(1−α/2)per cent 
percentiles of T* (T* (α /2) and T* (1- α /2), respectively) are used.  
For the estimation of a 100(1-α) per cent confidence interval for the difference in means, the confidence interval is given by: 
(M - T*
(1- α /2) SE(M), M - T* (α /2) SE(M)) 
where M is the observed difference in means and SE(M) its standard error.  
The distribution of bootstrap-t values (T*) is obtained in the same way as previously described 
for hypothesis testing. The 100α percentile is estimated by [CONTACT_941] α(B+1)th member of the ordered bootstrap sample if this is a whole number; otherwise linear interpolation must be used (Davison and Hinkley, 1997).  
As before for the bootstrap test, this method of obtaining a confidence interval is best performed 
on a variance stabilized scale. The confidence interval is thus calculated on the variance 
stabilized scale and back transformed to obtain an interval on the original scale. (See details on the variance stabilizing transformation in Section 12.1.4)  
12.1.[ADDRESS_846988] presented in Section 12.1.2 gives different results if a different 
scale is used for the bootstrap differences in means M
b*, and will perform best on a variance 
stabilized scale where M and SE(M) are independent.  
The test will be carried out after a variance stabilizing transformation of the bootstrap values 
Mb*, say function g. Note that this is not the same as transforming the data since transforming the 
bootstrap values M b* will still allow a comparison of arithmetic means.  
The test statistic calculated for each resample is then given by 
[CONTACT_634479]* = g(Mb*) − g(M).  
There is no longer a need to divide by [CONTACT_634480].  
An estimate of the P-value for the test is then obtained by [CONTACT_634481] = g(M) − g(M0),  
where M 0 is the null value for the difference in means, usually 0) with the distribution of T b* 
values.   
If none of the values of M b* is equal to 0, then g(M 0) is interpolated by  
 
𝑔(𝑀 0) =𝑔(𝑀0−)+𝑔(𝑀 0+)
2, 
 
where M 0+ is the smallest value of M b* that is greater than [ADDRESS_846989] value of M b* 
that is less than 0. In cases where M 0+ does not exist, g(M 0) is estimated by g(M 0-). In cases 
where M 0- does not exist, g(M 0) is estimated by g(M 0+).  REDACTED COPY The bootstrap hypothesis test presented in Section 12.1.[ADDRESS_846990] presented in Section 12.1.2 gives different results if a different 
M
REDACTED COPY Mb
REDACTED COPY b*
REDACTED COPY *, and will perform best on a variance 
REDACTED COPY , and will perform best on a variance 
REDACTED COPY SE(M) are independent. 
REDACTED COPY SE(M) are independent. 
The test will be carried out after a variance stabilizing transformation of the bootstrap values 
REDACTED COPY The test will be carried out after a variance stabilizing transformation of the bootstrap values 
. Note that this is not the same as transforming the data since transforming the 
REDACTED COPY . Note that this is not the same as transforming the data since transforming the 
low a comparison of arithmetic means. 
REDACTED COPY low a comparison of arithmetic means. 
The test statistic calculated for each resample is then given by[CONTACT_634482]. t values (T*) is obtained in the same way as previously described 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. t values (T*) is obtained in the same way as previously described 
e ordered 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e ordered 
bootstrap sample if this is a whole number; otherwise linear interpolation must be used (Davison 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. bootstrap sample if this is a whole number; otherwise linear interpolation must be used (Davison 
As before for the bootstrap test, this method of obtaining a confidence interval is best performed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. As before for the bootstrap test, this method of obtaining a confidence interval is best performed 
e. The confidence interval is thus calculated on the variance 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. e. The confidence interval is thus calculated on the variance 
stabilized scale and back transformed to obtain an interval on the original scale. (See details on 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. stabilized scale and back transformed to obtain an interval on the original scale. (See details on 
The bootstrap hypothesis test presented in Section 12.1.[ADDRESS_846991] statistic calculated for each resample is then given by
T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Tb
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. * = g(Mb*) − g(M).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. * = g(Mb*) − g(M).
There is no longer a need to divide by [CONTACT_634483]. There is no longer a need to divide by [CONTACT_634480].
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. stabilized scale this will be constant.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. value for the test is then obtained by [CONTACT_634484]. value for the test is then obtained by [CONTACT_634485], usually 0) with the distribution of T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. is the null value for the difference in means, usually 0) with the distribution of T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If none of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. If none of the 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 148 of 149 Details of an `automatic' method of finding an approximate variance stabilizing transformation g 
are given below. It was recommended to base this ‘automatic’ method on a Taylor series 
argument. For a random variable X with mean M and standard deviation s(M) that varies as a function of M, the transformation given by 
 (1)                              
        
has the property that the variance of g(X ) is approximately constant. 
The Non-Parametric Bootstrap-t Method with a variance stabilizing transformation 
The following steps describe the variance stabilized non-parametric bootstrap-t method for a 
difference in means: 
1.  Form a set of B bootstrap data sets sampled with replacement from the two groups Y 
and Z, as described in Section Error! Reference s ource not found. . The number of r
eplications B in this analysis is [ZIP_CODE]. 
2. Compute the difference in means M b* and standard error SE b* for each bootstrap data 
set, b=1, 2,..., B. 
3. Fit a curve to the points [M b* and SE b*] using a non-linear regression technique to 
produce a smooth function s such that s(M b*) is the average SE b* at M b*, using quadratic 
polynomials for the local regression and cubic interpolation polynomials in the blending method of the local polynomial fits. The generalized cross-validation smoothing criterion 
is applied for the fit. 
The size of the local neighborhood in the local fitting is determined by [CONTACT_634486] (θ), which indicates the proportion of the data points used for the local fitting. The value of the smoothing parameter θ that is used, is obtained by [CONTACT_634487]-validation smoothing criterion. The cubic interpolation method assumes that the maximum number of points in the leaf nodes of the kd tree (bucket size) is set to θ*k/5, where θ is the estimated smoothing parameter and k is the number of observations being used. 
4. Estimate the variance stabilizing transformation g(M) using equation (1) and a numerical integration technique. For the present analysis, the Simpson’s numerical integration method will be used. 
5. Compute a bootstrap-t confidence interval for the transformed values g(M
b*) in the way 
described previously in Part C, where α=0.05. The standard error will be approximately constant, so SE
b* and SE(g(M)) can be set equal to 1. Thus the CI for the transformed 
values will be calculated as follows: 
(g(M) - T *(1- α /2) ,    g(M) - T *(α /2)), 
where T* (1- α /2)   and   T* ( α /2)  are the percentiles of T b* = g(M b*) − g(M). 
Estimate the p-value for the hypothesis test as described previously in Section Error! R
eference source not found. . 
REDACTED COPY *] using a non
REDACTED COPY *] using a non
produce a smooth function s such that s(M
REDACTED COPY produce a smooth function s such that s(M
polynomials for the local regression and cubic interpolation polynomials in the blending 
REDACTED COPY polynomials for the local regression and cubic interpolation polynomials in the blending 
nomial fits. The generalized cross
REDACTED COPY nomial fits. The generalized cross
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. t Method with a variance stabilizing transformation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. t Method with a variance stabilizing transformation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. parametric bootstrap
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. parametric bootstrap -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. -t method for a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. t method for a 
acement from the two groups Y 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. acement from the two groups Y 
ource not found.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. ource not found.
* and standard error SE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. * and standard error SE
*] using a non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. *] using a non
produce a smooth function s such that s(M
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. produce a smooth function s such that s(M b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. b*) is the average SE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. *) is the average SE
polynomials for the local regression and cubic interpolation polynomials in the blending 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. polynomials for the local regression and cubic interpolation polynomials in the blending 
nomial fits. The generalized cross
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. nomial fits. The generalized cross
The size of the local neighborhood in the local fitting is determined by [CONTACT_634488]. The size of the local neighborhood in the local fitting is determined by [CONTACT_634486] (θ), which indicates the proportion of the data points u
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. smoothing parameter (θ), which indicates the proportion of the data points u
local fitting. The value of the smoothing parameter θ that is used, is obtained by 
[CONTACT_122253]. local fitting. The value of the smoothing parameter θ that is used, is obtained by 
[CONTACT_634489]. minimizing the generalized cross
method assumes that the maximum number of points in the leaf nodes of th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. method assumes that the maximum number of points in the leaf nodes of th
(bucket size) is set to θ*k/5, where θ is the estimated smoothing parameter and k is the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. (bucket size) is set to θ*k/5, where θ is the estimated smoothing parameter and k is the 
number of observations being used.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. number of observations being used.
Estimate the variance stabilizing transformation g(M) using equation (1) and a numerical 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Estimate the variance stabilizing transformation g(M) using equation (1) and a numerical 
integration technique. For the pr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. integration technique. For the pr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. method will be used.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. method will be used.
Compute a bootstrap
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Compute a bootstrap
described previously in Part C, where α=0.05. The standard error will be approximately 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. described previously in Part C, where α=0.05. The standard error will be approximately 
UCB   07 May 19  
Statistical Analysis Plan Certolizumab Pegol AS0005 
   
Confidential Page 149 of 149 6. The endpoints (ie, the estimated difference in means and the CI) calculated on the 
transformed scale can be mapped back to the original scale using the inverse transformation g
−1. Of note, when the value falls in between two existing values in the 
lookup table, the inverse transformation g−1 will be calculated using linear interpolation. 
(Programming note: For the CI, in the case where the CI exact limits cannot be determined because they fall outside the range of existing data, then the output will not display the limit which cannot be determined, but will display the following labels: “<min” or “>max”, where applicable.)  
The adequacy of the transformation can be checked by [CONTACT_15487] M
b* against the standard 
error on the variance stabilized scale, an approximation of which is given using the delta 
method. 
SE (g(M b*)) = SE b* / s(M b*) 
Change #73 
12.2 Compliance ratio calculation 
 Exposure Duration [b] (days) = week 94 Visit/last injection date –Week 48 Visit date + [ADDRESS_846992]-flare exposure 
duration, identified as “Exposure Duration [f]”, will use the last of the injection escape Visit 
dates: 
 Exposure Duration [f] (days) = last escape visit/last i njection date –Escape Week 0 Visit date 
+ 14 
Has been changed to: 
 Exposure Duration [b] (days) = week 94 Visit/last injection date – Week 48 injection/Week 
48 Visit date + [ADDRESS_846993]-flare exposure 
duration, identified as “Exposure Duration [f]”, will use the last of the injection escape Visit 
dates: 
 Exposure Duration [f] (days) = last escape visit/last injection date – first Escape Week 0 
injection /Escape Week 0 Visit date + [ADDRESS_846994]
duration, identified as “Exposure Duration [f]”, will use the last of the injection escape Visit 
REDACTED COPY duration, identified as “Exposure Duration [f]”, will use the last of the injection escape Visit 
Exposure Duration [f] (days) = last escape visit/last i
REDACTED COPY Exposure Duration [f] (days) = last escape visit/last i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. against the standard 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. against the standard 
error on the variance stabilized scale, an approximation of which is given using the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. error on the variance stabilized scale, an approximation of which is given using the 
Exposure Duration [b] (days) = week 94 Visit/last injection date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Exposure Duration [b] (days) = week 94 Visit/last injection date –
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. –Week 48 Visit date + 14
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Week 48 Visit date + [ADDRESS_846995]
duration, identified as “Exposure Duration [f]”, will use the last of the injection escape Visit 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. duration, identified as “Exposure Duration [f]”, will use the last of the injection escape Visit 
Exposure Duration [f] (days) = last escape visit/last i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Exposure Duration [f] (days) = last escape visit/last i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Exposure Duration [b] (days) = week 94 Visit/last injection date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Exposure Duration [b] (days) = week 94 Visit/last injection date 
The cumulative difference will be calculated for all visits from Week [ADDRESS_846996]
duration, identified as “Exposure Duration [f]”, will use the last of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. duration, identified as “Exposure Duration [f]”, will use the last of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Exposure Duration [f] (days) = last escape visit/last injection date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. Exposure Duration [f] (days) = last escape visit/last injection date 
injection /Escape Week 0 Visit date + 14
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. injection /Escape Week 0 Visit date + 14